<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>Biktarvy, INN-Bictegravir/Emtricitabine/Tenofovir Alafenamide</title>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
<meta name="generator" content="pdftohtml 0.36"/>
<meta name="author" content="CHMP"/>
<meta name="keywords" content="Biktarvy, INN-Bictegravir/Emtricitabine/Tenofovir Alafenamide"/>
<meta name="date" content="2022-11-14T13:59:52+00:00"/>
<meta name="subject" content="EPAR"/>
<style type="text/css">
<!--
.xflip {
    -moz-transform: scaleX(-1);
    -webkit-transform: scaleX(-1);
    -o-transform: scaleX(-1);
    transform: scaleX(-1);
    filter: fliph;
}
.yflip {
    -moz-transform: scaleY(-1);
    -webkit-transform: scaleY(-1);
    -o-transform: scaleY(-1);
    transform: scaleY(-1);
    filter: flipv;
}
.xyflip {
    -moz-transform: scaleX(-1) scaleY(-1);
    -webkit-transform: scaleX(-1) scaleY(-1);
    -o-transform: scaleX(-1) scaleY(-1);
    transform: scaleX(-1) scaleY(-1);
    filter: fliph + flipv;
}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<!-- Page 1 -->
<a name="1"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft10{font-size:17px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft11{font-size:12px;font-family:ArialMT;color:#000000;}
	.ft12{font-size:17px;font-family:TimesNewRomanPS;color:#000000;}
	.ft13{font-size:17px;line-height:19px;font-family:TimesNewRomanPS;color:#000000;}
	.ft14{font-size:17px;line-height:18px;font-family:TimesNewRomanPS;color:#000000;}
	.ft15{font-size:17px;line-height:18px;font-family:TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page1-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft10">&#160;</p>
<p style="position:absolute;top:1197px;left:440px;white-space:nowrap" class="ft11">1&#160;</p>
<p style="position:absolute;top:89px;left:447px;white-space:nowrap" class="ft14"><b>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;</b></p>
<p style="position:absolute;top:526px;left:412px;white-space:nowrap" class="ft12"><b>ANNEX&#160;I&#160;</b></p>
<p style="position:absolute;top:544px;left:447px;white-space:nowrap" class="ft12"><b>&#160;</b></p>
<p style="position:absolute;top:564px;left:264px;white-space:nowrap" class="ft12"><b>SUMMARY&#160;OF PRODUCT&#160;CHARACTERISTICS&#160;</b></p>
<p style="position:absolute;top:582px;left:447px;white-space:nowrap" class="ft12"><b>&#160;</b></p>
<p style="position:absolute;top:601px;left:106px;white-space:nowrap" class="ft15">&#160;<br/>&#160;</p>
<p style="position:absolute;top:620px;left:322px;white-space:nowrap" class="ft10">&#160;</p>
</div>
<!-- Page 2 -->
<a name="2"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft26{font-size:17px;font-family:SymbolMT;color:#000000;}
	.ft27{font-size:17px;font-family:TimesNewRomanPS;color:#000000;}
	.ft28{font-size:17px;line-height:19px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft29{font-size:17px;line-height:20px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft210{font-size:17px;line-height:19px;font-family:TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page2-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft20">&#160;</p>
<p style="position:absolute;top:1197px;left:430px;white-space:nowrap" class="ft21">2&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft22"><b>1.&#160;</b></p>
<p style="position:absolute;top:89px;left:149px;white-space:nowrap" class="ft22"><b>NAME OF THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft25">&#160;<br/>Biktarvy&#160;30&#160;mg/120&#160;mg/15&#160;mg film-coated&#160;tablets&#160;&#160;<br/>Biktarvy&#160;50&#160;mg/200&#160;mg/25&#160;mg film-coated&#160;tablets&#160;<br/>&#160;<br/>&#160;<br/><b>2.&#160;</b></p>
<p style="position:absolute;top:203px;left:149px;white-space:nowrap" class="ft22"><b>QUALITATIVE&#160;AND&#160;QUANTITATIVE&#160;COMPOSITION&#160;</b></p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft25">&#160;<br/>Biktarvy 30&#160;mg/120&#160;mg/15&#160;mg film-coated&#160;tablets&#160;<br/>&#160;<br/>Each film-coated&#160;tablet&#160;contains bictegravir&#160;sodium&#160;equivalent&#160;to&#160;30&#160;mg of&#160;bictegravir, 120&#160;mg of&#160;<br/>emtricitabine,&#160;and&#160;tenofovir&#160;alafenamide&#160;fumarate equivalent&#160;to 15&#160;mg of&#160;tenofovir&#160;alafenamide.&#160;<br/>&#160;<br/>Biktarvy 50&#160;mg/200&#160;mg/25&#160;mg film-coated&#160;tablets&#160;<br/>&#160;<br/>Each&#160;film-coated&#160;tablet&#160;contains&#160;bictegravir&#160;sodium&#160;equivalent&#160;to&#160;50&#160;mg of&#160;bictegravir, 200&#160;mg of&#160;<br/>emtricitabine,&#160;and&#160;tenofovir&#160;alafenamide&#160;fumarate equivalent&#160;to 25&#160;mg of&#160;tenofovir&#160;alafenamide.&#160;<br/>&#160;<br/>For&#160;the&#160;full&#160;list&#160;of&#160;excipients, see&#160;section&#160;6.1.&#160;<br/>&#160;<br/>&#160;<br/><b>3.&#160;</b></p>
<p style="position:absolute;top:488px;left:149px;white-space:nowrap" class="ft22"><b>PHARMACEUTICAL&#160;FORM&#160;</b></p>
<p style="position:absolute;top:506px;left:106px;white-space:nowrap" class="ft25">&#160;<br/>Film-coated&#160;tablet&#160;(tablet).&#160;<br/>&#160;<br/>Biktarvy 30&#160;mg/120&#160;mg/15&#160;mg&#160;film-coated&#160;tablets&#160;<br/>&#160;<br/>Pink, capsule-shaped,&#160;film-coated&#160;tablet,&#160;debossed with “BVY” on one&#160;side and a&#160;score line&#160;on the&#160;<br/>other&#160;side of&#160;the tablet. Each tablet&#160;is approximately 14&#160;mm&#160;x 6&#160;mm. &#160;The&#160;score line is only&#160;to&#160;<br/>facilitate&#160;breaking for&#160;ease&#160;of&#160;swallowing and not&#160;to&#160;divide&#160;into equal&#160;doses.&#160;<br/>&#160;<br/>Biktarvy 50&#160;mg/200&#160;mg/25&#160;mg&#160;film-coated&#160;tablets&#160;<br/>&#160;<br/>Purplish-brown,&#160;capsule-shaped,&#160;film-coated&#160;tablet&#160;debossed with&#160;“GSI” on one&#160;side and&#160;“9883” on&#160;<br/>the other&#160;side of&#160;the&#160;tablet.&#160;&#160;Each tablet&#160;is&#160;approximately 15&#160;mm&#160;&#160;8&#160;mm.&#160;<br/>&#160;<br/>&#160;<br/><b>4.&#160;</b></p>
<p style="position:absolute;top:792px;left:149px;white-space:nowrap" class="ft22"><b>CLINICAL&#160;PARTICULARS&#160;</b></p>
<p style="position:absolute;top:811px;left:106px;white-space:nowrap" class="ft25">&#160;<br/><b>4.1&#160;</b></p>
<p style="position:absolute;top:830px;left:149px;white-space:nowrap" class="ft22"><b>Therapeutic&#160;indications&#160;</b></p>
<p style="position:absolute;top:849px;left:106px;white-space:nowrap" class="ft28">&#160;<br/>Biktarvy&#160;is&#160;indicated&#160;for&#160;the treatment&#160;of&#160;human immunodeficiency virus-1&#160;(HIV-1)&#160;infection&#160;in&#160;adults&#160;<br/>and paediatric&#160;patients&#160;at&#160;least&#160;2&#160;years of&#160;age and weighing at&#160;least&#160;14&#160;kg&#160;without&#160;present&#160;or&#160;past&#160;<br/>evidence&#160;of&#160;viral&#160;resistance&#160;to&#160;the&#160;integrase&#160;inhibitor&#160;class, emtricitabine&#160;or&#160;tenofovir&#160;(see section&#160;5.1).&#160;<br/>&#160;<br/><b>4.2&#160;</b></p>
<p style="position:absolute;top:944px;left:149px;white-space:nowrap" class="ft22"><b>Posology and&#160;method of&#160;administration&#160;</b></p>
<p style="position:absolute;top:963px;left:106px;white-space:nowrap" class="ft210">&#160;<br/>Therapy should be initiated&#160;by a physician experienced&#160;in the&#160;management&#160;of&#160;HIV&#160;infection.&#160;<br/>&#160;<br/>Posology&#160;<br/>&#160;<br/><i>Paediatric patients at&#160;least&#160;2 years of&#160;age and weighing at&#160;least&#160;14</i>&#160;<i>kg to less&#160;than&#160;25&#160;kg&#160;<br/></i>One 30&#160;mg/120&#160;mg/15&#160;mg&#160;tablet&#160;to be&#160;taken&#160;once daily.&#160;<br/>&#160;<br/><i>Adults and&#160;paediatric patients weighing at&#160;least&#160;25&#160;kg&#160;<br/></i>One&#160;50&#160;mg/200&#160;mg/25&#160;mg&#160;tablet&#160;to be&#160;taken once daily.&#160;</p>
</div>
<!-- Page 3 -->
<a name="3"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft311{font-size:17px;line-height:18px;font-family:TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page3-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft30">&#160;</p>
<p style="position:absolute;top:1197px;left:430px;white-space:nowrap" class="ft31">3&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft35"><i>&#160;<br/>Missed&#160;doses&#160;<br/></i>If&#160;the&#160;patient&#160;misses&#160;a dose&#160;of&#160;Biktarvy&#160;within&#160;18&#160;hours&#160;of&#160;the time&#160;it&#160;is usually&#160;taken, the patient&#160;<br/>should take&#160;Biktarvy&#160;as&#160;soon as&#160;possible&#160;and&#160;resume the normal&#160;dosing&#160;schedule.&#160;&#160;If&#160;a patient&#160;misses a&#160;<br/>dose&#160;of&#160;Biktarvy&#160;by&#160;more&#160;than&#160;18&#160;hours,&#160;the patient&#160;should not&#160;take&#160;the&#160;missed dose&#160;and&#160;simply&#160;<br/>resume&#160;the&#160;usual&#160;dosing schedule.&#160;<br/>&#160;<br/>If&#160;the&#160;patient&#160;vomits within&#160;1&#160;hour&#160;of&#160;taking&#160;Biktarvy&#160;another&#160;tablet&#160;should be&#160;taken.&#160;&#160;If&#160;a patient&#160;<br/>vomits&#160;more&#160;than&#160;1&#160;hour&#160;after&#160;taking&#160;Biktarvy&#160;they do&#160;not&#160;need to take&#160;another&#160;dose&#160;of&#160;Biktarvy&#160;until&#160;<br/>the next&#160;regularly&#160;scheduled dose.&#160;<br/>&#160;<br/>Special&#160;populations&#160;<br/>&#160;<br/><i>Elderly</i>&#160;<br/>No dose&#160;adjustment&#160;of&#160;Biktarvy&#160;is&#160;required in&#160;patients&#160;aged&#160;≥&#160;65&#160;years&#160;(see&#160;sections&#160;4.8 and&#160;5.2).&#160;<br/><i>&#160;<br/>Hepatic impairment&#160;<br/></i>No dose&#160;adjustment&#160;of&#160;Biktarvy&#160;is&#160;required in&#160;patients&#160;with&#160;mild&#160;(Child-Pugh Class&#160;A)&#160;or&#160;moderate&#160;<br/>(Child-Pugh Class&#160;B)&#160;hepatic impairment.&#160;&#160;Biktarvy has not&#160;been&#160;studied in&#160;patients with severe&#160;<br/>hepatic&#160;impairment&#160;(Child-Pugh Class&#160;C),&#160;therefore Biktarvy is not&#160;recommended&#160;for&#160;use&#160;in patients&#160;<br/>with severe hepatic&#160;impairment&#160;(see&#160;sections&#160;4.4&#160;and&#160;5.2).&#160;<br/><i>&#160;<br/>Renal&#160;impairment&#160;<br/></i>No dose&#160;adjustment&#160;of&#160;Biktarvy&#160;is&#160;required in&#160;patients&#160;weighing&#160;≥&#160;35 kg&#160;with estimated creatinine&#160;<br/>clearance&#160;(CrCl)&#160;≥&#160;30&#160;mL/min.&#160;<br/>&#160;<br/>No dose&#160;adjustment&#160;of&#160;Biktarvy&#160;is&#160;required in&#160;adult&#160;patients with end stage&#160;renal&#160;disease&#160;(estimated&#160;<br/>creatinine clearance&#160;&lt;&#160;15&#160;mL/minute)&#160;who are receiving chronic&#160;haemodialysis. &#160;However, Biktarvy&#160;<br/>should generally be avoided&#160;and only be used in&#160;these&#160;patients if&#160;the potential&#160;benefits&#160;are&#160;considered&#160;<br/>to outweigh the potential&#160;risks&#160;(see&#160;sections 4.4 and&#160;5.2). &#160;On days of&#160;haemodialysis, Biktarvy&#160;should&#160;<br/>be administered&#160;after&#160;completion of&#160;haemodialysis treatment.&#160;<br/>&#160;<br/>Initiation of&#160;Biktarvy&#160;should be avoided&#160;in&#160;patients with estimated&#160;creatinine clearance&#160;≥15&#160;mL/min&#160;<br/>and &lt;&#160;30&#160;mL/min, or&#160;&lt;&#160;15&#160;mL/min who are not&#160;receiving chronic haemodialysis,&#160;as the&#160;safety of&#160;<br/>Biktarvy has&#160;not&#160;been established&#160;in these populations&#160;(see&#160;section 5.2).&#160;<br/>&#160;<br/>No data&#160;are available to make dose recommendations&#160;in patients weighing &lt;&#160;35&#160;kg&#160;with&#160;renal&#160;<br/>impairment&#160;or&#160;in paediatric&#160;patients less&#160;than 18 years&#160;with end stage&#160;renal&#160;disease.&#160;<br/>&#160;<br/><i>Paediatric population&#160;<br/></i>The safety and&#160;efficacy&#160;of&#160;Biktarvy&#160;in children&#160;less&#160;than 2 years&#160;of&#160;age or&#160;weighing less&#160;than&#160;14&#160;kg&#160;<br/>have&#160;not&#160;yet&#160;been established.&#160;&#160;No data are&#160;available.&#160;<br/>&#160;<br/>Method of&#160;administration&#160;<br/>&#160;<br/>Oral&#160;use.&#160;<br/>Biktarvy&#160;can be taken&#160;with&#160;or&#160;without&#160;food&#160;(see&#160;section&#160;5.2).&#160;<br/>Due to&#160;the bitter&#160;taste,&#160;it&#160;is&#160;recommended&#160;that&#160;the&#160;film-coated tablets&#160;should not&#160;be&#160;chewed&#160;or&#160;crushed.&#160;&#160;<br/>For patients who are unable&#160;to swallow&#160;the&#160;tablet&#160;whole, the&#160;tablet&#160;may be split&#160;in&#160;half&#160;and both&#160;halves&#160;<br/>taken&#160;one&#160;after&#160;the&#160;other,&#160;ensuring that&#160;the full&#160;dose&#160;is&#160;taken&#160;immediately.&#160;<br/>&#160;<br/><b>4.3&#160;</b></p>
<p style="position:absolute;top:1057px;left:149px;white-space:nowrap" class="ft32"><b>Contraindications&#160;</b></p>
<p style="position:absolute;top:1076px;left:106px;white-space:nowrap" class="ft35">&#160;<br/>Hypersensitivity&#160;to the active substances&#160;or&#160;to&#160;any of&#160;the excipients&#160;listed&#160;in&#160;section&#160;6.1.&#160;<br/>&#160;<br/>Co-administration with&#160;rifampicin&#160;and St.&#160;John’s&#160;wort&#160;(<i>Hypericum perforatum</i>)&#160;(see&#160;section&#160;4.5).&#160;<br/>&#160;</p>
</div>
<!-- Page 4 -->
<a name="4"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page4-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft40">&#160;</p>
<p style="position:absolute;top:1197px;left:430px;white-space:nowrap" class="ft41">4&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft42"><b>4.4&#160;</b></p>
<p style="position:absolute;top:89px;left:149px;white-space:nowrap" class="ft42"><b>Special&#160;warnings&#160;and&#160;precautions&#160;for use&#160;</b></p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft45">&#160;<br/>Patients&#160;co-infected&#160;with HIV&#160;and hepatitis&#160;B&#160;or&#160;C&#160;virus&#160;<br/>&#160;<br/>Patients with chronic hepatitis&#160;B&#160;or&#160;C&#160;treated with antiretroviral&#160;therapy are at&#160;an&#160;increased&#160;risk for&#160;<br/>severe and potentially fatal&#160;hepatic&#160;adverse&#160;reactions.&#160;<br/>&#160;<br/>There&#160;are&#160;limited&#160;safety and efficacy&#160;data for&#160;Biktarvy&#160;in patients co-infected with&#160;HIV-1 and&#160;<br/>hepatitis&#160;C&#160;virus&#160;(HCV).&#160;&#160;<br/>&#160;<br/>Biktarvy&#160;contains tenofovir&#160;alafenamide, which&#160;is&#160;active against&#160;hepatitis&#160;B&#160;virus&#160;(HBV).&#160;<br/>&#160;<br/>Discontinuation&#160;of&#160;Biktarvy&#160;therapy&#160;in patients co-infected with HIV&#160;and HBV&#160;may be associated&#160;<br/>with severe acute exacerbations of&#160;hepatitis.&#160;&#160;Patients&#160;co-infected&#160;with HIV&#160;and HBV&#160;who discontinue&#160;<br/>Biktarvy&#160;should be&#160;closely&#160;monitored with&#160;both&#160;clinical&#160;and&#160;laboratory follow-up for&#160;at&#160;least&#160;several&#160;<br/>months after&#160;stopping&#160;treatment.&#160;<br/>&#160;<br/>Liver&#160;disease&#160;<br/>&#160;<br/>The safety and&#160;efficacy&#160;of&#160;Biktarvy&#160;in patients with significant&#160;underlying&#160;liver&#160;disorders&#160;have not&#160;<br/>been established.&#160;<br/>&#160;<br/>Patients with pre-existing&#160;liver&#160;dysfunction,&#160;including&#160;chronic&#160;active&#160;hepatitis, have an&#160;increased&#160;<br/>frequency of&#160;liver&#160;function&#160;abnormalities&#160;during combination antiretroviral&#160;therapy (CART) and&#160;<br/>should be&#160;monitored&#160;according to standard practice.&#160;&#160;If&#160;there is evidence&#160;of&#160;worsening liver&#160;disease&#160;in&#160;<br/>such patients,&#160;interruption&#160;or&#160;discontinuation&#160;of&#160;treatment&#160;must&#160;be considered.&#160;<br/>&#160;<br/>Weight&#160;and&#160;metabolic parameters&#160;<br/>&#160;<br/>An increase in weight&#160;and in levels&#160;of&#160;blood&#160;lipids and&#160;glucose&#160;may occur&#160;during&#160;antiretroviral&#160;<br/>therapy.&#160;&#160;Such changes&#160;may in part&#160;be&#160;linked&#160;to disease control&#160;and&#160;lifestyle.&#160;&#160;For&#160;lipids,&#160;there&#160;is&#160;in&#160;<br/>some&#160;cases&#160;evidence&#160;for&#160;a&#160;treatment&#160;effect, while&#160;for&#160;weight&#160;gain&#160;there is no&#160;strong&#160;evidence&#160;relating&#160;<br/>this to&#160;any particular&#160;treatment.&#160;&#160;For&#160;monitoring of&#160;blood lipids and&#160;glucose,&#160;reference&#160;is&#160;made to&#160;<br/>established HIV&#160;treatment&#160;guidelines.&#160;&#160;Lipid disorders&#160;should be&#160;managed&#160;as&#160;clinically appropriate.&#160;<br/>&#160;<br/>Mitochondrial&#160;dysfunction&#160;following exposure&#160;<i>in&#160;utero</i>&#160;<br/>&#160;<br/>Nucleos(t)ide analogues may impact&#160;mitochondrial&#160;function to&#160;a variable degree,&#160;which&#160;is&#160;most&#160;<br/>pronounced with&#160;stavudine,&#160;didanosine and zidovudine.&#160;&#160;There have been reports of&#160;mitochondrial&#160;<br/>dysfunction&#160;in HIV&#160;negative infants exposed&#160;<i>in&#160;utero</i>&#160;and/or&#160;postnatally&#160;to nucleoside analogues;&#160;these&#160;<br/>have&#160;predominantly&#160;concerned treatment&#160;with regimens containing&#160;zidovudine.&#160;&#160;The main&#160;adverse&#160;<br/>reactions&#160;reported are haematological&#160;disorders (anaemia, neutropenia)&#160;and&#160;metabolic&#160;disorders&#160;<br/>(hyperlactatemia, hyperlipasemia).&#160;&#160;These&#160;events have&#160;often been transitory.&#160;&#160;Late&#160;onset&#160;neurological&#160;<br/>disorders have been&#160;reported rarely (hypertonia, convulsion,&#160;abnormal&#160;behaviour).&#160;&#160;Whether&#160;such&#160;<br/>neurological&#160;disorders are&#160;transient&#160;or&#160;permanent&#160;is currently unknown.&#160;&#160;These&#160;findings&#160;should be&#160;<br/>considered for&#160;any child exposed&#160;<i>in&#160;utero</i>&#160;to nucleos(t)ide analogues, who present&#160;with severe clinical&#160;<br/>findings of&#160;unknown&#160;aetiology,&#160;particularly neurologic&#160;findings.&#160;&#160;These&#160;findings do not&#160;affect&#160;current&#160;<br/>national&#160;recommendations&#160;to use&#160;antiretroviral&#160;therapy&#160;in pregnant&#160;women&#160;to prevent&#160;vertical&#160;<br/>transmission of&#160;HIV.&#160;<br/>&#160;<br/>Immune&#160;Reactivation&#160;Syndrome&#160;<br/>&#160;<br/>In HIV&#160;infected&#160;patients with severe immune&#160;deficiency at&#160;the&#160;time&#160;of&#160;institution&#160;of&#160;CART, an&#160;<br/>inflammatory&#160;reaction&#160;to asymptomatic or&#160;residual&#160;opportunistic pathogens&#160;may&#160;arise&#160;and cause&#160;<br/>serious&#160;clinical&#160;conditions,&#160;or&#160;aggravation of&#160;symptoms.&#160;&#160;Typically,&#160;such&#160;reactions&#160;have&#160;been observed&#160;<br/>within the first&#160;few weeks or&#160;months of&#160;initiation&#160;of&#160;CART.&#160;&#160;Relevant&#160;examples&#160;include&#160;<br/>cytomegalovirus&#160;retinitis, generalised&#160;and/or&#160;focal&#160;mycobacterial&#160;infections,&#160;and&#160;<i>Pneumocystis&#160;</i></p>
</div>
<!-- Page 5 -->
<a name="5"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft512{font-size:17px;line-height:15px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft513{font-size:17px;line-height:22px;font-family:TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page5-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft50">&#160;</p>
<p style="position:absolute;top:1197px;left:430px;white-space:nowrap" class="ft51">5&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft55"><i>jirovecii</i>&#160;pneumonia.&#160;&#160;Any inflammatory symptoms should be evaluated&#160;and&#160;treatment&#160;instituted when&#160;<br/>necessary.&#160;<br/>&#160;<br/>Autoimmune disorders&#160;(such as&#160;Graves’&#160;disease&#160;and autoimmune hepatitis)&#160;have&#160;also been reported&#160;to&#160;<br/>occur&#160;in&#160;the&#160;setting of&#160;immune reactivation;&#160;however,&#160;the reported&#160;time&#160;to onset&#160;is&#160;more variable and&#160;<br/>these events can&#160;occur&#160;many months&#160;after&#160;initiation of&#160;treatment.&#160;<br/>&#160;<br/>Opportunistic infections&#160;<br/>&#160;<br/>Patients&#160;should&#160;be advised&#160;that&#160;Biktarvy&#160;or&#160;any other&#160;antiretroviral&#160;therapy&#160;does&#160;not&#160;cure&#160;<br/>HIV&#160;infection&#160;and&#160;that&#160;they&#160;may&#160;still&#160;develop opportunistic&#160;infections and other&#160;complications of&#160;<br/>HIV&#160;infection.&#160;&#160;Therefore,&#160;patients&#160;should&#160;remain under&#160;close clinical&#160;observation by physicians&#160;<br/>experienced&#160;in&#160;the&#160;treatment&#160;of&#160;patients with HIV&#160;associated diseases.&#160;<br/>&#160;<br/>Osteonecrosis&#160;<br/>&#160;<br/>Although the&#160;aetiology is considered to&#160;be&#160;multifactorial&#160;(including&#160;corticosteroid&#160;use, alcohol&#160;<br/>consumption,&#160;severe&#160;immunosuppression, higher&#160;body&#160;mass index), cases&#160;of&#160;osteonecrosis have been&#160;<br/>reported particularly&#160;in patients with&#160;advanced HIV&#160;disease&#160;and/or&#160;long-term&#160;exposure&#160;to CART.&#160;&#160;<br/>Patients should&#160;be advised&#160;to seek&#160;medical&#160;advice&#160;if&#160;they experience&#160;joint&#160;aches and pain,&#160;joint&#160;<br/>stiffness&#160;or&#160;difficulty&#160;in&#160;movement.&#160;<br/>&#160;<br/>Nephrotoxicity&#160;<br/>&#160;<br/>Post-marketing cases of&#160;renal&#160;impairment,&#160;including&#160;acute&#160;renal&#160;failure&#160;and&#160;proximal&#160;renal&#160;<br/>tubulopathy have&#160;been&#160;reported&#160;with tenofovir&#160;alafenamide-containing products.&#160;&#160;A&#160;potential&#160;risk of&#160;<br/>nephrotoxicity&#160;resulting from&#160;chronic exposure&#160;to low&#160;levels of&#160;tenofovir&#160;due to&#160;dosing with&#160;tenofovir&#160;<br/>alafenamide cannot&#160;be&#160;excluded (see&#160;section&#160;5.3).&#160;<br/>&#160;<br/>It&#160;is recommended that&#160;renal&#160;function&#160;is assessed in&#160;all&#160;patients prior&#160;to, or&#160;when initiating,&#160;therapy&#160;<br/>with Biktarvy&#160;and&#160;that&#160;it&#160;is&#160;also&#160;monitored during&#160;therapy in all&#160;patients&#160;as&#160;clinically appropriate.&#160;&#160;In&#160;<br/>patients who develop&#160;clinically significant&#160;decreases in&#160;renal&#160;function, or&#160;evidence&#160;of&#160;proximal&#160;renal&#160;<br/>tubulopathy, discontinuation of&#160;Biktarvy&#160;should be&#160;considered.&#160;<br/>&#160;<br/>Patients with end stage&#160;renal&#160;disease&#160;on&#160;chronic&#160;haemodialysis&#160;<br/>&#160;<br/>Biktarvy&#160;should generally be avoided but&#160;may&#160;be used&#160;in adults with&#160;end stage renal&#160;disease&#160;<br/>(estimated CrCl&#160;&lt;&#160;15&#160;mL/min)&#160;on chronic haemodialysis if&#160;the potential&#160;benefits outweigh the&#160;<br/>potential&#160;risks&#160;(see section&#160;4.2). &#160;In a&#160;study of&#160;emtricitabine&#160;+ tenofovir&#160;alafenamide in combination&#160;<br/>with elvitegravir&#160;+ cobicistat&#160;as a&#160;fixed-dose&#160;combination tablet&#160;(E/C/F/TAF)&#160;in&#160;HIV-1 infected adults&#160;<br/>with end stage&#160;renal&#160;disease&#160;(estimated CrCl&#160;&lt;&#160;15&#160;mL/min)&#160;on&#160;chronic&#160;haemodialysis,&#160;efficacy was&#160;<br/>maintained through 96 weeks but&#160;emtricitabine exposure was&#160;significantly higher&#160;than in&#160;patients with&#160;<br/>normal&#160;renal&#160;function. &#160;Efficacy was also&#160;maintained in the&#160;extension phase&#160;of&#160;the&#160;study&#160;in which 10&#160;<br/>patients switched&#160;to Biktarvy for&#160;48 weeks. &#160;Although&#160;no additional&#160;adverse&#160;reactions were&#160;identified,&#160;<br/>the&#160;implications of&#160;increased emtricitabine exposure remain uncertain (see&#160;sections 4.8 and 5.2).&#160;<br/>&#160;<br/>Co-administration of&#160;other&#160;medicinal&#160;products&#160;<br/>&#160;<br/>Biktarvy&#160;should not&#160;be&#160;co-administered&#160;simultaneously&#160;with&#160;magnesium/aluminium-containing&#160;<br/>antacids or&#160;iron supplements under&#160;fasted conditions. &#160;Biktarvy&#160;should be&#160;administered at&#160;least&#160;2&#160;hours&#160;<br/>before, or&#160;with food 2&#160;hours after&#160;antacids&#160;containing&#160;magnesium&#160;and/or&#160;aluminium.&#160;&#160;Biktarvy&#160;should&#160;<br/>be administered at&#160;least&#160;2&#160;hours before&#160;iron supplements, or&#160;taken&#160;together&#160;with&#160;food (see&#160;section&#160;4.5).&#160;<br/>&#160;<br/>Some&#160;medicinal&#160;products&#160;are not&#160;recommended for&#160;co-administration with&#160;Biktarvy:&#160;atazanavir,&#160;<br/>carbamazepine,&#160;ciclosporin&#160;(IV&#160;or&#160;oral&#160;use),&#160;oxcarbazepine, phenobarbital,&#160;phenytoin,&#160;rifabutin,&#160;<br/>rifapentine, or&#160;sucralfate.&#160;<br/>&#160;</p>
</div>
<!-- Page 6 -->
<a name="6"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft614{font-size:15px;font-family:TimesNewRomanPS;color:#000000;}
	.ft615{font-size:15px;line-height:18px;font-family:TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page6-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft60">&#160;</p>
<p style="position:absolute;top:1197px;left:430px;white-space:nowrap" class="ft61">6&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft68">Biktarvy&#160;should not&#160;be&#160;co-administered with&#160;other&#160;antiretroviral&#160;medicinal&#160;products.&#160;<br/>&#160;<br/>Paediatric&#160;population&#160;<br/>&#160;<br/>Reductions in&#160;bone&#160;mineral&#160;density&#160;(BMD&#160;≥&#160;4%)&#160;of&#160;the spine and total&#160;body&#160;less&#160;head&#160;(TBLH)&#160;have&#160;<br/>been&#160;reported in&#160;patients&#160;aged between 3&#160;to&#160;&lt;&#160;12&#160;years&#160;who&#160;received&#160;tenofovir&#160;alafenamide-containing&#160;<br/>products&#160;for&#160;48 weeks (see&#160;section&#160;4.8).&#160;&#160;The&#160;long-term&#160;effects of&#160;changes&#160;in BMD on the&#160;growing&#160;<br/>bone, including the risk&#160;of&#160;fracture, are uncertain. &#160;A&#160;multidisciplinary approach&#160;is&#160;recommended to&#160;<br/>decide the appropriate monitoring during&#160;treatment.&#160;<br/>&#160;<br/>Excipients<b>&#160;<br/></b>&#160;<br/>This&#160;medicine&#160;contains less&#160;than 1&#160;mmol&#160;sodium&#160;(23 mg)&#160;per&#160;tablet,&#160;that&#160;is to say&#160;essentially&#160;<br/>‘sodium-free’.&#160;<br/>&#160;<br/><b>4.5&#160;</b></p>
<p style="position:absolute;top:374px;left:149px;white-space:nowrap" class="ft62"><b>Interaction&#160;with other&#160;medicinal&#160;products and other forms&#160;of&#160;interaction&#160;</b></p>
<p style="position:absolute;top:393px;left:106px;white-space:nowrap" class="ft65">&#160;<br/>Interaction studies&#160;have&#160;only been performed&#160;in&#160;adults.&#160;<br/>&#160;<br/>Biktarvy&#160;should not&#160;be&#160;administered&#160;concomitantly with medicinal&#160;products&#160;containing&#160;tenofovir&#160;<br/>alafenamide,&#160;tenofovir&#160;disoproxil,&#160;lamivudine or&#160;adefovir&#160;dipivoxil&#160;used&#160;for&#160;the&#160;treatment&#160;of&#160;<br/>HBV&#160;infection.&#160;<br/>&#160;<br/>Bictegravir&#160;<br/>&#160;<br/>Bictegravir<b>&#160;</b>is&#160;a substrate of&#160;CYP3A&#160;and UGT1A1.&#160;&#160;Co-administration of&#160;bictegravir&#160;and medicinal&#160;<br/>products&#160;that&#160;potently&#160;induce&#160;both CYP3A&#160;and UGT1A1, such as rifampicin&#160;or&#160;St.&#160;John’s wort,&#160;may&#160;<br/>significantly decrease&#160;plasma&#160;concentrations&#160;of&#160;bictegravir, which&#160;may&#160;result&#160;in a&#160;loss&#160;of&#160;therapeutic&#160;<br/>effect&#160;of&#160;Biktarvy&#160;and development&#160;of&#160;resistance,&#160;therefore&#160;co-administration is&#160;contraindicated&#160;(see&#160;<br/>section&#160;4.3).&#160;&#160;Co-administration&#160;of&#160;bictegravir&#160;with&#160;medicinal&#160;products&#160;that&#160;potently inhibit&#160;both&#160;<br/>CYP3A&#160;and UGT1A1, such as&#160;atazanavir,&#160;may significantly&#160;increase&#160;plasma&#160;concentrations of&#160;<br/>bictegravir,&#160;therefore&#160;co-administration&#160;is not&#160;recommended.&#160;&#160;<br/>&#160;<br/>Bictegravir&#160;is both a P-gp and a BCRP substrate.&#160;&#160;The&#160;clinical&#160;relevance&#160;of&#160;this feature is not&#160;<br/>established.&#160;&#160;Therefore, caution&#160;is&#160;recommended when&#160;bictegravir&#160;is combined&#160;with&#160;medicinal&#160;<br/>products&#160;known to inhibit&#160;P-gp&#160;and/or&#160;BCRP (e.g. macrolides, ciclosporin,&#160;verapamil, dronedarone,&#160;<br/>glecaprevir/pibrentasvir)&#160;(see&#160;also&#160;table below).&#160;<br/>&#160;<br/>Bictegravir<b>&#160;</b>inhibits organic&#160;cation&#160;transporter&#160;2&#160;(OCT2)&#160;and&#160;multidrug and&#160;toxin extrusion&#160;<br/>transporter&#160;1&#160;(MATE1)&#160;<i>in&#160;vitro</i>.&#160;&#160;Co-administration of&#160;Biktarvy&#160;with&#160;the OCT2&#160;and MATE1 substrate&#160;<br/>metformin did not&#160;result&#160;in&#160;a clinically&#160;significant&#160;increase&#160;in metformin exposure.&#160;&#160;Biktarvy&#160;may be&#160;<br/>co-administered&#160;with substrates&#160;of&#160;OCT2 and MATE1.&#160;&#160;<br/>&#160;<br/>Bictegravir<b>&#160;</b>is not&#160;an&#160;inhibitor&#160;or&#160;inducer&#160;of&#160;CYP&#160;<i>in&#160;vivo</i>.&#160;<br/>&#160;<br/>Emtricitabine&#160;<br/>&#160;<br/><i>In&#160;vitro</i>&#160;and&#160;clinical&#160;pharmacokinetic drug-drug&#160;interaction studies&#160;have&#160;shown&#160;that&#160;the potential&#160;for&#160;<br/>CYP-mediated&#160;interactions&#160;involving&#160;emtricitabine&#160;with other&#160;medicinal&#160;products&#160;is low.&#160;&#160;<br/>Co-administration of&#160;emtricitabine&#160;with&#160;medicinal&#160;products&#160;that&#160;are&#160;eliminated&#160;by&#160;active&#160;tubular&#160;<br/>secretion&#160;may&#160;increase&#160;concentrations of&#160;emtricitabine,&#160;and/or&#160;the co-administered&#160;medicinal&#160;product.&#160;&#160;<br/>Medicinal&#160;products&#160;that&#160;decrease renal&#160;function&#160;may&#160;increase&#160;concentrations of&#160;emtricitabine.&#160;<br/>&#160;<br/>Tenofovir&#160;alafenamide&#160;<br/>&#160;<br/>Tenofovir&#160;alafenamide is transported by P-glycoprotein (P-gp)&#160;and&#160;breast&#160;cancer&#160;resistance&#160;protein&#160;<br/>(BCRP).&#160;&#160;Co-administration of&#160;Biktarvy&#160;with&#160;medicinal&#160;products&#160;that&#160;strongly&#160;affect&#160;P-gp&#160;and BCRP&#160;</p>
</div>
<!-- Page 7 -->
<a name="7"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft716{font-size:10px;font-family:TimesNewRomanPS;color:#000000;}
	.ft717{font-size:15px;font-family:TimesNewRomanPS;color:#000000;}
	.ft718{font-size:15px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft719{font-size:15px;font-family:TimesNewRomanPS;color:#000000;}
	.ft720{font-size:10px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft721{font-size:15px;line-height:17px;font-family:TimesNewRomanPS;color:#000000;}
	.ft722{font-size:15px;line-height:17px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft723{font-size:15px;line-height:18px;font-family:TimesNewRomanPS;color:#000000;}
	.ft724{font-size:15px;line-height:14px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft725{font-size:15px;line-height:20px;font-family:TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page7-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft70">&#160;</p>
<p style="position:absolute;top:1197px;left:430px;white-space:nowrap" class="ft71">7&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft74">activity&#160;may&#160;lead to&#160;changes in&#160;tenofovir&#160;alafenamide&#160;absorption.&#160;&#160;Medicinal&#160;products&#160;that&#160;induce&#160;<br/>P-gp activity&#160;(e.g.&#160;rifabutin,&#160;carbamazepine, phenobarbital)&#160;are expected&#160;to decrease the&#160;absorption&#160;of&#160;<br/>tenofovir&#160;alafenamide,&#160;resulting&#160;in decreased&#160;plasma concentration of&#160;tenofovir&#160;alafenamide, which&#160;<br/>may&#160;lead to&#160;loss of&#160;therapeutic effect&#160;of&#160;Biktarvy&#160;and&#160;development&#160;of&#160;resistance.&#160;&#160;Co-administration of&#160;<br/>Biktarvy&#160;with&#160;other&#160;medicinal&#160;products&#160;that&#160;inhibit&#160;P-gp&#160;and BCRP&#160;may&#160;increase&#160;the absorption&#160;and&#160;<br/>plasma&#160;concentration of&#160;tenofovir&#160;alafenamide.&#160;<br/>&#160;<br/>Tenofovir&#160;alafenamide&#160;is&#160;not&#160;an&#160;inhibitor&#160;or&#160;inducer&#160;of&#160;CYP3A<i>&#160;in&#160;vivo</i>.&#160;<br/>&#160;<br/>Other&#160;interactions&#160;<br/>&#160;<br/>Interactions&#160;between&#160;Biktarvy&#160;or&#160;its individual&#160;component(s)&#160;and co-administered&#160;medicinal&#160;products&#160;<br/>are&#160;listed in Table&#160;1 below&#160;(increase&#160;is&#160;indicated&#160;as&#160;“↑”, decrease as&#160;“↓”&#160;and no&#160;change&#160;as “↔”;&#160;all&#160;No&#160;<br/>Effect&#160;Boundaries are 70%-143%).&#160;&#160;<br/>&#160;<br/><b>Table&#160;1:&#160;Interactions between&#160;Biktarvy&#160;or its&#160;individual&#160;component(s)&#160;and&#160;other medicinal&#160;<br/>products&#160;<br/>&#160;</b></p>
<p style="position:absolute;top:431px;left:151px;white-space:nowrap" class="ft714"><b>Medicinal product&#160;by&#160;</b></p>
<p style="position:absolute;top:449px;left:136px;white-space:nowrap" class="ft714"><b>therapeutic&#160;areas/possible&#160;</b></p>
<p style="position:absolute;top:466px;left:138px;white-space:nowrap" class="ft714"><b>mechanism&#160;of&#160;interaction&#160;</b></p>
<p style="position:absolute;top:431px;left:354px;white-space:nowrap" class="ft714"><b>Effects&#160;on medicinal product&#160;</b></p>
<p style="position:absolute;top:449px;left:427px;white-space:nowrap" class="ft714"><b>levels.&#160;</b></p>
<p style="position:absolute;top:466px;left:350px;white-space:nowrap" class="ft714"><b>Mean percent&#160;change&#160;in AUC,&#160;</b></p>
<p style="position:absolute;top:483px;left:415px;white-space:nowrap" class="ft714"><b>Cmax,&#160;Cmin&#160;</b></p>
<p style="position:absolute;top:431px;left:580px;white-space:nowrap" class="ft714"><b>Recommendation concerning&#160;</b></p>
<p style="position:absolute;top:449px;left:570px;white-space:nowrap" class="ft714"><b>co-administration with&#160;Biktarvy&#160;</b></p>
<p style="position:absolute;top:501px;left:115px;white-space:nowrap" class="ft722"><i><b>HERBAL&#160;PRODUCTS</b></i><b>&#160;<br/></b>St.&#160;John’s&#160;wort (<i>Hypericum&#160;<br/>perforatum</i>)&#160;<br/>&#160;<br/>(Induction&#160;of&#160;CYP3A,&#160;UGT1A1,&#160;<br/>and&#160;P-gp)<b>&#160;</b></p>
<p style="position:absolute;top:519px;left:341px;white-space:nowrap" class="ft722">Interaction&#160;not studied&#160;with&#160;any&#160;of&#160;<br/>the&#160;components&#160;of&#160;Biktarvy.&#160;<br/>Co-administration&#160;may&#160;decrease&#160;<br/>bictegravir&#160;and&#160;tenofovir&#160;<br/>alafenamide&#160;plasma&#160;<br/>concentrations.<b>&#160;</b></p>
<p style="position:absolute;top:519px;left:568px;white-space:nowrap" class="ft722">Co-administration&#160;with&#160;St.&#160;John’s&#160;<br/>wort is contraindicated,&#160;due&#160;to&#160;the&#160;<br/>effect of&#160;St.&#160;John’s&#160;wort on&#160;the&#160;<br/>bictegravir&#160;component of&#160;<br/>Biktarvy.<b>&#160;</b></p>
<p style="position:absolute;top:623px;left:115px;white-space:nowrap" class="ft722"><i><b>ANTI-INFECTIVES&#160;<br/></b></i><b>Antimycobacterials&#160;<br/></b>Rifampicin&#160;(600&#160;mg&#160;once&#160;daily),&#160;&#160;<br/>Bictegravir1&#160;<br/>&#160;<br/>(Induction&#160;of&#160;CYP3A,&#160;UGT1A1,&#160;<br/>and&#160;P-gp)&#160;</p>
<p style="position:absolute;top:659px;left:341px;white-space:nowrap" class="ft722">Bictegravir:&#160;<br/>AUC:&#160;↓&#160;75%&#160;<br/>Cmax:&#160;↓&#160;28%&#160;<br/>&#160;<br/>Interaction&#160;not studied&#160;with&#160;<br/>tenofovir&#160;alafenamide.&#160;&#160;&#160;<br/>Co-administration&#160;of&#160;rifampicin&#160;<br/>may&#160;decrease&#160;tenofovir&#160;<br/>alafenamide&#160;plasma&#160;<br/>concentrations.&#160;</p>
<p style="position:absolute;top:659px;left:569px;white-space:nowrap" class="ft722">Co-administration&#160;is&#160;<br/>contraindicated&#160;due&#160;to&#160;the&#160;effect&#160;<br/>of&#160;rifampicin&#160;on&#160;the&#160;bictegravir&#160;<br/>component of&#160;Biktarvy.&#160;</p>
<p style="position:absolute;top:832px;left:115px;white-space:nowrap" class="ft722">Rifabutin&#160;(300&#160;mg&#160;once&#160;daily),&#160;&#160;<br/>Bictegravir1&#160;<br/>&#160;<br/>(Induction&#160;of&#160;CYP3A&#160;and&#160;P-gp)&#160;</p>
<p style="position:absolute;top:832px;left:341px;white-space:nowrap" class="ft722">Bictegravir:&#160;<br/>AUC:&#160;↓&#160;38%&#160;<br/>Cmin:&#160;↓&#160;56%&#160;<br/>Cmax:&#160;↓&#160;20%&#160;<br/>&#160;<br/>Interaction&#160;not studied&#160;with&#160;<br/>tenofovir&#160;alafenamide.&#160;<br/>Co-administration&#160;of&#160;rifabutin&#160;may&#160;<br/>decrease&#160;tenofovir&#160;alafenamide&#160;<br/>plasma&#160;concentrations.&#160;</p>
<p style="position:absolute;top:832px;left:569px;white-space:nowrap" class="ft722">Co-administration&#160;is&#160;not&#160;<br/>recommended&#160;due&#160;to&#160;the&#160;expected&#160;<br/>decrease&#160;of&#160;tenofovir&#160;alafenamide.&#160;</p>
</div>
<!-- Page 8 -->
<a name="8"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page8-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft80">&#160;</p>
<p style="position:absolute;top:1197px;left:430px;white-space:nowrap" class="ft81">8&#160;</p>
<p style="position:absolute;top:90px;left:151px;white-space:nowrap" class="ft814"><b>Medicinal product&#160;by&#160;</b></p>
<p style="position:absolute;top:107px;left:136px;white-space:nowrap" class="ft814"><b>therapeutic&#160;areas/possible&#160;</b></p>
<p style="position:absolute;top:124px;left:138px;white-space:nowrap" class="ft814"><b>mechanism&#160;of&#160;interaction&#160;</b></p>
<p style="position:absolute;top:90px;left:354px;white-space:nowrap" class="ft814"><b>Effects&#160;on medicinal product&#160;</b></p>
<p style="position:absolute;top:107px;left:427px;white-space:nowrap" class="ft814"><b>levels.&#160;</b></p>
<p style="position:absolute;top:124px;left:350px;white-space:nowrap" class="ft814"><b>Mean percent&#160;change&#160;in AUC,&#160;</b></p>
<p style="position:absolute;top:141px;left:415px;white-space:nowrap" class="ft814"><b>Cmax,&#160;Cmin&#160;</b></p>
<p style="position:absolute;top:90px;left:580px;white-space:nowrap" class="ft814"><b>Recommendation concerning&#160;</b></p>
<p style="position:absolute;top:107px;left:570px;white-space:nowrap" class="ft814"><b>co-administration with&#160;Biktarvy&#160;</b></p>
<p style="position:absolute;top:159px;left:115px;white-space:nowrap" class="ft822">Rifapentine&#160;<br/>&#160;<br/>(Induction&#160;of&#160;CYP3A&#160;and&#160;P-gp)<b>&#160;</b></p>
<p style="position:absolute;top:159px;left:341px;white-space:nowrap" class="ft822">Interaction&#160;not studied&#160;with&#160;any&#160;of&#160;<br/>the&#160;components&#160;of&#160;Biktarvy.&#160;<br/>Co-administration&#160;of&#160;rifapentine&#160;<br/>may&#160;decrease&#160;bictegravir&#160;and&#160;<br/>tenofovir&#160;alafenamide&#160;plasma&#160;<br/>concentrations.&#160;</p>
<p style="position:absolute;top:159px;left:569px;white-space:nowrap" class="ft822">Co-administration&#160;is&#160;not&#160;<br/>recommended.&#160;</p>
<p style="position:absolute;top:264px;left:115px;white-space:nowrap" class="ft822"><b>HIV-1&#160;antiviral&#160;agents&#160;<br/></b>Atazanavir&#160;(300&#160;mg&#160;once&#160;daily),&#160;<br/>Cobicistat&#160;(150&#160;mg&#160;once&#160;daily),&#160;<br/>Bictegravir1&#160;<br/>&#160;<br/>(Inhibition&#160;of&#160;CYP3A,&#160;UGT1A1,&#160;<br/>and&#160;P-gp/BCRP)&#160;</p>
<p style="position:absolute;top:282px;left:341px;white-space:nowrap" class="ft825">Bictegravir:&#160;<br/>AUC:&#160;↑&#160;306%&#160;<br/>Cmax:&#160;↔&#160;</p>
<p style="position:absolute;top:282px;left:569px;white-space:nowrap" class="ft822">Co-administration&#160;is&#160;not&#160;<br/>recommended.&#160;</p>
<p style="position:absolute;top:386px;left:115px;white-space:nowrap" class="ft822">Atazanavir&#160;(400&#160;mg&#160;once&#160;daily),&#160;<br/>Bictegravir1&#160;<br/>&#160;<br/>(Inhibition&#160;of&#160;CYP3A&#160;and&#160;<br/>UGT1A1)<b>&#160;</b></p>
<p style="position:absolute;top:386px;left:341px;white-space:nowrap" class="ft825">Bictegravir:&#160;<br/>AUC:&#160;↑&#160;315%&#160;<br/>Cmax:&#160;↔<b>&#160;</b></p>
<p style="position:absolute;top:473px;left:115px;white-space:nowrap" class="ft822"><b>Hepatitis&#160;C&#160;virus&#160;antiviral&#160;agents&#160;<br/></b>Ledipasvir/Sofosbuvir&#160;<br/>(90&#160;mg/400&#160;mg&#160;once&#160;daily),&#160;<br/>Bictegravir/Emtricitabine/&#160;<br/>Tenofovir&#160;alafenamide2&#160;</p>
<p style="position:absolute;top:491px;left:341px;white-space:nowrap" class="ft822">Bictegravir:&#160;<br/>AUC:&#160;↔&#160;<br/>Cmin:&#160;↔&#160;<br/>Cmax:&#160;↔&#160;<br/>&#160;<br/>Emtricitabine:&#160;<br/>AUC:&#160;↔&#160;<br/>Cmin:&#160;↔&#160;<br/>Cmax:&#160;↔&#160;<br/>&#160;<br/>Tenofovir&#160;alafenamide:&#160;<br/>AUC:&#160;↔&#160;<br/>Cmax:&#160;↔&#160;<br/>&#160;<br/>Ledipasvir:&#160;<br/>AUC:&#160;↔&#160;<br/>Cmin:&#160;↔&#160;<br/>Cmax:&#160;↔&#160;<br/>&#160;<br/>Sofosbuvir:&#160;<br/>AUC:&#160;↔&#160;<br/>Cmax:&#160;↔&#160;<br/>&#160;<br/>Sofosbuvir&#160;metabolite GS-331007:&#160;<br/>AUC:&#160;↔&#160;<br/>Cmin:&#160;↔&#160;<br/>Cmax:&#160;↔&#160;</p>
<p style="position:absolute;top:491px;left:569px;white-space:nowrap" class="ft822">No&#160;dose&#160;adjustment is required&#160;<br/>upon&#160;co-administration.&#160;</p>
</div>
<!-- Page 9 -->
<a name="9"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft926{font-size:15px;line-height:13px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft927{font-size:15px;line-height:18px;font-family:TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page9-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft90">&#160;</p>
<p style="position:absolute;top:1197px;left:430px;white-space:nowrap" class="ft91">9&#160;</p>
<p style="position:absolute;top:90px;left:151px;white-space:nowrap" class="ft914"><b>Medicinal product&#160;by&#160;</b></p>
<p style="position:absolute;top:107px;left:136px;white-space:nowrap" class="ft914"><b>therapeutic&#160;areas/possible&#160;</b></p>
<p style="position:absolute;top:124px;left:138px;white-space:nowrap" class="ft914"><b>mechanism&#160;of&#160;interaction&#160;</b></p>
<p style="position:absolute;top:90px;left:354px;white-space:nowrap" class="ft914"><b>Effects&#160;on medicinal product&#160;</b></p>
<p style="position:absolute;top:107px;left:427px;white-space:nowrap" class="ft914"><b>levels.&#160;</b></p>
<p style="position:absolute;top:124px;left:350px;white-space:nowrap" class="ft914"><b>Mean percent&#160;change&#160;in AUC,&#160;</b></p>
<p style="position:absolute;top:141px;left:415px;white-space:nowrap" class="ft914"><b>Cmax,&#160;Cmin&#160;</b></p>
<p style="position:absolute;top:90px;left:580px;white-space:nowrap" class="ft914"><b>Recommendation concerning&#160;</b></p>
<p style="position:absolute;top:107px;left:570px;white-space:nowrap" class="ft914"><b>co-administration with&#160;Biktarvy&#160;</b></p>
<p style="position:absolute;top:159px;left:115px;white-space:nowrap" class="ft922">Sofosbuvir/Velpatasvir/&#160;<br/>Voxilaprevir&#160;<br/>(400/100/100&#160;+&#160;100&#160;mg3&#160;once&#160;<br/>daily),&#160;Bictegravir/Emtricitabine/&#160;<br/>Tenofovir&#160;alafenamide&#160;<br/>&#160;<br/>(Inhibition&#160;of&#160;P-gp/BCRP)&#160;</p>
<p style="position:absolute;top:159px;left:341px;white-space:nowrap" class="ft922">Bictegravir:&#160;<br/>AUC:&#160;↔&#160;<br/>Cmin:&#160;↔&#160;<br/>Cmax:&#160;↔&#160;<br/>&#160;<br/>Emtricitabine:&#160;<br/>AUC:&#160;↔&#160;<br/>Cmin:&#160;↔&#160;<br/>Cmax:&#160;↔&#160;<br/>&#160;<br/>Tenofovir&#160;alafenamide:&#160;<br/>AUC:&#160;↑&#160;57%&#160;<br/>Cmax:&#160;↑&#160;28%&#160;<br/>&#160;<br/>Sofosbuvir:&#160;<br/>AUC:&#160;↔&#160;<br/>Cmax:&#160;↔&#160;<br/>&#160;<br/>Sofosbuvir&#160;metabolite GS-331007:&#160;<br/>AUC:&#160;↔&#160;<br/>Cmin:&#160;↔&#160;<br/>Cmax:&#160;↔&#160;<br/>&#160;<br/>Velpatasvir:&#160;<br/>AUC:&#160;↔&#160;<br/>Cmin:&#160;↔&#160;<br/>Cmax:&#160;↔&#160;<br/>&#160;<br/>Voxilaprevir:&#160;<br/>AUC:&#160;↔&#160;<br/>Cmin:&#160;↔&#160;<br/>Cmax:&#160;↔&#160;</p>
<p style="position:absolute;top:159px;left:569px;white-space:nowrap" class="ft922">No&#160;dose&#160;adjustment is required&#160;<br/>upon&#160;co-administration.&#160;</p>
<p style="position:absolute;top:712px;left:115px;white-space:nowrap" class="ft922"><b>Antifungals<i>&#160;<br/></i></b>Voriconazole&#160;(300&#160;mg&#160;twice&#160;<br/>daily),&#160;Bictegravir1&#160;<br/>&#160;<br/>(Inhibition&#160;of&#160;CYP3A)&#160;</p>
<p style="position:absolute;top:730px;left:341px;white-space:nowrap" class="ft925">Bictegravir:&#160;<br/>AUC:&#160;↑&#160;61%&#160;<br/>Cmax:&#160;↔<i><b>&#160;</b></i></p>
<p style="position:absolute;top:730px;left:569px;white-space:nowrap" class="ft922">No&#160;dose&#160;adjustment is required&#160;<br/>upon&#160;co-administration.<i><b>&#160;</b></i></p>
<p style="position:absolute;top:800px;left:115px;white-space:nowrap" class="ft922">Itraconazole&#160;<br/>Posaconazole&#160;&#160;<br/>&#160;<br/>(Inhibition&#160;of&#160;P-gp/BCRP)&#160;</p>
<p style="position:absolute;top:800px;left:341px;white-space:nowrap" class="ft922">Interaction&#160;not studied&#160;with&#160;any&#160;of&#160;<br/>the&#160;components&#160;of&#160;Biktarvy.&#160;&#160;<br/>Co-administration&#160;of&#160;itraconazole&#160;<br/>or&#160;posaconazole&#160;may&#160;increase&#160;<br/>bictegravir<b>&#160;</b>plasma&#160;concentrations.&#160;</p>
<p style="position:absolute;top:887px;left:115px;white-space:nowrap" class="ft922"><b>Macrolides</b>&#160;<br/>Azithromycin&#160;<br/>Clarithromycin&#160;<br/>&#160;<br/>(Inhibition&#160;of&#160;P-gp)&#160;</p>
<p style="position:absolute;top:905px;left:341px;white-space:nowrap" class="ft922">Interaction&#160;not studied.&#160;&#160;<br/>Co-administration&#160;of&#160;azithromycin&#160;<br/>or&#160;clarithromycin&#160;may&#160;increase&#160;<br/>bictegravir&#160;plasma&#160;concentrations.&#160;</p>
<p style="position:absolute;top:905px;left:569px;white-space:nowrap" class="ft922">Caution&#160;is&#160;recommended&#160;due&#160;to&#160;<br/>the&#160;potential effect&#160;of&#160;these&#160;<br/>medicinal&#160;products&#160;on&#160;the&#160;<br/>bictegravir&#160;component of&#160;<br/>Biktarvy.&#160;<br/>&#160;</p>
</div>
<!-- Page 10 -->
<a name="10"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page10-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft100">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft101">10&#160;</p>
<p style="position:absolute;top:90px;left:151px;white-space:nowrap" class="ft1014"><b>Medicinal product&#160;by&#160;</b></p>
<p style="position:absolute;top:107px;left:136px;white-space:nowrap" class="ft1014"><b>therapeutic&#160;areas/possible&#160;</b></p>
<p style="position:absolute;top:124px;left:138px;white-space:nowrap" class="ft1014"><b>mechanism&#160;of&#160;interaction&#160;</b></p>
<p style="position:absolute;top:90px;left:354px;white-space:nowrap" class="ft1014"><b>Effects&#160;on medicinal product&#160;</b></p>
<p style="position:absolute;top:107px;left:427px;white-space:nowrap" class="ft1014"><b>levels.&#160;</b></p>
<p style="position:absolute;top:124px;left:350px;white-space:nowrap" class="ft1014"><b>Mean percent&#160;change&#160;in AUC,&#160;</b></p>
<p style="position:absolute;top:141px;left:415px;white-space:nowrap" class="ft1014"><b>Cmax,&#160;Cmin&#160;</b></p>
<p style="position:absolute;top:90px;left:580px;white-space:nowrap" class="ft1014"><b>Recommendation concerning&#160;</b></p>
<p style="position:absolute;top:107px;left:570px;white-space:nowrap" class="ft1014"><b>co-administration with&#160;Biktarvy&#160;</b></p>
<p style="position:absolute;top:159px;left:115px;white-space:nowrap" class="ft1022"><i><b>ANTICONVULSANTS&#160;<br/></b></i>Carbamazepine&#160;(titrated&#160;from&#160;<br/>100&#160;mg&#160;to&#160;300&#160;mg&#160;twice&#160;a&#160;day),&#160;<br/>Emtricitabine/Tenofovir&#160;<br/>alafenamide4&#160;<br/>&#160;<br/>(Induction&#160;of&#160;CYP3A,&#160;UGT1A1,&#160;<br/>and&#160;P-gp)&#160;</p>
<p style="position:absolute;top:177px;left:341px;white-space:nowrap" class="ft1022">Tenofovir&#160;alafenamide:&#160;<br/>AUC:&#160;↓&#160;54%&#160;<br/>Cmax:&#160;↓&#160;57%&#160;<br/>&#160;<br/>Interaction&#160;not studied&#160;with&#160;<br/>bictegravir.&#160;&#160;<br/>Co-administration&#160;of&#160;<br/>carbamazepine&#160;may&#160;decrease&#160;<br/>bictegravir<b>&#160;</b>plasma&#160;concentrations.&#160;</p>
<p style="position:absolute;top:177px;left:569px;white-space:nowrap" class="ft1022">Co-administration&#160;is&#160;not&#160;<br/>recommended.&#160;</p>
<p style="position:absolute;top:333px;left:115px;white-space:nowrap" class="ft1022">Oxcarbazepine&#160;<br/>Phenobarbital&#160;<br/>Phenytoin&#160;<br/>&#160;<br/>(Induction&#160;of&#160;CYP3A,&#160;UGT1A1,&#160;<br/>and&#160;P-gp)&#160;</p>
<p style="position:absolute;top:333px;left:341px;white-space:nowrap" class="ft1022">Interaction&#160;not studied&#160;with&#160;any&#160;of&#160;<br/>the&#160;components&#160;of&#160;Biktarvy.&#160;<br/>Co-administration&#160;of&#160;<br/>oxcarbazepine,&#160;phenobarbital,&#160;or&#160;<br/>phenytoin&#160;may&#160;decrease&#160;<br/>bictegravir<b>&#160;</b>and&#160;tenofovir&#160;<br/>alafenamide&#160;plasma&#160;<br/>concentrations.&#160;</p>
<p style="position:absolute;top:333px;left:569px;white-space:nowrap" class="ft1022">Co-administration&#160;is&#160;not&#160;<br/>recommended.&#160;</p>
<p style="position:absolute;top:472px;left:115px;white-space:nowrap" class="ft1022"><i><b>ANTACIDS,&#160;SUPPLEMENTS AND&#160;BUFFERED&#160;MEDICINES&#160;<br/></b></i>Magnesium/aluminium-containing&#160;<br/>antacid&#160;suspension&#160;(20&#160;mL&#160;single&#160;<br/>dose5),&#160;Bictegravir&#160;<br/>&#160;<br/>(Chelation&#160;with&#160;polyvalent&#160;<br/>cations)&#160;</p>
<p style="position:absolute;top:490px;left:341px;white-space:nowrap" class="ft1025">Bictegravir&#160;(antacid&#160;suspension&#160;<br/>2&#160;hours&#160;prior,&#160;fasted):&#160;<br/>AUC:&#160;↓&#160;52%&#160;<br/>Cmax:&#160;↓&#160;58%&#160;<br/>&#160;<br/>Bictegravir&#160;(antacid&#160;suspension&#160;<br/>after&#160;2&#160;hours,&#160;fasted):&#160;<br/>AUC:&#160;↔&#160;<br/>Cmax:&#160;↔&#160;<br/>&#160;<br/>Bictegravir&#160;(simultaneous&#160;<br/>administration,&#160;fasted):&#160;<br/>AUC:&#160;↓&#160;79%&#160;<br/>Cmax:&#160;↓&#160;80%&#160;<br/>&#160;<br/>Bictegravir&#160;(simultaneous&#160;<br/>administration&#160;with&#160;food):&#160;<br/>AUC:&#160;↓&#160;47%&#160;<br/>Cmax:&#160;↓&#160;49%&#160;</p>
<p style="position:absolute;top:490px;left:569px;white-space:nowrap" class="ft1022">Biktarvy&#160;should&#160;not be&#160;taken&#160;<br/>simultaneously&#160;with&#160;supplements&#160;<br/>containing&#160;magnesium&#160;and/or&#160;<br/>aluminium&#160;due&#160;to&#160;the&#160;expected&#160;<br/>substantial decrease&#160;of&#160;bictegravir&#160;<br/>exposure&#160;(see&#160;section&#160;4.4).&#160;<br/>&#160;<br/>Biktarvy&#160;should&#160;be&#160;administered&#160;<br/>at&#160;least 2&#160;hours&#160;before,&#160;or&#160;with&#160;<br/>food&#160;2&#160;hours&#160;after&#160;antacids&#160;<br/>containing&#160;magnesium&#160;and/or&#160;<br/>aluminium.&#160;</p>
<p style="position:absolute;top:819px;left:115px;white-space:nowrap" class="ft1022">Ferrous&#160;fumarate&#160;(324&#160;mg&#160;single&#160;<br/>dose),&#160;Bictegravir&#160;<br/>&#160;<br/>(Chelation&#160;with&#160;polyvalent&#160;<br/>cations)&#160;</p>
<p style="position:absolute;top:819px;left:341px;white-space:nowrap" class="ft1022">Bictegravir&#160;(simultaneous&#160;<br/>administration,&#160;fasted):&#160;<br/>AUC:&#160;↓&#160;63%&#160;<br/>Cmax:&#160;↓&#160;71%&#160;<br/>&#160;<br/>Bictegravir&#160;(simultaneous&#160;<br/>administration&#160;with&#160;food):&#160;<br/>AUC:&#160;↔&#160;<br/>Cmax:&#160;↓&#160;25%&#160;</p>
<p style="position:absolute;top:819px;left:569px;white-space:nowrap" class="ft1022">Biktarvy&#160;should&#160;be&#160;administered&#160;<br/>at&#160;least 2&#160;hours&#160;before&#160;iron&#160;<br/>supplements,&#160;or&#160;taken&#160;together&#160;<br/>with&#160;food.&#160;</p>
<p style="position:absolute;top:975px;left:115px;white-space:nowrap" class="ft1022">Calcium&#160;carbonate&#160;(1,200&#160;mg&#160;<br/>single&#160;dose),&#160;Bictegravir&#160;<br/>&#160;<br/>(Chelation&#160;with&#160;polyvalent&#160;<br/>cations)&#160;</p>
<p style="position:absolute;top:975px;left:341px;white-space:nowrap" class="ft1022">Bictegravir&#160;(simultaneous&#160;<br/>administration,&#160;fasted):&#160;<br/>AUC:&#160;↓&#160;33%&#160;<br/>Cmax:&#160;↓&#160;42%&#160;<br/>&#160;<br/>Bictegravir&#160;(simultaneous&#160;<br/>administration&#160;with&#160;food):&#160;<br/>AUC:&#160;↔&#160;<br/>Cmax:&#160;↔&#160;</p>
<p style="position:absolute;top:975px;left:569px;white-space:nowrap" class="ft1022">Biktarvy&#160;and&#160;calcium-containing&#160;<br/>supplements&#160;can&#160;be&#160;taken&#160;<br/>together,&#160;without regard&#160;to&#160;food.&#160;</p>
</div>
<!-- Page 11 -->
<a name="11"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page11-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft110">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft111">11&#160;</p>
<p style="position:absolute;top:90px;left:151px;white-space:nowrap" class="ft1114"><b>Medicinal product&#160;by&#160;</b></p>
<p style="position:absolute;top:107px;left:136px;white-space:nowrap" class="ft1114"><b>therapeutic&#160;areas/possible&#160;</b></p>
<p style="position:absolute;top:124px;left:138px;white-space:nowrap" class="ft1114"><b>mechanism&#160;of&#160;interaction&#160;</b></p>
<p style="position:absolute;top:90px;left:354px;white-space:nowrap" class="ft1114"><b>Effects&#160;on medicinal product&#160;</b></p>
<p style="position:absolute;top:107px;left:427px;white-space:nowrap" class="ft1114"><b>levels.&#160;</b></p>
<p style="position:absolute;top:124px;left:350px;white-space:nowrap" class="ft1114"><b>Mean percent&#160;change&#160;in AUC,&#160;</b></p>
<p style="position:absolute;top:141px;left:415px;white-space:nowrap" class="ft1114"><b>Cmax,&#160;Cmin&#160;</b></p>
<p style="position:absolute;top:90px;left:580px;white-space:nowrap" class="ft1114"><b>Recommendation concerning&#160;</b></p>
<p style="position:absolute;top:107px;left:570px;white-space:nowrap" class="ft1114"><b>co-administration with&#160;Biktarvy&#160;</b></p>
<p style="position:absolute;top:159px;left:115px;white-space:nowrap" class="ft1122">Sucralfate&#160;<br/>&#160;<br/>(Chelation&#160;with&#160;polyvalent&#160;<br/>cations)&#160;</p>
<p style="position:absolute;top:159px;left:341px;white-space:nowrap" class="ft1122">Interaction&#160;not studied&#160;with&#160;any&#160;of&#160;<br/>the&#160;components&#160;of&#160;Biktarvy.&#160;<br/>Co-administration&#160;may&#160;decrease&#160;<br/>bictegravir&#160;plasma&#160;concentrations.&#160;</p>
<p style="position:absolute;top:159px;left:569px;white-space:nowrap" class="ft1122">Co-administration&#160;not&#160;<br/>recommended.&#160;</p>
<p style="position:absolute;top:229px;left:115px;white-space:nowrap" class="ft1122"><i><b>ANTIDEPRESSANTS</b></i>&#160;<br/>Sertraline&#160;(50&#160;mg&#160;single&#160;dose),&#160;<br/>Tenofovir&#160;alafenamide6&#160;</p>
<p style="position:absolute;top:247px;left:341px;white-space:nowrap" class="ft1122">Tenofovir&#160;alafenamide:&#160;<br/>AUC:&#160;↔&#160;<br/>Cmax: ↔&#160;<br/>&#160;<br/>Sertraline:&#160;<br/>AUC:&#160;↔&#160;<br/>Cmax: ↔&#160;<br/>&#160;<br/>No&#160;interaction&#160;is&#160;expected&#160;with&#160;<br/>bictegravir&#160;and&#160;emtricitabine.&#160;</p>
<p style="position:absolute;top:247px;left:569px;white-space:nowrap" class="ft1122">No&#160;dose&#160;adjustment is required&#160;<br/>upon&#160;co-administration.&#160;</p>
<p style="position:absolute;top:420px;left:115px;white-space:nowrap" class="ft1122"><i><b>IMMUNOSUPPRESSANTS</b></i>&#160;<br/>Ciclosporin&#160;(IV&#160;or&#160;oral&#160;use)&#160;<br/>&#160;<br/>(P-gp&#160;inhibition)&#160;</p>
<p style="position:absolute;top:438px;left:341px;white-space:nowrap" class="ft1122">Interaction&#160;not studied&#160;with&#160;any&#160;of&#160;<br/>the&#160;components&#160;of&#160;Biktarvy.&#160;&#160;<br/>Co-administration&#160;of&#160;ciclosporin&#160;<br/>(IV&#160;or&#160;oral&#160;use)&#160;is&#160;expected&#160;to&#160;<br/>increase&#160;plasma&#160;concentrations&#160;of&#160;<br/>both&#160;bictegravir&#160;and&#160;tenofovir&#160;<br/>alafenamide.&#160;</p>
<p style="position:absolute;top:438px;left:569px;white-space:nowrap" class="ft1122">Co-administration&#160;of&#160;ciclosporin&#160;<br/>(IV&#160;or&#160;oral&#160;use)&#160;is&#160;not&#160;<br/>recommended.&#160;&#160;If&#160;the&#160;combination&#160;<br/>is&#160;needed,&#160;clinical&#160;and&#160;biological&#160;<br/>monitoring,&#160;notably&#160;renal&#160;<br/>function,&#160;is&#160;recommended.&#160;</p>
<p style="position:absolute;top:560px;left:115px;white-space:nowrap" class="ft1122"><i><b>ORAL&#160;ANTI-DIABETICS&#160;<br/></b></i>Metformin&#160;(500&#160;mg&#160;twice&#160;daily),&#160;<br/>Bictegravir/Emtricitabine/&#160;<br/>Tenofovir&#160;alafenamide&#160;<br/>&#160;<br/>(Inhibition&#160;of&#160;OCT2/MATE1)<b>&#160;</b></p>
<p style="position:absolute;top:578px;left:341px;white-space:nowrap" class="ft1122">Metformin:&#160;<br/>AUC:&#160;↑&#160;39%&#160;<br/>Cmin:&#160;↑&#160;36%&#160;<br/>Cmax:&#160;↔&#160;</p>
<p style="position:absolute;top:578px;left:569px;white-space:nowrap" class="ft1122">No&#160;dose&#160;adjustment is required&#160;<br/>upon&#160;co-administration</p>
<p style="position:absolute;top:594px;left:709px;white-space:nowrap" class="ft112"><b>&#160;</b>in&#160;patients&#160;</p>
<p style="position:absolute;top:612px;left:569px;white-space:nowrap" class="ft1122">with&#160;normal&#160;renal&#160;function.&#160;<br/>&#160;<br/>In&#160;patients&#160;with&#160;moderate&#160;renal&#160;<br/>impairment,&#160;close&#160;monitoring&#160;<br/>should&#160;be&#160;considered&#160;when&#160;<br/>starting&#160;co-administration&#160;of&#160;<br/>bictegravir&#160;with&#160;metformin,&#160;due&#160;to&#160;<br/>the&#160;increased&#160;risk&#160;for&#160;lactic&#160;<br/>acidosis&#160;in&#160;these&#160;patients.</p>
<p style="position:absolute;top:749px;left:721px;white-space:nowrap" class="ft110">&#160;&#160;A&#160;dose&#160;</p>
<p style="position:absolute;top:768px;left:569px;white-space:nowrap" class="ft1122">adjustment of&#160;metformin&#160;should&#160;<br/>be&#160;considered&#160;if&#160;required.<i><b>&#160;</b></i></p>
<p style="position:absolute;top:803px;left:115px;white-space:nowrap" class="ft1122"><i><b>ORAL&#160;CONTRACEPTIVES&#160;<br/></b></i>Norgestimate&#160;<br/>(0.180/0.215/0.250&#160;mg&#160;once&#160;<br/>daily)/ Ethinylestradiol&#160;(0.025&#160;mg&#160;<br/>once&#160;daily),&#160;Bictegravir1&#160;</p>
<p style="position:absolute;top:821px;left:341px;white-space:nowrap" class="ft1122">Norelgestromin:&#160;<br/>AUC:&#160;↔&#160;<br/>Cmin: ↔&#160;<br/>Cmax: ↔&#160;<br/>&#160;<br/>Norgestrel:&#160;<br/>AUC:&#160;↔&#160;<br/>Cmin: ↔&#160;<br/>Cmax: ↔&#160;<br/>&#160;<br/>Ethinylestradiol:&#160;<br/>AUC:&#160;↔&#160;<br/>Cmin: ↔&#160;<br/>Cmax: ↔&#160;</p>
<p style="position:absolute;top:821px;left:569px;white-space:nowrap" class="ft1122">No&#160;dose&#160;adjustment is required&#160;<br/>upon&#160;co-administration.&#160;</p>
<p style="position:absolute;top:891px;left:115px;white-space:nowrap" class="ft1122">Norgestimate&#160;<br/>(0.180/0.215/0.250&#160;mg&#160;once&#160;<br/>daily),&#160;Ethinylestradiol (0.025&#160;mg&#160;<br/>once&#160;daily),&#160;<br/>Emtricitabine/Tenofovir&#160;<br/>alafenamide4&#160;</p>
</div>
<!-- Page 12 -->
<a name="12"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft1228{font-size:14px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft1229{font-size:14px;font-family:TimesNewRomanPS;color:#000000;}
	.ft1230{font-size:14px;line-height:15px;font-family:TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page12-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft120">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft121">12&#160;</p>
<p style="position:absolute;top:90px;left:151px;white-space:nowrap" class="ft1214"><b>Medicinal product&#160;by&#160;</b></p>
<p style="position:absolute;top:107px;left:136px;white-space:nowrap" class="ft1214"><b>therapeutic&#160;areas/possible&#160;</b></p>
<p style="position:absolute;top:124px;left:138px;white-space:nowrap" class="ft1214"><b>mechanism&#160;of&#160;interaction&#160;</b></p>
<p style="position:absolute;top:90px;left:354px;white-space:nowrap" class="ft1214"><b>Effects&#160;on medicinal product&#160;</b></p>
<p style="position:absolute;top:107px;left:427px;white-space:nowrap" class="ft1214"><b>levels.&#160;</b></p>
<p style="position:absolute;top:124px;left:350px;white-space:nowrap" class="ft1214"><b>Mean percent&#160;change&#160;in AUC,&#160;</b></p>
<p style="position:absolute;top:141px;left:415px;white-space:nowrap" class="ft1214"><b>Cmax,&#160;Cmin&#160;</b></p>
<p style="position:absolute;top:90px;left:580px;white-space:nowrap" class="ft1214"><b>Recommendation concerning&#160;</b></p>
<p style="position:absolute;top:107px;left:570px;white-space:nowrap" class="ft1214"><b>co-administration with&#160;Biktarvy&#160;</b></p>
<p style="position:absolute;top:159px;left:115px;white-space:nowrap" class="ft1222"><i><b>SEDATIVES/HYPNOTICS</b></i>&#160;<br/>Midazolam&#160;(2&#160;mg,&#160;oral&#160;syrup,&#160;<br/>single&#160;dose),&#160;<br/>Bictegravir/Emtricitabine/&#160;<br/>Tenofovir&#160;alafenamide&#160;</p>
<p style="position:absolute;top:177px;left:341px;white-space:nowrap" class="ft1222">Midazolam:&#160;<br/>AUC:&#160;↔&#160;<br/>Cmax:&#160;↔&#160;</p>
<p style="position:absolute;top:177px;left:569px;white-space:nowrap" class="ft1222">No&#160;dose&#160;adjustment is required&#160;<br/>upon&#160;co-administration.&#160;</p>
<p style="position:absolute;top:247px;left:106px;white-space:nowrap" class="ft1230">1&#160;&#160;This study&#160;was conducted&#160;using<b>&#160;</b>bictegravir&#160;75&#160;mg&#160;single dose.&#160;<br/>2&#160;&#160;This study&#160;was conducted&#160;using&#160;bictegravir/emtricitabine/tenofovir&#160;alafenamide&#160;75/200/25&#160;mg&#160;once&#160;daily.&#160;<br/>3&#160;&#160;Study&#160;conducted&#160;with&#160;additional&#160;voxilaprevir&#160;100&#160;mg&#160;to&#160;achieve&#160;voxilaprevir&#160;exposures expected&#160;in&#160;HCV&#160;infected&#160;</p>
<p style="position:absolute;top:293px;left:128px;white-space:nowrap" class="ft1228">patients.&#160;</p>
<p style="position:absolute;top:309px;left:106px;white-space:nowrap" class="ft1230">4&#160;&#160;This study&#160;was&#160;conducted&#160;using&#160;emtricitabine/tenofovir&#160;alafenamide&#160;200/25&#160;mg&#160;once&#160;daily.&#160;<br/>5&#160;&#160;Maximum&#160;strength&#160;antacid&#160;contained&#160;80&#160;mg&#160;aluminium&#160;hydroxide,&#160;80&#160;mg&#160;magnesium&#160;hydroxide,&#160;and&#160;8&#160;mg&#160;</p>
<p style="position:absolute;top:340px;left:128px;white-space:nowrap" class="ft1228">simethicone&#160;per&#160;mL.&#160;</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft1228">6&#160;&#160;This study&#160;was conducted&#160;using&#160;elvitegravir/cobicistat/emtricitabine/tenofovir&#160;alafenamide&#160;150/150/200/10&#160;mg&#160;once&#160;</p>
<p style="position:absolute;top:371px;left:128px;white-space:nowrap" class="ft1228">daily.&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft120">&#160;</p>
<p style="position:absolute;top:411px;left:106px;white-space:nowrap" class="ft128">Based on&#160;drug&#160;interaction studies&#160;conducted with&#160;Biktarvy&#160;or&#160;the components of&#160;Biktarvy,&#160;no&#160;<br/>clinically significant&#160;drug&#160;interactions are expected with:&#160;amlodipine,&#160;atorvastatin,&#160;buprenorphine,&#160;<br/>drospirenone,&#160;famciclovir,&#160;famotidine,&#160;fluticasone,&#160;methadone,&#160;naloxone,&#160;norbuprenorphine,&#160;<br/>omeprazole&#160;or&#160;rosuvastatin.&#160;</p>
<p style="position:absolute;top:491px;left:106px;white-space:nowrap" class="ft124"><b>&#160;<br/>4.6&#160;</b></p>
<p style="position:absolute;top:510px;left:149px;white-space:nowrap" class="ft122"><b>Fertility, pregnancy and&#160;lactation&#160;</b></p>
<p style="position:absolute;top:529px;left:106px;white-space:nowrap" class="ft125">&#160;<br/>Pregnancy&#160;<br/>&#160;<br/>There&#160;are&#160;no or&#160;limited data&#160;(less&#160;than&#160;300&#160;pregnancy outcomes)&#160;from&#160;the use&#160;of&#160;bictegravir&#160;or&#160;<br/>tenofovir&#160;alafenamide&#160;in pregnant&#160;women.&#160;&#160;A&#160;large amount&#160;of&#160;data on pregnant&#160;women&#160;(more than&#160;<br/>1,000&#160;exposed&#160;outcomes)&#160;indicate&#160;no&#160;malformative nor&#160;foetal/neonatal&#160;toxicity associated with&#160;<br/>emtricitabine.&#160;<br/>&#160;<br/>Animal&#160;studies&#160;do not&#160;indicate direct&#160;or&#160;indirect&#160;harmful&#160;effects of&#160;emtricitabine&#160;with&#160;respect&#160;to&#160;<br/>fertility parameters, pregnancy, foetal&#160;development, parturition or&#160;postnatal&#160;development.&#160;&#160;Studies&#160;of&#160;<br/>bictegravir&#160;and tenofovir&#160;alafenamide,&#160;administered separately, in animals have shown no evidence&#160;of&#160;<br/>harmful&#160;effects on&#160;fertility&#160;parameters, pregnancy,&#160;or&#160;foetal&#160;development&#160;(see&#160;section&#160;5.3).&#160;<br/>&#160;<br/>Biktarvy&#160;should be&#160;used&#160;during&#160;pregnancy only if&#160;the potential&#160;benefit&#160;justifies&#160;the&#160;potential&#160;risk to&#160;<br/>the&#160;foetus.&#160;<br/>&#160;<br/>Breast-feeding&#160;<br/>&#160;<br/>It&#160;is not&#160;known whether&#160;bictegravir&#160;or&#160;tenofovir&#160;alafenamide&#160;is&#160;excreted in&#160;human&#160;milk.&#160;&#160;Emtricitabine&#160;<br/>is excreted in&#160;human&#160;milk.&#160;&#160;In animal&#160;studies,&#160;bictegravir&#160;was detected&#160;in&#160;the plasma of&#160;nursing&#160;rat&#160;<br/>pups likely due to the presence&#160;of&#160;bictegravir&#160;in&#160;milk,&#160;without&#160;effects on nursing&#160;pups.&#160;&#160;In animal&#160;<br/>studies&#160;it&#160;has&#160;been&#160;shown&#160;that&#160;tenofovir&#160;is excreted in&#160;milk.&#160;&#160;&#160;<br/>&#160;<br/>There&#160;is&#160;insufficient&#160;information on&#160;the&#160;effects of&#160;all&#160;the components&#160;of&#160;Biktarvy&#160;in newborns/infants,&#160;<br/>therefore&#160;Biktarvy&#160;should not&#160;be used&#160;during&#160;breast-feeding.&#160;<br/>&#160;<br/>In order&#160;to&#160;avoid&#160;transmission of&#160;HIV&#160;to&#160;the&#160;infant&#160;it&#160;is&#160;recommended that&#160;women&#160;living with HIV&#160;do&#160;<br/>not&#160;breast-feed their&#160;infants.&#160;<br/>&#160;<br/>Fertility&#160;<br/>&#160;<br/>No human data on&#160;the&#160;effect&#160;of&#160;Biktarvy&#160;on fertility are&#160;available.&#160;&#160;Animal&#160;studies&#160;indicate&#160;no&#160;effects&#160;<br/>of&#160;bictegravir,&#160;emtricitabine or&#160;tenofovir&#160;alafenamide&#160;on&#160;mating or&#160;fertility&#160;(see&#160;section&#160;5.3).&#160;<br/>&#160;</p>
</div>
<!-- Page 13 -->
<a name="13"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft1331{font-size:15px;line-height:18px;font-family:TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page13-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft130">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft131">13&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft132"><b>4.7&#160;</b></p>
<p style="position:absolute;top:89px;left:149px;white-space:nowrap" class="ft132"><b>Effects on&#160;ability&#160;to drive&#160;and&#160;use&#160;machines&#160;</b></p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft134">&#160;<br/>Biktarvy&#160;may&#160;have&#160;minor&#160;influence&#160;on the ability to drive and use machines.&#160;&#160;Patients&#160;should be&#160;<br/>informed&#160;that&#160;dizziness&#160;has&#160;been&#160;reported during&#160;treatment&#160;with&#160;the&#160;components&#160;of&#160;Biktarvy&#160;(see&#160;<br/>section&#160;4.8).&#160;&#160;<br/><b>&#160;<br/>4.8&#160;</b></p>
<p style="position:absolute;top:203px;left:149px;white-space:nowrap" class="ft132"><b>Undesirable&#160;effects&#160;</b></p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft135">&#160;<br/>Summary of&#160;the&#160;safety profile&#160;<br/>&#160;<br/>&#160;&#160;In clinical&#160;studies of&#160;treatment-naïve patients receiving&#160;Biktarvy, the&#160;most&#160;frequently reported&#160;<br/>adverse&#160;reactions&#160;in&#160;the double-blind phase&#160;(Week&#160;144)&#160;were headache&#160;(5%), diarrhoea&#160;(5%)&#160;and&#160;<br/>nausea&#160;(4%).&#160;<br/>&#160;<br/>Tabulated&#160;list&#160;of&#160;adverse&#160;reactions&#160;<br/>&#160;<br/>The assessment&#160;of&#160;adverse&#160;reactions&#160;is based&#160;on safety&#160;data&#160;from&#160;across&#160;all&#160;Phase&#160;2 and 3&#160;studies with&#160;<br/>Biktarvy<b>&#160;</b>and from&#160;post-marketing&#160;experience.&#160;&#160;The&#160;adverse reactions in Table&#160;2&#160;are listed by system&#160;<br/>organ&#160;class&#160;and frequency.&#160;&#160;Frequencies&#160;are defined&#160;as&#160;follows:&#160;common (≥&#160;1/100&#160;to &lt;&#160;1/10)&#160;<br/>uncommon (≥&#160;1/1.000&#160;to &lt;&#160;1/100)&#160;and&#160;rare&#160;(≥&#160;1/10.000&#160;to &lt;&#160;1/1.000).&#160;<br/>&#160;<br/><b>Table&#160;2:&#160;Tabulated&#160;list&#160;of&#160;adverse reactions</b>1&#160;<br/><b>&#160;</b></p>
<p style="position:absolute;top:526px;left:115px;white-space:nowrap" class="ft1314"><b>Frequency&#160;</b></p>
<p style="position:absolute;top:526px;left:285px;white-space:nowrap" class="ft1314"><b>Adverse&#160;reaction&#160;</b></p>
<p style="position:absolute;top:544px;left:115px;white-space:nowrap" class="ft1331"><i>Blood&#160;and&#160;lymphatic&#160;system&#160;disorders&#160;<br/></i>Uncommon:&#160;</p>
<p style="position:absolute;top:562px;left:285px;white-space:nowrap" class="ft1318">anaemia2&#160;</p>
<p style="position:absolute;top:580px;left:115px;white-space:nowrap" class="ft1331"><i>Psychiatric&#160;disorders&#160;<br/></i>Common:&#160;</p>
<p style="position:absolute;top:598px;left:285px;white-space:nowrap" class="ft1318">depression,&#160;abnormal&#160;dreams&#160;</p>
<p style="position:absolute;top:625px;left:115px;white-space:nowrap" class="ft1318">Uncommon:&#160;</p>
<p style="position:absolute;top:616px;left:285px;white-space:nowrap" class="ft1322">suicidal&#160;ideation,&#160;suicide&#160;attempt&#160;(particularly&#160;in&#160;patients&#160;with&#160;a&#160;pre-existing&#160;<br/>history&#160;of&#160;depression&#160;or&#160;psychiatric&#160;illness),&#160;anxiety,&#160;sleep&#160;disorders&#160;</p>
<p style="position:absolute;top:651px;left:115px;white-space:nowrap" class="ft1331"><i>Nervous&#160;system&#160;disorders&#160;<br/></i>Common:&#160;</p>
<p style="position:absolute;top:669px;left:285px;white-space:nowrap" class="ft1318">headache,&#160;dizziness&#160;</p>
<p style="position:absolute;top:687px;left:115px;white-space:nowrap" class="ft1331"><i>Gastrointestinal disorders&#160;<br/></i>Common:&#160;</p>
<p style="position:absolute;top:705px;left:285px;white-space:nowrap" class="ft1318">diarrhoea,&#160;nausea&#160;</p>
<p style="position:absolute;top:723px;left:115px;white-space:nowrap" class="ft1318">Uncommon:&#160;</p>
<p style="position:absolute;top:723px;left:285px;white-space:nowrap" class="ft1318">vomiting,&#160;abdominal&#160;pain,&#160;dyspepsia,&#160;flatulence&#160;</p>
<p style="position:absolute;top:741px;left:115px;white-space:nowrap" class="ft1327"><i>Hepatobiliary&#160;disorders</i>&#160;<br/>Uncommon:&#160;</p>
<p style="position:absolute;top:759px;left:285px;white-space:nowrap" class="ft1318">hyperbilirubinaemia&#160;</p>
<p style="position:absolute;top:777px;left:115px;white-space:nowrap" class="ft1331"><i>Skin&#160;and&#160;subcutaneous&#160;tissue&#160;disorders&#160;<br/></i>Uncommon:&#160;</p>
<p style="position:absolute;top:795px;left:285px;white-space:nowrap" class="ft1318">angioedema3,4,&#160;rash,&#160;pruritus,&#160;urticaria4&#160;</p>
<p style="position:absolute;top:813px;left:115px;white-space:nowrap" class="ft1318">Rare:&#160;</p>
<p style="position:absolute;top:813px;left:285px;white-space:nowrap" class="ft1318">Stevens-Johnson&#160;syndrome5&#160;</p>
<p style="position:absolute;top:831px;left:115px;white-space:nowrap" class="ft1331"><i>Musculoskeletal and&#160;connective&#160;tissue&#160;disorders&#160;<br/></i>Uncommon:&#160;</p>
<p style="position:absolute;top:849px;left:285px;white-space:nowrap" class="ft1318">arthralgia&#160;</p>
<p style="position:absolute;top:867px;left:115px;white-space:nowrap" class="ft1331"><i>General disorders&#160;and&#160;administration&#160;site&#160;conditions&#160;<br/></i>Common:&#160;</p>
<p style="position:absolute;top:885px;left:285px;white-space:nowrap" class="ft1318">fatigue&#160;</p>
<p style="position:absolute;top:903px;left:106px;white-space:nowrap" class="ft1328">1&#160;&#160;With&#160;the&#160;exception&#160;of&#160;angioedema,&#160;anaemia,&#160;urticaria&#160;and&#160;Stevens-Johnson&#160;syndrome&#160;(see&#160;footnotes&#160;2-5),&#160;all&#160;adverse&#160;</p>
<p style="position:absolute;top:918px;left:128px;white-space:nowrap" class="ft1330">reactions were&#160;identified&#160;from&#160;Biktarvy&#160;clinical&#160;studies.&#160;&#160;The&#160;frequencies&#160;were&#160;derived&#160;from&#160;the&#160;double-blind&#160;phase&#160;<br/>(Week&#160;144)&#160;of&#160;Phase&#160;3&#160;Biktarvy&#160;clinical&#160;studies&#160;in&#160;treatment-naïve&#160;patients (GS-US-380-1489&#160;and&#160;GS-US-380-1490).&#160;</p>
<p style="position:absolute;top:949px;left:106px;white-space:nowrap" class="ft1328">2&#160;&#160;This adverse&#160;reaction&#160;was not&#160;observed&#160;in&#160;the&#160;clinical&#160;studies&#160;of&#160;emtricitabine&#160;+&#160;tenofovir&#160;alafenamide-containing&#160;</p>
<p style="position:absolute;top:965px;left:128px;white-space:nowrap" class="ft1330">products but&#160;identified&#160;from&#160;clinical&#160;studies&#160;or&#160;post-marketing&#160;experience&#160;for&#160;emtricitabine&#160;when&#160;used&#160;with&#160;other&#160;<br/>antiretrovirals.&#160;</p>
<p style="position:absolute;top:996px;left:106px;white-space:nowrap" class="ft1330">3&#160;&#160;This&#160;adverse&#160;reaction&#160;was identified&#160;through&#160;post-marketing&#160;surveillance&#160;for&#160;emtricitabine-containing&#160;products.&#160;<br/>4&#160;&#160;This adverse&#160;reaction&#160;was identified&#160;through&#160;post-marketing&#160;surveillance&#160;for&#160;tenofovir&#160;alafenamide-containing&#160;products.&#160;<br/>5&#160;&#160;This adverse&#160;reaction&#160;was identified&#160;through&#160;post-marketing&#160;surveillance&#160;for&#160;Biktarvy.&#160;The&#160;frequency&#160;has been&#160;calculated&#160;</p>
<p style="position:absolute;top:1043px;left:128px;white-space:nowrap" class="ft1328">using&#160;3/X,&#160;where&#160;X represent&#160;the&#160;cumulative&#160;number&#160;of&#160;subjects exposed&#160;to&#160;Biktarvy&#160;in&#160;clinical&#160;trials (N=3963).&#160;</p>
<p style="position:absolute;top:1059px;left:106px;white-space:nowrap" class="ft135">&#160;<br/>Description&#160;of&#160;selected adverse&#160;reactions&#160;<br/>&#160;<br/><i>Metabolic&#160;parameters&#160;<br/></i>Weight&#160;and&#160;levels of&#160;blood&#160;lipids&#160;and glucose&#160;may&#160;increase&#160;during antiretroviral&#160;therapy&#160;(see&#160;<br/>section&#160;4.4).&#160;</p>
</div>
<!-- Page 14 -->
<a name="14"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft1432{font-size:12px;font-family:TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page14-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft140">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft141">14&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft145">&#160;<br/><i>Immune Reactivation&#160;Syndrome</i>&#160;<br/>In HIV&#160;infected patients with severe immune&#160;deficiency at&#160;the&#160;time&#160;of&#160;initiation of&#160;CART, an&#160;<br/>inflammatory&#160;reaction&#160;to asymptomatic or&#160;residual&#160;opportunistic infections&#160;may arise.&#160;&#160;Autoimmune&#160;<br/>disorders (such&#160;as&#160;Graves’&#160;disease&#160;and autoimmune hepatitis)&#160;have&#160;also been reported;&#160;however, the&#160;<br/>reported time to onset&#160;is&#160;more variable and these&#160;events can occur&#160;many&#160;months&#160;after&#160;initiation of&#160;<br/>treatment&#160;(see&#160;section&#160;4.4).&#160;<br/>&#160;<br/><i>Osteonecrosis</i>&#160;<br/>Cases&#160;of&#160;osteonecrosis have been&#160;reported, particularly in patients with generally&#160;acknowledged risk&#160;<br/>factors, advanced HIV&#160;disease or&#160;long-term&#160;exposure&#160;to&#160;CART.&#160;&#160;The frequency of&#160;this is unknown&#160;<br/>(see&#160;section&#160;4.4).&#160;<br/>&#160;<br/><i>Changes&#160;in&#160;serum&#160;creatinine&#160;<br/></i>Bictegravir&#160;has been shown&#160;to increase serum&#160;creatinine due&#160;to inhibition&#160;of&#160;tubular&#160;secretion of&#160;<br/>creatinine, however&#160;these&#160;changes&#160;are not&#160;considered to be clinically relevant&#160;since they do not&#160;reflect&#160;<br/>a change in glomerular&#160;filtration rate.&#160; Increases in&#160;serum&#160;creatinine&#160;occurred by&#160;Week 4 of&#160;treatment&#160;<br/>and remained stable&#160;through Week&#160;144. &#160;In&#160;Studies&#160;GS-US-380-1489 and&#160;GS-US-380-1490, median&#160;<br/>(Q1, Q3)&#160;serum&#160;creatinine increased&#160;by 0.11&#160;(0.03, 0.19)&#160;mg/dL&#160;(9.7&#160;[2.7,&#160;16.8]&#160;µmol/L),&#160;<br/>0.11&#160;(0.04,&#160;0.19)&#160;mg/dL (9.7&#160;[3.5,&#160;16.8]&#160;µmol/L), and&#160;0.12&#160;(0.06, 0.21)&#160;mg/dL&#160;<br/>(10.6&#160;[5.3,&#160;18.6]&#160;μmol/L)&#160;from&#160;baseline to&#160;Week&#160;144&#160;in the Biktarvy,&#160;<br/>abacavir/dolutegravir/lamivudine,&#160;and dolutegravir&#160;+&#160;emtricitabine/tenofovir&#160;alafenamide groups,&#160;<br/>respectively. &#160;There were no discontinuations&#160;due&#160;to renal&#160;adverse&#160;reactions&#160;through Week&#160;144&#160;in&#160;<br/>patients administered&#160;Biktarvy in clinical&#160;studies.&#160;<br/>&#160;<br/><i>Changes&#160;in bilirubin&#160;<br/></i>In Studies&#160;GS-US-380-1489 and GS-US-380-1490, total&#160;bilirubin&#160;increases were&#160;observed&#160;in&#160;17%&#160;of&#160;<br/>treatment-naïve patients administered Biktarvy&#160;through Week&#160;144. &#160;Increases were primarily Grade&#160;1&#160;<br/>(12%)&#160;and Grade 2&#160;(4%)&#160;(≥1.0 to 2.5 x Upper&#160;Limit&#160;of&#160;Normal&#160;[ULN]),&#160;and were&#160;not&#160;associated with&#160;<br/>hepatic&#160;adverse&#160;reactions or&#160;other&#160;liver&#160;related laboratory abnormalities. &#160;Five&#160;patients&#160;administered&#160;<br/>Biktarvy&#160;(1%)&#160;had grade&#160;3&#160;bilirubin&#160;increases&#160;that&#160;were not&#160;considered&#160;related&#160;to&#160;study&#160;drug.&#160; There&#160;<br/>were no&#160;discontinuations&#160;due to hepatic adverse&#160;reactions through Week&#160;144&#160;in Biktarvy&#160;clinical&#160;<br/>studies.&#160;<br/><i>&#160;<br/>Paediatric population&#160;<br/></i>The safety of&#160;Biktarvy&#160;was&#160;evaluated in 50 HIV-1 infected&#160;adolescents aged&#160;12&#160;to&#160;&lt;&#160;18 years&#160;and&#160;<br/>weighing&#160;≥&#160;35&#160;kg&#160;through&#160;Week&#160;96 (48-week main&#160;phase and 48-week&#160;extension), in 50&#160;children aged&#160;<br/>6 to &lt;&#160;12 years&#160;and&#160;weighing ≥&#160;25&#160;kg through Week 96&#160;(48-week&#160;main phase&#160;and&#160;48-week&#160;extension),&#160;<br/>and in&#160;22&#160;children&#160;≥&#160;2 years&#160;of&#160;age&#160;and&#160;weighing&#160;≥&#160;14&#160;to &lt;&#160;25&#160;kg&#160;through&#160;Week 24&#160;in an&#160;open-label&#160;<br/>clinical&#160;study (GS-US-380-1474). &#160;In&#160;this study,&#160;no new&#160;adverse&#160;reactions have&#160;been&#160;observed&#160;in&#160;<br/>paediatric&#160;subjects&#160;aged&#160;2 years&#160;and older&#160;living&#160;with&#160;HIV-1 as&#160;compared&#160;to adult&#160;subjects living&#160;with&#160;<br/>HIV-1.&#160;&#160;Bone&#160;mineral&#160;density&#160;data were not&#160;collected&#160;in this study.&#160;&#160;Reductions&#160;in&#160;BMD of the spine&#160;<br/>and of&#160;the&#160;TBLH&#160;≥&#160;4%&#160;have been&#160;reported&#160;in paediatric patients&#160;receiving&#160;other&#160;tenofovir&#160;alafenamide&#160;<br/>containing products&#160;for&#160;48&#160;weeks&#160;(see&#160;section 4.4).&#160;&#160;<br/><i>&#160;<br/></i>Other&#160;special&#160;populations&#160;<br/>&#160;<br/><i>Patients co-infected&#160;with&#160;hepatitis&#160;B</i>&#160;<br/>In 16 HIV/HBV&#160;co-infected adults&#160;administered&#160;Biktarvy&#160;(8 HIV/HBV&#160;treatment-naïve&#160;adults&#160;in&#160;<br/>Study&#160;GS-US-380-1490;&#160;8&#160;HIV/HBV&#160;suppressed&#160;adults&#160;in Study&#160;GS-US-380-1878), the safety profile&#160;<br/>of&#160;Biktarvy&#160;was&#160;similar&#160;to that&#160;in patients with HIV-1&#160;monoinfection&#160;(see&#160;section&#160;5.1).&#160;<br/>&#160;<br/><i>Elderly&#160;<br/></i>Studies&#160;GS-US-380-1844, GS-US-380-1878 and&#160;the dedicated&#160;Study&#160;GS-US-380-4449&#160;in patients&#160;<br/>≥&#160;65 years old (evaluation&#160;of&#160;86&#160;HIV-1 infected,&#160;virologically-suppressed subjects ≥&#160;65 years old)&#160;<br/>included&#160;111&#160;patients aged&#160;≥&#160;65&#160;years who&#160;received Biktarvy. &#160;In these&#160;patients,&#160;no differences&#160;in the&#160;<br/>safety profile of&#160;Biktarvy were observed.&#160;&#160;</p>
</div>
<!-- Page 15 -->
<a name="15"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft1533{font-size:18px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft1534{font-size:17px;font-family:TimesNewRomanPSMT;color:#0000ff;}
-->
</style>
<div id="page15-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft150">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft151">15&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft158">&#160;<br/><i>Patients with renal&#160;impairment&#160;<br/></i>The safety of&#160;emtricitabine&#160;+ tenofovir&#160;alafenamide was evaluated&#160;in a&#160;single&#160;arm,&#160;open-label&#160;clinical&#160;<br/>study&#160;(GS-US-292-1825), in which 55 virologically-suppressed HIV-1 infected patients with&#160;end&#160;stage&#160;<br/>renal&#160;disease&#160;(eGFRCG&#160;&lt;&#160;15&#160;mL/min)&#160;on chronic haemodialysis&#160;received emtricitabine&#160;+ tenofovir&#160;<br/>alafenamide&#160;in combination&#160;with elvitegravir&#160;+ cobicistat&#160;as a&#160;fixed-dose&#160;combination tablet&#160;for&#160;96&#160;<br/>weeks. In an&#160;extension phase&#160;of&#160;Study&#160;GS-US-292-1825, 10 patients switched&#160;to&#160;Biktarvy&#160;for&#160;48&#160;<br/>weeks. No additional&#160;adverse&#160;reactions were identified&#160;in patients with end stage&#160;renal&#160;disease on&#160;<br/>chronic haemodialysis in&#160;this study&#160;(see sections 4.4 and&#160;5.2).</p>
<p style="position:absolute;top:240px;left:514px;white-space:nowrap" class="ft1533">&#160;</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft155">&#160;<br/>Reporting&#160;of&#160;suspected adverse&#160;reactions&#160;<br/>&#160;<br/>Reporting&#160;suspected adverse reactions after&#160;authorisation of&#160;the&#160;medicinal&#160;product&#160;is&#160;important.&#160;&#160;<br/>It&#160;allows continued&#160;monitoring of&#160;the benefit/risk balance&#160;of&#160;the&#160;medicinal&#160;product.&#160;&#160;Healthcare&#160;<br/>professionals&#160;are&#160;asked to report&#160;any&#160;suspected adverse reactions via&#160;the national&#160;reporting system&#160;<br/>listed&#160;i<a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">n&#160;Appendix&#160;V.</a>&#160;<br/>&#160;<br/><b>4.9&#160;</b></p>
<p style="position:absolute;top:412px;left:149px;white-space:nowrap" class="ft152"><b>Overdose&#160;</b></p>
<p style="position:absolute;top:431px;left:106px;white-space:nowrap" class="ft155">&#160;<br/>If&#160;overdose&#160;occurs&#160;the patient&#160;must&#160;be&#160;monitored&#160;for&#160;evidence of&#160;toxicity (see&#160;section&#160;4.8).&#160;&#160;Treatment&#160;<br/>of&#160;overdose with&#160;Biktarvy&#160;consists&#160;of&#160;general&#160;supportive measures&#160;including&#160;monitoring&#160;of&#160;vital&#160;signs&#160;<br/>as&#160;well&#160;as observation of&#160;the clinical&#160;status of&#160;the patient.&#160;<br/>&#160;<br/>There&#160;is no specific antidote for&#160;overdose with&#160;Biktarvy.&#160;&#160;As bictegravir&#160;is highly&#160;bound to plasma&#160;<br/>proteins, it&#160;is unlikely&#160;that&#160;it&#160;will&#160;be significantly&#160;removed by haemodialysis or&#160;peritoneal&#160;dialysis.&#160;&#160;<br/>Emtricitabine can be&#160;removed by haemodialysis, which&#160;removes approximately 30%&#160;of&#160;the&#160;<br/>emtricitabine&#160;dose&#160;over&#160;a 3-hour&#160;dialysis period starting within 1.5&#160;hours of&#160;emtricitabine dosing.&#160;&#160;<br/>Tenofovir&#160;is&#160;efficiently removed by haemodialysis with an extraction&#160;coefficient&#160;of&#160;approximately&#160;<br/>54%.&#160;&#160;It&#160;is not&#160;known&#160;whether&#160;emtricitabine&#160;or&#160;tenofovir&#160;can be removed by&#160;peritoneal&#160;dialysis.&#160;&#160;<br/>&#160;<br/>&#160;<br/><b>5.&#160;</b></p>
<p style="position:absolute;top:677px;left:149px;white-space:nowrap" class="ft152"><b>PHARMACOLOGICAL&#160;PROPERTIES&#160;</b></p>
<p style="position:absolute;top:696px;left:106px;white-space:nowrap" class="ft155">&#160;<br/><b>5.1&#160;</b></p>
<p style="position:absolute;top:715px;left:149px;white-space:nowrap" class="ft152"><b>Pharmacodynamic properties&#160;</b></p>
<p style="position:absolute;top:734px;left:106px;white-space:nowrap" class="ft155">&#160;<br/>Pharmacotherapeutic group:&#160;Antiviral&#160;for&#160;systemic use;&#160;antivirals for&#160;treatment&#160;of&#160;HIV&#160;infections,&#160;<br/>combinations,&#160;ATC&#160;code:&#160;J05AR20&#160;<br/>&#160;<br/>Mechanism&#160;of&#160;action&#160;and pharmacodynamic effects&#160;<br/>&#160;<br/>Bictegravir&#160;is an&#160;integrase&#160;strand transfer&#160;inhibitor&#160;(INSTI)&#160;that&#160;binds&#160;to&#160;the integrase active&#160;site and&#160;<br/>blocks the strand transfer&#160;step of&#160;retroviral&#160;deoxyribonucleic&#160;acid (DNA)&#160;integration which&#160;is&#160;essential&#160;<br/>for&#160;the HIV&#160;replication&#160;cycle.&#160;&#160;Bictegravir&#160;has&#160;activity&#160;against&#160;HIV-1 and HIV-2.&#160;<br/>&#160;<br/>Emtricitabine&#160;is a&#160;nucleoside reverse transcriptase inhibitor&#160;(NRTI)&#160;and&#160;analogue&#160;of&#160;2’-deoxycytidine.&#160;&#160;<br/>Emtricitabine&#160;is phosphorylated&#160;by cellular&#160;enzymes&#160;to&#160;form&#160;emtricitabine&#160;triphosphate.&#160;&#160;Emtricitabine&#160;<br/>triphosphate inhibits HIV&#160;replication through&#160;incorporation into viral&#160;DNA&#160;by&#160;the&#160;HIV&#160;reverse&#160;<br/>transcriptase&#160;(RT), which results&#160;in DNA&#160;chain-termination.&#160;&#160;Emtricitabine has&#160;activity&#160;against&#160;HIV-1,&#160;<br/>HIV-2 and&#160;HBV.&#160;<br/>&#160;<br/>Tenofovir&#160;alafenamide is a&#160;nucleotide&#160;reverse transcriptase&#160;inhibitor&#160;(NtRTI)&#160;and&#160;phosphonamidate&#160;<br/>prodrug of&#160;tenofovir&#160;(2’-deoxyadenosine&#160;monophosphate&#160;analogue).&#160;&#160;Tenofovir&#160;alafenamide&#160;is&#160;<br/>permeable&#160;into cells and due to&#160;increased plasma&#160;stability&#160;and&#160;intracellular&#160;activation through&#160;<br/>hydrolysis by&#160;cathepsin&#160;A,&#160;tenofovir&#160;alafenamide&#160;is&#160;more efficient&#160;than&#160;tenofovir&#160;disoproxil&#160;in&#160;loading&#160;<br/>tenofovir&#160;into&#160;peripheral&#160;blood mononuclear&#160;cells&#160;(PBMCs)&#160;(including&#160;lymphocytes&#160;and other&#160;HIV&#160;<br/>target&#160;cells)&#160;and macrophages.&#160;&#160;Intracellular&#160;tenofovir&#160;is subsequently phosphorylated&#160;to the&#160;<br/>pharmacologically active&#160;metabolite&#160;tenofovir&#160;diphosphate.&#160;&#160;Tenofovir&#160;diphosphate inhibits HIV&#160;</p>
</div>
<!-- Page 16 -->
<a name="16"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page16-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft160">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft161">16&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft165">replication&#160;through&#160;incorporation&#160;into viral&#160;DNA&#160;by the HIV&#160;RT, which results&#160;in&#160;DNA&#160;chain-<br/>termination.&#160;&#160;Tenofovir&#160;has&#160;activity&#160;against&#160;HIV-1,&#160;HIV-2 and&#160;HBV.&#160;&#160;&#160;<br/>&#160;<br/>Antiviral&#160;activity&#160;<i>in&#160;vitro&#160;<br/></i>&#160;<br/>The antiviral&#160;activity of&#160;bictegravir&#160;against&#160;laboratory&#160;and clinical&#160;isolates&#160;of&#160;HIV-1 was&#160;assessed in&#160;<br/>lymphoblastoid cell&#160;lines, PBMCs, primary<b>&#160;</b>monocyte/macrophage&#160;cells,&#160;and CD4+ T-lymphocytes.&#160;&#160;<br/>The&#160;50%&#160;effective concentration (EC50)&#160;values&#160;for&#160;bictegravir&#160;were&#160;in&#160;the&#160;range of&#160;&lt;&#160;0.05&#160;to 6.6&#160;nM.&#160;&#160;<br/>The protein-adjusted EC95&#160;of&#160;bictegravir&#160;was&#160;361&#160;nM&#160;(0.162&#160;µg/mL)&#160;for&#160;wild type HIV-1&#160;virus.&#160;&#160;<br/>Bictegravir&#160;displayed&#160;antiviral&#160;activity&#160;in&#160;cell&#160;culture&#160;against&#160;HIV-1&#160;group&#160;(M, N,&#160;O), including&#160;<br/>subtypes&#160;A, B, C, D, E, F,&#160;and G&#160;(EC50&#160;values&#160;ranged from&#160;&lt;&#160;0.05&#160;to&#160;1.71&#160;nM), and&#160;activity&#160;against&#160;<br/>HIV-2 (EC50&#160;=&#160;1.1&#160;nM).&#160;<br/>&#160;<br/>The antiviral&#160;activity of&#160;emtricitabine&#160;against&#160;laboratory and clinical&#160;isolates&#160;of&#160;HIV-1&#160;was&#160;assessed&#160;in&#160;<br/>lymphoblastoid cell&#160;lines,&#160;the MAGI&#160;CCR5 cell&#160;line,&#160;and&#160;PBMCs.&#160;&#160;The EC50&#160;values&#160;for&#160;emtricitabine&#160;<br/>were&#160;in the range&#160;of&#160;0.0013&#160;to 0.64&#160;µM.&#160;&#160;Emtricitabine&#160;displayed antiviral&#160;activity&#160;in cell&#160;culture&#160;<br/>against&#160;HIV-1&#160;clades&#160;A, B,&#160;C, D, E, F, and&#160;G&#160;(EC50&#160;values&#160;ranged&#160;from&#160;0.007&#160;to 0.075&#160;µM)&#160;and&#160;<br/>showed activity against&#160;HIV-2 (EC50&#160;values&#160;ranged&#160;from&#160;0.007 to&#160;1.5&#160;µM).&#160;<br/>&#160;<br/>The antiviral&#160;activity of&#160;tenofovir&#160;alafenamide&#160;against&#160;laboratory&#160;and clinical&#160;isolates&#160;of&#160;HIV-1&#160;<br/>subtype&#160;B&#160;was&#160;assessed in&#160;lymphoblastoid cell&#160;lines, PBMCs, primary&#160;monocyte/macrophage&#160;cells,&#160;<br/>and CD4+&#160;T-lymphocytes.&#160;&#160;The EC50&#160;values&#160;for&#160;tenofovir&#160;alafenamide&#160;were&#160;in&#160;the&#160;range of&#160;2.0 to&#160;<br/>14.7&#160;nM.&#160;&#160;Tenofovir&#160;alafenamide&#160;displayed antiviral&#160;activity in cell&#160;culture against&#160;all&#160;HIV-1&#160;groups&#160;<br/>(M, N, O),&#160;including&#160;subtypes&#160;A, B, C, D, E, F, and G&#160;(EC50&#160;values&#160;ranged from&#160;0.10 to&#160;12.0&#160;nM)&#160;and&#160;<br/>activity against&#160;HIV-2 (EC50&#160;values ranged&#160;from&#160;0.91&#160;to 2.63&#160;nM).&#160;<br/>&#160;<br/>Resistance&#160;<br/>&#160;<br/><i>In&#160;vitro&#160;<br/></i>HIV-1&#160;isolates with reduced susceptibility&#160;to&#160;bictegravir<b>&#160;</b>have&#160;been selected&#160;in cell&#160;culture.&#160;&#160;In one&#160;<br/>selection,&#160;amino&#160;acid substitutions&#160;M50I&#160;and&#160;R263K&#160;emerged&#160;and phenotypic susceptibility&#160;to&#160;<br/>bictegravir&#160;was&#160;reduced&#160;1.3-, 2.2-, and 2.9-fold for&#160;M50I,&#160;R263K, and M50I&#160;+&#160;R263K, respectively.&#160;&#160;<br/>In a second selection, amino acid substitutions T66I&#160;and S153F&#160;emerged&#160;and phenotypic susceptibility&#160;<br/>to&#160;bictegravir<b>&#160;</b>was&#160;shifted&#160;0.4-, 1.9-, and 0.5-fold for&#160;T66I, S153F, and T66I&#160;+&#160;S153F, respectively.&#160;<br/>&#160;<br/>HIV-1&#160;isolates with reduced susceptibility&#160;to&#160;emtricitabine<b>&#160;</b>have&#160;been&#160;selected&#160;in&#160;cell&#160;culture&#160;and&#160;had&#160;<br/>M184V/I&#160;mutations&#160;in HIV-1&#160;RT.&#160;<br/>&#160;<br/>HIV-1&#160;isolates&#160;with reduced susceptibility&#160;to&#160;tenofovir&#160;alafenamide&#160;have&#160;been&#160;selected in&#160;cell&#160;culture&#160;<br/>and&#160;had&#160;the&#160;K65R&#160;mutation&#160;in HIV-1&#160;RT; in addition,&#160;a K70E&#160;mutation in&#160;HIV-1&#160;RT has been&#160;<br/>transiently observed.&#160;&#160;HIV-1&#160;isolates&#160;with&#160;the&#160;K65R&#160;mutation&#160;have&#160;low&#160;level&#160;reduced susceptibility&#160;to&#160;<br/>abacavir, emtricitabine,&#160;tenofovir, and lamivudine.&#160;&#160;<i>In&#160;vitro</i>&#160;drug resistance selection studies with&#160;<br/>tenofovir&#160;alafenamide&#160;have&#160;shown no development&#160;of&#160;high-level&#160;resistance&#160;after&#160;extended culture.&#160;<br/>&#160;<br/><i>In&#160;vivo</i>&#160;<br/>In treatment-naïve&#160;patients&#160;(Studies&#160;GS-US-380-1489 and GS-US-380-1490),&#160;through Week&#160;144 of&#160;<br/>the double-blind phase&#160;or&#160;96 weeks of&#160;the open-label&#160;extension&#160;phase,&#160;no patient&#160;receiving&#160;Biktarvy,&#160;<br/>with HIV-1 RNA&#160;≥&#160;200&#160;copies/mL at&#160;the time of&#160;confirmed virologic failure or&#160;early&#160;study drug&#160;<br/>discontinuation,&#160;had HIV-1&#160;with&#160;treatment-emergent&#160;genotypic&#160;or&#160;phenotypic resistance&#160;to bictegravir,&#160;<br/>emtricitabine,&#160;or&#160;tenofovir&#160;alafenamide&#160;in the&#160;final&#160;resistance&#160;analysis population (n&#160;=&#160;11&#160;with data). &#160;<br/>At&#160;the&#160;time of&#160;study entry,&#160;one treatment-naïve patient&#160;had pre-existing INSTI&#160;resistance-associated&#160;<br/>mutations Q148H&#160;+ G140S&#160;and had&#160;HIV-1 RNA&#160;&lt;&#160;50 copies/mL at&#160;Week&#160;4 through Week&#160;144.&#160;In&#160;<br/>addition, 6 patients had the&#160;pre-existing INSTI&#160;resistance-associated&#160;mutation T97A;&#160;all&#160;had&#160;HIV-1&#160;<br/>RNA&#160;&lt; 50 copies/mL&#160;at&#160;Week&#160;144&#160;or&#160;the&#160;last&#160;visit.&#160;<br/><i>&#160;<br/></i>In virologically-suppressed&#160;patients&#160;(Studies&#160;GS-US-380-1844 and GS-US-380-1878),&#160;no&#160;patients&#160;<br/>receiving Biktarvy, with HIV-1 RNA&#160;≥&#160;200 copies/mL&#160;at&#160;the&#160;time of&#160;confirmed virologic&#160;failure,&#160;</p>
</div>
<!-- Page 17 -->
<a name="17"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft1735{font-size:18px;font-family:TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page17-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft170">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft171">17&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft175">Week&#160;48, or&#160;early&#160;study drug discontinuation,&#160;had HIV-1 with treatment-emergent&#160;genotypic or&#160;<br/>phenotypic resistance&#160;to bictegravir, emtricitabine, or&#160;tenofovir&#160;alafenamide in&#160;the&#160;final&#160;resistance&#160;<br/>analysis population (n&#160;=&#160;2).</p>
<p style="position:absolute;top:126px;left:287px;white-space:nowrap" class="ft1735"><b>&#160;</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft175"><i>&#160;<br/>Cross-resistance&#160;&#160;<br/></i>The susceptibility of&#160;bictegravir&#160;was&#160;tested against&#160;64&#160;INSTI-resistant&#160;clinical&#160;isolates&#160;(20 with&#160;single&#160;<br/>substitutions&#160;and 44 with 2&#160;or&#160;more&#160;substitutions).&#160;&#160;Of&#160;these,&#160;all&#160;single and&#160;double&#160;mutant&#160;isolates&#160;<br/>lacking Q148H/K/R&#160;and 10&#160;of&#160;24&#160;isolates&#160;with Q148H/K/R&#160;with&#160;additional&#160;INSTI&#160;resistance&#160;<br/>associated&#160;substitutions had&#160;≤&#160;2.5-fold&#160;reduced susceptibility&#160;to bictegravir;&#160;&gt;&#160;2.5-fold reduced&#160;<br/>susceptibility&#160;to&#160;bictegravir&#160;was&#160;found for&#160;14&#160;of&#160;the 24&#160;isolates&#160;that&#160;contained G140A/C/S and&#160;<br/>Q148H/R/K&#160;substitutions&#160;in integrase.&#160;&#160;Of&#160;those, 9 of&#160;the 14 isolates&#160;had additional&#160;mutations at&#160;<br/>L74M, T97A, or&#160;E138A/K.&#160;&#160;In a separate study, site-directed&#160;mutants with G118R&#160;and T97A+G118R&#160;<br/>had&#160;3.4-&#160;and&#160;2.8-fold reduced susceptibility to&#160;bictegravir,&#160;respectively.&#160;&#160;The&#160;relevance of&#160;these&#160;<br/><i>in&#160;vitro</i>&#160;cross-resistance&#160;data remains&#160;to be established&#160;in clinical&#160;practice.&#160;<br/>&#160;<br/>Bictegravir&#160;demonstrated equivalent&#160;antiviral&#160;activity&#160;against&#160;5&#160;nonnucleoside&#160;reverse&#160;transcriptase&#160;<br/>inhibitor&#160;(NNRTI)-resistant, 3 NRTI-resistant, and&#160;4&#160;protease&#160;inhibitor&#160;(PI)-resistant&#160;HIV-1&#160;mutant&#160;<br/>clones compared&#160;with the&#160;wild-type strain.&#160;<br/>&#160;<br/>Emtricitabine-resistant&#160;viruses with&#160;the&#160;M184V/I&#160;substitution were cross-resistant&#160;to lamivudine,&#160;but&#160;<br/>retained sensitivity&#160;to didanosine, stavudine,&#160;tenofovir,&#160;and zidovudine.&#160;&#160;&#160;<br/>&#160;<br/>The K65R&#160;and K70E&#160;mutations&#160;result&#160;in&#160;reduced&#160;susceptibility to&#160;abacavir, didanosine,&#160;lamivudine,&#160;<br/>emtricitabine,&#160;and&#160;tenofovir, but&#160;retain&#160;sensitivity&#160;to&#160;zidovudine.&#160;&#160;Multinucleoside&#160;resistant&#160;HIV-1&#160;<br/>with a T69S double&#160;insertion mutation&#160;or&#160;with&#160;a Q151M mutation complex&#160;including K65R&#160;showed&#160;<br/>reduced susceptibility&#160;to&#160;tenofovir&#160;alafenamide.&#160;&#160;&#160;<br/>&#160;<br/>Clinical&#160;data&#160;<br/>&#160;<br/>The efficacy&#160;and&#160;safety&#160;of&#160;Biktarvy&#160;in HIV-1 infected,&#160;treatment-naïve adults are&#160;based&#160;on 48-week&#160;<br/>and&#160;144-week&#160;data from&#160;two randomised, double-blind, active-controlled&#160;studies,&#160;GS-US-380-1489&#160;<br/>(n&#160;=&#160;629)&#160;and GS-US-380-1490&#160;(n&#160;=&#160;645).&#160;&#160;Furthermore, additional&#160;efficacy&#160;and&#160;safety&#160;data&#160;are&#160;<br/>available&#160;from&#160;adults who&#160;received open-label&#160;Biktarvy&#160;for&#160;an additional&#160;96 weeks&#160;after&#160;Week&#160;144&#160;in&#160;<br/>an&#160;optional&#160;extension phase&#160;of&#160;these&#160;studies&#160;(n&#160;=&#160;1025).&#160;<br/>&#160;<br/>The efficacy&#160;and&#160;safety&#160;of&#160;Biktarvy&#160;in virologically-suppressed HIV-1 infected adults are based on&#160;<br/>48-week data from&#160;a&#160;randomised, double-blind, active-controlled study, GS-US-380-1844 (n&#160;=&#160;563);&#160;<br/>and a&#160;randomised,&#160;open-label, active-controlled study,&#160;GS-US-380-1878 (n&#160;=&#160;577).&#160;<br/>&#160;<br/><i>HIV-1&#160;infected,&#160;treatment-naïve&#160;patients&#160;<br/></i>In Study&#160;GS-US-380-1489, patients were randomised&#160;in a 1:1&#160;ratio to&#160;receive either&#160;<br/>bictegravir/emtricitabine/tenofovir&#160;alafenamide&#160;(B/F/TAF)&#160;(n&#160;=&#160;314)&#160;or&#160;<br/>abacavir/dolutegravir/lamivudine&#160;(600/50/300&#160;mg)&#160;(n&#160;=&#160;315)&#160;once&#160;daily.&#160;&#160;In Study&#160;GS-US-380-1490,&#160;<br/>patients were randomised&#160;in a 1:1&#160;ratio to&#160;receive either&#160;B/F/TAF&#160;(n&#160;=&#160;320)&#160;or&#160;<br/>dolutegravir&#160;+&#160;emtricitabine/tenofovir&#160;alafenamide&#160;(50+200/25&#160;mg)&#160;(n&#160;=&#160;325)&#160;once daily.&#160;<br/>&#160;<br/>In Studies&#160;GS-US-380-1489 and&#160;GS-US-380-1490, the&#160;mean age was 35&#160;years&#160;(range&#160;18-77), 89%&#160;<br/>were&#160;male, 58%&#160;were White, 33%&#160;were Black, and&#160;3%&#160;were Asian.&#160;&#160;Twenty-four&#160;percent&#160;(24%)&#160;of&#160;<br/>patients identified as&#160;Hispanic/Latino.&#160;&#160;The prevalence&#160;of&#160;different&#160;subtypes&#160;was&#160;comparable&#160;across&#160;all&#160;<br/>three treatment&#160;groups, with subtype&#160;B&#160;predominant&#160;in&#160;both groups;&#160;11%&#160;were&#160;non-B&#160;subtypes.&#160;&#160;The&#160;<br/>mean&#160;baseline plasma HIV-1&#160;RNA&#160;was&#160;4.4&#160;log10&#160;copies/mL&#160;(range&#160;1.3-6.6).&#160;&#160;The&#160;mean&#160;baseline CD4+&#160;<br/>cell&#160;count&#160;was 460&#160;cells/mm3&#160;(range&#160;0-1,636)&#160;and 11%&#160;had CD4+ cell&#160;counts&#160;less than 200&#160;cells/mm3.&#160;&#160;<br/>Eighteen percent&#160;of&#160;patients had baseline viral&#160;loads&#160;greater&#160;than 100,000&#160;copies/mL.&#160;&#160;In both studies,&#160;<br/>patients were stratified by&#160;baseline&#160;HIV-1&#160;RNA&#160;(less than or&#160;equal&#160;to 100,000&#160;copies/mL, greater&#160;than&#160;<br/>100,000&#160;copies/mL&#160;to&#160;less than or&#160;equal&#160;to 400,000&#160;copies/mL,&#160;or&#160;greater&#160;than 400,000&#160;copies/mL), by&#160;<br/>CD4+&#160;cell&#160;count&#160;(less&#160;than&#160;50&#160;cells/µL, 50-199&#160;cells/µL,&#160;or&#160;greater&#160;than or&#160;equal&#160;to 200&#160;cells/µL), and&#160;<br/>by region&#160;(US or&#160;ex-US).&#160;</p>
</div>
<!-- Page 18 -->
<a name="18"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft1836{font-size:15px;line-height:17px;font-family:TimesNewRomanPS;color:#000000;}
	.ft1837{font-size:15px;line-height:14px;font-family:TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page18-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft180">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft181">18&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft184">&#160;<br/>Treatment&#160;outcomes&#160;of&#160;Studies&#160;GS-US-380-1489 and&#160;GS-US-380-1490 through&#160;Weeks&#160;48&#160;and&#160;144&#160;<br/>are presented&#160;in Table&#160;3.&#160;<br/>&#160;<br/><b>Table&#160;3:&#160;Pooled&#160;virologic&#160;outcomes&#160;of&#160;Studies&#160;GS-US-380-1489 and&#160;GS-US-380-1490&#160;at&#160;<br/>Weeks&#160;48a&#160;and&#160;144b&#160;<br/>&#160;</b></p>
<p style="position:absolute;top:222px;left:115px;white-space:nowrap" class="ft1818">&#160;</p>
<p style="position:absolute;top:222px;left:370px;white-space:nowrap" class="ft1814"><b>Week&#160;48&#160;&#160;</b></p>
<p style="position:absolute;top:222px;left:643px;white-space:nowrap" class="ft1814"><b>Week&#160;144&#160;&#160;</b></p>
<p style="position:absolute;top:275px;left:115px;white-space:nowrap" class="ft1818">&#160;</p>
<p style="position:absolute;top:249px;left:277px;white-space:nowrap" class="ft1814"><b>B/F/TAF&#160;</b></p>
<p style="position:absolute;top:266px;left:275px;white-space:nowrap" class="ft1814"><b>(n&#160;=&#160;634)c&#160;</b></p>
<p style="position:absolute;top:240px;left:361px;white-space:nowrap" class="ft1814"><b>ABC/DTG/</b></p>
<p style="position:absolute;top:258px;left:383px;white-space:nowrap" class="ft1814"><b>3TC&#160;</b></p>
<p style="position:absolute;top:275px;left:367px;white-space:nowrap" class="ft1814"><b>(n&#160;=&#160;315)d&#160;</b></p>
<p style="position:absolute;top:240px;left:468px;white-space:nowrap" class="ft1814"><b>DTG&#160;+&#160;</b></p>
<p style="position:absolute;top:258px;left:468px;white-space:nowrap" class="ft1814"><b>F/TAF&#160;</b></p>
<p style="position:absolute;top:275px;left:459px;white-space:nowrap" class="ft1814"><b>(n&#160;=&#160;325)e&#160;</b></p>
<p style="position:absolute;top:240px;left:553px;white-space:nowrap" class="ft1814"><b>B/F/TAF&#160;</b></p>
<p style="position:absolute;top:258px;left:551px;white-space:nowrap" class="ft1814"><b>(n&#160;=&#160;634)c&#160;</b></p>
<p style="position:absolute;top:240px;left:638px;white-space:nowrap" class="ft1814"><b>ABC/DTG/</b></p>
<p style="position:absolute;top:258px;left:660px;white-space:nowrap" class="ft1814"><b>3TC&#160;</b></p>
<p style="position:absolute;top:275px;left:643px;white-space:nowrap" class="ft1814"><b>(n&#160;=&#160;315)d&#160;</b></p>
<p style="position:absolute;top:240px;left:744px;white-space:nowrap" class="ft1814"><b>DTG&#160;+&#160;</b></p>
<p style="position:absolute;top:258px;left:744px;white-space:nowrap" class="ft1814"><b>F/TAF&#160;</b></p>
<p style="position:absolute;top:275px;left:736px;white-space:nowrap" class="ft1814"><b>(n&#160;=&#160;325)e&#160;</b></p>
<p style="position:absolute;top:293px;left:115px;white-space:nowrap" class="ft1836"><b>HIV-1&#160;RNA&#160;<br/>&lt;&#160;50&#160;copies/mL&#160;&#160;</b></p>
<p style="position:absolute;top:293px;left:292px;white-space:nowrap" class="ft1818">91%&#160;</p>
<p style="position:absolute;top:293px;left:384px;white-space:nowrap" class="ft1818">93%&#160;</p>
<p style="position:absolute;top:293px;left:476px;white-space:nowrap" class="ft1818">93%&#160;</p>
<p style="position:absolute;top:293px;left:568px;white-space:nowrap" class="ft1818">82%&#160;</p>
<p style="position:absolute;top:293px;left:660px;white-space:nowrap" class="ft1818">84%&#160;</p>
<p style="position:absolute;top:293px;left:752px;white-space:nowrap" class="ft1818">84%&#160;</p>
<p style="position:absolute;top:328px;left:136px;white-space:nowrap" class="ft1822">Treatment&#160;<br/>difference&#160;<br/>(95%&#160;CI)&#160;B/F/TAF&#160;<br/>vs&#160;Comparator&#160;</p>
<p style="position:absolute;top:328px;left:303px;white-space:nowrap" class="ft1818">-&#160;</p>
<p style="position:absolute;top:328px;left:380px;white-space:nowrap" class="ft1818">-2.1%&#160;</p>
<p style="position:absolute;top:346px;left:369px;white-space:nowrap" class="ft1818">(-5.9% to&#160;</p>
<p style="position:absolute;top:363px;left:380px;white-space:nowrap" class="ft1818">1.6%)&#160;</p>
<p style="position:absolute;top:328px;left:472px;white-space:nowrap" class="ft1818">-1.9%&#160;</p>
<p style="position:absolute;top:346px;left:461px;white-space:nowrap" class="ft1818">(-5.6% to&#160;</p>
<p style="position:absolute;top:363px;left:472px;white-space:nowrap" class="ft1818">1.8%)&#160;</p>
<p style="position:absolute;top:328px;left:582px;white-space:nowrap" class="ft1818">&#160;</p>
<p style="position:absolute;top:346px;left:580px;white-space:nowrap" class="ft1818">-&#160;</p>
<p style="position:absolute;top:328px;left:656px;white-space:nowrap" class="ft1818">-2.7%&#160;</p>
<p style="position:absolute;top:346px;left:646px;white-space:nowrap" class="ft1818">(-7.8% to&#160;</p>
<p style="position:absolute;top:363px;left:656px;white-space:nowrap" class="ft1818">2.4%)&#160;</p>
<p style="position:absolute;top:328px;left:748px;white-space:nowrap" class="ft1818">-1.9%&#160;</p>
<p style="position:absolute;top:346px;left:738px;white-space:nowrap" class="ft1818">(-7.0% to&#160;</p>
<p style="position:absolute;top:363px;left:748px;white-space:nowrap" class="ft1818">3.1%)&#160;</p>
<p style="position:absolute;top:398px;left:115px;white-space:nowrap" class="ft1837"><b>HIV-1&#160;RNA&#160;<br/>≥&#160;50&#160;copies/mLf&#160;</b></p>
<p style="position:absolute;top:398px;left:295px;white-space:nowrap" class="ft1818">3%&#160;</p>
<p style="position:absolute;top:398px;left:388px;white-space:nowrap" class="ft1818">3%&#160;</p>
<p style="position:absolute;top:398px;left:480px;white-space:nowrap" class="ft1818">1%&#160;</p>
<p style="position:absolute;top:398px;left:572px;white-space:nowrap" class="ft1818">3%&#160;</p>
<p style="position:absolute;top:398px;left:664px;white-space:nowrap" class="ft1818">3%&#160;</p>
<p style="position:absolute;top:398px;left:756px;white-space:nowrap" class="ft1818">3%&#160;</p>
<p style="position:absolute;top:433px;left:115px;white-space:nowrap" class="ft1836"><b>No&#160;virologic&#160;data&#160;at&#160;<br/>week&#160;48&#160;or&#160;144&#160;<br/>window&#160;</b></p>
<p style="position:absolute;top:433px;left:295px;white-space:nowrap" class="ft1818">6%&#160;</p>
<p style="position:absolute;top:433px;left:388px;white-space:nowrap" class="ft1818">4%&#160;</p>
<p style="position:absolute;top:433px;left:480px;white-space:nowrap" class="ft1818">6%&#160;</p>
<p style="position:absolute;top:433px;left:568px;white-space:nowrap" class="ft1818">16%&#160;</p>
<p style="position:absolute;top:433px;left:660px;white-space:nowrap" class="ft1818">13%&#160;</p>
<p style="position:absolute;top:433px;left:752px;white-space:nowrap" class="ft1818">13%&#160;</p>
<p style="position:absolute;top:486px;left:136px;white-space:nowrap" class="ft1822">Discontinued&#160;<br/>study&#160;drug&#160;due&#160;to&#160;<br/>AE&#160;or&#160;deathg&#160;</p>
<p style="position:absolute;top:486px;left:291px;white-space:nowrap" class="ft1818">&lt;1%&#160;</p>
<p style="position:absolute;top:486px;left:388px;white-space:nowrap" class="ft1818">1%&#160;</p>
<p style="position:absolute;top:486px;left:480px;white-space:nowrap" class="ft1818">1%&#160;</p>
<p style="position:absolute;top:486px;left:572px;white-space:nowrap" class="ft1818">2%&#160;</p>
<p style="position:absolute;top:486px;left:664px;white-space:nowrap" class="ft1818">2%&#160;</p>
<p style="position:absolute;top:486px;left:756px;white-space:nowrap" class="ft1818">3%&#160;</p>
<p style="position:absolute;top:538px;left:136px;white-space:nowrap" class="ft1822">Discontinued&#160;<br/>study&#160;drug&#160;due&#160;to&#160;<br/>other&#160;reasons&#160;and&#160;<br/>last&#160;available&#160;HIV-<br/>1&#160;RNA&#160;<br/>&lt;&#160;50&#160;copies/mLh&#160;</p>
<p style="position:absolute;top:538px;left:295px;white-space:nowrap" class="ft1818">4%&#160;</p>
<p style="position:absolute;top:538px;left:388px;white-space:nowrap" class="ft1818">3%&#160;</p>
<p style="position:absolute;top:538px;left:480px;white-space:nowrap" class="ft1818">4%&#160;</p>
<p style="position:absolute;top:538px;left:568px;white-space:nowrap" class="ft1818">13%&#160;</p>
<p style="position:absolute;top:538px;left:660px;white-space:nowrap" class="ft1818">11%&#160;</p>
<p style="position:absolute;top:538px;left:756px;white-space:nowrap" class="ft1818">9%&#160;</p>
<p style="position:absolute;top:642px;left:136px;white-space:nowrap" class="ft1822">Missing&#160;data&#160;<br/>during&#160;window&#160;but&#160;<br/>on&#160;study&#160;drug&#160;</p>
<p style="position:absolute;top:642px;left:295px;white-space:nowrap" class="ft1818">2%&#160;</p>
<p style="position:absolute;top:642px;left:383px;white-space:nowrap" class="ft1818">&lt;1%&#160;</p>
<p style="position:absolute;top:642px;left:480px;white-space:nowrap" class="ft1818">1%&#160;</p>
<p style="position:absolute;top:642px;left:572px;white-space:nowrap" class="ft1818">1%&#160;</p>
<p style="position:absolute;top:642px;left:660px;white-space:nowrap" class="ft1818">&lt;1%&#160;</p>
<p style="position:absolute;top:642px;left:756px;white-space:nowrap" class="ft1818">1%&#160;</p>
<p style="position:absolute;top:695px;left:115px;white-space:nowrap" class="ft1836"><b>Proportion (%)&#160;of&#160;<br/>patients&#160;with&#160;<br/>HIV-1&#160;RNA&#160;<br/>&lt;&#160;50&#160;copies/mL&#160;by&#160;<br/>subgroup</b>&#160;</p>
<p style="position:absolute;top:695px;left:306px;white-space:nowrap" class="ft1818">&#160;</p>
<p style="position:absolute;top:695px;left:398px;white-space:nowrap" class="ft1818">&#160;</p>
<p style="position:absolute;top:695px;left:490px;white-space:nowrap" class="ft1818">&#160;</p>
<p style="position:absolute;top:695px;left:582px;white-space:nowrap" class="ft1818">&#160;</p>
<p style="position:absolute;top:695px;left:674px;white-space:nowrap" class="ft1818">&#160;</p>
<p style="position:absolute;top:695px;left:766px;white-space:nowrap" class="ft1818">&#160;</p>
<p style="position:absolute;top:782px;left:115px;white-space:nowrap" class="ft1818">By&#160;baseline&#160;viral&#160;load&#160;</p>
<p style="position:absolute;top:796px;left:136px;white-space:nowrap" class="ft1822">≤&#160;100,000&#160;copies/<br/>mL&#160;<br/>&gt;&#160;100,000&#160;copies/<br/>mL&#160;</p>
<p style="position:absolute;top:782px;left:306px;white-space:nowrap" class="ft1818">&#160;</p>
<p style="position:absolute;top:799px;left:292px;white-space:nowrap" class="ft1822">92%&#160;<br/>87%&#160;</p>
<p style="position:absolute;top:782px;left:398px;white-space:nowrap" class="ft1818">&#160;</p>
<p style="position:absolute;top:799px;left:384px;white-space:nowrap" class="ft1822">94%&#160;<br/>90%&#160;</p>
<p style="position:absolute;top:782px;left:490px;white-space:nowrap" class="ft1818">&#160;</p>
<p style="position:absolute;top:799px;left:476px;white-space:nowrap" class="ft1822">93%&#160;<br/>94%&#160;</p>
<p style="position:absolute;top:782px;left:582px;white-space:nowrap" class="ft1818">&#160;</p>
<p style="position:absolute;top:799px;left:568px;white-space:nowrap" class="ft1822">82%&#160;<br/>79%&#160;</p>
<p style="position:absolute;top:782px;left:674px;white-space:nowrap" class="ft1818">&#160;</p>
<p style="position:absolute;top:799px;left:660px;white-space:nowrap" class="ft1822">86%&#160;<br/>74%&#160;</p>
<p style="position:absolute;top:782px;left:766px;white-space:nowrap" class="ft1818">&#160;</p>
<p style="position:absolute;top:799px;left:752px;white-space:nowrap" class="ft1822">84%&#160;<br/>83%&#160;</p>
<p style="position:absolute;top:869px;left:115px;white-space:nowrap" class="ft1822">By&#160;baseline&#160;CD4+&#160;cell&#160;<br/>count&#160;</p>
<p style="position:absolute;top:903px;left:136px;white-space:nowrap" class="ft1824">&lt;&#160;200&#160;cells/mm3&#160;<br/>≥&#160;200&#160;cells/mm3&#160;</p>
<p style="position:absolute;top:869px;left:306px;white-space:nowrap" class="ft1818">&#160;</p>
<p style="position:absolute;top:886px;left:292px;white-space:nowrap" class="ft1822">90%&#160;<br/>91%&#160;</p>
<p style="position:absolute;top:869px;left:398px;white-space:nowrap" class="ft1818">&#160;</p>
<p style="position:absolute;top:886px;left:384px;white-space:nowrap" class="ft1822">81%&#160;<br/>94%&#160;</p>
<p style="position:absolute;top:869px;left:490px;white-space:nowrap" class="ft1818">&#160;</p>
<p style="position:absolute;top:886px;left:472px;white-space:nowrap" class="ft1818">100%&#160;</p>
<p style="position:absolute;top:903px;left:476px;white-space:nowrap" class="ft1818">92%&#160;</p>
<p style="position:absolute;top:869px;left:582px;white-space:nowrap" class="ft1818">&#160;</p>
<p style="position:absolute;top:886px;left:568px;white-space:nowrap" class="ft1822">80%&#160;<br/>82%&#160;</p>
<p style="position:absolute;top:869px;left:674px;white-space:nowrap" class="ft1818">&#160;</p>
<p style="position:absolute;top:886px;left:660px;white-space:nowrap" class="ft1822">69%&#160;<br/>86%&#160;</p>
<p style="position:absolute;top:869px;left:766px;white-space:nowrap" class="ft1818">&#160;</p>
<p style="position:absolute;top:886px;left:752px;white-space:nowrap" class="ft1822">91%&#160;<br/>83%&#160;</p>
<p style="position:absolute;top:939px;left:115px;white-space:nowrap" class="ft1836"><b>HIV-1&#160;RNA&#160;<br/>&lt;&#160;20&#160;copies/mL&#160;</b></p>
<p style="position:absolute;top:939px;left:292px;white-space:nowrap" class="ft1818">85%&#160;</p>
<p style="position:absolute;top:939px;left:384px;white-space:nowrap" class="ft1818">87%&#160;</p>
<p style="position:absolute;top:939px;left:476px;white-space:nowrap" class="ft1818">87%&#160;</p>
<p style="position:absolute;top:939px;left:568px;white-space:nowrap" class="ft1818">78%&#160;</p>
<p style="position:absolute;top:939px;left:660px;white-space:nowrap" class="ft1818">82%&#160;</p>
<p style="position:absolute;top:939px;left:752px;white-space:nowrap" class="ft1818">79%&#160;</p>
</div>
<!-- Page 19 -->
<a name="19"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft1938{font-size:14px;line-height:18px;font-family:TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page19-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft190">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft191">19&#160;</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft1928">ABC&#160;=&#160;abacavir<b>&#160;</b></p>
<p style="position:absolute;top:88px;left:234px;white-space:nowrap" class="ft1928">DTG&#160;=&#160;dolutegravir&#160;</p>
<p style="position:absolute;top:88px;left:362px;white-space:nowrap" class="ft1928">3TC&#160;=&#160;lamivudine&#160;</p>
<p style="position:absolute;top:88px;left:489px;white-space:nowrap" class="ft1928">F/TAF&#160;=&#160;emtricitabine/tenofovir&#160;alafenamide&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft1930">a&#160;&#160;Week&#160;48&#160;window was between&#160;Day&#160;295&#160;and&#160;378&#160;(inclusive).&#160;<br/>b&#160;&#160;Week&#160;144&#160;window was between&#160;Day&#160;967&#160;and&#160;1050&#160;(inclusive).&#160;<br/>c&#160;&#160;Pooled&#160;from&#160;Study&#160;GS-US-380-1489&#160;(n&#160;=&#160;314)&#160;and&#160;Study&#160;GS-US-380-1490&#160;(n&#160;=&#160;320).&#160;<br/>d&#160;&#160;Study&#160;GS-US-380-1489.&#160;<br/>e&#160;&#160;Study&#160;GS-US-380-1490.&#160;<br/>f&#160;</p>
<p style="position:absolute;top:179px;left:128px;white-space:nowrap" class="ft1930">Includes&#160;patients who&#160;had&#160;≥&#160;50&#160;copies/mL in&#160;the&#160;Week&#160;48&#160;or&#160;144&#160;window;&#160;patients who&#160;discontinued&#160;early&#160;due&#160;to&#160;lack&#160;or&#160;<br/>loss&#160;of&#160;efficacy&#160;(n&#160;=&#160;0);&#160;patients&#160;who&#160;discontinued&#160;for&#160;reasons&#160;other&#160;than&#160;an&#160;adverse&#160;event&#160;(AE),&#160;death&#160;or&#160;lack&#160;or&#160;loss&#160;of&#160;<br/>efficacy&#160;(B/F/TAF&#160;n&#160;=&#160;12&#160;and&#160;15;&#160;ABC/DTG/3TC&#160;n&#160;=&#160;2&#160;and&#160;7;&#160;DTG+F/TAF&#160;n&#160;=&#160;3&#160;and&#160;6,&#160;at&#160;Weeks&#160;48&#160;and&#160;144,&#160;<br/>respectively)&#160;and&#160;at&#160;the&#160;time&#160;of&#160;discontinuation&#160;had&#160;a&#160;viral&#160;value&#160;of&#160;≥&#160;50&#160;copies/mL.&#160;</p>
<p style="position:absolute;top:244px;left:106px;white-space:nowrap" class="ft1928">g&#160;&#160;Includes&#160;patients who&#160;discontinued&#160;due&#160;to&#160;AE&#160;or&#160;death&#160;at&#160;any&#160;time&#160;point&#160;from&#160;Day&#160;1&#160;through&#160;the&#160;time&#160;window&#160;if&#160;this&#160;</p>
<p style="position:absolute;top:259px;left:128px;white-space:nowrap" class="ft1928">resulted&#160;in&#160;no&#160;virologic&#160;data on&#160;treatment&#160;during&#160;the&#160;specified&#160;window.&#160;</p>
<p style="position:absolute;top:275px;left:106px;white-space:nowrap" class="ft1928">h&#160;&#160;Includes&#160;patients who&#160;discontinued&#160;for&#160;reasons other&#160;than&#160;an&#160;AE,&#160;death&#160;or&#160;lack&#160;or&#160;loss&#160;of&#160;efficacy,&#160;e.g.&#160;withdrew consent,&#160;</p>
<p style="position:absolute;top:290px;left:128px;white-space:nowrap" class="ft1928">loss&#160;to&#160;follow-up,&#160;etc.&#160;</p>
<p style="position:absolute;top:306px;left:106px;white-space:nowrap" class="ft198">&#160;<br/>B/F/TAF was&#160;non-inferior&#160;in achieving HIV-1&#160;RNA&#160;&lt;&#160;50&#160;copies/mL&#160;at&#160;both&#160;Weeks&#160;48&#160;and&#160;144&#160;when&#160;<br/>compared to&#160;abacavir/dolutegravir/lamivudine&#160;and&#160;to&#160;dolutegravir&#160;+&#160;emtricitabine/tenofovir&#160;<br/>alafenamide,&#160;respectively.&#160;&#160;Treatment&#160;outcomes&#160;between treatment&#160;groups&#160;were similar&#160;across&#160;<br/>subgroups by age,&#160;sex,&#160;race, baseline viral&#160;load, baseline CD4+ cell&#160;count, and&#160;region.&#160;<br/>&#160;<br/>In Studies&#160;GS-US-380-1489 and&#160;GS-US-380-1490, the mean increase from&#160;baseline in CD4+&#160;cell&#160;<br/>count&#160;at&#160;Week&#160;144&#160;was&#160;288,&#160;317, and&#160;289&#160;cells/mm3&#160;in&#160;the pooled&#160;B/F/TAF,&#160;<br/>abacavir/dolutegravir/lamivudine,&#160;and&#160;dolutegravir&#160;+&#160;emtricitabine/tenofovir&#160;alafenamide&#160;groups,&#160;<br/>respectively.&#160;<br/>&#160;<br/>In the optional&#160;96&#160;week&#160;open-label&#160;extension phase of&#160;Studies&#160;GS-US-380-1489&#160;<br/>and&#160;GS-US-380-1490, high&#160;rates&#160;of&#160;virologic suppression were&#160;achieved and&#160;maintained.&#160;<br/>&#160;<br/><i>HIV-1&#160;infected, virologically&#160;-suppressed&#160;patients&#160;<br/></i>In Study&#160;GS-US-380-1844, the efficacy and safety of&#160;switching&#160;from&#160;a&#160;regimen of&#160;<br/>dolutegravir&#160;+&#160;abacavir/lamivudine&#160;or&#160;abacavir/dolutegravir/lamivudine&#160;to&#160;B/F/TAF&#160;were evaluated in&#160;<br/>a randomised, double-blind&#160;study&#160;of&#160;virologically-suppressed (HIV-1&#160;RNA&#160;&lt;&#160;50&#160;copies/mL) HIV-1&#160;<br/>infected adults (n&#160;=&#160;563).&#160;&#160;Patients must&#160;have been stably suppressed&#160;(HIV-1&#160;RNA&#160;&lt;&#160;50&#160;copies/mL)&#160;on&#160;<br/>their&#160;baseline regimen&#160;for&#160;at&#160;least&#160;3&#160;months prior&#160;to study entry.&#160;&#160;Patients were&#160;randomised&#160;in&#160;a 1:1&#160;<br/>ratio&#160;to either&#160;switch&#160;to&#160;B/F/TAF&#160;at&#160;baseline&#160;(n&#160;=&#160;282),&#160;or&#160;stay on&#160;their&#160;baseline&#160;antiretroviral&#160;regimen&#160;<br/>(n&#160;=&#160;281).&#160;&#160;Patients had a&#160;mean age of&#160;45&#160;years&#160;(range&#160;20-71), 89%&#160;were male, 73%&#160;were White, and&#160;<br/>22%&#160;were Black.&#160;&#160;Seventeen percent&#160;(17%)&#160;of&#160;patients&#160;identified as&#160;Hispanic/Latino.&#160;&#160;The prevalence&#160;<br/>of&#160;different&#160;HIV-1 subtypes&#160;was&#160;comparable between treatment&#160;groups,&#160;with subtype&#160;B&#160;predominant&#160;<br/>in both groups;&#160;5%&#160;were&#160;non-B&#160;subtypes.&#160;&#160;The&#160;mean baseline CD4+&#160;cell&#160;count&#160;was&#160;723&#160;cells/mm3&#160;<br/>(range&#160;124-2,444).&#160;&#160;<br/>&#160;<br/>In Study&#160;GS-US-380-1878, the efficacy and safety of&#160;switching&#160;from&#160;either&#160;abacavir/lamivudine&#160;or&#160;<br/>emtricitabine/tenofovir&#160;disoproxil&#160;fumarate&#160;(200/300&#160;mg)&#160;plus&#160;atazanavir&#160;or&#160;darunavir&#160;(boosted by&#160;<br/>either&#160;cobicistat&#160;or&#160;ritonavir)&#160;to&#160;B/F/TAF&#160;were evaluated in a&#160;randomised, open-label&#160;study&#160;of&#160;<br/>virologically-suppressed HIV-1 infected&#160;adults&#160;(n&#160;=&#160;577).&#160;&#160;Patients must&#160;have&#160;been stably&#160;suppressed&#160;<br/>on their&#160;baseline&#160;regimen for&#160;at&#160;least&#160;6&#160;months and&#160;must&#160;not&#160;have been previously&#160;treated with&#160;any&#160;<br/>INSTI.&#160;&#160;Patients were randomised&#160;in a&#160;1:1&#160;ratio&#160;to&#160;either&#160;switch to&#160;B/F/TAF&#160;(n&#160;=&#160;290), or&#160;stay on their&#160;<br/>baseline antiretroviral&#160;regimen&#160;(n&#160;=&#160;287).&#160;&#160;Patients&#160;had a mean&#160;age&#160;of&#160;46&#160;years (range&#160;20-79), 83%&#160;<br/>were&#160;male, 66%&#160;were White, and 26%&#160;were Black.&#160;&#160;Nineteen percent&#160;(19%)&#160;of&#160;patients identified as&#160;<br/>Hispanic/Latino.&#160;&#160;The&#160;mean&#160;baseline CD4+ cell&#160;count&#160;was&#160;663&#160;cells/mm3&#160;(range&#160;62-2,582).&#160;&#160;The&#160;<br/>prevalence&#160;of&#160;different&#160;subtypes&#160;was&#160;comparable across treatment&#160;groups, with subtype&#160;B&#160;predominant&#160;<br/>in both&#160;groups;&#160;11%&#160;were&#160;non-B&#160;subtypes.&#160;&#160;Patients were stratified by&#160;prior&#160;treatment&#160;regimen.&#160;&#160;At&#160;<br/>screening, 15%&#160;of&#160;patients&#160;were receiving&#160;abacavir/lamivudine&#160;plus&#160;atazanavir&#160;or&#160;darunavir&#160;(boosted&#160;<br/>by either&#160;cobicistat&#160;or&#160;ritonavir)&#160;and 85%&#160;of&#160;patients were&#160;receiving&#160;emtricitabine/tenofovir&#160;disoproxil&#160;<br/>fumarate&#160;plus&#160;atazanavir&#160;or&#160;darunavir&#160;(boosted by either&#160;cobicistat&#160;or&#160;ritonavir).&#160;&#160;<br/>&#160;<br/>Treatment&#160;outcomes&#160;of&#160;Studies&#160;GS-US-380-1844 and&#160;GS-US-380-1878 through&#160;Week&#160;48 are&#160;<br/>presented in Table&#160;4.&#160;<br/>&#160;</p>
</div>
<!-- Page 20 -->
<a name="20"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft2039{font-size:10px;line-height:19px;font-family:TimesNewRomanPS;color:#000000;}
	.ft2040{font-size:14px;line-height:12px;font-family:TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page20-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft201">20&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft2039"><b>Table&#160;4:&#160;Virologic&#160;outcomes&#160;of&#160;Studies&#160;GS-US-380-1844 and&#160;GS-US-380-1878&#160;at&#160;Week&#160;48a&#160;<br/></b>&#160;</p>
<p style="position:absolute;top:128px;left:115px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:128px;left:392px;white-space:nowrap" class="ft2014"><b>Study&#160;GS-US-380-1844</b></p>
<p style="position:absolute;top:127px;left:540px;white-space:nowrap" class="ft202"><b>&#160;</b></p>
<p style="position:absolute;top:128px;left:619px;white-space:nowrap" class="ft2014"><b>Study&#160;GS-US-380-1878</b></p>
<p style="position:absolute;top:127px;left:767px;white-space:nowrap" class="ft202"><b>&#160;</b></p>
<p style="position:absolute;top:198px;left:115px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:165px;left:373px;white-space:nowrap" class="ft2036"><b>B/F/TAF&#160;<br/>(n&#160;=&#160;282)</b></p>
<p style="position:absolute;top:181px;left:430px;white-space:nowrap" class="ft202"><b>&#160;</b></p>
<p style="position:absolute;top:165px;left:468px;white-space:nowrap" class="ft2014"><b>ABC/DTG/3TC&#160;</b></p>
<p style="position:absolute;top:182px;left:490px;white-space:nowrap" class="ft2014"><b>(n&#160;=&#160;281)</b></p>
<p style="position:absolute;top:181px;left:547px;white-space:nowrap" class="ft202"><b>&#160;</b></p>
<p style="position:absolute;top:165px;left:602px;white-space:nowrap" class="ft2036"><b>B/F/TAF&#160;<br/>(n&#160;=&#160;290)</b></p>
<p style="position:absolute;top:181px;left:659px;white-space:nowrap" class="ft202"><b>&#160;</b></p>
<p style="position:absolute;top:147px;left:694px;white-space:nowrap" class="ft2014"><b>Baseline&#160;ATV-&#160;</b></p>
<p style="position:absolute;top:165px;left:695px;white-space:nowrap" class="ft2014"><b>or&#160;DRV-based&#160;</b></p>
<p style="position:absolute;top:182px;left:715px;white-space:nowrap" class="ft2014"><b>regimen&#160;</b></p>
<p style="position:absolute;top:199px;left:712px;white-space:nowrap" class="ft2014"><b>(n&#160;=&#160;287)</b></p>
<p style="position:absolute;top:198px;left:769px;white-space:nowrap" class="ft202"><b>&#160;</b></p>
<p style="position:absolute;top:217px;left:115px;white-space:nowrap" class="ft2014"><b>HIV-1&#160;RNA&#160;&lt;&#160;50&#160;copies/mL&#160;</b></p>
<p style="position:absolute;top:216px;left:296px;white-space:nowrap" class="ft202"><b>&#160;</b></p>
<p style="position:absolute;top:217px;left:388px;white-space:nowrap" class="ft2018">94%</p>
<p style="position:absolute;top:216px;left:416px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:217px;left:505px;white-space:nowrap" class="ft2018">95%</p>
<p style="position:absolute;top:216px;left:533px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:217px;left:617px;white-space:nowrap" class="ft2018">92%</p>
<p style="position:absolute;top:216px;left:644px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:217px;left:727px;white-space:nowrap" class="ft2018">89%</p>
<p style="position:absolute;top:216px;left:755px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:235px;left:136px;white-space:nowrap" class="ft2018">Treatment&#160;difference&#160;(95%&#160;CI)</p>
<p style="position:absolute;top:234px;left:322px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:235px;left:397px;white-space:nowrap" class="ft2018">-1.4% (-5.5% to&#160;2.6%)</p>
<p style="position:absolute;top:234px;left:534px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:235px;left:627px;white-space:nowrap" class="ft2018">3.2% (-1.6% to&#160;8.2%)</p>
<p style="position:absolute;top:234px;left:759px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:253px;left:115px;white-space:nowrap" class="ft2014"><b>HIV-1&#160;RNA&#160;≥&#160;50&#160;copies/mLb</b></p>
<p style="position:absolute;top:252px;left:298px;white-space:nowrap" class="ft202"><b>&#160;</b></p>
<p style="position:absolute;top:253px;left:392px;white-space:nowrap" class="ft2018">1%</p>
<p style="position:absolute;top:252px;left:412px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:253px;left:503px;white-space:nowrap" class="ft2018">&lt;&#160;1%</p>
<p style="position:absolute;top:252px;left:535px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:253px;left:621px;white-space:nowrap" class="ft2018">2%</p>
<p style="position:absolute;top:252px;left:641px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:253px;left:731px;white-space:nowrap" class="ft2018">2%</p>
<p style="position:absolute;top:252px;left:751px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:272px;left:136px;white-space:nowrap" class="ft2018">Treatment&#160;difference&#160;(95%&#160;CI)&#160;</p>
<p style="position:absolute;top:273px;left:400px;white-space:nowrap" class="ft2018">0.7% (-1.0% to&#160;2.8%)</p>
<p style="position:absolute;top:271px;left:531px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:273px;left:627px;white-space:nowrap" class="ft2018">0.0% (-2.5% to&#160;2.5%)</p>
<p style="position:absolute;top:271px;left:759px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:292px;left:115px;white-space:nowrap" class="ft2036"><b>No&#160;virologic&#160;data&#160;at&#160;Week&#160;48&#160;<br/>window</b></p>
<p style="position:absolute;top:308px;left:165px;white-space:nowrap" class="ft202"><b>&#160;</b></p>
<p style="position:absolute;top:301px;left:392px;white-space:nowrap" class="ft2018">5%</p>
<p style="position:absolute;top:300px;left:412px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:301px;left:509px;white-space:nowrap" class="ft2018">5%</p>
<p style="position:absolute;top:300px;left:529px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:301px;left:621px;white-space:nowrap" class="ft2018">6%</p>
<p style="position:absolute;top:300px;left:641px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:301px;left:731px;white-space:nowrap" class="ft2018">9%</p>
<p style="position:absolute;top:300px;left:751px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:327px;left:136px;white-space:nowrap" class="ft2022">Discontinued&#160;study&#160;drug&#160;due&#160;to&#160;<br/>AE&#160;or&#160;death&#160;and&#160;last&#160;available&#160;<br/>HIV-1&#160;RNA&#160;&lt;&#160;50&#160;copies/mL</p>
<p style="position:absolute;top:361px;left:309px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:345px;left:392px;white-space:nowrap" class="ft2018">2%</p>
<p style="position:absolute;top:343px;left:412px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:345px;left:509px;white-space:nowrap" class="ft2018">1%</p>
<p style="position:absolute;top:343px;left:529px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:345px;left:621px;white-space:nowrap" class="ft2018">1%</p>
<p style="position:absolute;top:343px;left:641px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:345px;left:731px;white-space:nowrap" class="ft2018">1%</p>
<p style="position:absolute;top:343px;left:751px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:380px;left:136px;white-space:nowrap" class="ft2022">Discontinued&#160;study&#160;drug&#160;due&#160;to&#160;<br/>other&#160;reasons&#160;and&#160;last&#160;available&#160;<br/>HIV-1&#160;RNA&#160;&lt;&#160;50&#160;copies/mLc</p>
<p style="position:absolute;top:413px;left:313px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:397px;left:392px;white-space:nowrap" class="ft2018">2%</p>
<p style="position:absolute;top:396px;left:412px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:397px;left:509px;white-space:nowrap" class="ft2018">3%</p>
<p style="position:absolute;top:396px;left:529px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:397px;left:621px;white-space:nowrap" class="ft2018">3%</p>
<p style="position:absolute;top:396px;left:641px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:397px;left:731px;white-space:nowrap" class="ft2018">7%</p>
<p style="position:absolute;top:396px;left:751px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:432px;left:136px;white-space:nowrap" class="ft2022">Missing&#160;data&#160;during&#160;window&#160;but&#160;<br/>on&#160;study&#160;drug</p>
<p style="position:absolute;top:448px;left:219px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:441px;left:392px;white-space:nowrap" class="ft2018">2%</p>
<p style="position:absolute;top:440px;left:412px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:441px;left:509px;white-space:nowrap" class="ft2018">1%</p>
<p style="position:absolute;top:440px;left:529px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:441px;left:621px;white-space:nowrap" class="ft2018">2%</p>
<p style="position:absolute;top:440px;left:641px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:441px;left:731px;white-space:nowrap" class="ft2018">2%</p>
<p style="position:absolute;top:440px;left:751px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:467px;left:106px;white-space:nowrap" class="ft2028">ABC&#160;=&#160;abacavir&#160;</p>
<p style="position:absolute;top:467px;left:234px;white-space:nowrap" class="ft2028">ATV&#160;=&#160;atazanavir&#160;</p>
<p style="position:absolute;top:467px;left:362px;white-space:nowrap" class="ft2028">DRV&#160;=&#160;darunavir<b>&#160;</b></p>
<p style="position:absolute;top:467px;left:489px;white-space:nowrap" class="ft2028">DTG&#160;<b>=&#160;</b>dolutegravir&#160;</p>
<p style="position:absolute;top:467px;left:617px;white-space:nowrap" class="ft2028">3TC&#160;=&#160;lamivudine&#160;</p>
<p style="position:absolute;top:483px;left:106px;white-space:nowrap" class="ft2030">a&#160;&#160;Week&#160;48&#160;window was between&#160;Day&#160;295&#160;and&#160;378&#160;(inclusive).&#160;<br/>b&#160;&#160;Includes&#160;patients who&#160;had&#160;≥&#160;50&#160;copies/mL in&#160;the&#160;Week&#160;48&#160;window;&#160;patients who&#160;discontinued&#160;early&#160;due&#160;to&#160;lack&#160;or&#160;loss&#160;of&#160;</p>
<p style="position:absolute;top:514px;left:128px;white-space:nowrap" class="ft2040">efficacy;&#160;patients who&#160;discontinued&#160;for&#160;reasons&#160;other&#160;than&#160;lack&#160;or&#160;loss&#160;of&#160;efficacy&#160;and&#160;at&#160;the&#160;time&#160;of&#160;discontinuation&#160;had&#160;a&#160;<br/>viral&#160;value&#160;of&#160;≥&#160;50&#160;copies/mL.&#160;</p>
<p style="position:absolute;top:545px;left:106px;white-space:nowrap" class="ft2028">c&#160;&#160;Includes&#160;patients who&#160;discontinued&#160;for&#160;reasons other&#160;than&#160;an&#160;AE,&#160;death&#160;or&#160;lack&#160;or&#160;loss&#160;of&#160;efficacy,&#160;e.g.&#160;withdrew consent,&#160;</p>
<p style="position:absolute;top:560px;left:128px;white-space:nowrap" class="ft2028">loss&#160;to&#160;follow-up,&#160;etc.&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft205">&#160;<br/>B/F/TAF was&#160;non-inferior&#160;to the&#160;control&#160;regimen&#160;in both studies.&#160;&#160;Treatment&#160;outcomes&#160;between&#160;<br/>treatment&#160;groups were&#160;similar&#160;across&#160;subgroups&#160;by age, sex,&#160;race, and&#160;region.&#160;<br/>&#160;<br/>In GS-US-380-1844, the&#160;mean change&#160;from&#160;baseline&#160;in CD4+&#160;cell&#160;count&#160;at&#160;Week&#160;48&#160;<br/>was&#160;-31&#160;cells/mm3&#160;in patients who switched&#160;to B/F/TAF and 4&#160;cells/mm3&#160;in patients who stayed on&#160;<br/>abacavir/dolutegravir/lamivudine.&#160;&#160;In GS-US-380-1878, the&#160;mean change&#160;from&#160;baseline in CD4+&#160;cell&#160;<br/>count&#160;at&#160;Week&#160;48 was 25&#160;cells/mm3&#160;in patients who&#160;switched to B/F/TAF and 0&#160;cells/mm3&#160;in patients&#160;<br/>who stayed on&#160;their&#160;baseline regimen.&#160;<br/>&#160;<br/><i>Patients co-infected&#160;with HIV and HBV&#160;<br/></i>The&#160;number&#160;of&#160;patients&#160;co-infected with HIV&#160;and HBV&#160;treated with B/F/TAF is limited.&#160;&#160;In&#160;<br/>Study&#160;GS-US-380-1490, 8&#160;patients with HIV/HBV&#160;co-infection&#160;at&#160;baseline were randomised to&#160;<br/>receive B/F/TAF. At&#160;Week&#160;48, 7 patients were HBV&#160;suppressed&#160;(HBV&#160;DNA&#160;&lt;&#160;29&#160;IU/mL) and had&#160;<br/>HIV-1&#160;RNA&#160;&lt;&#160;50&#160;copies/mL. &#160;One patient&#160;had&#160;missing&#160;HBV&#160;DNA&#160;data at&#160;Week&#160;48. &#160;At&#160;Week&#160;144,&#160;5&#160;<br/>patients were HBV&#160;suppressed and had HIV-1 RNA&#160;&lt;&#160;50 copies/mL. &#160;Three&#160;patients had&#160;missing&#160;<br/>HBV&#160;DNA&#160;data at&#160;Week&#160;144&#160;(1&#160;lost&#160;to&#160;follow-up&#160;from&#160;Week 48, 1 lost&#160;to&#160;follow-up after&#160;Week 72,&#160;<br/>and&#160;1&#160;lost&#160;to&#160;follow-up after&#160;Week 120).&#160;<br/>&#160;<br/>In Study&#160;GS-US-380-1878, at&#160;Week&#160;48, 100%&#160;(8/8)&#160;of&#160;the patients co-infected with HIV/HBV&#160;at&#160;<br/>baseline in&#160;the&#160;B/F/TAF&#160;arm&#160;maintained&#160;HBV&#160;DNA&#160;&lt;&#160;29&#160;IU/mL&#160;(missing&#160;=&#160;excluded analysis)&#160;and&#160;<br/>HIV&#160;RNA&#160;&lt;&#160;50&#160;copies/mL.&#160;<br/>&#160;<br/>Paediatric&#160;population&#160;<br/>&#160;<br/>In Study GS-US-380-1474, the pharmacokinetics, safety and efficacy of&#160;B/F/TAF in&#160;<br/>virologically-suppressed children&#160;and adolescents with&#160;HIV&#160;between the ages&#160;of&#160;12 to &lt;&#160;18 years&#160;<br/>(≥&#160;35&#160;kg)&#160;(n&#160;=&#160;50), between&#160;the ages&#160;of&#160;6&#160;to &lt;&#160;12 years&#160;(≥&#160;25&#160;kg)&#160;(n&#160;=&#160;50), and&#160;≥&#160;2&#160;years of&#160;age&#160;(≥&#160;14&#160;<br/>to &lt;&#160;25&#160;kg)&#160;(n&#160;=&#160;22)&#160;were&#160;evaluated.&#160;<br/>&#160;<br/>Cohort&#160;1:&#160;Virologically-suppressed adolescents (n&#160;=&#160;50;&#160;12&#160;to &lt;&#160;18 years;&#160;≥&#160;35 kg)&#160;&#160;</p>
</div>
<!-- Page 21 -->
<a name="21"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page21-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft210">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft211">21&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft218">Patients in&#160;Cohort&#160;1 had a&#160;mean&#160;age&#160;of&#160;14&#160;years&#160;(range:&#160;12&#160;to 17)&#160;and a&#160;mean baseline weight&#160;of&#160;<br/>51.7&#160;kg&#160;(range:&#160;35&#160;to 123),&#160;64%&#160;were female, 27%&#160;were Asian, and&#160;65%&#160;were&#160;Black. &#160;At baseline,&#160;<br/>median CD4+&#160;cell&#160;count&#160;was&#160;750&#160;cells/mm3&#160;(range:&#160;337 to 1207),&#160;and&#160;median CD4+%&#160;was 33%&#160;<br/>(range:&#160;19%&#160;to 45%).&#160;<br/>&#160;<br/>After&#160;switching&#160;to B/F/TAF, 98%&#160;(49/50)&#160;of&#160;patients&#160;in&#160;Cohort&#160;1 remained suppressed&#160;(HIV-1 RNA&#160;<br/>&lt;&#160;50 copies/mL)&#160;at&#160;Week&#160;48. &#160;The&#160;mean&#160;change from&#160;baseline in CD4+ cell&#160;count&#160;at&#160;Week 48&#160;<br/>was&#160;-22&#160;cells/mm3. &#160;Two&#160;of&#160;50 subjects&#160;met&#160;the criteria&#160;for&#160;inclusion&#160;in&#160;the&#160;resistance&#160;analysis&#160;<br/>population through Week 48. &#160;No emergent&#160;resistance&#160;to B/F/TAF was detected&#160;through&#160;Week&#160;48.&#160;<br/>&#160;<br/>Cohort&#160;2:&#160;Virologically-suppressed children (n&#160;=&#160;50;&#160;6&#160;to &lt;&#160;12&#160;years;&#160;≥&#160;25&#160;kg)&#160;&#160;<br/>Patients in&#160;Cohort&#160;2 had&#160;a&#160;mean&#160;age&#160;of&#160;10&#160;years&#160;(range:&#160;6&#160;to 11)&#160;and&#160;a&#160;mean&#160;baseline weight&#160;of&#160;31.9&#160;kg&#160;<br/>(range:&#160;25 to 69), 54%&#160;were female, 22%&#160;were Asian&#160;and 72%&#160;were&#160;Black. &#160;At&#160;baseline, median&#160;<br/>CD4+ cell&#160;count&#160;was 898&#160;cells/mm3&#160;(range&#160;390&#160;to 1991)&#160;and&#160;median CD4+%&#160;was&#160;37%&#160;(range:&#160;19%&#160;to&#160;<br/>53%).&#160;<br/>&#160;<br/>After&#160;switching&#160;to B/F/TAF, 98%&#160;(49/50)&#160;of&#160;patients&#160;in&#160;Cohort&#160;2 remained suppressed&#160;(HIV-1 RNA&#160;<br/>&lt;&#160;50 copies/mL)&#160;at&#160;Week 48. &#160;The&#160;mean&#160;change from&#160;baseline in CD4+ cell&#160;count&#160;at&#160;Week&#160;48&#160;<br/>was&#160;-40&#160;cells/mm3. &#160;No&#160;patient&#160;qualified&#160;for&#160;resistance&#160;analysis through Week 48.&#160;<br/>&#160;<br/>Cohort&#160;3:&#160;Virologically-suppressed children (n&#160;=&#160;22;&#160;≥&#160;2 years;&#160;≥&#160;14&#160;kg&#160;to &lt;&#160;25&#160;kg)&#160;&#160;<br/>Patients in&#160;Cohort&#160;3 had a&#160;mean&#160;age&#160;of&#160;5&#160;years&#160;(range:&#160;3 to 9)&#160;and&#160;a&#160;mean&#160;baseline weight&#160;of&#160;18.8&#160;kg&#160;<br/>(range:&#160;14 to 24), 50%&#160;were female, 23%&#160;were Asian&#160;and 73%&#160;were&#160;Black. &#160;At&#160;baseline, median&#160;<br/>CD4+ cell&#160;count&#160;was 962&#160;cells/mm3&#160;(range&#160;365&#160;to 1986)&#160;and&#160;median CD4+%&#160;was&#160;32%&#160;(range:&#160;24%&#160;to&#160;<br/>46%).&#160;<br/>&#160;<br/>After&#160;switching&#160;to B/F/TAF, 91%&#160;(20/22)&#160;of&#160;patients&#160;in&#160;Cohort&#160;3 remained suppressed&#160;(HIV-1 RNA&#160;<br/>&lt;&#160;50 copies/mL)&#160;at&#160;Week 24. &#160;The&#160;mean&#160;change from&#160;baseline in CD4+ cell&#160;count&#160;at&#160;Week 24 was&#160;<br/>−126 cells/mm3, and&#160;the mean change&#160;in CD4+%&#160;from&#160;baseline&#160;to&#160;Week 24 was&#160;0.2%&#160;(range:&#160;-7.7%&#160;<br/>to 7.5%).&#160;&#160;No patient&#160;qualified&#160;for&#160;resistance&#160;analysis through&#160;Week 24.&#160;<br/>&#160;<br/>The European&#160;Medicines Agency has&#160;deferred the obligation to submit&#160;the&#160;results&#160;of&#160;studies&#160;with&#160;<br/>Biktarvy&#160;in one or&#160;more&#160;subsets of&#160;the&#160;paediatric population&#160;in&#160;the&#160;treatment&#160;of&#160;human&#160;<br/>HIV-1&#160;infection&#160;(see&#160;section&#160;4.2 for&#160;information on paediatric use).&#160;<br/>&#160;<br/><b>5.2&#160;</b></p>
<p style="position:absolute;top:753px;left:149px;white-space:nowrap" class="ft212"><b>Pharmacokinetic properties&#160;</b></p>
<p style="position:absolute;top:772px;left:106px;white-space:nowrap" class="ft218">&#160;<br/>Absorption&#160;<br/>&#160;<br/>Bictegravir&#160;is absorbed following oral&#160;administration&#160;with peak plasma&#160;concentrations&#160;occurring at&#160;<br/>2.0-4.0&#160;hours&#160;after&#160;administration of&#160;B/F/TAF.&#160;&#160;Relative to&#160;fasting conditions, the&#160;administration&#160;of&#160;<br/>B/F/TAF&#160;with either&#160;a moderate fat&#160;(~600&#160;kcal, 27%&#160;fat)&#160;or&#160;high fat&#160;meal&#160;(~800&#160;kcal, 50%&#160;fat)&#160;<br/>resulted in an&#160;increase&#160;in&#160;bictegravir&#160;AUC&#160;(24%).&#160;&#160;This modest&#160;change&#160;is not&#160;considered clinically&#160;<br/>meaningful&#160;and&#160;B/F/TAF&#160;can be&#160;administered with or&#160;without&#160;food.&#160;<br/>&#160;<br/>Following oral&#160;administration of&#160;B/F/TAF&#160;with or&#160;without&#160;food&#160;in HIV-1&#160;infected&#160;adults,&#160;the&#160;multiple&#160;<br/>dose&#160;mean (CV%)&#160;pharmacokinetic parameters of&#160;bictegravir&#160;were Cmax&#160;=&#160;6.15&#160;µg/mL (22.9%),&#160;<br/>AUCtau&#160;=&#160;102&#160;µg•h/mL (26.9%),&#160;and Ctrough&#160;=&#160;2.61&#160;µg/mL (35.2%).&#160;<br/>&#160;<br/>Emtricitabine&#160;is&#160;rapidly&#160;and&#160;extensively absorbed following oral&#160;administration with peak plasma&#160;<br/>concentrations&#160;occurring&#160;at&#160;1.5-2.0&#160;hours&#160;after&#160;administration of&#160;B/F/TAF.&#160;&#160;The&#160;mean&#160;absolute&#160;<br/>bioavailability&#160;of&#160;emtricitabine&#160;from&#160;200&#160;mg&#160;hard capsules&#160;was&#160;93%.&#160;&#160;Emtricitabine&#160;systemic exposure&#160;<br/>was&#160;unaffected when&#160;emtricitabine&#160;was&#160;administered&#160;with&#160;food&#160;and&#160;B/F/TAF&#160;can&#160;be administered with&#160;<br/>or&#160;without&#160;food.&#160;<br/>&#160;</p>
</div>
<!-- Page 22 -->
<a name="22"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page22-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft220">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft221">22&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft225">Following oral&#160;administration&#160;of&#160;B/F/TAF&#160;with or&#160;without&#160;food&#160;in HIV-1 infected&#160;adults,&#160;the&#160;multiple&#160;<br/>dose&#160;mean (CV%)&#160;pharmacokinetic parameters of&#160;emtricitabine were Cmax&#160;=&#160;2.13&#160;µg/mL (34.7%),&#160;<br/>AUCtau&#160;=&#160;12.3&#160;µg•h/mL (29.2%),&#160;and Ctrough&#160;=&#160;0.096&#160;µg/mL&#160;(37.4%).&#160;<br/>&#160;<br/>Tenofovir&#160;alafenamide&#160;is rapidly absorbed following&#160;oral&#160;administration with&#160;peak&#160;plasma&#160;<br/>concentrations&#160;occurring&#160;at&#160;0.5-2.0&#160;hours after&#160;administration of&#160;B/F/TAF.&#160;&#160;Relative to&#160;fasting&#160;<br/>conditions,&#160;the&#160;administration of&#160;tenofovir&#160;alafenamide&#160;with&#160;a&#160;moderate fat&#160;meal&#160;(~600&#160;kcal,&#160;27%&#160;fat)&#160;<br/>and a&#160;high&#160;fat&#160;meal&#160;(~800&#160;kcal, 50%&#160;fat)&#160;resulted&#160;in&#160;an&#160;increase&#160;in&#160;AUClast&#160;by&#160;48%&#160;and&#160;63%,&#160;<br/>respectively.&#160;&#160;These&#160;modest&#160;changes&#160;are not&#160;considered&#160;clinically&#160;meaningful&#160;and&#160;B/F/TAF&#160;can be&#160;<br/>administered with or&#160;without&#160;food.&#160;&#160;<br/>&#160;<br/>Following oral&#160;administration of&#160;B/F/TAF&#160;with or&#160;without&#160;food&#160;in HIV-1 infected&#160;adults,&#160;the&#160;multiple&#160;<br/>dose&#160;mean (CV%)&#160;pharmacokinetic parameters of&#160;tenofovir&#160;alafenamide were Cmax&#160;=&#160;0.121&#160;µg/mL&#160;<br/>(15.4%),&#160;and AUCtau&#160;=&#160;0.142&#160;µg•h/mL (17.3%).&#160;<br/>&#160;<br/>Distribution&#160;<br/>&#160;<br/><i>In&#160;vitro</i>&#160;binding of&#160;bictegravir<b>&#160;</b>to human plasma proteins was &gt;&#160;99%&#160;(free fraction&#160;~0.25%).&#160;&#160;The&#160;<br/><i>in&#160;vitro</i>&#160;human blood&#160;to plasma&#160;bictegravir<b>&#160;</b>concentration ratio was&#160;0.64.&#160;<br/><i>&#160;<br/>In&#160;vitro</i>&#160;binding of&#160;emtricitabine&#160;to human plasma proteins was&#160;&lt;&#160;4%&#160;and independent&#160;of&#160;<br/>concentration over&#160;the&#160;range of&#160;0.02&#160;to&#160;200&#160;µg/mL.&#160;&#160;At&#160;peak plasma&#160;concentration,&#160;the&#160;mean plasma&#160;to&#160;<br/>blood&#160;emtricitabine&#160;concentration&#160;ratio was ~1.0 and&#160;the mean semen to plasma&#160;emtricitabine&#160;<br/>concentration&#160;ratio was&#160;~4.0.&#160;<br/>&#160;<br/><i>In&#160;vitro</i>&#160;binding of&#160;tenofovir&#160;to human plasma proteins&#160;is&#160;&lt;&#160;0.7%&#160;and&#160;is&#160;independent&#160;of&#160;concentration&#160;<br/>over&#160;the&#160;range of&#160;0.01-25&#160;µg/mL.&#160;&#160;<i>Ex&#160;vivo</i>&#160;binding&#160;of&#160;tenofovir&#160;alafenamide&#160;to&#160;human plasma proteins&#160;<br/>in samples&#160;collected during&#160;clinical&#160;studies was&#160;approximately 80%.&#160;&#160;&#160;<br/>&#160;<br/>Biotransformation&#160;<br/>&#160;<br/>Metabolism&#160;is&#160;the&#160;major&#160;clearance&#160;pathway&#160;for&#160;bictegravir&#160;in humans.&#160;&#160;<i>In&#160;vitro</i>&#160;phenotyping studies&#160;<br/>showed&#160;that&#160;bictegravir&#160;is primarily metabolised by CYP3A&#160;and UGT1A1.&#160;&#160;Following a single dose&#160;<br/>oral&#160;administration of&#160;[14C]-bictegravir, ~60%&#160;of&#160;the dose&#160;from&#160;faeces included unchanged parent,&#160;<br/>desfluoro-hydroxy-BIC-cysteine-conjugate,&#160;and other&#160;minor&#160;oxidative&#160;metabolites.&#160;&#160;Thirty-five&#160;<br/>percent&#160;of&#160;the dose&#160;was recovered from&#160;urine&#160;and consisted primarily of&#160;the glucuronide of&#160;bictegravir&#160;<br/>and other&#160;minor&#160;oxidative&#160;metabolites&#160;and&#160;their&#160;phase&#160;II&#160;conjugates.&#160;&#160;Renal&#160;clearance&#160;of&#160;the&#160;unchanged&#160;<br/>parent&#160;was&#160;minimal.&#160;<br/>&#160;<br/>Following administration of&#160;[14C]-emtricitabine, complete&#160;recovery of&#160;the&#160;emtricitabine&#160;dose was&#160;<br/>achieved&#160;in urine (~86%)&#160;and faeces&#160;(~14%).&#160;&#160;Thirteen percent&#160;of&#160;the&#160;dose&#160;was&#160;recovered&#160;in the urine&#160;<br/>as&#160;three putative&#160;metabolites.&#160;&#160;The biotransformation&#160;of&#160;emtricitabine&#160;includes oxidation of&#160;the thiol&#160;<br/>moiety&#160;to&#160;form&#160;the 3’-sulfoxide diastereomers&#160;(~9%&#160;of&#160;dose)&#160;and&#160;conjugation with&#160;glucuronic acid&#160;to&#160;<br/>form&#160;2’-O-glucuronide&#160;(~4%&#160;of&#160;dose).&#160;&#160;No other&#160;metabolites were&#160;identifiable.&#160;<br/>&#160;<br/>Metabolism&#160;is a&#160;major&#160;elimination&#160;pathway for&#160;tenofovir&#160;alafenamide&#160;in humans, accounting&#160;for&#160;<br/>&gt;&#160;80%&#160;of&#160;an oral&#160;dose.&#160;&#160;<i>In&#160;vitro</i>&#160;studies&#160;have&#160;shown that&#160;tenofovir&#160;alafenamide&#160;is&#160;metabolised&#160;to&#160;<br/>tenofovir&#160;(major&#160;metabolite)&#160;by cathepsin&#160;A&#160;in&#160;PBMCs&#160;(including&#160;lymphocytes&#160;and other&#160;HIV&#160;target&#160;<br/>cells)&#160;and&#160;macrophages;&#160;and by carboxylesterase-1 in&#160;hepatocytes.&#160;&#160;<i>In&#160;vivo</i>,&#160;tenofovir&#160;alafenamide&#160;is&#160;<br/>hydrolysed within&#160;cells&#160;to&#160;form&#160;tenofovir&#160;(major&#160;metabolite), which is phosphorylated&#160;to&#160;the&#160;active&#160;<br/>metabolite,&#160;tenofovir&#160;diphosphate.&#160;&#160;In human&#160;clinical&#160;studies, a&#160;25&#160;mg oral&#160;dose&#160;of&#160;tenofovir&#160;<br/>alafenamide&#160;resulted&#160;in tenofovir&#160;diphosphate concentrations&#160;&gt;&#160;4-fold higher&#160;in PBMCs and&#160;&gt;&#160;90%&#160;<br/>lower&#160;concentrations of&#160;tenofovir&#160;in plasma&#160;as&#160;compared to&#160;a&#160;245&#160;mg oral&#160;dose of&#160;tenofovir&#160;disoproxil.&#160;<br/>&#160;</p>
</div>
<!-- Page 23 -->
<a name="23"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft2341{font-size:17px;line-height:15px;font-family:TimesNewRomanPS;color:#000000;}
	.ft2342{font-size:17px;line-height:22px;font-family:TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page23-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft230">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft231">23&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft235">Elimination&#160;<br/>&#160;<br/>Bictegravir&#160;is primarily eliminated by hepatic metabolism.&#160;&#160;Renal&#160;excretion of&#160;intact&#160;bictegravir&#160;is&#160;a&#160;<br/>minor&#160;pathway (~1%&#160;of&#160;dose).&#160;&#160;The plasma bictegravir&#160;half-life was&#160;17.3&#160;hours.&#160;&#160;<br/>&#160;<br/>Emtricitabine&#160;is primarily excreted&#160;by the kidneys&#160;by both glomerular&#160;filtration and active&#160;tubular&#160;<br/>secretion.&#160;&#160;The plasma&#160;emtricitabine&#160;half-life was approximately&#160;10&#160;hours.&#160;<br/>&#160;<br/>Tenofovir&#160;alafenamide&#160;is eliminated&#160;following&#160;metabolism&#160;to&#160;tenofovir.&#160;&#160;Tenofovir&#160;alafenamide&#160;and&#160;<br/>tenofovir&#160;have&#160;a&#160;median&#160;plasma&#160;half-life of&#160;0.51 and&#160;32.37&#160;hours, respectively.&#160;&#160;Tenofovir&#160;is&#160;<br/>eliminated by&#160;the kidneys&#160;by&#160;both&#160;glomerular&#160;filtration&#160;and active tubular&#160;secretion.&#160;&#160;Renal&#160;excretion&#160;<br/>of&#160;intact&#160;tenofovir&#160;alafenamide&#160;is a&#160;minor&#160;pathway with&#160;less than&#160;1%&#160;of&#160;the dose eliminated&#160;in urine.&#160;&#160;&#160;<br/>&#160;<br/>Linearity&#160;<br/>&#160;<br/>The multiple dose&#160;pharmacokinetics&#160;of&#160;bictegravir&#160;are&#160;dose&#160;proportional&#160;over&#160;the&#160;dose&#160;range&#160;of&#160;25 to&#160;<br/>100&#160;mg.&#160;&#160;The&#160;multiple dose&#160;pharmacokinetics of&#160;emtricitabine are dose&#160;proportional&#160;over&#160;the&#160;dose&#160;<br/>range&#160;of&#160;25 to&#160;200&#160;mg.&#160;&#160;Tenofovir&#160;alafenamide&#160;exposures&#160;are dose&#160;proportional&#160;over&#160;the dose&#160;range&#160;of&#160;<br/>8&#160;mg&#160;to 125&#160;mg.&#160;<br/>&#160;<br/>Other&#160;special&#160;populations&#160;<br/>&#160;<br/><i>Hepatic&#160;impairment&#160;<br/></i>Clinically&#160;relevant&#160;changes&#160;in the pharmacokinetics&#160;of&#160;bictegravir&#160;were not&#160;observed in&#160;subjects with&#160;<br/>moderate hepatic&#160;impairment. &#160;The&#160;pharmacokinetics&#160;of&#160;emtricitabine have not&#160;been studied&#160;in&#160;<br/>subjects with hepatic&#160;impairment;&#160;however,&#160;emtricitabine is&#160;not&#160;significantly&#160;metabolised by liver&#160;<br/>enzymes,&#160;so&#160;the&#160;impact&#160;of&#160;liver&#160;impairment&#160;should be&#160;limited. &#160;Clinically&#160;relevant&#160;changes in the&#160;<br/>pharmacokinetics&#160;of&#160;tenofovir&#160;alafenamide&#160;or&#160;its metabolite&#160;tenofovir&#160;were not&#160;observed in patients&#160;<br/>with&#160;mild,&#160;moderate, or&#160;severe hepatic&#160;impairment.&#160;<br/><i>&#160;<br/>Renal&#160;impairment:&#160;<br/>Severe Renal&#160;Impairment&#160;(estimated creatinine clearance&#160;≥&#160;15 and &lt; 30 mL/minute)&#160;<br/></i>No clinically&#160;relevant&#160;differences&#160;in bictegravir,&#160;tenofovir&#160;alafenamide,&#160;or&#160;tenofovir&#160;pharmacokinetics&#160;<br/>were observed between healthy&#160;subjects&#160;and subjects&#160;with severe&#160;renal&#160;impairment&#160;(estimated&#160;<br/>CrCl&#160;≥&#160;15&#160;mL/min and&#160;&lt;&#160;30&#160;mL/min)&#160;in Phase&#160;1 Studies.&#160;&#160;In a&#160;separate Phase&#160;1&#160;study of&#160;emtricitabine&#160;<br/>alone,&#160;mean&#160;systemic&#160;emtricitabine exposure was higher&#160;in patients with severe renal&#160;impairment&#160;<br/>(CrCl&#160;&lt;&#160;30&#160;mL/min)&#160;(33.7&#160;µg•h/mL)&#160;than&#160;in&#160;subjects&#160;with normal&#160;renal&#160;function&#160;(11.8&#160;µg•h/mL). &#160;The&#160;<br/>safety of&#160;Biktarvy has not&#160;been established in&#160;subjects&#160;with estimated creatinine&#160;<br/>clearance&#160;≥&#160;15&#160;mL/min and&#160;&lt;&#160;30&#160;mL/min.&#160;<br/>&#160;<br/><i>End Stage Renal&#160;Disease&#160;(estimated&#160;creatinine clearance&#160;&lt;&#160;15&#160;mL/minute)&#160;<br/></i>Exposures&#160;of&#160;emtricitabine&#160;and tenofovir&#160;in&#160;12 patients&#160;with end stage renal&#160;disease (estimated&#160;<br/>CrCl&#160;&lt;&#160;15&#160;mL/min)&#160;on chronic haemodialysis who received&#160;emtricitabine +&#160;tenofovir&#160;alafenamide&#160;in&#160;<br/>combination with elvitegravir&#160;+ cobicistat&#160;as&#160;a&#160;fixed dose&#160;combination tablet&#160;in Study GS-US-292-<br/>1825 were significantly&#160;higher&#160;than&#160;in patients with normal&#160;renal&#160;function. &#160;No clinically relevant&#160;<br/>differences&#160;in tenofovir&#160;alafenamide&#160;pharmacokinetics&#160;were observed&#160;in patients with&#160;end stage renal&#160;<br/>disease&#160;on chronic haemodialysis&#160;as&#160;compared to&#160;those&#160;with normal&#160;renal&#160;function. &#160;In the extension&#160;<br/>phase&#160;of&#160;Study GS-US-292-1825, lower&#160;bictegravir&#160;Ctrough&#160;was&#160;observed&#160;in patients with&#160;end&#160;stage&#160;<br/>renal&#160;disease who&#160;received&#160;Biktarvy&#160;compared to patients with normal&#160;renal&#160;function, but&#160;this&#160;<br/>difference was not&#160;considered clinically&#160;relevant.&#160;&#160;No additional&#160;adverse&#160;reactions&#160;were&#160;identified in&#160;<br/>patients with end stage&#160;renal&#160;disease&#160;on&#160;chronic&#160;haemodialysis in this&#160;study (see&#160;section 4.8).&#160;<br/>&#160;<br/>There&#160;are&#160;no pharmacokinetic&#160;data on bictegravir,&#160;emtricitabine&#160;or&#160;tenofovir&#160;alafenamide&#160;in patients&#160;<br/>with end stage&#160;renal&#160;disease&#160;(estimated CrCl&#160;&lt;&#160;15&#160;mL/min)&#160;not&#160;on&#160;chronic&#160;haemodialysis. &#160;The safety&#160;<br/>of&#160;Biktarvy has not&#160;been established&#160;in these patients.&#160;<br/>&#160;</p>
</div>
<!-- Page 24 -->
<a name="24"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page24-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft240">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft241">24&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft244"><i>Age, gender&#160;and race&#160;<br/></i>Pharmacokinetics&#160;of&#160;bictegravir, emtricitabine, and&#160;tenofovir&#160;have&#160;not&#160;been&#160;fully evaluated&#160;in&#160;the&#160;<br/>elderly&#160;(≥&#160;65&#160;years of&#160;age).&#160;&#160;Population analyses&#160;using&#160;pooled&#160;pharmacokinetic data from&#160;adult&#160;studies&#160;<br/>did not&#160;identify any&#160;clinically relevant&#160;differences&#160;due&#160;to age, gender&#160;or&#160;race&#160;on&#160;the&#160;exposures&#160;of&#160;<br/>bictegravir, emtricitabine, or&#160;tenofovir&#160;alafenamide.&#160;<br/><i>&#160;<br/>Paediatric&#160;population&#160;&#160;<br/></i>Mean&#160;bictegravir&#160;Cmax, and&#160;exposures&#160;of&#160;emtricitabine&#160;and tenofovir&#160;alafenamide (AUC&#160;and/or&#160;Cmax),&#160;<br/>achieved&#160;in 50&#160;children between the ages&#160;of&#160;6 to &lt;&#160;12&#160;years (≥&#160;25 kg)&#160;who&#160;received the&#160;<br/>50&#160;mg/200&#160;mg/25&#160;mg dose&#160;of&#160;B/F/TAF and&#160;in 22&#160;children&#160;≥&#160;2 years of&#160;age&#160;(≥&#160;14 to &lt;&#160;25&#160;kg)&#160;who&#160;<br/>received the 30&#160;mg/120&#160;mg/15&#160;mg dose&#160;of&#160;B/F/TAF, in Study GS-US-380-1474&#160;were generally higher&#160;<br/>than&#160;exposures in&#160;adults.&#160;&#160;The exposures&#160;of&#160;bictegravir,&#160;emtricitabine, tenofovir&#160;alafenamide&#160;and&#160;<br/>tenofovir&#160;in children, adolescents, and adults are presented&#160;in Table&#160;5.&#160;<br/>&#160;<br/><b>Table&#160;5:&#160;Exposures of&#160;Bictegravir, Emtricitabine, Tenofovir Alafenamide&#160;and&#160;Tenofovir&#160;in&#160;<br/>Children, Adolescents,&#160;and Adults&#160;<br/>&#160;</b></p>
<p style="position:absolute;top:412px;left:115px;white-space:nowrap" class="ft2418">&#160;</p>
<p style="position:absolute;top:409px;left:247px;white-space:nowrap" class="ft2414"><b>Children aged&#160;≥&#160;2&#160;</b></p>
<p style="position:absolute;top:429px;left:288px;white-space:nowrap" class="ft2414"><b>years&#160;</b></p>
<p style="position:absolute;top:444px;left:255px;white-space:nowrap" class="ft2414"><b>≥&#160;14&#160;to&#160;&lt;&#160;25&#160;kga&#160;</b></p>
<p style="position:absolute;top:412px;left:400px;white-space:nowrap" class="ft2414"><b>Children aged&#160;6&#160;</b></p>
<p style="position:absolute;top:429px;left:410px;white-space:nowrap" class="ft2414"><b>to&#160;&lt;&#160;12&#160;years&#160;</b></p>
<p style="position:absolute;top:444px;left:425px;white-space:nowrap" class="ft2414"><b>≥&#160;25&#160;kga&#160;</b></p>
<p style="position:absolute;top:412px;left:531px;white-space:nowrap" class="ft2414"><b>Adolescents&#160;aged&#160;</b></p>
<p style="position:absolute;top:429px;left:536px;white-space:nowrap" class="ft2414"><b>12&#160;to&#160;&lt;&#160;18&#160;years&#160;</b></p>
<p style="position:absolute;top:444px;left:560px;white-space:nowrap" class="ft2414"><b>≥&#160;35&#160;kga&#160;</b></p>
<p style="position:absolute;top:412px;left:696px;white-space:nowrap" class="ft2414"><b>Adultsb&#160;</b></p>
<p style="position:absolute;top:429px;left:661px;white-space:nowrap" class="ft2414"><b>&#160;</b></p>
<p style="position:absolute;top:465px;left:115px;white-space:nowrap" class="ft2418">&#160;</p>
<p style="position:absolute;top:465px;left:276px;white-space:nowrap" class="ft2414"><b>B/F/TAF&#160;</b></p>
<p style="position:absolute;top:482px;left:234px;white-space:nowrap" class="ft2414"><b>(30&#160;mg/120&#160;mg/15&#160;mg)&#160;</b></p>
<p style="position:absolute;top:465px;left:556px;white-space:nowrap" class="ft2414"><b>B/F/TAF&#160;&#160;</b></p>
<p style="position:absolute;top:482px;left:514px;white-space:nowrap" class="ft2414"><b>(50&#160;mg/200&#160;mg/25&#160;mg)&#160;</b></p>
<p style="position:absolute;top:500px;left:115px;white-space:nowrap" class="ft2414"><b>&#160;</b></p>
<p style="position:absolute;top:500px;left:286px;white-space:nowrap" class="ft2418">n&#160;=&#160;12&#160;</p>
<p style="position:absolute;top:500px;left:432px;white-space:nowrap" class="ft2418">n&#160;=&#160;25&#160;</p>
<p style="position:absolute;top:500px;left:566px;white-space:nowrap" class="ft2418">n&#160;=&#160;24&#160;</p>
<p style="position:absolute;top:500px;left:700px;white-space:nowrap" class="ft2418">n&#160;=&#160;77&#160;</p>
<p style="position:absolute;top:518px;left:115px;white-space:nowrap" class="ft2414"><b>BIC&#160;</b></p>
<p style="position:absolute;top:518px;left:234px;white-space:nowrap" class="ft2418">&#160;</p>
<p style="position:absolute;top:518px;left:392px;white-space:nowrap" class="ft2418">&#160;</p>
<p style="position:absolute;top:518px;left:526px;white-space:nowrap" class="ft2418">&#160;</p>
<p style="position:absolute;top:518px;left:661px;white-space:nowrap" class="ft2418">&#160;</p>
<p style="position:absolute;top:538px;left:127px;white-space:nowrap" class="ft2424">AUCtau&#160;<br/>(ng•h/mL)&#160;</p>
<p style="position:absolute;top:536px;left:255px;white-space:nowrap" class="ft2418">108&#160;364.5&#160;(22.9)&#160;</p>
<p style="position:absolute;top:536px;left:401px;white-space:nowrap" class="ft2418">121&#160;034.2&#160;(36.4)&#160;</p>
<p style="position:absolute;top:536px;left:536px;white-space:nowrap" class="ft2418">109&#160;668.1&#160;(30.6)&#160;</p>
<p style="position:absolute;top:536px;left:673px;white-space:nowrap" class="ft2418">94&#160;227.1&#160;(34.7)&#160;</p>
<p style="position:absolute;top:575px;left:127px;white-space:nowrap" class="ft2427">Cmax&#160;<br/>(ng/mL)&#160;</p>
<p style="position:absolute;top:573px;left:259px;white-space:nowrap" class="ft2418">10&#160;040.0&#160;(19.9)&#160;</p>
<p style="position:absolute;top:573px;left:405px;white-space:nowrap" class="ft2418">10&#160;988.8&#160;(28.3)&#160;</p>
<p style="position:absolute;top:573px;left:543px;white-space:nowrap" class="ft2418">8&#160;087.1&#160;(29.9)&#160;</p>
<p style="position:absolute;top:573px;left:677px;white-space:nowrap" class="ft2418">6&#160;801.6&#160;(30.1)&#160;</p>
<p style="position:absolute;top:613px;left:127px;white-space:nowrap" class="ft2422">Ctau&#160;<br/>(ng/mL)&#160;</p>
<p style="position:absolute;top:611px;left:260px;white-space:nowrap" class="ft2418">1&#160;924.5&#160;(78.3)c&#160;</p>
<p style="position:absolute;top:611px;left:406px;white-space:nowrap" class="ft2418">2&#160;366.6&#160;(78.8)d&#160;</p>
<p style="position:absolute;top:611px;left:543px;white-space:nowrap" class="ft2418">2&#160;327.4&#160;(48.6)&#160;</p>
<p style="position:absolute;top:611px;left:675px;white-space:nowrap" class="ft2418">2&#160;256.7&#160;(47.3)g&#160;</p>
<p style="position:absolute;top:648px;left:115px;white-space:nowrap" class="ft2414"><b>FTC&#160;</b></p>
<p style="position:absolute;top:648px;left:305px;white-space:nowrap" class="ft2418">&#160;</p>
<p style="position:absolute;top:648px;left:451px;white-space:nowrap" class="ft2418">&#160;</p>
<p style="position:absolute;top:648px;left:586px;white-space:nowrap" class="ft2418">&#160;</p>
<p style="position:absolute;top:648px;left:720px;white-space:nowrap" class="ft2418">&#160;</p>
<p style="position:absolute;top:667px;left:127px;white-space:nowrap" class="ft2424">AUCtau&#160;<br/>(ng•h/mL)&#160;</p>
<p style="position:absolute;top:667px;left:259px;white-space:nowrap" class="ft2418">14&#160;991.2&#160;(21.9)&#160;</p>
<p style="position:absolute;top:667px;left:405px;white-space:nowrap" class="ft2418">17&#160;565.1&#160;(36.9)&#160;</p>
<p style="position:absolute;top:667px;left:539px;white-space:nowrap" class="ft2418">13&#160;579.1&#160;(21.7)&#160;</p>
<p style="position:absolute;top:667px;left:673px;white-space:nowrap" class="ft2418">12&#160;293.6&#160;(29.2)&#160;</p>
<p style="position:absolute;top:702px;left:127px;white-space:nowrap" class="ft2422">Cmax&#160;<br/>(ng/mL)&#160;</p>
<p style="position:absolute;top:702px;left:262px;white-space:nowrap" class="ft2418">3&#160;849.2&#160;(34.7)&#160;</p>
<p style="position:absolute;top:702px;left:408px;white-space:nowrap" class="ft2418">3&#160;888.4&#160;(31.0)&#160;</p>
<p style="position:absolute;top:702px;left:543px;white-space:nowrap" class="ft2418">2&#160;689.2&#160;(34.0)&#160;</p>
<p style="position:absolute;top:702px;left:677px;white-space:nowrap" class="ft2418">2&#160;127.0&#160;(34.7)&#160;</p>
<p style="position:absolute;top:737px;left:127px;white-space:nowrap" class="ft2422">Ctau&#160;<br/>(ng/mL)&#160;</p>
<p style="position:absolute;top:737px;left:262px;white-space:nowrap" class="ft2418">210.3&#160;(242.9)c&#160;</p>
<p style="position:absolute;top:737px;left:408px;white-space:nowrap" class="ft2418">226.7&#160;(322.8)d&#160;</p>
<p style="position:absolute;top:737px;left:553px;white-space:nowrap" class="ft2418">64.4&#160;(25.0)&#160;</p>
<p style="position:absolute;top:737px;left:684px;white-space:nowrap" class="ft2418">96.0&#160;(37.4)h&#160;</p>
<p style="position:absolute;top:772px;left:115px;white-space:nowrap" class="ft2414"><b>TAF&#160;</b></p>
<p style="position:absolute;top:772px;left:305px;white-space:nowrap" class="ft2418">&#160;</p>
<p style="position:absolute;top:772px;left:451px;white-space:nowrap" class="ft2418">&#160;</p>
<p style="position:absolute;top:772px;left:586px;white-space:nowrap" class="ft2418">&#160;</p>
<p style="position:absolute;top:772px;left:720px;white-space:nowrap" class="ft2418">&#160;</p>
<p style="position:absolute;top:790px;left:127px;white-space:nowrap" class="ft2424">AUCtau&#160;<br/>(ng•h/mL)&#160;</p>
<p style="position:absolute;top:790px;left:268px;white-space:nowrap" class="ft2418">305.4&#160;(42.6)&#160;</p>
<p style="position:absolute;top:790px;left:412px;white-space:nowrap" class="ft2418">434.5&#160;(94.9)e&#160;</p>
<p style="position:absolute;top:790px;left:544px;white-space:nowrap" class="ft2418">347.9&#160;(113.2)f&#160;</p>
<p style="position:absolute;top:790px;left:683px;white-space:nowrap" class="ft2418">229.3&#160;(63.0)&#160;</p>
<p style="position:absolute;top:825px;left:127px;white-space:nowrap" class="ft2422">Cmax&#160;<br/>(ng/mL)&#160;</p>
<p style="position:absolute;top:825px;left:268px;white-space:nowrap" class="ft2418">413.8&#160;(31.0)&#160;</p>
<p style="position:absolute;top:825px;left:412px;white-space:nowrap" class="ft2418">581.8&#160;(99.9)d&#160;</p>
<p style="position:absolute;top:825px;left:545px;white-space:nowrap" class="ft2418">333.9&#160;(110.6)&#160;</p>
<p style="position:absolute;top:825px;left:683px;white-space:nowrap" class="ft2418">276.5&#160;(62.4)&#160;</p>
<p style="position:absolute;top:861px;left:127px;white-space:nowrap" class="ft2422">Ctau&#160;<br/>(ng/mL)&#160;</p>
<p style="position:absolute;top:861px;left:292px;white-space:nowrap" class="ft2418">N/A&#160;</p>
<p style="position:absolute;top:861px;left:438px;white-space:nowrap" class="ft2418">N/A&#160;</p>
<p style="position:absolute;top:861px;left:573px;white-space:nowrap" class="ft2418">N/A&#160;</p>
<p style="position:absolute;top:861px;left:707px;white-space:nowrap" class="ft2418">N/A&#160;</p>
<p style="position:absolute;top:896px;left:115px;white-space:nowrap" class="ft2414"><b>TFV&#160;</b></p>
<p style="position:absolute;top:896px;left:305px;white-space:nowrap" class="ft2418">&#160;</p>
<p style="position:absolute;top:896px;left:451px;white-space:nowrap" class="ft2418">&#160;</p>
<p style="position:absolute;top:896px;left:586px;white-space:nowrap" class="ft2418">&#160;</p>
<p style="position:absolute;top:896px;left:720px;white-space:nowrap" class="ft2418">&#160;</p>
<p style="position:absolute;top:914px;left:127px;white-space:nowrap" class="ft2424">AUCtau&#160;<br/>(ng•h/mL)&#160;</p>
<p style="position:absolute;top:914px;left:268px;white-space:nowrap" class="ft2418">326.6&#160;(23.8)&#160;</p>
<p style="position:absolute;top:914px;left:414px;white-space:nowrap" class="ft2418">427.7&#160;(28.5)&#160;</p>
<p style="position:absolute;top:914px;left:549px;white-space:nowrap" class="ft2418">333.5&#160;(31.5)&#160;</p>
<p style="position:absolute;top:914px;left:682px;white-space:nowrap" class="ft2418">292.6&#160;(27.4)i&#160;</p>
<p style="position:absolute;top:949px;left:127px;white-space:nowrap" class="ft2422">Cmax&#160;<br/>(ng/mL)&#160;</p>
<p style="position:absolute;top:949px;left:272px;white-space:nowrap" class="ft2418">21.9&#160;(29.2)&#160;</p>
<p style="position:absolute;top:949px;left:418px;white-space:nowrap" class="ft2418">35.5&#160;(89.0)&#160;</p>
<p style="position:absolute;top:949px;left:553px;white-space:nowrap" class="ft2418">24.0&#160;(64.2)&#160;</p>
<p style="position:absolute;top:949px;left:685px;white-space:nowrap" class="ft2418">15.2&#160;(26.1)i&#160;</p>
<p style="position:absolute;top:984px;left:127px;white-space:nowrap" class="ft2422">Ctau&#160;<br/>(ng/mL)&#160;</p>
<p style="position:absolute;top:984px;left:269px;white-space:nowrap" class="ft2418">10.3&#160;(30.5)c&#160;</p>
<p style="position:absolute;top:984px;left:415px;white-space:nowrap" class="ft2418">14.0&#160;(30.2)d&#160;</p>
<p style="position:absolute;top:984px;left:553px;white-space:nowrap" class="ft2418">11.1&#160;(32.4)&#160;</p>
<p style="position:absolute;top:984px;left:685px;white-space:nowrap" class="ft2418">10.6&#160;(28.5)i&#160;</p>
<p style="position:absolute;top:1019px;left:106px;white-space:nowrap" class="ft2430">BIC&#160;=&#160;bictegravir;&#160;FTC&#160;=&#160;emtricitabine;&#160;TAF&#160;=&#160;tenofovir&#160;alafenamide&#160;fumarate;&#160;TFV = tenofovir&#160;<br/>N/A = not&#160;applicable;&#160;%CV =&#160;percentage&#160;coefficient&#160;of&#160;variation<b>&#160;</b></p>
</div>
<!-- Page 25 -->
<a name="25"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft2543{font-size:14px;font-family:ArialMT;color:#000000;}
-->
</style>
<div id="page25-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft250">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft251">25&#160;</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft2530">Data are&#160;presented&#160;as mean&#160;(%CV).&#160;<br/>a&#160;&#160;Intensive&#160;PK data from&#160;Study&#160;GS-US-380-1474&#160;<br/>b&#160;&#160;Intensive&#160;PK data from&#160;Studies&#160;GS-US-380-1489,&#160;GS-US-380-1490,&#160;GS-US-380-1844,&#160;GS-US-380-1878&#160;for&#160;BIC,&#160;FTC&#160;</p>
<p style="position:absolute;top:135px;left:128px;white-space:nowrap" class="ft2530">and&#160;TAF&#160;PK exposures and&#160;population&#160;PK data from&#160;Studies&#160;GS-US-292-0104&#160;and&#160;GS-US-292-0111&#160;for&#160;TFV PK&#160;<br/>exposures&#160;</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft2530">c&#160;&#160;n&#160;=&#160;11&#160;&#160;<br/>d&#160;&#160;n&#160;=&#160;24&#160;&#160;<br/>e&#160;&#160;n&#160;=&#160;22&#160;&#160;<br/>f&#160;</p>
<p style="position:absolute;top:213px;left:128px;white-space:nowrap" class="ft2528">n&#160;=&#160;23&#160;</p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft2530">g&#160;&#160;n&#160;=&#160;75&#160;<br/>h&#160;&#160;n&#160;=&#160;74&#160;&#160;<br/>i&#160;</p>
<p style="position:absolute;top:259px;left:128px;white-space:nowrap" class="ft2528">n&#160;=&#160;841&#160;</p>
<p style="position:absolute;top:275px;left:106px;white-space:nowrap" class="ft258">&#160;<br/><b>5.3&#160;</b></p>
<p style="position:absolute;top:294px;left:149px;white-space:nowrap" class="ft252"><b>Preclinical&#160;safety data&#160;</b></p>
<p style="position:absolute;top:313px;left:106px;white-space:nowrap" class="ft258">&#160;<br/>Bictegravir&#160;was&#160;not&#160;mutagenic or&#160;clastogenic&#160;in&#160;conventional&#160;genotoxicity&#160;assays.&#160;</p>
<p style="position:absolute;top:362px;left:106px;white-space:nowrap" class="ft255">Bictegravir&#160;was&#160;not&#160;carcinogenic&#160;in&#160;a 6-month&#160;rasH2&#160;transgenic&#160;mouse&#160;study&#160;(at&#160;doses of&#160;up&#160;to&#160;<br/>100&#160;mg/kg/day&#160;in&#160;males&#160;and 300&#160;mg/kg/day in&#160;females, which&#160;resulted&#160;in exposures&#160;of&#160;approximately&#160;<br/>15&#160;and&#160;23&#160;times,&#160;in&#160;males&#160;and females,&#160;respectively, the exposure&#160;in humans&#160;at&#160;the&#160;recommended&#160;<br/>human&#160;dose)&#160;nor&#160;in&#160;a 2-year&#160;rat&#160;study&#160;(at&#160;doses&#160;of&#160;up&#160;to 300&#160;mg/kg/day, which resulted in&#160;exposures&#160;of&#160;<br/>approximately 31&#160;times&#160;the&#160;exposure&#160;in humans).&#160;&#160;<br/>&#160;<br/>Studies&#160;of&#160;bictegravir&#160;in monkeys&#160;revealed the liver&#160;as the primary&#160;target&#160;organ of&#160;toxicity.&#160;&#160;<br/>Hepatobiliary&#160;toxicity was&#160;described in a 39-week&#160;study at&#160;a&#160;dosage&#160;of&#160;1,000&#160;mg/kg/day, which&#160;<br/>resulted in exposures&#160;of&#160;approximately 16&#160;times&#160;the exposure in&#160;humans&#160;at&#160;the&#160;recommended human&#160;<br/>dose, and was&#160;partially reversible&#160;after&#160;a 4-week&#160;recovery period.&#160;&#160;<br/>&#160;<br/>Studies&#160;in animals&#160;with bictegravir&#160;have&#160;shown no evidence of&#160;teratogenicity or&#160;an&#160;effect&#160;on&#160;<br/>reproductive function.&#160;&#160;In offspring from&#160;rat&#160;and rabbit&#160;dams&#160;treated with&#160;bictegravir&#160;during&#160;<br/>pregnancy,&#160;there were no toxicologically&#160;significant&#160;effects&#160;on developmental&#160;endpoints.&#160;<br/>&#160;<br/>Non-clinical&#160;data on emtricitabine reveal&#160;no&#160;special&#160;hazard&#160;for&#160;humans&#160;based on conventional&#160;studies&#160;<br/>of&#160;safety pharmacology, repeated&#160;dose&#160;toxicity, genotoxicity,&#160;carcinogenic&#160;potential,&#160;toxicity&#160;to&#160;<br/>reproduction and&#160;development.&#160;&#160;Emtricitabine&#160;has&#160;demonstrated&#160;low&#160;carcinogenic&#160;potential&#160;in&#160;mice&#160;<br/>and rats.&#160;<br/>&#160;<br/>Non-clinical&#160;studies&#160;of&#160;tenofovir&#160;alafenamide&#160;in rats&#160;and&#160;dogs&#160;revealed bone and&#160;kidney&#160;as&#160;the primary&#160;<br/>target&#160;organs&#160;of&#160;toxicity.&#160;&#160;Bone toxicity was&#160;observed&#160;as reduced&#160;bone&#160;mineral&#160;density in&#160;rats and dogs&#160;<br/>at&#160;tenofovir&#160;exposures&#160;at&#160;least&#160;43&#160;times&#160;greater&#160;than&#160;those&#160;expected&#160;after&#160;administration of&#160;B/F/TAF.&#160;&#160;<br/>A&#160;minimal&#160;infiltration&#160;of&#160;histiocytes&#160;was present&#160;in the&#160;eye&#160;in dogs at&#160;tenofovir&#160;alafenamide and&#160;<br/>tenofovir&#160;exposures&#160;of&#160;approximately&#160;14 and&#160;43&#160;times&#160;greater, respectively,&#160;than&#160;those&#160;expected&#160;after&#160;<br/>administration&#160;of&#160;B/F/TAF.&#160;<br/>&#160;<br/>Tenofovir&#160;alafenamide was&#160;not&#160;mutagenic or&#160;clastogenic&#160;in conventional&#160;genotoxicity assays.&#160;<br/>&#160;<br/>Because there&#160;is&#160;a lower&#160;tenofovir&#160;exposure&#160;in&#160;rats and mice&#160;after&#160;the&#160;administration of&#160;tenofovir&#160;<br/>alafenamide compared to&#160;tenofovir&#160;disoproxil,&#160;carcinogenicity studies&#160;and a&#160;rat&#160;peri-postnatal&#160;study&#160;<br/>were conducted only with&#160;tenofovir&#160;disoproxil.&#160;&#160;No special&#160;hazard for&#160;humans was revealed&#160;in&#160;<br/>conventional&#160;studies&#160;of&#160;carcinogenic potential&#160;and toxicity to&#160;reproduction and development.&#160;&#160;<br/>Reproductive&#160;toxicity&#160;studies&#160;in&#160;rats&#160;and rabbits&#160;showed no effects&#160;on&#160;mating,&#160;fertility, pregnancy or&#160;<br/>foetal&#160;parameters.&#160;&#160;However, tenofovir&#160;disoproxil&#160;reduced the viability&#160;index and&#160;weight&#160;of&#160;pups&#160;in a&#160;<br/>peri-postnatal&#160;toxicity study at&#160;maternally&#160;toxic doses.&#160;<br/>&#160;<br/>&#160;</p>
</div>
<!-- Page 26 -->
<a name="26"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft2644{font-size:17px;font-family:ArialMT;color:#000000;}
-->
</style>
<div id="page26-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft260">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft261">26&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft262"><b>6.&#160;</b></p>
<p style="position:absolute;top:89px;left:149px;white-space:nowrap" class="ft262"><b>PHARMACEUTICAL&#160;PARTICULARS&#160;</b></p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft265">&#160;<br/><b>6.1&#160;</b></p>
<p style="position:absolute;top:127px;left:149px;white-space:nowrap" class="ft262"><b>List&#160;of&#160;excipients&#160;</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft265">&#160;<br/>Tablet&#160;core&#160;<br/>Microcrystalline&#160;cellulose&#160;(E460)&#160;<br/>Croscarmellose sodium&#160;(E468)&#160;<br/>Magnesium&#160;stearate&#160;(E470b)&#160;<br/>&#160;<br/>Film-coating&#160;<br/>Polyvinyl&#160;alcohol&#160;(E203)&#160;<br/>Titanium&#160;dioxide&#160;(E171)&#160;<br/>Macrogol&#160;(E1521)&#160;<br/>Talc&#160;(E553b)&#160;<br/>Iron oxide red (E172)&#160;<br/>Iron oxide black&#160;(E172)&#160;<br/>&#160;<br/><b>6.2&#160;</b></p>
<p style="position:absolute;top:412px;left:149px;white-space:nowrap" class="ft262"><b>Incompatibilities&#160;</b></p>
<p style="position:absolute;top:431px;left:106px;white-space:nowrap" class="ft265">&#160;<br/>Not&#160;applicable.&#160;<br/>&#160;<br/><b>6.3&#160;</b></p>
<p style="position:absolute;top:488px;left:149px;white-space:nowrap" class="ft262"><b>Shelf&#160;life&#160;</b></p>
<p style="position:absolute;top:506px;left:106px;white-space:nowrap" class="ft265">&#160;<br/>Bottle&#160;<br/>3&#160;years&#160;<br/>&#160;<br/>Blister&#160;<br/>2&#160;years&#160;<br/>&#160;<br/><b>6.4&#160;</b></p>
<p style="position:absolute;top:639px;left:149px;white-space:nowrap" class="ft262"><b>Special&#160;precautions for storage&#160;</b></p>
<p style="position:absolute;top:658px;left:106px;white-space:nowrap" class="ft265">&#160;<br/>Bottle&#160;<br/>Store&#160;in&#160;the&#160;original&#160;package in order&#160;to protect&#160;from&#160;moisture.&#160;&#160;Keep&#160;the&#160;bottle tightly&#160;closed.&#160;&#160;Do not&#160;<br/>use&#160;if&#160;seal&#160;over&#160;bottle opening is&#160;broken or&#160;missing.&#160;<br/>&#160;<br/>Blister&#160;<br/>Store&#160;in&#160;the&#160;original&#160;package in order&#160;to protect&#160;from&#160;moisture. &#160;Do not&#160;use if&#160;foil&#160;over&#160;blister&#160;is broken&#160;<br/>or&#160;pierced.&#160;<br/>&#160;<br/><b>6.5&#160;</b></p>
<p style="position:absolute;top:829px;left:149px;white-space:nowrap" class="ft262"><b>Nature and&#160;contents of&#160;container&#160;</b></p>
<p style="position:absolute;top:848px;left:106px;white-space:nowrap" class="ft265">&#160;<br/>The following pack configurations&#160;are available:&#160;<br/>&#160;<br/>Bottle&#160;<br/>Biktarvy&#160;30&#160;mg/120&#160;mg/15&#160;mg tablets&#160;and&#160;50&#160;mg/200&#160;mg/25&#160;mg tablets&#160;are packaged in white, high&#160;<br/>density polyethylene (HDPE) bottle with a&#160;polypropylene&#160;continuous-thread, child-resistant&#160;cap,&#160;lined&#160;<br/>with an induction&#160;activated&#160;aluminium&#160;foil&#160;liner&#160;containing 30&#160;film-coated&#160;tablets.&#160;&#160;Each&#160;bottle&#160;<br/>contains&#160;silica&#160;gel&#160;desiccant&#160;and polyester&#160;coil.&#160;<br/>&#160;</p>
<p style="position:absolute;top:1019px;left:149px;white-space:nowrap" class="ft260">-&#160;</p>
<p style="position:absolute;top:1019px;left:191px;white-space:nowrap" class="ft260">Outer&#160;carton&#160;containing&#160;1 bottle of&#160;30&#160;film-coated tablets&#160;</p>
<p style="position:absolute;top:1038px;left:149px;white-space:nowrap" class="ft260">-&#160;</p>
<p style="position:absolute;top:1038px;left:191px;white-space:nowrap" class="ft260">Outer&#160;carton&#160;containing&#160;90&#160;(3&#160;bottles&#160;of&#160;30)&#160;film-coated tablets.&#160;</p>
<p style="position:absolute;top:1057px;left:106px;white-space:nowrap" class="ft265">&#160;<br/>Blister&#160;<br/>Biktarvy 50&#160;mg/200&#160;mg/25&#160;mg blister&#160;packs&#160;consisting&#160;of&#160;polyvinyl&#160;<br/>chloride/polyethylene/polychlorotrifluoroethylene (PVC/PE/PCTFE)&#160;film, sealed&#160;to aluminium&#160;foil&#160;<br/>lidding&#160;material&#160;fitted with&#160;a molecular&#160;sieve desiccant&#160;within each blister&#160;cavity.&#160;&#160;<br/>&#160;</p>
</div>
<!-- Page 27 -->
<a name="27"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page27-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft270">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft271">27&#160;</p>
<p style="position:absolute;top:89px;left:149px;white-space:nowrap" class="ft270">-&#160;</p>
<p style="position:absolute;top:89px;left:191px;white-space:nowrap" class="ft278">Outer&#160;carton&#160;containing&#160;30&#160;film-coated&#160;tablets&#160;(4&#160;x&#160;blister&#160;strips containing 7&#160;film-coated&#160;<br/>tablets and&#160;1&#160;x&#160;blister&#160;strip&#160;containing 2&#160;film-coated tablets).&#160;</p>
<p style="position:absolute;top:127px;left:149px;white-space:nowrap" class="ft270">-&#160;</p>
<p style="position:absolute;top:127px;left:191px;white-space:nowrap" class="ft270">Outer&#160;carton&#160;containing&#160;90&#160;(3&#160;blister&#160;packs&#160;of&#160;30)&#160;film-coated tablets.&#160;</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft275">&#160;<br/>Not&#160;all&#160;pack sizes&#160;may be&#160;marketed.&#160;<br/>&#160;<br/><b>6.6&#160;</b></p>
<p style="position:absolute;top:203px;left:149px;white-space:nowrap" class="ft272"><b>Special&#160;precautions for disposal&#160;</b></p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft275">&#160;<br/>Any unused&#160;medicinal&#160;product&#160;or&#160;waste&#160;material&#160;should be disposed of&#160;in&#160;accordance&#160;with local&#160;<br/>requirements.&#160;<br/>&#160;<br/>&#160;<br/><b>7.&#160;</b></p>
<p style="position:absolute;top:317px;left:149px;white-space:nowrap" class="ft272"><b>MARKETING AUTHORISATION&#160;HOLDER&#160;</b></p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft278">&#160;<br/>Gilead Sciences&#160;Ireland UC&#160;<br/>Carrigtohill&#160;<br/>County Cork, T45 DP77&#160;<br/>Ireland&#160;<br/>&#160;<br/>&#160;<br/><b>8.&#160;</b></p>
<p style="position:absolute;top:469px;left:149px;white-space:nowrap" class="ft272"><b>MARKETING AUTHORISATION&#160;NUMBER(S)&#160;</b></p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft278">&#160;<br/>EU/1/18/1289/001&#160;<br/>EU/1/18/1289/002&#160;<br/>EU/1/18/1289/003&#160;<br/>EU/1/18/1289/004&#160;<br/>EU/1/18/1289/005&#160;<br/>EU/1/18/1289/006&#160;<br/>&#160;<br/>&#160;<br/><b>9.&#160;</b></p>
<p style="position:absolute;top:658px;left:149px;white-space:nowrap" class="ft272"><b>DATE&#160;OF FIRST&#160;AUTHORISATION/RENEWAL&#160;OF THE&#160;AUTHORISATION&#160;</b></p>
<p style="position:absolute;top:677px;left:106px;white-space:nowrap" class="ft278">&#160;<br/>Date of&#160;first&#160;authorisation:&#160;21 June&#160;2018&#160;<br/>&#160;<br/>&#160;<br/><b>10.&#160;</b></p>
<p style="position:absolute;top:753px;left:149px;white-space:nowrap" class="ft272"><b>DATE&#160;OF REVISION&#160;OF THE&#160;TEXT&#160;</b></p>
<p style="position:absolute;top:772px;left:106px;white-space:nowrap" class="ft275">&#160;<br/>Detailed&#160;information on&#160;this medicinal&#160;product&#160;is available&#160;on the website of&#160;the European Medicines&#160;<br/>Agenc<a href="http://www.ema.europa.eu/">y&#160;http://www.ema.europa.eu.</a>&#160;<br/><b>&#160;</b></p>
<p style="position:absolute;top:829px;left:322px;white-space:nowrap" class="ft270">&#160;</p>
</div>
<!-- Page 28 -->
<a name="28"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page28-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft280">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft281">28&#160;</p>
<p style="position:absolute;top:89px;left:447px;white-space:nowrap" class="ft285">&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;</p>
<p style="position:absolute;top:506px;left:409px;white-space:nowrap" class="ft282"><b>ANNEX&#160;II</b>&#160;</p>
<p style="position:absolute;top:526px;left:447px;white-space:nowrap" class="ft280">&#160;</p>
<p style="position:absolute;top:544px;left:191px;white-space:nowrap" class="ft282"><b>A.&#160;</b></p>
<p style="position:absolute;top:544px;left:234px;white-space:nowrap" class="ft283"><b>MANUFACTURER(S) RESPONSIBLE&#160;FOR BATCH&#160;<br/>RELEASE&#160;</b></p>
<p style="position:absolute;top:582px;left:436px;white-space:nowrap" class="ft280">&#160;</p>
<p style="position:absolute;top:601px;left:191px;white-space:nowrap" class="ft282"><b>B.&#160;</b></p>
<p style="position:absolute;top:601px;left:234px;white-space:nowrap" class="ft284"><b>CONDITIONS&#160;OR&#160;RESTRICTIONS REGARDING&#160;SUPPLY&#160;<br/>AND&#160;USE&#160;</b></p>
<p style="position:absolute;top:639px;left:191px;white-space:nowrap" class="ft283"><b>&#160;<br/>C.&#160;</b></p>
<p style="position:absolute;top:658px;left:234px;white-space:nowrap" class="ft284"><b>OTHER&#160;CONDITIONS&#160;AND&#160;REQUIREMENTS OF THE&#160;<br/>MARKETING AUTHORISATION&#160;</b></p>
<p style="position:absolute;top:696px;left:191px;white-space:nowrap" class="ft284"><b>&#160;<br/>D.&#160;</b></p>
<p style="position:absolute;top:715px;left:234px;white-space:nowrap" class="ft283"><b>CONDITIONS&#160;OR&#160;RESTRICTIONS WITH&#160;REGARD&#160;TO&#160;<br/>THE&#160;SAFE&#160;AND&#160;EFFECTIVE&#160;USE&#160;OF THE&#160;MEDICINAL&#160;<br/>PRODUCT&#160;</b></p>
</div>
<!-- Page 29 -->
<a name="29"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page29-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft290">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft291">29&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft292"><b>A.&#160;</b></p>
<p style="position:absolute;top:89px;left:149px;white-space:nowrap" class="ft292"><b>MANUFACTURER(S) RESPONSIBLE&#160;FOR BATCH&#160;RELEASE&#160;</b></p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft295">&#160;<br/>Name&#160;and address&#160;of&#160;the&#160;manufacturer(s)&#160;responsible&#160;for&#160;batch&#160;release&#160;<br/>&#160;<br/>Gilead Sciences&#160;Ireland UC&#160;<br/>IDA&#160;Business&#160;&amp;&#160;Technology Park&#160;<br/>Carrigtohill&#160;<br/>County Cork&#160;<br/>Ireland&#160;<br/>&#160;<br/>&#160;<br/><b>B.&#160;</b></p>
<p style="position:absolute;top:298px;left:149px;white-space:nowrap" class="ft292"><b>CONDITIONS&#160;OR&#160;RESTRICTIONS REGARDING&#160;SUPPLY&#160;AND&#160;USE&#160;</b></p>
<p style="position:absolute;top:317px;left:106px;white-space:nowrap" class="ft295">&#160;<br/>Medicinal&#160;product&#160;subject&#160;to&#160;restricted&#160;medical&#160;prescription (see&#160;Annex&#160;I:&#160;Summary of&#160;Product&#160;<br/>Characteristics,&#160;section&#160;4.2).&#160;<br/>&#160;<br/>&#160;<br/><b>C.&#160;</b></p>
<p style="position:absolute;top:412px;left:149px;white-space:nowrap" class="ft293"><b>OTHER&#160;CONDITIONS&#160;AND&#160;REQUIREMENTS OF THE&#160;MARKETING&#160;<br/>AUTHORISATION&#160;</b></p>
<p style="position:absolute;top:450px;left:106px;white-space:nowrap" class="ft2912">&#160;<br/>•&#160;</p>
<p style="position:absolute;top:470px;left:149px;white-space:nowrap" class="ft292"><b>Periodic&#160;safety&#160;update&#160;reports&#160;(PSURs)&#160;</b></p>
<p style="position:absolute;top:489px;left:106px;white-space:nowrap" class="ft295">&#160;<br/>The requirements&#160;for&#160;submission of&#160;PSURs&#160;for&#160;this&#160;medicinal&#160;product&#160;are set&#160;out&#160;in the&#160;list&#160;of&#160;Union&#160;<br/>reference&#160;dates&#160;(EURD&#160;list)&#160;provided&#160;for&#160;under&#160;Article&#160;107c(7)&#160;of&#160;Directive&#160;2001/83/EC&#160;and&#160;any&#160;<br/>subsequent&#160;updates published on the European&#160;medicines&#160;web-portal.&#160;<br/>&#160;<br/>&#160;<br/><b>D.&#160;</b></p>
<p style="position:absolute;top:603px;left:149px;white-space:nowrap" class="ft294"><b>CONDITIONS&#160;OR&#160;RESTRICTIONS WITH&#160;REGARD&#160;TO&#160;THE&#160;SAFE&#160;AND&#160;<br/>EFFECTIVE&#160;USE&#160;OF THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:641px;left:106px;white-space:nowrap" class="ft290">&#160;</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft296">•&#160;</p>
<p style="position:absolute;top:661px;left:149px;white-space:nowrap" class="ft292"><b>Risk&#160;management&#160;plan&#160;(RMP)&#160;</b></p>
<p style="position:absolute;top:680px;left:106px;white-space:nowrap" class="ft2912">&#160;<br/>The&#160;marketing authorisation holder&#160;(MAH)&#160;shall&#160;perform&#160;the&#160;required pharmacovigilance&#160;activities&#160;<br/>and interventions detailed&#160;in the&#160;agreed&#160;RMP&#160;presented in&#160;Module&#160;1.8.2 of&#160;the&#160;marketing&#160;authorisation&#160;<br/>and any&#160;agreed&#160;subsequent&#160;updates&#160;of&#160;the RMP.&#160;<br/>&#160;<br/>An updated RMP&#160;should be&#160;submitted:&#160;<br/>•&#160;</p>
<p style="position:absolute;top:795px;left:149px;white-space:nowrap" class="ft290">At&#160;the&#160;request&#160;of&#160;the European Medicines&#160;Agency;&#160;</p>
<p style="position:absolute;top:810px;left:106px;white-space:nowrap" class="ft296">•&#160;</p>
<p style="position:absolute;top:815px;left:149px;white-space:nowrap" class="ft295">Whenever&#160;the&#160;risk&#160;management&#160;system&#160;is&#160;modified,&#160;especially as the result&#160;of&#160;new&#160;information&#160;<br/>being&#160;received&#160;that&#160;may lead to a&#160;significant&#160;change&#160;to&#160;the benefit/risk profile&#160;or&#160;as&#160;the&#160;result&#160;of&#160;<br/>an important&#160;(pharmacovigilance or&#160;risk&#160;minimisation)&#160;milestone being&#160;reached.<b>&#160;</b></p>
<p style="position:absolute;top:872px;left:106px;white-space:nowrap" class="ft290">&#160;</p>
<p style="position:absolute;top:872px;left:322px;white-space:nowrap" class="ft290">&#160;</p>
</div>
<!-- Page 30 -->
<a name="30"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page30-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft300">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft301">30&#160;</p>
<p style="position:absolute;top:89px;left:447px;white-space:nowrap" class="ft304"><b>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;</b></p>
<p style="position:absolute;top:506px;left:406px;white-space:nowrap" class="ft302"><b>ANNEX&#160;III&#160;</b></p>
<p style="position:absolute;top:526px;left:447px;white-space:nowrap" class="ft302"><b>&#160;</b></p>
<p style="position:absolute;top:544px;left:294px;white-space:nowrap" class="ft302"><b>LABELLING AND&#160;PACKAGE&#160;LEAFLET&#160;</b></p>
<p style="position:absolute;top:564px;left:447px;white-space:nowrap" class="ft302"><b>&#160;</b></p>
<p style="position:absolute;top:564px;left:663px;white-space:nowrap" class="ft300">&#160;</p>
</div>
<!-- Page 31 -->
<a name="31"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page31-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft310">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft311">31&#160;</p>
<p style="position:absolute;top:89px;left:447px;white-space:nowrap" class="ft314"><b>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;</b></p>
<p style="position:absolute;top:506px;left:387px;white-space:nowrap" class="ft312"><b>A. LABELLING&#160;</b></p>
</div>
<!-- Page 32 -->
<a name="32"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft3245{font-size:17px;line-height:21px;font-family:TimesNewRomanPS;color:#000000;}
	.ft3246{font-size:17px;line-height:21px;font-family:TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page32-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft320">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft321">32&#160;</p>
<p style="position:absolute;top:91px;left:106px;white-space:nowrap" class="ft3246"><b>PARTICULARS TO&#160;APPEAR&#160;ON&#160;THE&#160;OUTER&#160;PACKAGING&#160;AND&#160;THE&#160;IMMEDIATE&#160;<br/>PACKAGING&#160;<br/>&#160;<br/>BOTTLE&#160;AND&#160;CARTON&#160;LABELLING&#160;<br/></b>&#160;<br/>&#160;<br/><b>1.&#160;</b></p>
<p style="position:absolute;top:210px;left:149px;white-space:nowrap" class="ft322"><b>NAME OF THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:231px;left:106px;white-space:nowrap" class="ft3246">&#160;<br/>Biktarvy 30&#160;mg/120&#160;mg/15&#160;mg&#160;film-coated&#160;tablets&#160;<br/>bictegravir/emtricitabine/tenofovir&#160;alafenamide&#160;<br/>&#160;<br/>&#160;<br/><b>2.&#160;</b></p>
<p style="position:absolute;top:328px;left:149px;white-space:nowrap" class="ft322"><b>STATEMENT&#160;OF ACTIVE&#160;SUBSTANCE(S)&#160;</b></p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft3246">&#160;<br/>Each film-coated&#160;tablet&#160;contains bictegravir&#160;sodium&#160;equivalent&#160;to&#160;30&#160;mg of&#160;bictegravir, 120&#160;mg of&#160;<br/>emtricitabine,&#160;and&#160;tenofovir&#160;alafenamide&#160;fumarate equivalent&#160;to 15&#160;mg of&#160;tenofovir&#160;alafenamide.&#160;<br/>&#160;<br/>&#160;<br/><b>3.&#160;</b></p>
<p style="position:absolute;top:447px;left:149px;white-space:nowrap" class="ft322"><b>LIST&#160;OF EXCIPIENTS&#160;</b></p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft3246">&#160;<br/>&#160;<br/><b>4.&#160;</b></p>
<p style="position:absolute;top:508px;left:149px;white-space:nowrap" class="ft322"><b>PHARMACEUTICAL&#160;FORM AND&#160;CONTENTS&#160;</b></p>
<p style="position:absolute;top:529px;left:106px;white-space:nowrap" class="ft3246">&#160;<br/>30&#160;film-coated&#160;tablets&#160;<br/>&#160;<br/>90&#160;(3&#160;bottles of&#160;30)&#160;film-coated&#160;tablets&#160;<br/>&#160;<br/>&#160;<br/><b>5.&#160;</b></p>
<p style="position:absolute;top:645px;left:149px;white-space:nowrap" class="ft322"><b>METHOD&#160;AND&#160;ROUTE(S) OF ADMINISTRATION&#160;</b></p>
<p style="position:absolute;top:666px;left:106px;white-space:nowrap" class="ft3246">&#160;<br/>Oral&#160;use&#160;<br/>&#160;<br/>Read the package leaflet&#160;before&#160;use.&#160;<br/>&#160;<br/>&#160;<br/><b>6.&#160;</b></p>
<p style="position:absolute;top:783px;left:149px;white-space:nowrap" class="ft323"><b>SPECIAL&#160;WARNING THAT&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;MUST&#160;BE&#160;STORED&#160;OUT&#160;<br/>OF THE&#160;SIGHT&#160;AND&#160;REACH&#160;OF CHILDREN&#160;</b></p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft3246">&#160;<br/>Keep out&#160;of&#160;the&#160;sight&#160;and reach of&#160;children.&#160;<br/>&#160;<br/>&#160;<br/><b>7.&#160;</b></p>
<p style="position:absolute;top:901px;left:149px;white-space:nowrap" class="ft322"><b>OTHER&#160;SPECIAL&#160;WARNING(S), IF NECESSARY&#160;</b></p>
<p style="position:absolute;top:922px;left:106px;white-space:nowrap" class="ft3246">&#160;<br/>&#160;<br/><b>8.&#160;</b></p>
<p style="position:absolute;top:962px;left:149px;white-space:nowrap" class="ft322"><b>EXPIRY&#160;DATE&#160;</b></p>
<p style="position:absolute;top:984px;left:106px;white-space:nowrap" class="ft3246">&#160;<br/>EXP&#160;<br/>&#160;<br/>&#160;<br/><b>9.&#160;</b></p>
<p style="position:absolute;top:1062px;left:149px;white-space:nowrap" class="ft322"><b>SPECIAL&#160;STORAGE&#160;CONDITIONS&#160;</b></p>
<p style="position:absolute;top:1083px;left:106px;white-space:nowrap" class="ft325">&#160;<br/>Store&#160;in&#160;the&#160;original&#160;package in order&#160;to protect&#160;from&#160;moisture. &#160;<b>Keep&#160;the bottle&#160;tightly&#160;closed.</b>&#160;<br/>&#160;<br/>&#160;</p>
</div>
<!-- Page 33 -->
<a name="33"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft3347{font-size:17px;font-family:TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page33-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft330">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft331">33&#160;</p>
<p style="position:absolute;top:91px;left:106px;white-space:nowrap" class="ft332"><b>10.&#160;</b></p>
<p style="position:absolute;top:91px;left:149px;white-space:nowrap" class="ft333"><b>SPECIAL&#160;PRECAUTIONS FOR&#160;DISPOSAL&#160;OF&#160;UNUSED&#160;MEDICINAL&#160;PRODUCTS&#160;<br/>OR&#160;WASTE&#160;MATERIALS DERIVED&#160;FROM SUCH&#160;MEDICINAL&#160;PRODUCTS, IF&#160;<br/>APPROPRIATE&#160;</b></p>
<p style="position:absolute;top:151px;left:106px;white-space:nowrap" class="ft3346">&#160;<br/>&#160;<br/><b>11.&#160;</b></p>
<p style="position:absolute;top:191px;left:149px;white-space:nowrap" class="ft332"><b>NAME AND&#160;ADDRESS&#160;OF THE&#160;MARKETING&#160;AUTHORISATION&#160;HOLDER&#160;</b></p>
<p style="position:absolute;top:213px;left:106px;white-space:nowrap" class="ft3346">&#160;<br/>Gilead Sciences&#160;Ireland UC&#160;<br/>Carrigtohill&#160;<br/>County Cork, T45 DP77&#160;<br/>Ireland&#160;<br/>&#160;<br/>&#160;<br/><b>12.&#160;</b></p>
<p style="position:absolute;top:349px;left:149px;white-space:nowrap" class="ft332"><b>MARKETING AUTHORISATION&#160;NUMBER(S)&#160;</b></p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft3346">&#160;<br/>EU/1/18/1289/005&#160;30&#160;film-coated tablets&#160;<br/>EU/1/18/1289/006&#160;90&#160;(3&#160;bottles&#160;of&#160;30)&#160;film-coated&#160;tablets&#160;<br/>&#160;<br/>&#160;<br/><b>13.&#160;</b></p>
<p style="position:absolute;top:467px;left:149px;white-space:nowrap" class="ft332"><b>BATCH&#160;NUMBER&#160;</b></p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft3346">&#160;<br/>Lot&#160;<br/>&#160;<br/>&#160;<br/><b>14.&#160;</b></p>
<p style="position:absolute;top:566px;left:149px;white-space:nowrap" class="ft332"><b>GENERAL&#160;CLASSIFICATION&#160;FOR SUPPLY&#160;</b></p>
<p style="position:absolute;top:587px;left:106px;white-space:nowrap" class="ft335">&#160;<br/>&#160;</p>
<p style="position:absolute;top:629px;left:106px;white-space:nowrap" class="ft332"><b>15.&#160;</b></p>
<p style="position:absolute;top:629px;left:149px;white-space:nowrap" class="ft332"><b>INSTRUCTIONS ON USE&#160;</b></p>
<p style="position:absolute;top:650px;left:106px;white-space:nowrap" class="ft3346">&#160;<br/>&#160;<br/><b>16.&#160;</b></p>
<p style="position:absolute;top:691px;left:149px;white-space:nowrap" class="ft332"><b>INFORMATION&#160;IN BRAILLE&#160;</b></p>
<p style="position:absolute;top:710px;left:106px;white-space:nowrap" class="ft3346">&#160;<br/>Biktarvy 30&#160;mg/120&#160;mg/15&#160;mg&#160;[Outer&#160;packaging only]&#160;<br/>&#160;<br/>&#160;<br/><b>17.&#160;</b></p>
<p style="position:absolute;top:789px;left:149px;white-space:nowrap" class="ft332"><b>UNIQUE&#160;IDENTIFIER&#160;–&#160;2D&#160;BARCODE<i>&#160;</i></b></p>
<p style="position:absolute;top:808px;left:106px;white-space:nowrap" class="ft3346">&#160;<br/>2D&#160;barcode carrying the unique&#160;identifier&#160;included. [Outer&#160;packaging only]&#160;<br/>&#160;<br/>&#160;<br/><b>18.&#160;</b></p>
<p style="position:absolute;top:887px;left:149px;white-space:nowrap" class="ft332"><b>UNIQUE&#160;IDENTIFIER&#160;-&#160;HUMAN&#160;READABLE&#160;DATA<i>&#160;</i></b></p>
<p style="position:absolute;top:906px;left:106px;white-space:nowrap" class="ft338">&#160;<br/>PC&#160;{number}&#160;<br/>SN&#160;{number}&#160;<br/>NN&#160;{number}&#160;<br/>&#160;</p>
<p style="position:absolute;top:982px;left:322px;white-space:nowrap" class="ft330">&#160;</p>
</div>
<!-- Page 34 -->
<a name="34"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page34-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft340">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft341">34&#160;</p>
<p style="position:absolute;top:91px;left:106px;white-space:nowrap" class="ft3446"><b>PARTICULARS TO&#160;APPEAR&#160;ON&#160;THE&#160;OUTER&#160;PACKAGING&#160;AND&#160;THE&#160;IMMEDIATE&#160;<br/>PACKAGING&#160;<br/>&#160;<br/>BOTTLE&#160;AND&#160;CARTON&#160;LABELLING&#160;<br/></b>&#160;<br/>&#160;<br/><b>1.&#160;</b></p>
<p style="position:absolute;top:208px;left:149px;white-space:nowrap" class="ft342"><b>NAME OF THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:229px;left:106px;white-space:nowrap" class="ft3446">&#160;<br/>Biktarvy&#160;50&#160;mg/200&#160;mg/25&#160;mg&#160;film-coated&#160;tablets&#160;<br/>bictegravir/emtricitabine/tenofovir&#160;alafenamide&#160;<br/>&#160;<br/>&#160;<br/><b>2.&#160;</b></p>
<p style="position:absolute;top:327px;left:149px;white-space:nowrap" class="ft342"><b>STATEMENT&#160;OF ACTIVE&#160;SUBSTANCE(S)&#160;</b></p>
<p style="position:absolute;top:348px;left:106px;white-space:nowrap" class="ft3446">&#160;<br/>Each film-coated&#160;tablet&#160;contains&#160;bictegravir&#160;sodium&#160;equivalent&#160;to&#160;50&#160;mg of&#160;bictegravir,&#160;200&#160;mg of&#160;<br/>emtricitabine&#160;and&#160;tenofovir&#160;alafenamide&#160;fumarate&#160;equivalent&#160;to&#160;25&#160;mg of&#160;tenofovir&#160;alafenamide.&#160;<br/>&#160;<br/>&#160;<br/><b>3.&#160;</b></p>
<p style="position:absolute;top:445px;left:149px;white-space:nowrap" class="ft342"><b>LIST&#160;OF&#160;EXCIPIENTS&#160;</b></p>
<p style="position:absolute;top:466px;left:106px;white-space:nowrap" class="ft3446">&#160;<br/>&#160;<br/><b>4.&#160;</b></p>
<p style="position:absolute;top:506px;left:149px;white-space:nowrap" class="ft342"><b>PHARMACEUTICAL&#160;FORM AND&#160;CONTENTS&#160;</b></p>
<p style="position:absolute;top:528px;left:106px;white-space:nowrap" class="ft3446">&#160;<br/>30&#160;film-coated&#160;tablets&#160;<br/>&#160;<br/>90&#160;(3&#160;bottles of&#160;30)&#160;film-coated&#160;tablets&#160;<br/>&#160;<br/>&#160;<br/><b>5.&#160;</b></p>
<p style="position:absolute;top:644px;left:149px;white-space:nowrap" class="ft342"><b>METHOD&#160;AND&#160;ROUTE(S) OF ADMINISTRATION&#160;</b></p>
<p style="position:absolute;top:665px;left:106px;white-space:nowrap" class="ft3446">&#160;<br/>Oral&#160;use&#160;<br/>&#160;<br/>Read the package leaflet&#160;before&#160;use.&#160;<br/>&#160;<br/>&#160;<br/><b>6.&#160;</b></p>
<p style="position:absolute;top:781px;left:149px;white-space:nowrap" class="ft343"><b>SPECIAL&#160;WARNING THAT&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;MUST&#160;BE&#160;STORED&#160;OUT&#160;<br/>OF THE&#160;SIGHT&#160;AND&#160;REACH&#160;OF CHILDREN&#160;</b></p>
<p style="position:absolute;top:821px;left:106px;white-space:nowrap" class="ft3446">&#160;<br/>Keep out&#160;of&#160;the&#160;sight&#160;and reach of&#160;children.&#160;<br/>&#160;<br/>&#160;<br/><b>7.&#160;</b></p>
<p style="position:absolute;top:899px;left:149px;white-space:nowrap" class="ft342"><b>OTHER&#160;SPECIAL&#160;WARNING(S), IF NECESSARY&#160;</b></p>
<p style="position:absolute;top:920px;left:106px;white-space:nowrap" class="ft3446">&#160;<br/>&#160;<br/><b>8.&#160;</b></p>
<p style="position:absolute;top:961px;left:149px;white-space:nowrap" class="ft342"><b>EXPIRY&#160;DATE&#160;</b></p>
<p style="position:absolute;top:982px;left:106px;white-space:nowrap" class="ft3446">&#160;<br/>EXP&#160;<br/>&#160;<br/>&#160;<br/><b>9.&#160;</b></p>
<p style="position:absolute;top:1060px;left:149px;white-space:nowrap" class="ft342"><b>SPECIAL&#160;STORAGE&#160;CONDITIONS&#160;</b></p>
<p style="position:absolute;top:1081px;left:106px;white-space:nowrap" class="ft348">&#160;<br/>Store&#160;in&#160;the&#160;original&#160;package in order&#160;to&#160;protect&#160;from&#160;moisture.&#160;&#160;<b>Keep&#160;the bottle&#160;tightly&#160;closed.</b>&#160;<br/>&#160;<br/>&#160;</p>
</div>
<!-- Page 35 -->
<a name="35"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page35-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft350">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft351">35&#160;</p>
<p style="position:absolute;top:91px;left:106px;white-space:nowrap" class="ft352"><b>10.&#160;</b></p>
<p style="position:absolute;top:91px;left:149px;white-space:nowrap" class="ft353"><b>SPECIAL&#160;PRECAUTIONS FOR&#160;DISPOSAL&#160;OF&#160;UNUSED&#160;MEDICINAL&#160;PRODUCTS&#160;<br/>OR&#160;WASTE&#160;MATERIALS DERIVED&#160;FROM SUCH&#160;MEDICINAL&#160;PRODUCTS, IF&#160;<br/>APPROPRIATE&#160;</b></p>
<p style="position:absolute;top:151px;left:106px;white-space:nowrap" class="ft3546">&#160;<br/>&#160;<br/><b>11.&#160;</b></p>
<p style="position:absolute;top:191px;left:149px;white-space:nowrap" class="ft352"><b>NAME AND&#160;ADDRESS&#160;OF THE&#160;MARKETING&#160;AUTHORISATION&#160;HOLDER&#160;</b></p>
<p style="position:absolute;top:213px;left:106px;white-space:nowrap" class="ft3546">&#160;<br/>Gilead Sciences&#160;Ireland UC&#160;<br/>Carrigtohill&#160;<br/>County Cork, T45 DP77&#160;<br/>Ireland&#160;<br/>&#160;<br/>&#160;<br/><b>12.&#160;</b></p>
<p style="position:absolute;top:349px;left:149px;white-space:nowrap" class="ft352"><b>MARKETING AUTHORISATION&#160;NUMBER(S)&#160;</b></p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft3546">&#160;<br/>EU/1/18/1289/001&#160;30&#160;film-coated tablets&#160;<br/>EU/1/18/1289/002&#160;90&#160;(3&#160;bottles&#160;of&#160;30)&#160;film-coated&#160;tablets&#160;<br/>&#160;<br/>&#160;<br/><b>13.&#160;</b></p>
<p style="position:absolute;top:467px;left:149px;white-space:nowrap" class="ft352"><b>BATCH&#160;NUMBER&#160;</b></p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft3546">&#160;<br/>Lot&#160;<br/>&#160;<br/>&#160;<br/><b>14.&#160;</b></p>
<p style="position:absolute;top:566px;left:149px;white-space:nowrap" class="ft352"><b>GENERAL&#160;CLASSIFICATION&#160;FOR SUPPLY&#160;</b></p>
<p style="position:absolute;top:587px;left:106px;white-space:nowrap" class="ft355">&#160;<br/>&#160;</p>
<p style="position:absolute;top:629px;left:106px;white-space:nowrap" class="ft352"><b>15.&#160;</b></p>
<p style="position:absolute;top:629px;left:149px;white-space:nowrap" class="ft352"><b>INSTRUCTIONS ON USE&#160;</b></p>
<p style="position:absolute;top:650px;left:106px;white-space:nowrap" class="ft3546">&#160;<br/>&#160;<br/><b>16.&#160;</b></p>
<p style="position:absolute;top:691px;left:149px;white-space:nowrap" class="ft352"><b>INFORMATION&#160;IN BRAILLE&#160;</b></p>
<p style="position:absolute;top:710px;left:106px;white-space:nowrap" class="ft3546">&#160;<br/>Biktarvy&#160;50&#160;mg/200&#160;mg/25&#160;mg&#160;[Outer&#160;packaging only]&#160;<br/>&#160;<br/>&#160;<br/><b>17.&#160;</b></p>
<p style="position:absolute;top:789px;left:149px;white-space:nowrap" class="ft352"><b>UNIQUE&#160;IDENTIFIER&#160;–&#160;2D&#160;BARCODE<i>&#160;</i></b></p>
<p style="position:absolute;top:808px;left:106px;white-space:nowrap" class="ft3546">&#160;<br/>2D&#160;barcode carrying the unique&#160;identifier&#160;included.&#160;[Outer&#160;packaging only]&#160;<br/>&#160;<br/>&#160;<br/><b>18.&#160;</b></p>
<p style="position:absolute;top:887px;left:149px;white-space:nowrap" class="ft352"><b>UNIQUE&#160;IDENTIFIER&#160;-&#160;HUMAN&#160;READABLE&#160;DATA<i>&#160;</i></b></p>
<p style="position:absolute;top:906px;left:106px;white-space:nowrap" class="ft358">&#160;<br/>PC&#160;{number}&#160;<br/>SN&#160;{number}&#160;<br/>NN&#160;{number}&#160;<br/>[Outer&#160;packaging only]&#160;</p>
</div>
<!-- Page 36 -->
<a name="36"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page36-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft360">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft361">36&#160;</p>
<p style="position:absolute;top:91px;left:106px;white-space:nowrap" class="ft3646"><b>PARTICULARS TO&#160;APPEAR&#160;ON&#160;THE&#160;OUTER&#160;PACKAGING&#160;<br/>&#160;<br/>OUTER&#160;CARTON&#160;OF UNIT BLISTER&#160;PACK&#160;<br/></b>&#160;<br/>&#160;<br/><b>1.&#160;</b></p>
<p style="position:absolute;top:189px;left:149px;white-space:nowrap" class="ft362"><b>NAME OF THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:210px;left:106px;white-space:nowrap" class="ft3646">&#160;<br/>Biktarvy 50&#160;mg/200&#160;mg/25&#160;mg&#160;film-coated&#160;tablets&#160;<br/>bictegravir/emtricitabine/tenofovir&#160;alafenamide&#160;<br/>&#160;<br/>&#160;<br/><b>2.&#160;</b></p>
<p style="position:absolute;top:308px;left:149px;white-space:nowrap" class="ft362"><b>STATEMENT&#160;OF ACTIVE&#160;SUBSTANCE(S)&#160;</b></p>
<p style="position:absolute;top:329px;left:106px;white-space:nowrap" class="ft3646">&#160;<br/>Each film-coated&#160;tablet&#160;contains bictegravir&#160;sodium&#160;equivalent&#160;to&#160;50&#160;mg of&#160;bictegravir, 200&#160;mg of&#160;<br/>emtricitabine&#160;and&#160;tenofovir&#160;alafenamide&#160;fumarate&#160;equivalent&#160;to 25&#160;mg of&#160;tenofovir&#160;alafenamide.&#160;<br/>&#160;<br/>&#160;<br/><b>3.&#160;</b></p>
<p style="position:absolute;top:426px;left:149px;white-space:nowrap" class="ft362"><b>LIST&#160;OF EXCIPIENTS&#160;</b></p>
<p style="position:absolute;top:447px;left:106px;white-space:nowrap" class="ft3646">&#160;<br/>&#160;<br/><b>4.&#160;</b></p>
<p style="position:absolute;top:487px;left:149px;white-space:nowrap" class="ft362"><b>PHARMACEUTICAL&#160;FORM AND&#160;CONTENTS&#160;</b></p>
<p style="position:absolute;top:509px;left:106px;white-space:nowrap" class="ft3646">&#160;<br/>30&#160;film-coated&#160;tablets&#160;&#160;<br/>&#160;<br/>&#160;<br/><b>5.&#160;</b></p>
<p style="position:absolute;top:587px;left:149px;white-space:nowrap" class="ft362"><b>METHOD&#160;AND&#160;ROUTE(S) OF ADMINISTRATION&#160;</b></p>
<p style="position:absolute;top:608px;left:106px;white-space:nowrap" class="ft3646">&#160;<br/>Oral&#160;use&#160;<br/>&#160;<br/>Read the package leaflet&#160;before&#160;use.&#160;<br/>&#160;<br/>&#160;<br/><b>6.&#160;</b></p>
<p style="position:absolute;top:724px;left:149px;white-space:nowrap" class="ft363"><b>SPECIAL&#160;WARNING THAT&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;MUST&#160;BE&#160;STORED&#160;OUT&#160;<br/>OF THE&#160;SIGHT&#160;AND&#160;REACH&#160;OF CHILDREN&#160;</b></p>
<p style="position:absolute;top:764px;left:106px;white-space:nowrap" class="ft3646">&#160;<br/>Keep out&#160;of&#160;the&#160;sight&#160;and reach of&#160;children.&#160;<br/>&#160;<br/>&#160;<br/><b>7.&#160;</b></p>
<p style="position:absolute;top:843px;left:149px;white-space:nowrap" class="ft362"><b>OTHER&#160;SPECIAL&#160;WARNING(S), IF NECESSARY&#160;</b></p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft3646">&#160;<br/>&#160;<br/><b>8.&#160;</b></p>
<p style="position:absolute;top:904px;left:149px;white-space:nowrap" class="ft362"><b>EXPIRY&#160;DATE&#160;</b></p>
<p style="position:absolute;top:925px;left:106px;white-space:nowrap" class="ft3646">&#160;<br/>EXP&#160;<br/>&#160;<br/>&#160;<br/><b>9.&#160;</b></p>
<p style="position:absolute;top:1003px;left:149px;white-space:nowrap" class="ft362"><b>SPECIAL&#160;STORAGE&#160;CONDITIONS&#160;</b></p>
<p style="position:absolute;top:1024px;left:106px;white-space:nowrap" class="ft368">&#160;<br/>Store&#160;in&#160;the&#160;original&#160;package in order&#160;to protect&#160;from&#160;moisture.<b>&#160;<br/></b>&#160;<br/>&#160;</p>
</div>
<!-- Page 37 -->
<a name="37"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page37-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft370">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft371">37&#160;</p>
<p style="position:absolute;top:91px;left:106px;white-space:nowrap" class="ft372"><b>10.&#160;</b></p>
<p style="position:absolute;top:91px;left:149px;white-space:nowrap" class="ft373"><b>SPECIAL&#160;PRECAUTIONS FOR&#160;DISPOSAL&#160;OF&#160;UNUSED&#160;MEDICINAL&#160;PRODUCTS&#160;<br/>OR&#160;WASTE&#160;MATERIALS DERIVED&#160;FROM SUCH&#160;MEDICINAL&#160;PRODUCTS, IF&#160;<br/>APPROPRIATE&#160;</b></p>
<p style="position:absolute;top:151px;left:106px;white-space:nowrap" class="ft3746">&#160;<br/>&#160;<br/><b>11.&#160;</b></p>
<p style="position:absolute;top:191px;left:149px;white-space:nowrap" class="ft372"><b>NAME AND&#160;ADDRESS&#160;OF THE&#160;MARKETING&#160;AUTHORISATION&#160;HOLDER&#160;</b></p>
<p style="position:absolute;top:213px;left:106px;white-space:nowrap" class="ft3746">&#160;<br/>Gilead Sciences&#160;Ireland UC&#160;<br/>Carrigtohill&#160;<br/>County Cork, T45 DP77&#160;<br/>Ireland&#160;<br/>&#160;<br/>&#160;<br/><b>12.&#160;</b></p>
<p style="position:absolute;top:349px;left:149px;white-space:nowrap" class="ft372"><b>MARKETING AUTHORISATION&#160;NUMBER(S)&#160;</b></p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft3746">&#160;<br/>EU/1/18/1289/003&#160;30&#160;film-coated tablets&#160;<br/>&#160;<br/>&#160;<br/><b>13.&#160;</b></p>
<p style="position:absolute;top:448px;left:149px;white-space:nowrap" class="ft372"><b>BATCH&#160;NUMBER&#160;</b></p>
<p style="position:absolute;top:469px;left:106px;white-space:nowrap" class="ft3746">&#160;<br/>Lot&#160;<br/>&#160;<br/>&#160;<br/><b>14.&#160;</b></p>
<p style="position:absolute;top:547px;left:149px;white-space:nowrap" class="ft372"><b>GENERAL&#160;CLASSIFICATION&#160;FOR SUPPLY&#160;</b></p>
<p style="position:absolute;top:569px;left:106px;white-space:nowrap" class="ft375">&#160;<br/>&#160;</p>
<p style="position:absolute;top:610px;left:106px;white-space:nowrap" class="ft372"><b>15.&#160;</b></p>
<p style="position:absolute;top:610px;left:149px;white-space:nowrap" class="ft372"><b>INSTRUCTIONS ON USE&#160;</b></p>
<p style="position:absolute;top:631px;left:106px;white-space:nowrap" class="ft3746">&#160;<br/>&#160;<br/><b>16.&#160;</b></p>
<p style="position:absolute;top:672px;left:149px;white-space:nowrap" class="ft372"><b>INFORMATION&#160;IN BRAILLE&#160;</b></p>
<p style="position:absolute;top:691px;left:106px;white-space:nowrap" class="ft3746">&#160;<br/>Biktarvy&#160;[Outer&#160;packaging&#160;only]&#160;<br/>&#160;<br/>&#160;<br/><b>17.&#160;</b></p>
<p style="position:absolute;top:770px;left:149px;white-space:nowrap" class="ft372"><b>UNIQUE&#160;IDENTIFIER&#160;–&#160;2D&#160;BARCODE<i>&#160;</i></b></p>
<p style="position:absolute;top:789px;left:106px;white-space:nowrap" class="ft3746">&#160;<br/>2D&#160;barcode carrying the unique&#160;identifier&#160;included.&#160;&#160;<br/>&#160;<br/>&#160;<br/><b>18.&#160;</b></p>
<p style="position:absolute;top:868px;left:149px;white-space:nowrap" class="ft372"><b>UNIQUE&#160;IDENTIFIER&#160;-&#160;HUMAN&#160;READABLE&#160;DATA<i>&#160;</i></b></p>
<p style="position:absolute;top:887px;left:106px;white-space:nowrap" class="ft378">&#160;<br/>PC&#160;{number}&#160;<br/>SN&#160;{number}&#160;<br/>NN&#160;{number}&#160;</p>
</div>
<!-- Page 38 -->
<a name="38"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page38-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft380">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft381">38&#160;</p>
<p style="position:absolute;top:91px;left:106px;white-space:nowrap" class="ft3846"><b>PARTICULARS TO&#160;APPEAR&#160;ON&#160;THE&#160;OUTER&#160;PACKAGING&#160;<br/>&#160;<br/>OUTER&#160;CARTON&#160;OF BLISTER&#160;MULTIPACK&#160;(INCLUDING BLUE&#160;BOX)&#160;<br/>&#160;<br/></b>&#160;<br/><b>1.&#160;</b></p>
<p style="position:absolute;top:189px;left:149px;white-space:nowrap" class="ft382"><b>NAME OF THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:210px;left:106px;white-space:nowrap" class="ft3846">&#160;<br/>Biktarvy 50&#160;mg/200&#160;mg/25&#160;mg&#160;film-coated&#160;tablets&#160;<br/>bictegravir/emtricitabine/tenofovir&#160;alafenamide&#160;<br/>&#160;<br/>&#160;<br/><b>2.&#160;</b></p>
<p style="position:absolute;top:308px;left:149px;white-space:nowrap" class="ft382"><b>STATEMENT&#160;OF ACTIVE&#160;SUBSTANCE(S)&#160;</b></p>
<p style="position:absolute;top:329px;left:106px;white-space:nowrap" class="ft3846">&#160;<br/>Each film-coated&#160;tablet&#160;contains bictegravir&#160;sodium&#160;equivalent&#160;to&#160;50&#160;mg of&#160;bictegravir, 200&#160;mg of&#160;<br/>emtricitabine&#160;and&#160;tenofovir&#160;alafenamide&#160;fumarate&#160;equivalent&#160;to 25&#160;mg of&#160;tenofovir&#160;alafenamide.&#160;<br/>&#160;<br/>&#160;<br/><b>3.&#160;</b></p>
<p style="position:absolute;top:426px;left:149px;white-space:nowrap" class="ft382"><b>LIST&#160;OF EXCIPIENTS&#160;</b></p>
<p style="position:absolute;top:447px;left:106px;white-space:nowrap" class="ft3846">&#160;<br/>&#160;<br/><b>4.&#160;</b></p>
<p style="position:absolute;top:487px;left:149px;white-space:nowrap" class="ft382"><b>PHARMACEUTICAL&#160;FORM AND&#160;CONTENTS&#160;</b></p>
<p style="position:absolute;top:509px;left:106px;white-space:nowrap" class="ft3846">&#160;<br/>Multipack:&#160;90&#160;(3&#160;blister&#160;packs of&#160;30)&#160;film-coated tablets&#160;<br/>&#160;<br/>&#160;<br/><b>5.&#160;</b></p>
<p style="position:absolute;top:587px;left:149px;white-space:nowrap" class="ft382"><b>METHOD&#160;AND&#160;ROUTE(S) OF ADMINISTRATION&#160;</b></p>
<p style="position:absolute;top:608px;left:106px;white-space:nowrap" class="ft3846">&#160;<br/>Oral&#160;use&#160;<br/>&#160;<br/>Read the package leaflet&#160;before&#160;use.&#160;<br/>&#160;<br/>&#160;<br/><b>6.&#160;</b></p>
<p style="position:absolute;top:724px;left:149px;white-space:nowrap" class="ft383"><b>SPECIAL&#160;WARNING THAT&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;MUST&#160;BE&#160;STORED&#160;OUT&#160;<br/>OF THE&#160;SIGHT&#160;AND&#160;REACH&#160;OF CHILDREN&#160;</b></p>
<p style="position:absolute;top:764px;left:106px;white-space:nowrap" class="ft3846">&#160;<br/>Keep out&#160;of&#160;the&#160;sight&#160;and reach of&#160;children.&#160;<br/>&#160;<br/>&#160;<br/><b>7.&#160;</b></p>
<p style="position:absolute;top:843px;left:149px;white-space:nowrap" class="ft382"><b>OTHER&#160;SPECIAL&#160;WARNING(S), IF NECESSARY&#160;</b></p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft3846">&#160;<br/>&#160;<br/><b>8.&#160;</b></p>
<p style="position:absolute;top:904px;left:149px;white-space:nowrap" class="ft382"><b>EXPIRY&#160;DATE&#160;</b></p>
<p style="position:absolute;top:925px;left:106px;white-space:nowrap" class="ft3846">&#160;<br/>EXP&#160;<br/>&#160;<br/>&#160;<br/><b>9.&#160;</b></p>
<p style="position:absolute;top:1003px;left:149px;white-space:nowrap" class="ft382"><b>SPECIAL&#160;STORAGE&#160;CONDITIONS&#160;</b></p>
<p style="position:absolute;top:1024px;left:106px;white-space:nowrap" class="ft388">&#160;<br/>Store&#160;in&#160;the&#160;original&#160;package in order&#160;to protect&#160;from&#160;moisture.<b>&#160;<br/></b>&#160;<br/>&#160;</p>
</div>
<!-- Page 39 -->
<a name="39"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page39-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft390">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft391">39&#160;</p>
<p style="position:absolute;top:91px;left:106px;white-space:nowrap" class="ft392"><b>10.&#160;</b></p>
<p style="position:absolute;top:91px;left:149px;white-space:nowrap" class="ft393"><b>SPECIAL&#160;PRECAUTIONS FOR&#160;DISPOSAL&#160;OF&#160;UNUSED&#160;MEDICINAL&#160;PRODUCTS&#160;<br/>OR&#160;WASTE&#160;MATERIALS DERIVED&#160;FROM SUCH&#160;MEDICINAL&#160;PRODUCTS, IF&#160;<br/>APPROPRIATE&#160;</b></p>
<p style="position:absolute;top:151px;left:106px;white-space:nowrap" class="ft3946">&#160;<br/>&#160;<br/><b>11.&#160;</b></p>
<p style="position:absolute;top:191px;left:149px;white-space:nowrap" class="ft392"><b>NAME AND&#160;ADDRESS&#160;OF THE&#160;MARKETING&#160;AUTHORISATION&#160;HOLDER&#160;</b></p>
<p style="position:absolute;top:213px;left:106px;white-space:nowrap" class="ft3946">&#160;<br/>Gilead Sciences&#160;Ireland UC&#160;<br/>Carrigtohill&#160;<br/>County Cork, T45 DP77&#160;<br/>Ireland&#160;<br/>&#160;<br/>&#160;<br/><b>12.&#160;</b></p>
<p style="position:absolute;top:349px;left:149px;white-space:nowrap" class="ft392"><b>MARKETING AUTHORISATION&#160;NUMBER(S)&#160;</b></p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft3946">&#160;<br/>EU/1/18/1289/004&#160;90&#160;(3&#160;blister&#160;packs&#160;of&#160;30)&#160;film-coated tablets&#160;<br/>&#160;<br/>&#160;<br/><b>13.&#160;</b></p>
<p style="position:absolute;top:448px;left:149px;white-space:nowrap" class="ft392"><b>BATCH&#160;NUMBER&#160;</b></p>
<p style="position:absolute;top:469px;left:106px;white-space:nowrap" class="ft3946">&#160;<br/>Lot&#160;<br/>&#160;<br/>&#160;<br/><b>14.&#160;</b></p>
<p style="position:absolute;top:547px;left:149px;white-space:nowrap" class="ft392"><b>GENERAL&#160;CLASSIFICATION&#160;FOR SUPPLY&#160;</b></p>
<p style="position:absolute;top:569px;left:106px;white-space:nowrap" class="ft395">&#160;<br/>&#160;</p>
<p style="position:absolute;top:610px;left:106px;white-space:nowrap" class="ft392"><b>15.&#160;</b></p>
<p style="position:absolute;top:610px;left:149px;white-space:nowrap" class="ft392"><b>INSTRUCTIONS ON USE&#160;</b></p>
<p style="position:absolute;top:631px;left:106px;white-space:nowrap" class="ft3946">&#160;<br/>&#160;<br/><b>16.&#160;</b></p>
<p style="position:absolute;top:672px;left:149px;white-space:nowrap" class="ft392"><b>INFORMATION&#160;IN BRAILLE&#160;</b></p>
<p style="position:absolute;top:691px;left:106px;white-space:nowrap" class="ft3946">&#160;<br/>Biktarvy&#160;[Outer&#160;packaging&#160;only]&#160;<br/>&#160;<br/>&#160;<br/><b>17.&#160;</b></p>
<p style="position:absolute;top:770px;left:149px;white-space:nowrap" class="ft392"><b>UNIQUE&#160;IDENTIFIER&#160;–&#160;2D&#160;BARCODE<i>&#160;</i></b></p>
<p style="position:absolute;top:789px;left:106px;white-space:nowrap" class="ft3946">&#160;<br/>2D&#160;barcode carrying the unique&#160;identifier&#160;included.&#160;&#160;<br/>&#160;<br/>&#160;<br/><b>18.&#160;</b></p>
<p style="position:absolute;top:868px;left:149px;white-space:nowrap" class="ft392"><b>UNIQUE&#160;IDENTIFIER&#160;-&#160;HUMAN&#160;READABLE&#160;DATA<i>&#160;</i></b></p>
<p style="position:absolute;top:887px;left:106px;white-space:nowrap" class="ft398">&#160;<br/>PC&#160;{number}&#160;<br/>SN&#160;{number}&#160;<br/>NN&#160;{number}&#160;</p>
</div>
<!-- Page 40 -->
<a name="40"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page40-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft400">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft401">40&#160;</p>
<p style="position:absolute;top:91px;left:106px;white-space:nowrap" class="ft4046"><b>PARTICULARS TO&#160;APPEAR&#160;ON&#160;THE&#160;OUTER&#160;PACKAGING&#160;<br/>&#160;<br/>INTERMEDIATE&#160;CARTON&#160;OF BLISTER&#160;MULTIPACK&#160;(WITHOUT&#160;BLUE&#160;BOX)&#160;<br/>&#160;<br/></b>&#160;<br/><b>1.&#160;</b></p>
<p style="position:absolute;top:189px;left:149px;white-space:nowrap" class="ft402"><b>NAME OF THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:210px;left:106px;white-space:nowrap" class="ft4046">&#160;<br/>Biktarvy 50&#160;mg/200&#160;mg/25&#160;mg&#160;film-coated&#160;tablets&#160;<br/>bictegravir/emtricitabine/tenofovir&#160;alafenamide&#160;<br/>&#160;<br/>&#160;<br/><b>2.&#160;</b></p>
<p style="position:absolute;top:308px;left:149px;white-space:nowrap" class="ft402"><b>STATEMENT&#160;OF ACTIVE&#160;SUBSTANCE(S)&#160;</b></p>
<p style="position:absolute;top:329px;left:106px;white-space:nowrap" class="ft4046">&#160;<br/>Each film-coated&#160;tablet&#160;contains bictegravir&#160;sodium&#160;equivalent&#160;to&#160;50&#160;mg of&#160;bictegravir, 200&#160;mg of&#160;<br/>emtricitabine&#160;and&#160;tenofovir&#160;alafenamide&#160;fumarate&#160;equivalent&#160;to 25&#160;mg of&#160;tenofovir&#160;alafenamide.&#160;<br/>&#160;<br/>&#160;<br/><b>3.&#160;</b></p>
<p style="position:absolute;top:426px;left:149px;white-space:nowrap" class="ft402"><b>LIST&#160;OF EXCIPIENTS&#160;</b></p>
<p style="position:absolute;top:447px;left:106px;white-space:nowrap" class="ft4046">&#160;<br/>&#160;<br/><b>4.&#160;</b></p>
<p style="position:absolute;top:487px;left:149px;white-space:nowrap" class="ft402"><b>PHARMACEUTICAL&#160;FORM AND&#160;CONTENTS&#160;</b></p>
<p style="position:absolute;top:509px;left:106px;white-space:nowrap" class="ft4046">&#160;<br/>30&#160;film-coated&#160;tablets.&#160;Component&#160;of&#160;a multipack. Not&#160;to&#160;be&#160;sold separately.&#160;<br/>&#160;<br/>&#160;<br/><b>5.&#160;</b></p>
<p style="position:absolute;top:587px;left:149px;white-space:nowrap" class="ft402"><b>METHOD&#160;AND&#160;ROUTE(S) OF ADMINISTRATION&#160;</b></p>
<p style="position:absolute;top:608px;left:106px;white-space:nowrap" class="ft4046">&#160;<br/>Oral&#160;use&#160;<br/>&#160;<br/>Read the package leaflet&#160;before&#160;use.&#160;<br/>&#160;<br/>&#160;<br/><b>6.&#160;</b></p>
<p style="position:absolute;top:724px;left:149px;white-space:nowrap" class="ft403"><b>SPECIAL&#160;WARNING THAT&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;MUST&#160;BE&#160;STORED&#160;OUT&#160;<br/>OF THE&#160;SIGHT&#160;AND&#160;REACH&#160;OF CHILDREN&#160;</b></p>
<p style="position:absolute;top:764px;left:106px;white-space:nowrap" class="ft4046">&#160;<br/>Keep out&#160;of&#160;the&#160;sight&#160;and reach of&#160;children.&#160;<br/>&#160;<br/>&#160;<br/><b>7.&#160;</b></p>
<p style="position:absolute;top:843px;left:149px;white-space:nowrap" class="ft402"><b>OTHER&#160;SPECIAL&#160;WARNING(S), IF NECESSARY&#160;</b></p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft4046">&#160;<br/>&#160;<br/><b>8.&#160;</b></p>
<p style="position:absolute;top:904px;left:149px;white-space:nowrap" class="ft402"><b>EXPIRY&#160;DATE&#160;</b></p>
<p style="position:absolute;top:925px;left:106px;white-space:nowrap" class="ft4046">&#160;<br/>EXP&#160;<br/>&#160;<br/>&#160;<br/><b>9.&#160;</b></p>
<p style="position:absolute;top:1003px;left:149px;white-space:nowrap" class="ft402"><b>SPECIAL&#160;STORAGE&#160;CONDITIONS&#160;</b></p>
<p style="position:absolute;top:1024px;left:106px;white-space:nowrap" class="ft408">&#160;<br/>Store&#160;in&#160;the&#160;original&#160;package in order&#160;to protect&#160;from&#160;moisture.<b>&#160;<br/></b>&#160;<br/>&#160;</p>
</div>
<!-- Page 41 -->
<a name="41"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page41-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft410">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft411">41&#160;</p>
<p style="position:absolute;top:91px;left:106px;white-space:nowrap" class="ft412"><b>10.&#160;</b></p>
<p style="position:absolute;top:91px;left:149px;white-space:nowrap" class="ft413"><b>SPECIAL&#160;PRECAUTIONS FOR&#160;DISPOSAL&#160;OF&#160;UNUSED&#160;MEDICINAL&#160;PRODUCTS&#160;<br/>OR&#160;WASTE&#160;MATERIALS DERIVED&#160;FROM SUCH&#160;MEDICINAL&#160;PRODUCTS, IF&#160;<br/>APPROPRIATE&#160;</b></p>
<p style="position:absolute;top:151px;left:106px;white-space:nowrap" class="ft4146">&#160;<br/>&#160;<br/><b>11.&#160;</b></p>
<p style="position:absolute;top:191px;left:149px;white-space:nowrap" class="ft412"><b>NAME AND&#160;ADDRESS&#160;OF THE&#160;MARKETING&#160;AUTHORISATION&#160;HOLDER&#160;</b></p>
<p style="position:absolute;top:213px;left:106px;white-space:nowrap" class="ft4146">&#160;<br/>Gilead Sciences&#160;Ireland UC&#160;<br/>Carrigtohill&#160;<br/>County Cork, T45 DP77&#160;<br/>Ireland&#160;<br/>&#160;<br/>&#160;<br/><b>12.&#160;</b></p>
<p style="position:absolute;top:349px;left:149px;white-space:nowrap" class="ft412"><b>MARKETING AUTHORISATION&#160;NUMBER(S)&#160;</b></p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft4146">&#160;<br/>EU/1/18/1289/004&#160;90&#160;(3&#160;blister&#160;packs&#160;of&#160;30)&#160;film-coated tablets&#160;<br/>&#160;<br/>&#160;<br/><b>13.&#160;</b></p>
<p style="position:absolute;top:448px;left:149px;white-space:nowrap" class="ft412"><b>BATCH&#160;NUMBER&#160;</b></p>
<p style="position:absolute;top:469px;left:106px;white-space:nowrap" class="ft4146">&#160;<br/>Lot&#160;<br/>&#160;<br/>&#160;<br/><b>14.&#160;</b></p>
<p style="position:absolute;top:547px;left:149px;white-space:nowrap" class="ft412"><b>GENERAL&#160;CLASSIFICATION&#160;FOR SUPPLY&#160;</b></p>
<p style="position:absolute;top:569px;left:106px;white-space:nowrap" class="ft415">&#160;<br/>&#160;</p>
<p style="position:absolute;top:610px;left:106px;white-space:nowrap" class="ft412"><b>15.&#160;</b></p>
<p style="position:absolute;top:610px;left:149px;white-space:nowrap" class="ft412"><b>INSTRUCTIONS ON USE&#160;</b></p>
<p style="position:absolute;top:631px;left:106px;white-space:nowrap" class="ft4146">&#160;<br/>&#160;<br/><b>16.&#160;</b></p>
<p style="position:absolute;top:672px;left:149px;white-space:nowrap" class="ft412"><b>INFORMATION&#160;IN BRAILLE&#160;</b></p>
<p style="position:absolute;top:691px;left:106px;white-space:nowrap" class="ft4146">&#160;<br/>Biktarvy&#160;[Outer&#160;packaging&#160;only]&#160;<br/>&#160;<br/>&#160;<br/><b>17.&#160;</b></p>
<p style="position:absolute;top:770px;left:149px;white-space:nowrap" class="ft412"><b>UNIQUE&#160;IDENTIFIER&#160;–&#160;2D&#160;BARCODE<i>&#160;</i></b></p>
<p style="position:absolute;top:789px;left:106px;white-space:nowrap" class="ft4146">&#160;<br/>&#160;<br/><b>18.&#160;</b></p>
<p style="position:absolute;top:830px;left:149px;white-space:nowrap" class="ft412"><b>UNIQUE&#160;IDENTIFIER&#160;-&#160;HUMAN&#160;READABLE&#160;DATA<i>&#160;</i></b></p>
<p style="position:absolute;top:849px;left:106px;white-space:nowrap" class="ft415">&#160;<br/>&#160;</p>
</div>
<!-- Page 42 -->
<a name="42"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page42-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft420">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft421">42&#160;</p>
<p style="position:absolute;top:91px;left:106px;white-space:nowrap" class="ft4246"><b>MINIMUM PARTICULARS TO&#160;APPEAR&#160;ON&#160;BLISTERS OR STRIPS&#160;<br/>&#160;<br/>BLISTER&#160;(7&#160;tablet&#160;blister&#160;pack)&#160;<br/></b>&#160;<br/>&#160;<br/><b>1.&#160;</b></p>
<p style="position:absolute;top:191px;left:149px;white-space:nowrap" class="ft422"><b>NAME OF THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:212px;left:106px;white-space:nowrap" class="ft4246">&#160;<br/>Biktarvy 50&#160;mg/200&#160;mg/25&#160;mg&#160;tablets&#160;<br/>bictegravir/emtricitabine/tenofovir&#160;alafenamide&#160;<br/>&#160;<br/>&#160;<br/><b>2.&#160;</b></p>
<p style="position:absolute;top:309px;left:149px;white-space:nowrap" class="ft422"><b>NAME OF THE&#160;MARKETING AUTHORISATION&#160;HOLDER&#160;</b></p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft4246">&#160;<br/>Gilead Sciences&#160;Ireland UC&#160;<br/>&#160;<br/>&#160;<br/><b>3.&#160;</b></p>
<p style="position:absolute;top:409px;left:149px;white-space:nowrap" class="ft422"><b>EXPIRY&#160;DATE&#160;</b></p>
<p style="position:absolute;top:430px;left:106px;white-space:nowrap" class="ft4246">&#160;<br/>EXP&#160;<br/>&#160;<br/>&#160;<br/><b>4.&#160;</b></p>
<p style="position:absolute;top:508px;left:149px;white-space:nowrap" class="ft422"><b>BATCH&#160;NUMBER&#160;</b></p>
<p style="position:absolute;top:529px;left:106px;white-space:nowrap" class="ft4246">&#160;<br/>Lot&#160;<br/>&#160;<br/>&#160;<br/><b>5.&#160;</b></p>
<p style="position:absolute;top:607px;left:149px;white-space:nowrap" class="ft422"><b>OTHER&#160;</b></p>
<p style="position:absolute;top:628px;left:106px;white-space:nowrap" class="ft425">&#160;<br/>Mon.&#160;<br/>Tue.&#160;<br/>Wed.&#160;<br/>Thu.&#160;<br/>Fri.&#160;<br/>Sat.&#160;<br/>Sun.&#160;</p>
</div>
<!-- Page 43 -->
<a name="43"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page43-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft430">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft431">43&#160;</p>
<p style="position:absolute;top:91px;left:106px;white-space:nowrap" class="ft4346"><b>MINIMUM PARTICULARS TO&#160;APPEAR&#160;ON&#160;BLISTERS OR STRIPS&#160;<br/>&#160;<br/>BLISTER&#160;(2&#160;tablet&#160;blister&#160;pack)&#160;<br/></b>&#160;<br/>&#160;<br/><b>1.&#160;</b></p>
<p style="position:absolute;top:191px;left:149px;white-space:nowrap" class="ft432"><b>NAME OF THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:212px;left:106px;white-space:nowrap" class="ft4346">&#160;<br/>Biktarvy 50&#160;mg/200&#160;mg/25&#160;mg&#160;tablets&#160;<br/>bictegravir/emtricitabine/tenofovir&#160;alafenamide&#160;<br/>&#160;<br/>&#160;<br/><b>2.&#160;</b></p>
<p style="position:absolute;top:309px;left:149px;white-space:nowrap" class="ft432"><b>NAME OF THE&#160;MARKETING AUTHORISATION&#160;HOLDER&#160;</b></p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft4346">&#160;<br/>Gilead Sciences&#160;Ireland UC&#160;<br/>&#160;<br/>&#160;<br/><b>3.&#160;</b></p>
<p style="position:absolute;top:409px;left:149px;white-space:nowrap" class="ft432"><b>EXPIRY&#160;DATE&#160;</b></p>
<p style="position:absolute;top:430px;left:106px;white-space:nowrap" class="ft4346">&#160;<br/>EXP&#160;<br/>&#160;<br/>&#160;<br/><b>4.&#160;</b></p>
<p style="position:absolute;top:508px;left:149px;white-space:nowrap" class="ft432"><b>BATCH&#160;NUMBER&#160;</b></p>
<p style="position:absolute;top:529px;left:106px;white-space:nowrap" class="ft4346">&#160;<br/>Lot&#160;<br/>&#160;<br/>&#160;<br/><b>5.&#160;</b></p>
<p style="position:absolute;top:607px;left:149px;white-space:nowrap" class="ft432"><b>OTHER&#160;</b></p>
<p style="position:absolute;top:628px;left:106px;white-space:nowrap" class="ft435">&#160;<br/>Day&#160;Underlined blank&#160;space included.&#160;&#160;<br/>Day&#160;Underlined blank&#160;space included.&#160;&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;</p>
<p style="position:absolute;top:742px;left:322px;white-space:nowrap" class="ft430">&#160;</p>
</div>
<!-- Page 44 -->
<a name="44"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page44-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft440">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft441">44&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft445">&#160;<br/>&#160;<br/>&#160;</p>
<p style="position:absolute;top:146px;left:447px;white-space:nowrap" class="ft444"><b>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;</b></p>
<p style="position:absolute;top:506px;left:355px;white-space:nowrap" class="ft442"><b>B. PACKAGE&#160;LEAFLET&#160;</b></p>
</div>
<!-- Page 45 -->
<a name="45"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft4548{font-size:17px;font-family:BCDEEE+Wingdings;color:#000000;}
	.ft4549{font-size:17px;line-height:15px;font-family:TimesNewRomanPS;color:#000000;}
	.ft4550{font-size:17px;line-height:22px;font-family:TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page45-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft450">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft451">45&#160;</p>
<p style="position:absolute;top:89px;left:303px;white-space:nowrap" class="ft452"><b>Package&#160;leaflet:&#160;Information for&#160;the user&#160;</b></p>
<p style="position:absolute;top:108px;left:447px;white-space:nowrap" class="ft450">&#160;</p>
<p style="position:absolute;top:127px;left:273px;white-space:nowrap" class="ft452"><b>Biktarvy 30&#160;mg/120&#160;mg/15&#160;mg&#160;film-coated&#160;tablets&#160;</b></p>
<p style="position:absolute;top:146px;left:290px;white-space:nowrap" class="ft450">bictegravir/emtricitabine/tenofovir&#160;alafenamide&#160;</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft454">&#160;<br/><b>Read all&#160;of&#160;this leaflet&#160;carefully before you&#160;start&#160;taking this&#160;medicine because&#160;it&#160;contains&#160;<br/>important&#160;information&#160;for you.&#160;<br/></b>-&#160;</p>
<p style="position:absolute;top:222px;left:149px;white-space:nowrap" class="ft450">Keep this&#160;leaflet.&#160;&#160;You may&#160;need&#160;to read&#160;it&#160;again.&#160;</p>
<p style="position:absolute;top:241px;left:106px;white-space:nowrap" class="ft450">-&#160;</p>
<p style="position:absolute;top:241px;left:149px;white-space:nowrap" class="ft450">If&#160;you have any&#160;further&#160;questions,&#160;ask your&#160;doctor&#160;or&#160;pharmacist.&#160;</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft450">-&#160;</p>
<p style="position:absolute;top:260px;left:149px;white-space:nowrap" class="ft458">This&#160;medicine has&#160;been prescribed&#160;for&#160;you only.&#160;&#160;Do&#160;not&#160;pass&#160;it&#160;on&#160;to others.&#160;&#160;It&#160;may harm&#160;them,&#160;<br/>even&#160;if&#160;their&#160;signs of&#160;illness&#160;are&#160;the&#160;same as yours.&#160;</p>
<p style="position:absolute;top:298px;left:106px;white-space:nowrap" class="ft450">-&#160;</p>
<p style="position:absolute;top:298px;left:149px;white-space:nowrap" class="ft455">If&#160;you get&#160;any&#160;side effects, talk&#160;to your&#160;doctor&#160;or&#160;pharmacist.&#160;&#160;This&#160;includes&#160;any possible&#160;side&#160;<br/>effects not&#160;listed&#160;in&#160;this leaflet.&#160;&#160;See&#160;section&#160;4.&#160;</p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft455">&#160;<br/><b>If&#160;Biktarvy has been prescribed&#160;for your&#160;child, please&#160;note that&#160;all&#160;the&#160;information&#160;in&#160;this&#160;leaflet&#160;<br/>is addressed to&#160;your&#160;child&#160;(in&#160;this&#160;case please&#160;read “your child”&#160;instead of&#160;“you”).&#160;<br/>&#160;<br/>What&#160;is&#160;in this&#160;leaflet&#160;<br/></b>&#160;<br/>1.&#160;</p>
<p style="position:absolute;top:450px;left:149px;white-space:nowrap" class="ft450">What&#160;Biktarvy&#160;is and what&#160;it&#160;is used&#160;for&#160;</p>
<p style="position:absolute;top:469px;left:106px;white-space:nowrap" class="ft450">2.&#160;</p>
<p style="position:absolute;top:469px;left:149px;white-space:nowrap" class="ft450">What&#160;you need&#160;to know&#160;before you take&#160;Biktarvy&#160;</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft450">3.&#160;</p>
<p style="position:absolute;top:488px;left:149px;white-space:nowrap" class="ft450">How&#160;to take&#160;Biktarvy&#160;</p>
<p style="position:absolute;top:506px;left:106px;white-space:nowrap" class="ft450">4.&#160;</p>
<p style="position:absolute;top:506px;left:149px;white-space:nowrap" class="ft450">Possible&#160;side effects&#160;</p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft450">5.&#160;</p>
<p style="position:absolute;top:526px;left:149px;white-space:nowrap" class="ft450">How&#160;to store&#160;Biktarvy&#160;</p>
<p style="position:absolute;top:544px;left:106px;white-space:nowrap" class="ft450">6.&#160;</p>
<p style="position:absolute;top:544px;left:149px;white-space:nowrap" class="ft450">Contents of&#160;the pack and other&#160;information&#160;</p>
<p style="position:absolute;top:564px;left:106px;white-space:nowrap" class="ft458">&#160;<br/>&#160;<br/><b>1.&#160;</b></p>
<p style="position:absolute;top:601px;left:149px;white-space:nowrap" class="ft452"><b>What&#160;Biktarvy&#160;is and&#160;what&#160;it&#160;is used&#160;for&#160;</b></p>
<p style="position:absolute;top:620px;left:106px;white-space:nowrap" class="ft450">&#160;</p>
<p style="position:absolute;top:639px;left:104px;white-space:nowrap" class="ft450">Biktarvy&#160;contains three active&#160;substances:&#160;</p>
<p style="position:absolute;top:654px;left:106px;white-space:nowrap" class="ft456">•&#160;</p>
<p style="position:absolute;top:660px;left:149px;white-space:nowrap" class="ft452"><b>bictegravir,</b>&#160;an antiretroviral&#160;medicine&#160;known as&#160;an integrase<b>&#160;</b>strand&#160;transfer&#160;inhibitor&#160;(INSTI)&#160;</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft456">•&#160;</p>
<p style="position:absolute;top:680px;left:149px;white-space:nowrap" class="ft455"><b>emtricitabine,</b>&#160;an&#160;antiretroviral&#160;medicine of&#160;a&#160;type&#160;known as&#160;a nucleoside&#160;reverse&#160;transcriptase&#160;<br/>inhibitor&#160;(NRTI)&#160;</p>
<p style="position:absolute;top:714px;left:106px;white-space:nowrap" class="ft456">•&#160;</p>
<p style="position:absolute;top:719px;left:149px;white-space:nowrap" class="ft455"><b>tenofovir alafenamide,</b>&#160;an&#160;antiretroviral&#160;medicine of&#160;a&#160;type known as&#160;a nucleotide&#160;reverse&#160;<br/>transcriptase inhibitor&#160;(NtRTI)&#160;</p>
<p style="position:absolute;top:757px;left:104px;white-space:nowrap" class="ft450">&#160;</p>
<p style="position:absolute;top:776px;left:106px;white-space:nowrap" class="ft455">Biktarvy&#160;is&#160;a single tablet&#160;for&#160;the treatment&#160;of&#160;human&#160;immunodeficiency virus 1&#160;(HIV-1)&#160;infection&#160;in&#160;<br/>adults, adolescents and&#160;children 2&#160;years of&#160;age and&#160;older, who weigh&#160;at&#160;least&#160;14&#160;kg.&#160;</p>
<p style="position:absolute;top:814px;left:104px;white-space:nowrap" class="ft455">&#160;<br/>Biktarvy&#160;reduces&#160;the&#160;amount&#160;of&#160;HIV&#160;in&#160;your&#160;body.&#160;&#160;This will&#160;improve your&#160;immune system&#160;and reduce&#160;</p>
<p style="position:absolute;top:852px;left:106px;white-space:nowrap" class="ft458">the&#160;risk of&#160;developing&#160;illnesses&#160;linked&#160;to HIV&#160;infection.&#160;<br/>&#160;<br/>&#160;<br/><b>2.&#160;</b></p>
<p style="position:absolute;top:909px;left:149px;white-space:nowrap" class="ft452"><b>What you need&#160;to know&#160;before you&#160;take&#160;Biktarvy</b>&#160;</p>
<p style="position:absolute;top:928px;left:106px;white-space:nowrap" class="ft454">&#160;<br/><b>Do not take&#160;Biktarvy&#160;<br/>&#160;</b></p>
<p style="position:absolute;top:980px;left:106px;white-space:nowrap" class="ft456">•&#160;</p>
<p style="position:absolute;top:986px;left:149px;white-space:nowrap" class="ft455"><b>If&#160;you are&#160;allergic&#160;to&#160;bictegravir,&#160;emtricitabine,&#160;tenofovir alafenamide</b>&#160;or&#160;any&#160;of&#160;the other&#160;<br/>ingredients of&#160;this&#160;medicine&#160;(listed&#160;in section&#160;6).&#160;</p>
<p style="position:absolute;top:1024px;left:106px;white-space:nowrap" class="ft450">&#160;</p>
<p style="position:absolute;top:1038px;left:106px;white-space:nowrap" class="ft456">•&#160;</p>
<p style="position:absolute;top:1044px;left:149px;white-space:nowrap" class="ft455"><b>If&#160;you are&#160;currently taking&#160;any of&#160;the&#160;following medicines:</b>&#160;<br/>-&#160;</p>
<p style="position:absolute;top:1063px;left:191px;white-space:nowrap" class="ft452"><b>rifampicin&#160;</b>used to&#160;treat&#160;some bacterial&#160;infections&#160;such as&#160;tuberculosis&#160;</p>
<p style="position:absolute;top:1082px;left:149px;white-space:nowrap" class="ft450">-&#160;</p>
<p style="position:absolute;top:1082px;left:191px;white-space:nowrap" class="ft455"><b>St.&#160;John’s&#160;wort&#160;</b>(<i>Hypericum&#160;perforatum</i>), a&#160;herbal&#160;remedy&#160;used&#160;for&#160;depression and&#160;<br/>anxiety,&#160;or&#160;products&#160;that&#160;contain it.&#160;</p>
<p style="position:absolute;top:1120px;left:106px;white-space:nowrap" class="ft4513">&#160;<br/>→<b>&#160;</b>If&#160;any of&#160;these&#160;apply&#160;to&#160;you,&#160;<b>do not&#160;take&#160;Biktarvy&#160;and tell&#160;your doctor&#160;immediately.</b>&#160;<br/><b>&#160;</b></p>
</div>
<!-- Page 46 -->
<a name="46"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft4651{font-size:17px;font-family:BCDFEE+Calibri;color:#006fc0;}
-->
</style>
<div id="page46-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft460">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft461">46&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft463"><b>Warnings and precautions&#160;<br/></b>&#160;<br/><b>Talk to&#160;your doctor before taking&#160;Biktarvy:&#160;<br/>&#160;</b></p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft466">•&#160;</p>
<p style="position:absolute;top:166px;left:149px;white-space:nowrap" class="ft464"><b>If&#160;you have&#160;liver&#160;problems or&#160;a history of&#160;liver&#160;disease, including hepatitis.</b>&#160;&#160;Patients with&#160;<br/>liver&#160;disease&#160;including&#160;chronic hepatitis&#160;B&#160;or&#160;C, who&#160;are treated with&#160;antiretrovirals, have&#160;a&#160;<br/>higher&#160;risk&#160;of&#160;severe and potentially fatal&#160;liver&#160;complications.&#160;&#160;If&#160;you have hepatitis&#160;B&#160;infection,&#160;<br/>your&#160;doctor&#160;will&#160;carefully consider&#160;the best&#160;treatment&#160;regimen&#160;for&#160;you.<b>&#160;<br/>&#160;</b></p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft466">•&#160;</p>
<p style="position:absolute;top:262px;left:149px;white-space:nowrap" class="ft465"><b>If&#160;you have hepatitis&#160;B&#160;infection.</b>&#160;&#160;Liver&#160;problems&#160;may become worse&#160;after&#160;you stop taking&#160;<br/>Biktarvy.&#160;<b>&#160;</b></p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft4648">→<b>&#160;</b>Do not&#160;stop&#160;taking&#160;Biktarvy&#160;if&#160;you have hepatitis&#160;B.&#160;&#160;Talk&#160;to your&#160;doctor&#160;first.&#160;&#160;For&#160;more details, see&#160;</p>
<p style="position:absolute;top:319px;left:128px;white-space:nowrap" class="ft460">section&#160;3,&#160;<i>Do not&#160;stop&#160;taking&#160;Biktarvy.</i><b>&#160;</b></p>
<p style="position:absolute;top:338px;left:150px;white-space:nowrap" class="ft460">&#160;</p>
<p style="position:absolute;top:353px;left:106px;white-space:nowrap" class="ft466">•&#160;</p>
<p style="position:absolute;top:358px;left:149px;white-space:nowrap" class="ft462"><b>If&#160;you have had kidney disease&#160;or&#160;if&#160;tests have shown problems&#160;with&#160;your kidneys.</b></p>
<p style="position:absolute;top:357px;left:724px;white-space:nowrap" class="ft4651"><b>&#160;&#160;</b>Your&#160;</p>
<p style="position:absolute;top:377px;left:150px;white-space:nowrap" class="ft468">doctor&#160;may order&#160;blood&#160;tests to&#160;monitor&#160;how&#160;your&#160;kidneys&#160;work&#160;when starting and&#160;during&#160;<br/>treatment&#160;with Biktarvy.&#160;</p>
<p style="position:absolute;top:415px;left:106px;white-space:nowrap" class="ft468"><b>&#160;<br/>While you&#160;are&#160;taking&#160;Biktarvy&#160;<br/></b>&#160;<br/>Once&#160;you&#160;start&#160;taking&#160;Biktarvy, look out&#160;for:&#160;<br/>&#160;</p>
<p style="position:absolute;top:506px;left:106px;white-space:nowrap" class="ft466">•&#160;</p>
<p style="position:absolute;top:511px;left:149px;white-space:nowrap" class="ft462"><b>Signs&#160;of&#160;inflammation or infection&#160;</b></p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft466">•&#160;</p>
<p style="position:absolute;top:531px;left:149px;white-space:nowrap" class="ft462"><b>Joint pain,&#160;stiffness</b>&#160;or&#160;<b>bone problems</b>&#160;</p>
<p style="position:absolute;top:550px;left:106px;white-space:nowrap" class="ft4612">&#160;<br/>→<b>&#160;If&#160;you notice&#160;any of&#160;these&#160;symptoms, tell&#160;your&#160;doctor immediately.</b>&#160;&#160;For&#160;more&#160;information see&#160;</p>
<p style="position:absolute;top:588px;left:128px;white-space:nowrap" class="ft460">section&#160;4,&#160;<i>Possible side&#160;effects</i>.&#160;</p>
<p style="position:absolute;top:607px;left:106px;white-space:nowrap" class="ft465">&#160;<br/>There&#160;is&#160;a&#160;possibility that&#160;you may experience kidney&#160;problems when&#160;taking Biktarvy over&#160;a long&#160;<br/>period of&#160;time&#160;(see&#160;<i>Warnings and precautions</i>).&#160;<br/>&#160;<br/>This&#160;medicine&#160;is not&#160;a&#160;cure&#160;for&#160;HIV&#160;infection.&#160;&#160;While taking&#160;Biktarvy&#160;you&#160;may&#160;still&#160;develop infections&#160;<br/>or&#160;other&#160;illnesses associated&#160;with HIV&#160;infection.&#160;<br/>&#160;<br/><b>Children and&#160;adolescents&#160;<br/></b>&#160;<br/><b>Do not give this&#160;medicine&#160;to children&#160;under&#160;2&#160;years&#160;of&#160;age,</b>&#160;or&#160;weighing&#160;less than 14&#160;kg&#160;regardless&#160;<br/>of&#160;age.&#160;The use&#160;of&#160;Biktarvy&#160;in children&#160;under&#160;2&#160;years of&#160;age,&#160;or&#160;weighing&#160;less than&#160;14&#160;kg&#160;has not&#160;yet&#160;<br/>been studied.&#160;For&#160;children&#160;and adolescents&#160;who weigh&#160;25&#160;kg&#160;or&#160;more,&#160;Biktarvy&#160;50&#160;mg/200&#160;mg/25&#160;mg&#160;<br/>film-coated&#160;tablets&#160;are&#160;available.&#160;&#160;&#160;<br/>&#160;<br/>Loss of&#160;bone&#160;mass&#160;has&#160;been&#160;reported in&#160;some children from&#160;3 to&#160;less&#160;than 12 years&#160;of&#160;age who&#160;<br/>received one&#160;of&#160;the&#160;medicinal&#160;products&#160;(tenofovir&#160;alafenamide)&#160;contained&#160;in Biktarvy.&#160;&#160;The effects&#160;on&#160;<br/>long&#160;term&#160;bone health and future fracture risk&#160;in children is&#160;uncertain.&#160;&#160;Your&#160;doctor&#160;will&#160;monitor&#160;your&#160;<br/>child’s&#160;bone&#160;health&#160;as&#160;needed.&#160;<br/>&#160;<br/><b>Other&#160;medicines&#160;and&#160;Biktarvy&#160;<br/></b>&#160;<br/><b>Tell&#160;your doctor&#160;or pharmacist&#160;if&#160;you are taking, have recently&#160;taken or might take any other&#160;<br/>medicines.</b>&#160;&#160;Biktarvy&#160;may interact&#160;with other&#160;medicines.&#160;&#160;As&#160;a&#160;result, the amounts&#160;of&#160;Biktarvy&#160;or&#160;other&#160;<br/>medicines&#160;in your&#160;blood&#160;may&#160;change.&#160;&#160;This&#160;may&#160;stop&#160;your&#160;medicines&#160;from&#160;working properly, or&#160;may&#160;<br/>make&#160;any&#160;side effects worse.&#160;&#160;In some cases, your&#160;doctor&#160;may need&#160;to adjust&#160;your&#160;dose&#160;or&#160;check your&#160;<br/>blood&#160;levels.&#160;<br/>&#160;</p>
</div>
<!-- Page 47 -->
<a name="47"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page47-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft470">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft471">47&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft4712"><b>Medicines that&#160;must&#160;never be taken&#160;with&#160;Biktarvy:</b>&#160;<br/>•&#160;</p>
<p style="position:absolute;top:109px;left:149px;white-space:nowrap" class="ft472"><b>rifampicin&#160;</b>used to&#160;treat&#160;some bacterial&#160;infections&#160;such as&#160;tuberculosis&#160;</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft476">•&#160;</p>
<p style="position:absolute;top:129px;left:149px;white-space:nowrap" class="ft475"><b>St.&#160;John’s&#160;wort&#160;</b>(<i>Hypericum&#160;perforatum</i>), a&#160;herbal&#160;remedy&#160;used&#160;for&#160;depression and anxiety,&#160;or&#160;<br/>products&#160;that&#160;contain&#160;it.&#160;</p>
<p style="position:absolute;top:167px;left:106px;white-space:nowrap" class="ft474"><b>&#160;<br/></b>→<b>&#160;</b>If&#160;you are taking&#160;any&#160;of&#160;these&#160;medicines,&#160;<b>do not&#160;take&#160;Biktarvy&#160;and&#160;tell&#160;your doctor&#160;immediately.&#160;<br/>&#160;<br/>Talk to&#160;your doctor if&#160;you&#160;are&#160;taking:&#160;<br/></b>&#160;</p>
<p style="position:absolute;top:258px;left:106px;white-space:nowrap" class="ft476">•&#160;</p>
<p style="position:absolute;top:263px;left:149px;white-space:nowrap" class="ft474"><b>medicines&#160;used for treating HIV&#160;and/or hepatitis&#160;B,</b>&#160;containing:<b>&#160;<br/></b>-&#160;</p>
<p style="position:absolute;top:282px;left:187px;white-space:nowrap" class="ft478">adefovir&#160;dipivoxil,&#160;atazanavir, bictegravir,&#160;emtricitabine, lamivudine,&#160;tenofovir&#160;<br/>alafenamide, or&#160;tenofovir&#160;disoproxil&#160;</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft476">•&#160;</p>
<p style="position:absolute;top:322px;left:149px;white-space:nowrap" class="ft475"><b>antibiotics used&#160;to&#160;treat&#160;bacterial&#160;infections,</b>&#160;containing:&#160;<br/>-&#160;</p>
<p style="position:absolute;top:340px;left:187px;white-space:nowrap" class="ft470">azithromycin,&#160;clarithromycin,&#160;rifabutin or&#160;rifapentine&#160;</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft476">•&#160;</p>
<p style="position:absolute;top:361px;left:149px;white-space:nowrap" class="ft475"><b>anticonvulsants</b>&#160;used to&#160;treat&#160;epilepsy,&#160;containing:&#160;<br/>-&#160;</p>
<p style="position:absolute;top:380px;left:187px;white-space:nowrap" class="ft470">carbamazepine,&#160;oxcarbazepine, phenobarbital&#160;or&#160;phenytoin&#160;</p>
<p style="position:absolute;top:395px;left:106px;white-space:nowrap" class="ft476">•&#160;</p>
<p style="position:absolute;top:400px;left:149px;white-space:nowrap" class="ft475"><b>immunosuppressants</b>&#160;used&#160;to control&#160;your&#160;body’s immune&#160;response after&#160;a&#160;transplant,&#160;<br/>containing&#160;ciclosporin&#160;</p>
<p style="position:absolute;top:434px;left:106px;white-space:nowrap" class="ft476">•&#160;</p>
<p style="position:absolute;top:439px;left:149px;white-space:nowrap" class="ft472"><b>ulcer-healing medicines</b>&#160;containing&#160;sucralfate&#160;</p>
<p style="position:absolute;top:458px;left:106px;white-space:nowrap" class="ft4712">&#160;<br/>→<b>&#160;Tell&#160;your doctor&#160;if&#160;you are taking any of&#160;these&#160;medicines.</b>&#160;&#160;Do not&#160;stop your&#160;treatment&#160;without&#160;</p>
<p style="position:absolute;top:496px;left:128px;white-space:nowrap" class="ft470">contacting your&#160;doctor.&#160;</p>
<p style="position:absolute;top:515px;left:106px;white-space:nowrap" class="ft475">&#160;<br/><b>Get&#160;advice&#160;from&#160;a doctor&#160;or pharmacist&#160;if&#160;you are&#160;taking:&#160;</b></p>
<p style="position:absolute;top:549px;left:106px;white-space:nowrap" class="ft476">•&#160;</p>
<p style="position:absolute;top:554px;left:149px;white-space:nowrap" class="ft475"><b>antacids</b>&#160;to treat&#160;stomach ulcers, heartburn, or&#160;acid&#160;reflux,&#160;containing&#160;aluminium&#160;and/or&#160;<br/>magnesium&#160;hydroxide&#160;&#160;</p>
<p style="position:absolute;top:588px;left:106px;white-space:nowrap" class="ft476">•&#160;</p>
<p style="position:absolute;top:593px;left:149px;white-space:nowrap" class="ft472"><b>mineral&#160;supplements&#160;</b>or<b>&#160;vitamins&#160;</b>containing&#160;magnesium&#160;or&#160;iron&#160;</p>
<p style="position:absolute;top:612px;left:106px;white-space:nowrap" class="ft4712">&#160;<br/>→<b>&#160;Get&#160;advice&#160;from&#160;your&#160;doctor or pharmacist&#160;before&#160;taking&#160;Biktarvy</b>&#160;if&#160;you&#160;are&#160;taking&#160;any of&#160;</p>
<p style="position:absolute;top:650px;left:128px;white-space:nowrap" class="ft478">these medicines.&#160;<br/><b>Antacids and&#160;magnesium&#160;supplements:&#160;</b>you will&#160;need to&#160;take&#160;Biktarvy at&#160;least&#160;2&#160;hours&#160;<b>before</b>&#160;<br/>antacids or&#160;supplements&#160;containing aluminium&#160;and/or&#160;magnesium.&#160;&#160;Or&#160;you&#160;can&#160;take Biktarvy with&#160;<br/>food&#160;at&#160;least&#160;2&#160;hours&#160;<b>after.</b>&#160;<br/><b>Iron supplements:</b>&#160;you will&#160;need to&#160;take Biktarvy at&#160;least&#160;2&#160;hours&#160;<b>before</b>&#160;iron supplements, or&#160;you&#160;<br/>can take&#160;them&#160;together&#160;with&#160;food.&#160;</p>
<p style="position:absolute;top:764px;left:106px;white-space:nowrap" class="ft473">&#160;<br/><b>Pregnancy&#160;and&#160;breast-feeding&#160;<br/></b>&#160;</p>
<p style="position:absolute;top:817px;left:106px;white-space:nowrap" class="ft476">•&#160;</p>
<p style="position:absolute;top:822px;left:149px;white-space:nowrap" class="ft475">If&#160;you are pregnant&#160;or&#160;breast-feeding,&#160;think you&#160;may be&#160;pregnant&#160;or&#160;are planning to&#160;have&#160;a&#160;baby,&#160;<br/>ask your&#160;doctor&#160;or&#160;pharmacist&#160;for&#160;advice&#160;before&#160;taking&#160;this medicine.&#160;</p>
<p style="position:absolute;top:856px;left:106px;white-space:nowrap" class="ft476">•&#160;</p>
<p style="position:absolute;top:861px;left:149px;white-space:nowrap" class="ft475">Tell&#160;your&#160;doctor&#160;immediately if&#160;you&#160;become&#160;pregnant&#160;and ask about&#160;the potential&#160;benefits and&#160;<br/>risks of&#160;your&#160;antiretroviral&#160;therapy to&#160;you and your&#160;child.&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft475">&#160;<br/>If&#160;you have taken&#160;Biktarvy&#160;during your&#160;pregnancy, your&#160;doctor&#160;may request&#160;regular&#160;blood tests and&#160;<br/>other&#160;diagnostic&#160;tests&#160;to&#160;monitor&#160;the development&#160;of&#160;your&#160;child.&#160;&#160;In children whose&#160;mothers took&#160;<br/>nucleoside&#160;reverse&#160;transcriptase&#160;inhibitors&#160;(NRTIs)&#160;during pregnancy, the benefit&#160;from&#160;the protection&#160;<br/>against&#160;HIV&#160;outweighed the risk of&#160;side effects.&#160;<br/>&#160;<br/><b>Do not breast-feed during&#160;treatment&#160;with&#160;Biktarvy.</b>&#160;&#160;This&#160;is because&#160;some of&#160;the active substances&#160;<br/>in this&#160;medicine&#160;pass into human&#160;breast&#160;milk.&#160;&#160;Breast-feeding is not&#160;recommended&#160;in women&#160;living&#160;<br/>with&#160;HIV&#160;because&#160;HIV&#160;infection can be passed on&#160;to&#160;the baby&#160;in breast&#160;milk.&#160;&#160;If&#160;you are&#160;<br/>breast-feeding, or&#160;thinking&#160;about&#160;breast-feeding, you should&#160;<b>discuss&#160;it&#160;with your&#160;doctor&#160;as soon as&#160;<br/>possible</b>.&#160;<br/><b>&#160;</b></p>
</div>
<!-- Page 48 -->
<a name="48"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page48-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft480">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft481">48&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft485"><b>Driving and&#160;using&#160;machines&#160;<br/></b>&#160;<br/>Biktarvy&#160;can cause dizziness.&#160;&#160;If&#160;you&#160;feel&#160;dizzy when taking Biktarvy,&#160;do not&#160;drive&#160;or&#160;ride&#160;a bicycle&#160;<br/>and do not&#160;use&#160;any tools&#160;or&#160;machines.&#160;<br/>&#160;<br/><b>Biktarvy contains sodium&#160;<br/></b>&#160;<br/>This&#160;medicine&#160;contains less&#160;than 1&#160;mmol&#160;sodium&#160;(23 mg)&#160;per&#160;tablet,&#160;that&#160;is to say&#160;essentially&#160;<br/>‘sodium-free’.&#160;<br/>&#160;<br/>&#160;<br/><b>3.&#160;</b></p>
<p style="position:absolute;top:298px;left:149px;white-space:nowrap" class="ft482"><b>How&#160;to&#160;take&#160;Biktarvy&#160;</b></p>
<p style="position:absolute;top:317px;left:106px;white-space:nowrap" class="ft4812">&#160;<br/>Always&#160;take&#160;this&#160;medicine&#160;exactly&#160;as&#160;your&#160;doctor&#160;has&#160;told you.&#160;&#160;Check&#160;with your&#160;doctor&#160;or&#160;pharmacist&#160;<br/>if&#160;you are not&#160;sure.&#160;<br/>&#160;<br/>There&#160;are&#160;two strengths of&#160;Biktarvy&#160;tablets. Your&#160;doctor&#160;will&#160;prescribe&#160;the&#160;appropriate&#160;tablet&#160;for&#160;your&#160;<br/>age&#160;and weight.&#160;&#160;<br/>&#160;<br/><b>The&#160;recommended&#160;dose&#160;is:&#160;<br/></b>&#160;<br/><b>Children 2 years&#160;of&#160;age and&#160;older, who weigh&#160;at&#160;least&#160;14&#160;kg but&#160;less than 25&#160;kg:&#160;</b>one&#160;tablet&#160;each&#160;<br/>day with or&#160;without&#160;food&#160;(one 30&#160;mg/120&#160;mg/15&#160;mg tablet).&#160;<br/>&#160;<br/>Due to&#160;the bitter&#160;taste,&#160;it&#160;is&#160;recommended&#160;not&#160;to&#160;chew&#160;or&#160;crush&#160;the&#160;tablet.&#160;<br/>If&#160;you have difficulty&#160;swallowing the&#160;tablet&#160;whole,&#160;you&#160;can split&#160;it&#160;in half. Take&#160;both halves of&#160;the&#160;<br/>tablet&#160;one after&#160;the&#160;other&#160;to&#160;get&#160;the&#160;full&#160;dose. Do not&#160;store the split&#160;tablet.&#160;<br/>&#160;<br/>The score&#160;line on&#160;the&#160;tablet&#160;is only&#160;there to help you&#160;break the tablet&#160;if&#160;your&#160;child&#160;has&#160;difficulty&#160;<br/>swallowing&#160;it&#160;whole.&#160;<br/>&#160;<br/>The 90-day&#160;multipack&#160;contains&#160;three&#160;30-day&#160;packs&#160;together.&#160;<br/>→<b>&#160;Get&#160;advice&#160;from&#160;a doctor&#160;or pharmacist&#160;if&#160;you are&#160;taking:&#160;</b></p>
<p style="position:absolute;top:711px;left:106px;white-space:nowrap" class="ft486">•&#160;</p>
<p style="position:absolute;top:717px;left:149px;white-space:nowrap" class="ft485"><b>antacids</b>&#160;to treat&#160;stomach ulcers, heartburn, or&#160;acid&#160;reflux,&#160;containing&#160;aluminium&#160;and/or&#160;<br/>magnesium&#160;hydroxide&#160;</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft486">•&#160;</p>
<p style="position:absolute;top:756px;left:149px;white-space:nowrap" class="ft482"><b>mineral&#160;supplements</b>&#160;or&#160;<b>vitamins</b>&#160;containing&#160;magnesium&#160;or&#160;iron&#160;</p>
<p style="position:absolute;top:771px;left:106px;white-space:nowrap" class="ft488">→<b>&#160;See section&#160;2&#160;for&#160;more information&#160;</b>on taking these&#160;medicines&#160;with&#160;Biktarvy.&#160;<br/>&#160;<br/>If&#160;you are on dialysis,&#160;take&#160;your&#160;daily dose of&#160;Biktarvy&#160;following completion of&#160;dialysis.&#160;<br/>&#160;<br/><b>If&#160;you&#160;take&#160;more&#160;Biktarvy&#160;than&#160;you&#160;should&#160;<br/></b>&#160;<br/>If&#160;you take&#160;more than the&#160;recommended dose&#160;of&#160;Biktarvy&#160;you&#160;may be at&#160;higher&#160;risk of&#160;side&#160;effects&#160;of&#160;<br/>this medicine (see&#160;section&#160;4,&#160;<i>Possible side effects</i>).&#160;<br/>&#160;<br/>Contact&#160;your&#160;doctor&#160;or&#160;nearest&#160;emergency department&#160;immediately&#160;for&#160;advice.&#160;&#160;Keep&#160;or&#160;take&#160;the tablet&#160;<br/>bottle&#160;or&#160;carton&#160;with you so&#160;that&#160;you&#160;can easily&#160;describe what&#160;you have taken.&#160;<br/>&#160;<br/><b>If&#160;you&#160;forget&#160;to take&#160;Biktarvy&#160;<br/></b>&#160;<br/>It&#160;is&#160;important&#160;not&#160;to&#160;miss&#160;a&#160;dose&#160;of&#160;Biktarvy.&#160;<br/>&#160;<br/>If&#160;you&#160;miss&#160;a dose:&#160;</p>
<p style="position:absolute;top:1093px;left:106px;white-space:nowrap" class="ft486">•&#160;</p>
<p style="position:absolute;top:1098px;left:149px;white-space:nowrap" class="ft485"><b>If&#160;you notice&#160;within&#160;18&#160;hours</b>&#160;of&#160;the&#160;time you usually&#160;take&#160;Biktarvy, you&#160;must&#160;take the&#160;tablet&#160;as&#160;<br/>soon as possible.&#160;&#160;Then&#160;take the&#160;next&#160;dose as&#160;usual.&#160;</p>
<p style="position:absolute;top:1132px;left:106px;white-space:nowrap" class="ft486">•&#160;</p>
<p style="position:absolute;top:1138px;left:149px;white-space:nowrap" class="ft485"><b>If&#160;you notice&#160;18&#160;hours&#160;or&#160;more</b>&#160;after&#160;the time you&#160;usually take&#160;Biktarvy,&#160;then do&#160;not&#160;take&#160;the&#160;<br/>missed&#160;dose.&#160;&#160;Wait&#160;and&#160;take&#160;the next&#160;dose&#160;at&#160;your&#160;usual&#160;time.&#160;</p>
</div>
<!-- Page 49 -->
<a name="49"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page49-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft490">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft491">49&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft4912">&#160;<br/><b>If&#160;you vomit&#160;</b>less&#160;than&#160;1&#160;hour&#160;after&#160;taking&#160;Biktarvy,&#160;take another&#160;tablet.&#160;&#160;If&#160;you vomit&#160;more&#160;than&#160;1&#160;hour&#160;<br/>after&#160;taking&#160;Biktarvy&#160;you do not&#160;need&#160;to&#160;take&#160;another&#160;tablet&#160;until&#160;your&#160;next&#160;regularly scheduled&#160;tablet.&#160;<br/>&#160;<br/><b>Do not stop taking&#160;Biktarvy&#160;<br/></b>&#160;<br/><b>Do not stop taking&#160;Biktarvy&#160;without&#160;talking to your&#160;doctor.</b>&#160;&#160;Stopping&#160;Biktarvy&#160;can seriously affect&#160;<br/>how&#160;future&#160;treatment&#160;works.&#160;&#160;If&#160;Biktarvy&#160;is&#160;stopped&#160;for&#160;any reason, speak&#160;to your&#160;doctor&#160;before you&#160;<br/>restart&#160;taking&#160;Biktarvy&#160;tablets.&#160;<br/>&#160;<br/><b>When your&#160;supply of&#160;Biktarvy&#160;starts&#160;to run&#160;low,</b>&#160;get&#160;more from&#160;your&#160;doctor&#160;or&#160;pharmacist.&#160;&#160;This&#160;is&#160;<br/>very&#160;important&#160;because the&#160;amount&#160;of&#160;virus&#160;may start&#160;to increase&#160;if&#160;the&#160;medicine&#160;is stopped&#160;for&#160;even&#160;a&#160;<br/>short&#160;time.&#160;&#160;The&#160;disease&#160;may then&#160;become&#160;harder&#160;to&#160;treat.&#160;<br/>&#160;<br/><b>If&#160;you have both&#160;HIV&#160;infection&#160;and&#160;hepatitis&#160;B,</b>&#160;it&#160;is&#160;especially&#160;important&#160;not&#160;to&#160;stop your&#160;Biktarvy&#160;<br/>treatment&#160;without&#160;talking&#160;to&#160;your&#160;doctor&#160;first.&#160;&#160;You may require blood&#160;tests&#160;for&#160;several&#160;months after&#160;<br/>stopping&#160;treatment.&#160;&#160;In some patients with&#160;advanced&#160;liver&#160;disease or&#160;cirrhosis,&#160;stopping&#160;treatment&#160;is&#160;<br/>not&#160;recommended as&#160;this&#160;may lead to worsening of&#160;your&#160;hepatitis, which&#160;may&#160;be life-threatening.&#160;<br/>&#160;<br/>→<b>&#160;Tell&#160;your&#160;doctor&#160;immediately</b>&#160;about&#160;new or&#160;unusual&#160;symptoms after&#160;you&#160;stop treatment,&#160;</p>
<p style="position:absolute;top:469px;left:128px;white-space:nowrap" class="ft490">particularly&#160;symptoms you&#160;associate with hepatitis&#160;B&#160;infection.&#160;</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft498">&#160;<br/>If&#160;you have any&#160;further&#160;questions on&#160;the use&#160;of&#160;this&#160;medicine, ask your&#160;doctor&#160;or&#160;pharmacist.&#160;<br/>&#160;<br/>&#160;<br/><b>4.&#160;</b></p>
<p style="position:absolute;top:564px;left:149px;white-space:nowrap" class="ft492"><b>Possible&#160;side&#160;effects&#160;</b></p>
<p style="position:absolute;top:582px;left:106px;white-space:nowrap" class="ft493">&#160;<br/>Like&#160;all&#160;medicines,&#160;this medicine can cause&#160;side effects, although not&#160;everybody gets&#160;them.&#160;<br/>&#160;<br/><b>Possible&#160;side&#160;effects:&#160;tell&#160;a&#160;doctor immediately&#160;<br/></b>&#160;</p>
<p style="position:absolute;top:673px;left:106px;white-space:nowrap" class="ft496">•&#160;</p>
<p style="position:absolute;top:679px;left:149px;white-space:nowrap" class="ft498"><b>Any signs&#160;of&#160;inflammation or infection.</b>&#160;&#160;In some patients with advanced&#160;HIV&#160;infection&#160;<br/>(AIDS) and a history of&#160;opportunistic infections&#160;(infections that&#160;occur&#160;in people with&#160;a weak&#160;<br/>immune system), signs&#160;and&#160;symptoms of&#160;inflammation&#160;from&#160;previous&#160;infections&#160;may occur&#160;soon&#160;<br/>after&#160;HIV&#160;treatment&#160;is&#160;started.&#160;&#160;It&#160;is thought&#160;that&#160;these&#160;symptoms are due&#160;to an&#160;improvement&#160;in&#160;<br/>the body’s immune&#160;response, enabling the body to&#160;fight&#160;infections&#160;that&#160;may have&#160;been present&#160;<br/>with no&#160;obvious&#160;symptoms.&#160;</p>
<p style="position:absolute;top:792px;left:106px;white-space:nowrap" class="ft4912">&#160;<br/>•&#160;</p>
<p style="position:absolute;top:813px;left:149px;white-space:nowrap" class="ft498"><b>Autoimmune disorders,</b>&#160;when the immune&#160;system&#160;attacks&#160;healthy body tissue,&#160;may also occur&#160;<br/>after&#160;you start&#160;taking&#160;medicines&#160;for&#160;HIV&#160;infection.&#160;&#160;Autoimmune disorders may occur&#160;many&#160;<br/>months after&#160;the&#160;start&#160;of&#160;treatment.&#160;&#160;Look&#160;out&#160;for&#160;any&#160;symptoms of&#160;infection or&#160;other&#160;symptoms&#160;<br/>such as:&#160;<br/>-&#160;</p>
<p style="position:absolute;top:888px;left:191px;white-space:nowrap" class="ft490">muscle weakness&#160;</p>
<p style="position:absolute;top:907px;left:149px;white-space:nowrap" class="ft490">-&#160;</p>
<p style="position:absolute;top:907px;left:191px;white-space:nowrap" class="ft490">weakness beginning&#160;in&#160;the&#160;hands&#160;and feet&#160;and&#160;moving&#160;up towards&#160;the&#160;trunk of&#160;the&#160;body&#160;</p>
<p style="position:absolute;top:926px;left:149px;white-space:nowrap" class="ft490">-&#160;</p>
<p style="position:absolute;top:926px;left:191px;white-space:nowrap" class="ft490">palpitations,&#160;tremor&#160;or&#160;hyperactivity&#160;</p>
<p style="position:absolute;top:945px;left:149px;white-space:nowrap" class="ft490">&#160;</p>
<p style="position:absolute;top:961px;left:106px;white-space:nowrap" class="ft4948">→<b>&#160;If&#160;you notice&#160;these or&#160;any&#160;symptoms of&#160;inflammation or infection, tell&#160;your doctor&#160;</b></p>
<p style="position:absolute;top:983px;left:128px;white-space:nowrap" class="ft492"><b>immediately.&#160;</b></p>
<p style="position:absolute;top:1002px;left:106px;white-space:nowrap" class="ft494">&#160;<br/><b>Common&#160;side effects&#160;<br/></b>(<i>may affect&#160;up to&#160;1 in&#160;10 people</i>)<i>&#160;</i></p>
<p style="position:absolute;top:1055px;left:106px;white-space:nowrap" class="ft496">•&#160;</p>
<p style="position:absolute;top:1060px;left:149px;white-space:nowrap" class="ft490">depression&#160;</p>
<p style="position:absolute;top:1075px;left:106px;white-space:nowrap" class="ft496">•&#160;</p>
<p style="position:absolute;top:1081px;left:149px;white-space:nowrap" class="ft490">abnormal&#160;dreams&#160;</p>
<p style="position:absolute;top:1095px;left:106px;white-space:nowrap" class="ft496">•&#160;</p>
<p style="position:absolute;top:1101px;left:149px;white-space:nowrap" class="ft490">headache&#160;</p>
<p style="position:absolute;top:1116px;left:106px;white-space:nowrap" class="ft496">•&#160;</p>
<p style="position:absolute;top:1121px;left:149px;white-space:nowrap" class="ft490">dizziness&#160;</p>
<p style="position:absolute;top:1136px;left:106px;white-space:nowrap" class="ft496">•&#160;</p>
<p style="position:absolute;top:1141px;left:149px;white-space:nowrap" class="ft490">diarrhoea&#160;</p>
<p style="position:absolute;top:1156px;left:106px;white-space:nowrap" class="ft496">•&#160;</p>
<p style="position:absolute;top:1161px;left:149px;white-space:nowrap" class="ft490">feeling&#160;sick (<i>nausea</i>)&#160;</p>
</div>
<!-- Page 50 -->
<a name="50"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page50-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft500">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft501">50&#160;</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft506">•&#160;</p>
<p style="position:absolute;top:90px;left:149px;white-space:nowrap" class="ft500">tiredness&#160;(<i>fatigue</i>)&#160;</p>
<p style="position:absolute;top:109px;left:106px;white-space:nowrap" class="ft5012">&#160;<br/><b>Uncommon side effects&#160;<br/></b>(<i>may affect&#160;up to&#160;1 in&#160;100&#160;people</i>)&#160;<br/>•&#160;</p>
<p style="position:absolute;top:167px;left:149px;white-space:nowrap" class="ft500">anaemia&#160;</p>
<p style="position:absolute;top:182px;left:106px;white-space:nowrap" class="ft506">•&#160;</p>
<p style="position:absolute;top:188px;left:149px;white-space:nowrap" class="ft500">vomiting&#160;</p>
<p style="position:absolute;top:202px;left:106px;white-space:nowrap" class="ft506">•&#160;</p>
<p style="position:absolute;top:208px;left:149px;white-space:nowrap" class="ft500">stomach&#160;pain&#160;</p>
<p style="position:absolute;top:223px;left:106px;white-space:nowrap" class="ft506">•&#160;</p>
<p style="position:absolute;top:228px;left:149px;white-space:nowrap" class="ft500">problems with digestion resulting&#160;in discomfort&#160;after&#160;meals&#160;(<i>dyspepsia</i>)&#160;</p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft506">•&#160;</p>
<p style="position:absolute;top:248px;left:149px;white-space:nowrap" class="ft500">wind (<i>flatulence</i>)&#160;</p>
<p style="position:absolute;top:263px;left:106px;white-space:nowrap" class="ft506">•&#160;</p>
<p style="position:absolute;top:268px;left:149px;white-space:nowrap" class="ft500">swelling&#160;of&#160;the&#160;face, lips,&#160;tongue or&#160;throat&#160;(<i>angioedema</i>)&#160;</p>
<p style="position:absolute;top:283px;left:106px;white-space:nowrap" class="ft506">•&#160;</p>
<p style="position:absolute;top:288px;left:149px;white-space:nowrap" class="ft500">itching&#160;(<i>pruritus</i>)&#160;</p>
<p style="position:absolute;top:303px;left:106px;white-space:nowrap" class="ft506">•&#160;</p>
<p style="position:absolute;top:309px;left:149px;white-space:nowrap" class="ft500">rash&#160;</p>
<p style="position:absolute;top:323px;left:106px;white-space:nowrap" class="ft506">•&#160;</p>
<p style="position:absolute;top:329px;left:149px;white-space:nowrap" class="ft500">hives&#160;(<i>urticaria</i>)&#160;</p>
<p style="position:absolute;top:344px;left:106px;white-space:nowrap" class="ft506">•&#160;</p>
<p style="position:absolute;top:349px;left:149px;white-space:nowrap" class="ft500">joint&#160;pain&#160;(<i>arthralgia</i>)&#160;</p>
<p style="position:absolute;top:364px;left:106px;white-space:nowrap" class="ft506">•&#160;</p>
<p style="position:absolute;top:369px;left:149px;white-space:nowrap" class="ft505">suicidal&#160;thoughts&#160;and suicide attempt&#160;(particularly&#160;in&#160;patients who have had&#160;depression or&#160;<br/>mental&#160;health problems before)&#160;</p>
<p style="position:absolute;top:403px;left:106px;white-space:nowrap" class="ft506">•&#160;</p>
<p style="position:absolute;top:408px;left:149px;white-space:nowrap" class="ft500">anxiety&#160;</p>
<p style="position:absolute;top:423px;left:106px;white-space:nowrap" class="ft506">•&#160;</p>
<p style="position:absolute;top:428px;left:149px;white-space:nowrap" class="ft500">sleep disorders&#160;</p>
<p style="position:absolute;top:447px;left:106px;white-space:nowrap" class="ft5012">&#160;<br/><i>Blood&#160;tests may&#160;also show:</i>&#160;<br/>•&#160;</p>
<p style="position:absolute;top:486px;left:149px;white-space:nowrap" class="ft500">higher&#160;levels of&#160;substances&#160;called bilirubin&#160;and/or&#160;serum&#160;creatinine&#160;in&#160;the&#160;blood&#160;</p>
<p style="position:absolute;top:505px;left:106px;white-space:nowrap" class="ft503">&#160;<br/><b>Rare&#160;side effects&#160;&#160;<br/></b><i>(may affect&#160;up to&#160;1 in&#160;1000&#160;people)<b>&#160;</b></i></p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft506">•&#160;</p>
<p style="position:absolute;top:564px;left:149px;white-space:nowrap" class="ft505">Stevens-Johnson syndrome&#160;(SJS)&#160;is&#160;a serious&#160;life-threatening condition which usually starts&#160;<br/>with&#160;flu-&#160;like&#160;symptoms. A&#160;few days later&#160;other&#160;symptoms appear&#160;including:&#160;<br/>-&#160;</p>
<p style="position:absolute;top:601px;left:191px;white-space:nowrap" class="ft500">Painful&#160;red or&#160;purple skin&#160;that&#160;looks&#160;burned and peels&#160;off&#160;</p>
<p style="position:absolute;top:620px;left:149px;white-space:nowrap" class="ft500">-&#160;</p>
<p style="position:absolute;top:620px;left:191px;white-space:nowrap" class="ft500">Blisters on&#160;your&#160;skin,&#160;mouth, nose,&#160;and genitals&#160;</p>
<p style="position:absolute;top:639px;left:149px;white-space:nowrap" class="ft500">-&#160;</p>
<p style="position:absolute;top:639px;left:191px;white-space:nowrap" class="ft508">Red, painful, watery&#160;eyes&#160;<br/>&#160;</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft5048">→<b>&#160;If&#160;you have any&#160;of&#160;these symptoms,&#160;stop your&#160;medicine&#160;immediately and&#160;tell&#160;your doctor&#160;</b></p>
<p style="position:absolute;top:696px;left:128px;white-space:nowrap" class="ft502"><b>straight&#160;away.&#160;</b></p>
<p style="position:absolute;top:733px;left:106px;white-space:nowrap" class="ft505">→<b>&#160;If&#160;any of&#160;the side effects get&#160;serious, tell&#160;your doctor.&#160;<br/></b>&#160;<br/><b>Other effects&#160;that&#160;may be&#160;seen during&#160;HIV&#160;treatment&#160;<br/></b>&#160;<br/>The frequency of&#160;the following side effects is not&#160;known (frequency cannot&#160;be&#160;estimated&#160;from&#160;the&#160;<br/>available data).&#160;<br/>&#160;</p>
<p style="position:absolute;top:865px;left:106px;white-space:nowrap" class="ft506">•&#160;</p>
<p style="position:absolute;top:870px;left:149px;white-space:nowrap" class="ft505"><b>Bone problems.</b>&#160;&#160;Some patients taking combination antiretroviral&#160;medicines&#160;such&#160;as&#160;Biktarvy&#160;<br/>may develop a&#160;bone&#160;disease&#160;called&#160;<i>osteonecrosis</i>&#160;(death&#160;of&#160;bone tissue caused by&#160;loss&#160;of&#160;blood&#160;<br/>supply to&#160;the&#160;bone).&#160;&#160;Taking this type of&#160;medicine for&#160;a long&#160;time, taking corticosteroids,&#160;<br/>drinking&#160;alcohol, having&#160;a&#160;very weak immune&#160;system,&#160;and being overweight,&#160;may&#160;be some of&#160;<br/>the&#160;many&#160;risk&#160;factors for&#160;developing&#160;this disease.&#160;&#160;Signs of&#160;osteonecrosis&#160;are:&#160;<br/>-&#160;</p>
<p style="position:absolute;top:965px;left:191px;white-space:nowrap" class="ft500">joint&#160;stiffness&#160;</p>
<p style="position:absolute;top:984px;left:149px;white-space:nowrap" class="ft500">-&#160;</p>
<p style="position:absolute;top:984px;left:191px;white-space:nowrap" class="ft500">joint&#160;aches&#160;and pains (especially of&#160;the hip, knee&#160;and shoulder)&#160;</p>
<p style="position:absolute;top:1003px;left:149px;white-space:nowrap" class="ft500">-&#160;</p>
<p style="position:absolute;top:1003px;left:191px;white-space:nowrap" class="ft500">difficulty&#160;with&#160;movement&#160;</p>
<p style="position:absolute;top:1018px;left:106px;white-space:nowrap" class="ft505">→<b>&#160;If&#160;you notice&#160;any of&#160;these&#160;symptoms tell&#160;your doctor.&#160;<br/></b>&#160;<br/>During HIV&#160;therapy there&#160;may be an&#160;increase&#160;in weight&#160;and&#160;in&#160;levels&#160;of&#160;blood&#160;lipids and glucose.&#160;&#160;This&#160;<br/>is partly&#160;linked&#160;to restored&#160;health and life style, and&#160;in&#160;the case&#160;of&#160;blood&#160;lipids sometimes&#160;to&#160;the HIV&#160;<br/>medicines&#160;themselves.&#160;&#160;Your&#160;doctor&#160;will&#160;test&#160;for&#160;these&#160;changes.&#160;<br/>&#160;</p>
</div>
<!-- Page 51 -->
<a name="51"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page51-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft510">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft511">51&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft515"><b>Reporting of&#160;side&#160;effects&#160;<br/></b>If&#160;you get&#160;any&#160;side effects, talk&#160;to your&#160;doctor&#160;or&#160;pharmacist.&#160;&#160;This&#160;includes&#160;any possible&#160;side effects&#160;<br/>not&#160;listed&#160;in&#160;this leaflet.&#160;&#160;You can also&#160;report&#160;side effects directly&#160;via the national&#160;reporting&#160;system&#160;<br/>listed&#160;i<a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">n&#160;Appendix&#160;V.</a>&#160;&#160;By reporting&#160;side effects you&#160;can help&#160;provide&#160;more&#160;information on&#160;the&#160;safety&#160;<br/>of&#160;this&#160;medicine.&#160;<br/>&#160;<br/>&#160;<br/><b>5.&#160;</b></p>
<p style="position:absolute;top:222px;left:149px;white-space:nowrap" class="ft512"><b>How&#160;to&#160;store&#160;Biktarvy&#160;</b></p>
<p style="position:absolute;top:241px;left:106px;white-space:nowrap" class="ft515">&#160;<br/>Keep this&#160;medicine&#160;out&#160;of&#160;the sight&#160;and&#160;reach of&#160;children.&#160;<br/>&#160;<br/>Do not&#160;use this&#160;medicine&#160;after&#160;the&#160;expiry&#160;date which is&#160;stated on the&#160;carton and&#160;bottle&#160;or&#160;blister&#160;strips&#160;<br/>after&#160;{EXP}.&#160;&#160;The expiry date&#160;refers to&#160;the&#160;last&#160;day of&#160;that&#160;month.&#160;<br/>&#160;<br/>Store&#160;in&#160;the&#160;original&#160;package in order&#160;to protect&#160;from&#160;moisture.&#160;&#160;Keep&#160;the&#160;bottle&#160;tightly&#160;closed.&#160;&#160;Do not&#160;<br/>use&#160;if&#160;the seal&#160;over&#160;the bottle opening&#160;is broken or&#160;missing.&#160;<br/>&#160;<br/>Do not&#160;throw&#160;away any&#160;medicines&#160;via wastewater&#160;or&#160;household waste.&#160;&#160;Ask your&#160;pharmacist&#160;how&#160;to&#160;<br/>throw&#160;away&#160;medicines&#160;you&#160;no longer&#160;use.&#160;&#160;These&#160;measures&#160;will&#160;help protect&#160;the environment.&#160;<br/>&#160;<br/>&#160;<br/><b>6.&#160;</b></p>
<p style="position:absolute;top:488px;left:149px;white-space:nowrap" class="ft512"><b>Contents of&#160;the pack and&#160;other&#160;information&#160;</b></p>
<p style="position:absolute;top:506px;left:106px;white-space:nowrap" class="ft518">&#160;<br/><b>What&#160;Biktarvy&#160;contains&#160;<br/></b>&#160;<br/><b>The active&#160;substances are</b>&#160;bictegravir,&#160;emtricitabine&#160;and tenofovir&#160;alafenamide.&#160;&#160;Each Biktarvy&#160;tablet&#160;<br/>contains&#160;bictegravir&#160;sodium&#160;equivalent&#160;to 30&#160;mg&#160;of&#160;bictegravir,&#160;120&#160;mg of&#160;emtricitabine&#160;and&#160;tenofovir&#160;<br/>alafenamide&#160;fumarate&#160;equivalent&#160;to 15&#160;mg of&#160;tenofovir&#160;alafenamide.&#160;<br/>&#160;<br/><b>The other ingredients are&#160;<br/>&#160;<br/></b><i>Tablet&#160;core&#160;<br/></i>Microcrystalline&#160;cellulose&#160;(E460), croscarmellose&#160;sodium&#160;(E468),&#160;magnesium&#160;stearate&#160;(E470b).&#160;<br/>&#160;<br/><i>Film-coating&#160;<br/></i>Polyvinyl&#160;alcohol&#160;(E203),&#160;titanium&#160;dioxide&#160;(E171),&#160;macrogol&#160;(E1521), talc&#160;(E553b), iron oxide red&#160;<br/>(E172), iron oxide&#160;black (E172).&#160;<br/>&#160;<br/><b>What&#160;Biktarvy&#160;looks&#160;like&#160;and&#160;contents&#160;of&#160;the pack&#160;<br/></b>&#160;<br/>Biktarvy 30&#160;mg/120&#160;mg/15&#160;mg film-coated&#160;tablets&#160;are&#160;pink,&#160;capsule-shaped,&#160;film-coated tablets,&#160;<br/>debossed with “BVY” on one side and a score line&#160;on the other&#160;side of&#160;the&#160;tablet.&#160;<br/>&#160;<br/>The tablets&#160;are&#160;supplied in&#160;a bottle. Not&#160;all&#160;pack sizes&#160;may be marketed.&#160;<br/>&#160;<br/>Biktarvy&#160;comes&#160;in bottles&#160;of&#160;30&#160;tablets and&#160;in packs made up of&#160;3&#160;bottles, each containing&#160;30&#160;tablets.&#160;&#160;<br/>Each bottle contains a&#160;silica&#160;gel&#160;desiccant&#160;that&#160;must&#160;be&#160;kept&#160;in&#160;the bottle&#160;to help&#160;protect&#160;your&#160;tablets.&#160;&#160;<br/>The silica&#160;gel&#160;desiccant&#160;is&#160;contained&#160;in&#160;a separate&#160;sachet&#160;or&#160;canister&#160;and should not&#160;be swallowed.&#160;<br/>&#160;<br/><b>Marketing&#160;Authorisation&#160;Holder&#160;<br/></b>Gilead Sciences&#160;Ireland UC&#160;<br/>Carrigtohill&#160;<br/>County Cork, T45 DP77&#160;<br/>Ireland&#160;<br/>&#160;</p>
</div>
<!-- Page 52 -->
<a name="52"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page52-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft520">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft521">52&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft525"><b>Manufacturer&#160;<br/></b>Gilead Sciences&#160;Ireland UC&#160;<br/>IDA&#160;Business&#160;&amp;&#160;Technology Park&#160;<br/>Carrigtohill&#160;<br/>County Cork&#160;<br/>Ireland&#160;<br/>&#160;<br/>For any&#160;information about&#160;this&#160;medicine, please&#160;contact&#160;the local&#160;representative of&#160;the&#160;Marketing&#160;<br/>Authorisation Holder:&#160;<br/>&#160;</p>
<p style="position:absolute;top:279px;left:115px;white-space:nowrap" class="ft528"><b>België/Belgique/Belgien&#160;<br/></b>Gilead Sciences&#160;Belgium&#160;SRL-BV&#160;<br/>Tél/Tel:&#160;+ 32 (0)&#160;24 01 35&#160;50&#160;<br/>&#160;</p>
<p style="position:absolute;top:279px;left:463px;white-space:nowrap" class="ft528"><b>Lietuva&#160;<br/></b>Gilead Sciences&#160;Ireland UC&#160;<br/>Tel.:&#160;+ 353&#160;(0)&#160;1&#160;686&#160;1888&#160;<br/>&#160;</p>
<p style="position:absolute;top:351px;left:115px;white-space:nowrap" class="ft5213"><b>България&#160;<br/></b>Gilead Sciences&#160;Ireland UC&#160;<br/>Тел.:&#160;+ 353&#160;(0)&#160;1 686 1888&#160;<br/>&#160;</p>
<p style="position:absolute;top:355px;left:463px;white-space:nowrap" class="ft525"><b>Luxembourg/Luxemburg&#160;<br/></b>Gilead Sciences&#160;Belgium&#160;SRL-BV&#160;<br/>Tél/Tel:&#160;+ 32 (0)&#160;24 01 35&#160;50&#160;<br/>&#160;</p>
<p style="position:absolute;top:427px;left:115px;white-space:nowrap" class="ft525"><b>Česká republika&#160;<br/></b>Gilead Sciences&#160;s.r.o.&#160;<br/>Tel:&#160;+ 420&#160;(0)&#160;910&#160;871&#160;986&#160;<br/>&#160;</p>
<p style="position:absolute;top:431px;left:463px;white-space:nowrap" class="ft525"><b>Magyarország&#160;<br/></b>Gilead Sciences&#160;Ireland UC&#160;<br/>Tel.:&#160;+ 353&#160;(0)&#160;1 686&#160;1888&#160;<br/>&#160;</p>
<p style="position:absolute;top:506px;left:115px;white-space:nowrap" class="ft528"><b>Danmark&#160;<br/></b>Gilead Sciences&#160;Sweden AB&#160;<br/>Tlf:&#160;+ 46&#160;(0)&#160;8 5057&#160;1849&#160;<br/>&#160;</p>
<p style="position:absolute;top:506px;left:463px;white-space:nowrap" class="ft528"><b>Malta&#160;<br/></b>Gilead Sciences&#160;Ireland UC&#160;<br/>Tel:&#160;+ 353&#160;(0)&#160;1 686&#160;1888&#160;<br/>&#160;</p>
<p style="position:absolute;top:582px;left:115px;white-space:nowrap" class="ft525"><b>Deutschland&#160;<br/></b>Gilead Sciences&#160;GmbH&#160;<br/>Tel:&#160;+ 49&#160;(0)&#160;89 899890-0&#160;<br/>&#160;</p>
<p style="position:absolute;top:582px;left:463px;white-space:nowrap" class="ft525"><b>Nederland&#160;<br/></b>Gilead Sciences&#160;Netherlands B.V.&#160;<br/>Tel:&#160;+ 31&#160;(0)&#160;20 718&#160;36 98&#160;<br/>&#160;</p>
<p style="position:absolute;top:658px;left:115px;white-space:nowrap" class="ft528"><b>Eesti&#160;<br/></b>Gilead Sciences&#160;Ireland UC&#160;<br/>Tel.:&#160;+ 353&#160;(0)&#160;1 686&#160;1888&#160;</p>
<p style="position:absolute;top:658px;left:463px;white-space:nowrap" class="ft525"><b>Norge&#160;<br/></b>Gilead Sciences&#160;Sweden AB&#160;<br/>Tlf:&#160;+ 46&#160;(0)&#160;8 5057&#160;1849&#160;<br/>&#160;</p>
<p style="position:absolute;top:731px;left:115px;white-space:nowrap" class="ft5213"><b>Ελλάδα&#160;<br/></b>Gilead Sciences&#160;Ελλάς&#160;Μ.ΕΠΕ.&#160;<br/>Τηλ:&#160;+ 30&#160;(0)&#160;210 8930&#160;100&#160;<br/>&#160;</p>
<p style="position:absolute;top:734px;left:463px;white-space:nowrap" class="ft528"><b>Österreich&#160;<br/></b>Gilead Sciences&#160;GesmbH&#160;<br/>Tel:&#160;+ 43&#160;(0)&#160;1 260 830&#160;<br/>&#160;</p>
<p style="position:absolute;top:810px;left:115px;white-space:nowrap" class="ft525"><b>España&#160;<br/></b>Gilead Sciences, S.L.&#160;<br/>Tel:&#160;+ 34&#160;(0)&#160;91 378&#160;98 30&#160;<br/>&#160;</p>
<p style="position:absolute;top:810px;left:463px;white-space:nowrap" class="ft525"><b>Polska&#160;<br/></b>Gilead Sciences&#160;Poland&#160;Sp.&#160;z o.o.&#160;<br/>Tel.:&#160;+&#160;48&#160;(0)&#160;22 262&#160;8702&#160;<br/>&#160;</p>
<p style="position:absolute;top:886px;left:115px;white-space:nowrap" class="ft528"><b>France&#160;<br/></b>Gilead Sciences&#160;<br/>Tél:&#160;+ 33&#160;(0)&#160;1 46 09&#160;41 00&#160;<br/>&#160;</p>
<p style="position:absolute;top:886px;left:463px;white-space:nowrap" class="ft528"><b>Portugal&#160;<br/></b>Gilead Sciences, Lda.&#160;<br/>Tel:&#160;+ 351&#160;(0)&#160;21 7928790&#160;<br/>&#160;</p>
<p style="position:absolute;top:962px;left:115px;white-space:nowrap" class="ft525"><b>Hrvatska&#160;<br/></b>Gilead Sciences&#160;Ireland UC&#160;<br/>Tel:&#160;+ 353&#160;(0)&#160;1 686&#160;1888&#160;<br/>&#160;</p>
<p style="position:absolute;top:962px;left:463px;white-space:nowrap" class="ft525"><b>România&#160;<br/></b>Gilead Sciences&#160;(GSR)&#160;S.R.L&#160;&#160;<br/>Tel:&#160;+ 40 31 631 18 00&#160;<br/>&#160;</p>
<p style="position:absolute;top:1038px;left:115px;white-space:nowrap" class="ft525"><b>Ireland&#160;<br/></b>Gilead Sciences&#160;Ireland UC&#160;<br/>Tel:&#160;+&#160;353&#160;(0)&#160;214 825 999&#160;<br/>&#160;</p>
<p style="position:absolute;top:1038px;left:463px;white-space:nowrap" class="ft525"><b>Slovenija&#160;<br/></b>Gilead Sciences&#160;Ireland UC&#160;<br/>Tel:&#160;+ 353&#160;(0)&#160;1 686&#160;1888&#160;<br/>&#160;</p>
</div>
<!-- Page 53 -->
<a name="53"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page53-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft530">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft531">53&#160;</p>
<p style="position:absolute;top:89px;left:115px;white-space:nowrap" class="ft538"><b>Ísland&#160;<br/></b>Gilead Sciences&#160;Sweden AB&#160;<br/>Sími:&#160;+ 46&#160;(0)&#160;8 5057 1849&#160;<br/>&#160;</p>
<p style="position:absolute;top:89px;left:463px;white-space:nowrap" class="ft538"><b>Slovenská republika&#160;<br/></b>Gilead Sciences&#160;Slovakia&#160;s.r.o.&#160;<br/>Tel:&#160;+&#160;421&#160;(0)&#160;232&#160;121&#160;210&#160;<br/>&#160;</p>
<p style="position:absolute;top:165px;left:115px;white-space:nowrap" class="ft535"><b>Italia&#160;<br/></b>Gilead Sciences&#160;S.r.l.&#160;<br/>Tel:&#160;+ 39&#160;02&#160;439201&#160;<br/>&#160;</p>
<p style="position:absolute;top:165px;left:463px;white-space:nowrap" class="ft535"><b>Suomi/Finland&#160;<br/></b>Gilead Sciences&#160;Sweden AB&#160;<br/>Puh/Tel:&#160;+ 46&#160;(0)&#160;8&#160;5057 1849&#160;<br/>&#160;</p>
<p style="position:absolute;top:237px;left:115px;white-space:nowrap" class="ft5313"><b>Κύπρος&#160;<br/></b>Gilead Sciences&#160;Ελλάς&#160;Μ.ΕΠΕ.&#160;<br/>Τηλ:&#160;+ 30&#160;(0)&#160;210 8930&#160;100&#160;<br/>&#160;</p>
<p style="position:absolute;top:241px;left:463px;white-space:nowrap" class="ft535"><b>Sverige&#160;<br/></b>Gilead Sciences&#160;Sweden AB&#160;<br/>Tel:&#160;+ 46&#160;(0)&#160;8 5057&#160;1849&#160;<br/>&#160;</p>
<p style="position:absolute;top:317px;left:115px;white-space:nowrap" class="ft538"><b>Latvija&#160;<br/></b>Gilead Sciences&#160;Ireland UC&#160;<br/>Tel.:&#160;+ 353&#160;(0)&#160;1 686&#160;1888&#160;<br/>&#160;</p>
<p style="position:absolute;top:317px;left:463px;white-space:nowrap" class="ft538"><b>United&#160;Kingdom&#160;(Northern Ireland)&#160;&#160;<br/></b>Gilead Sciences&#160;Ireland UC&#160;<br/>Tel:&#160;+ 44&#160;(0)&#160;8000 113 700&#160;<br/>&#160;</p>
<p style="position:absolute;top:393px;left:106px;white-space:nowrap" class="ft535"><b>&#160;<br/>This&#160;leaflet&#160;was&#160;last&#160;revised in&#160;.&#160;<br/></b>&#160;<br/>Detailed&#160;information on&#160;this medicine&#160;is&#160;available on&#160;the European&#160;Medicines Agency web&#160;site:&#160;<br/><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu.</a>&#160;<br/>&#160;</p>
<p style="position:absolute;top:488px;left:322px;white-space:nowrap" class="ft530">&#160;</p>
</div>
<!-- Page 54 -->
<a name="54"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page54-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft540">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft541">54&#160;</p>
<p style="position:absolute;top:89px;left:303px;white-space:nowrap" class="ft542"><b>Package&#160;leaflet:&#160;Information for&#160;the user&#160;</b></p>
<p style="position:absolute;top:108px;left:447px;white-space:nowrap" class="ft540">&#160;</p>
<p style="position:absolute;top:127px;left:273px;white-space:nowrap" class="ft542"><b>Biktarvy 50&#160;mg/200&#160;mg/25&#160;mg&#160;film-coated&#160;tablets&#160;</b></p>
<p style="position:absolute;top:146px;left:290px;white-space:nowrap" class="ft540">bictegravir/emtricitabine/tenofovir&#160;alafenamide&#160;</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft544">&#160;<br/><b>Read all&#160;of&#160;this leaflet&#160;carefully before you&#160;start&#160;taking this&#160;medicine because&#160;it&#160;contains&#160;<br/>important&#160;information&#160;for you.&#160;<br/></b>-&#160;</p>
<p style="position:absolute;top:222px;left:149px;white-space:nowrap" class="ft540">Keep this&#160;leaflet.&#160;&#160;You may&#160;need&#160;to read&#160;it&#160;again.&#160;</p>
<p style="position:absolute;top:241px;left:106px;white-space:nowrap" class="ft540">-&#160;</p>
<p style="position:absolute;top:241px;left:149px;white-space:nowrap" class="ft540">If&#160;you have any&#160;further&#160;questions,&#160;ask&#160;your&#160;doctor&#160;or&#160;pharmacist.&#160;</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft540">-&#160;</p>
<p style="position:absolute;top:260px;left:149px;white-space:nowrap" class="ft548">This&#160;medicine has&#160;been prescribed&#160;for&#160;you only. &#160;Do&#160;not&#160;pass&#160;it&#160;on&#160;to others.&#160;&#160;It&#160;may harm&#160;them,&#160;<br/>even&#160;if&#160;their&#160;signs of&#160;illness&#160;are&#160;the&#160;same as yours.&#160;</p>
<p style="position:absolute;top:298px;left:106px;white-space:nowrap" class="ft540">-&#160;</p>
<p style="position:absolute;top:298px;left:149px;white-space:nowrap" class="ft545">If&#160;you get&#160;any&#160;side effects, talk&#160;to your&#160;doctor&#160;or&#160;pharmacist.&#160;&#160;This&#160;includes&#160;any possible&#160;side&#160;<br/>effects not&#160;listed&#160;in&#160;this leaflet.&#160; See&#160;section&#160;4.&#160;</p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft545">&#160;<br/><b>If&#160;Biktarvy has been prescribed&#160;for your&#160;child, please&#160;note that&#160;all&#160;the&#160;information&#160;in&#160;this&#160;leaflet&#160;<br/>is addressed to&#160;your&#160;child&#160;(in&#160;this&#160;case please&#160;read “your child”&#160;instead of&#160;“you”).&#160;<br/>&#160;<br/>What&#160;is&#160;in this&#160;leaflet&#160;<br/></b>&#160;<br/>1.&#160;</p>
<p style="position:absolute;top:450px;left:149px;white-space:nowrap" class="ft540">What&#160;Biktarvy&#160;is and what&#160;it&#160;is used&#160;for&#160;</p>
<p style="position:absolute;top:469px;left:106px;white-space:nowrap" class="ft540">2.&#160;</p>
<p style="position:absolute;top:469px;left:149px;white-space:nowrap" class="ft540">What&#160;you need&#160;to know&#160;before you take&#160;Biktarvy&#160;</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft540">3.&#160;</p>
<p style="position:absolute;top:488px;left:149px;white-space:nowrap" class="ft540">How&#160;to take&#160;Biktarvy&#160;</p>
<p style="position:absolute;top:506px;left:106px;white-space:nowrap" class="ft540">4.&#160;</p>
<p style="position:absolute;top:506px;left:149px;white-space:nowrap" class="ft540">Possible&#160;side effects&#160;</p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft540">5.&#160;</p>
<p style="position:absolute;top:526px;left:149px;white-space:nowrap" class="ft540">How&#160;to store&#160;Biktarvy&#160;</p>
<p style="position:absolute;top:544px;left:106px;white-space:nowrap" class="ft540">6.&#160;</p>
<p style="position:absolute;top:544px;left:149px;white-space:nowrap" class="ft540">Contents of&#160;the pack and other&#160;information&#160;</p>
<p style="position:absolute;top:564px;left:106px;white-space:nowrap" class="ft548">&#160;<br/>&#160;<br/><b>1.&#160;</b></p>
<p style="position:absolute;top:601px;left:149px;white-space:nowrap" class="ft542"><b>What&#160;Biktarvy&#160;is and&#160;what&#160;it&#160;is used&#160;for&#160;</b></p>
<p style="position:absolute;top:620px;left:106px;white-space:nowrap" class="ft540">&#160;</p>
<p style="position:absolute;top:639px;left:104px;white-space:nowrap" class="ft540">Biktarvy&#160;contains three active substances:&#160;</p>
<p style="position:absolute;top:654px;left:106px;white-space:nowrap" class="ft546">•&#160;</p>
<p style="position:absolute;top:660px;left:149px;white-space:nowrap" class="ft542"><b>bictegravir,</b>&#160;an antiretroviral&#160;medicine known as&#160;an integrase<b>&#160;</b>strand&#160;transfer&#160;inhibitor&#160;(INSTI)&#160;</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft546">•&#160;</p>
<p style="position:absolute;top:680px;left:149px;white-space:nowrap" class="ft545"><b>emtricitabine,</b>&#160;an&#160;antiretroviral&#160;medicine of&#160;a&#160;type&#160;known as&#160;a nucleoside&#160;reverse&#160;transcriptase&#160;<br/>inhibitor&#160;(NRTI)&#160;</p>
<p style="position:absolute;top:714px;left:106px;white-space:nowrap" class="ft546">•&#160;</p>
<p style="position:absolute;top:719px;left:149px;white-space:nowrap" class="ft545"><b>tenofovir alafenamide,</b>&#160;an&#160;antiretroviral&#160;medicine of&#160;a&#160;type known as&#160;a nucleotide&#160;reverse&#160;<br/>transcriptase inhibitor&#160;(NtRTI)&#160;</p>
<p style="position:absolute;top:757px;left:104px;white-space:nowrap" class="ft540">&#160;</p>
<p style="position:absolute;top:776px;left:106px;white-space:nowrap" class="ft545">Biktarvy&#160;is&#160;a single tablet&#160;for&#160;the treatment&#160;of&#160;human&#160;immunodeficiency virus 1&#160;(HIV-1)&#160;infection&#160;in&#160;<br/>adults, adolescents and&#160;children 2&#160;years of&#160;age and&#160;older, who weigh&#160;at&#160;least&#160;14&#160;kg.&#160;</p>
<p style="position:absolute;top:814px;left:104px;white-space:nowrap" class="ft545">&#160;<br/>Biktarvy&#160;reduces&#160;the&#160;amount&#160;of&#160;HIV&#160;in&#160;your&#160;body. &#160;This will&#160;improve your&#160;immune system&#160;and reduce&#160;</p>
<p style="position:absolute;top:852px;left:106px;white-space:nowrap" class="ft548">the&#160;risk of&#160;developing&#160;illnesses&#160;linked&#160;to HIV&#160;infection.&#160;<br/>&#160;<br/>&#160;<br/><b>2.&#160;</b></p>
<p style="position:absolute;top:909px;left:149px;white-space:nowrap" class="ft542"><b>What you need&#160;to know&#160;before you&#160;take&#160;Biktarvy</b>&#160;</p>
<p style="position:absolute;top:928px;left:106px;white-space:nowrap" class="ft544">&#160;<br/><b>Do not take&#160;Biktarvy&#160;<br/>&#160;</b></p>
<p style="position:absolute;top:980px;left:106px;white-space:nowrap" class="ft546">•&#160;</p>
<p style="position:absolute;top:986px;left:149px;white-space:nowrap" class="ft545"><b>If&#160;you are&#160;allergic&#160;to bictegravir, emtricitabine,&#160;tenofovir alafenamide</b>&#160;or&#160;any&#160;of&#160;the other&#160;<br/>ingredients of&#160;this&#160;medicine&#160;(listed&#160;in section&#160;6).&#160;</p>
<p style="position:absolute;top:1024px;left:106px;white-space:nowrap" class="ft540">&#160;</p>
<p style="position:absolute;top:1038px;left:106px;white-space:nowrap" class="ft546">•&#160;</p>
<p style="position:absolute;top:1044px;left:149px;white-space:nowrap" class="ft545"><b>If&#160;you are&#160;currently taking any of&#160;the&#160;following medicines:</b>&#160;<br/>-&#160;</p>
<p style="position:absolute;top:1063px;left:191px;white-space:nowrap" class="ft542"><b>rifampicin&#160;</b>used to&#160;treat&#160;some bacterial&#160;infections&#160;such as&#160;tuberculosis&#160;</p>
<p style="position:absolute;top:1082px;left:149px;white-space:nowrap" class="ft540">-&#160;</p>
<p style="position:absolute;top:1082px;left:191px;white-space:nowrap" class="ft545"><b>St.&#160;John’s&#160;wort&#160;</b>(<i>Hypericum&#160;perforatum</i>), a&#160;herbal&#160;remedy&#160;used&#160;for&#160;depression and&#160;<br/>anxiety, or&#160;products&#160;that&#160;contain it.&#160;</p>
<p style="position:absolute;top:1120px;left:106px;white-space:nowrap" class="ft5413">&#160;<br/>→<b>&#160;</b>If&#160;any of&#160;these&#160;apply to&#160;you,&#160;<b>do not&#160;take Biktarvy and tell&#160;your doctor&#160;immediately.</b>&#160;<br/><b>&#160;</b></p>
</div>
<!-- Page 55 -->
<a name="55"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page55-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft550">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft551">55&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft553"><b>Warnings and precautions&#160;<br/></b>&#160;<br/><b>Talk to&#160;your doctor before taking Biktarvy:&#160;<br/>&#160;</b></p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft556">•&#160;</p>
<p style="position:absolute;top:166px;left:149px;white-space:nowrap" class="ft554"><b>If&#160;you have&#160;liver&#160;problems or&#160;a history of&#160;liver&#160;disease, including hepatitis.</b>&#160;&#160;Patients with&#160;<br/>liver&#160;disease&#160;including&#160;chronic hepatitis&#160;B&#160;or&#160;C, who&#160;are treated with&#160;antiretrovirals, have&#160;a&#160;<br/>higher&#160;risk&#160;of&#160;severe and potentially fatal&#160;liver&#160;complications. &#160;If&#160;you have hepatitis&#160;B&#160;infection,&#160;<br/>your&#160;doctor&#160;will&#160;carefully consider&#160;the best&#160;treatment&#160;regimen&#160;for&#160;you.<b>&#160;<br/>&#160;</b></p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft556">•&#160;</p>
<p style="position:absolute;top:262px;left:149px;white-space:nowrap" class="ft555"><b>If&#160;you have hepatitis&#160;B&#160;infection.</b>&#160;&#160;Liver&#160;problems&#160;may become worse&#160;after&#160;you stop taking&#160;<br/>Biktarvy.&#160;<b>&#160;</b></p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft5548">→<b>&#160;</b>Do not&#160;stop&#160;taking Biktarvy if&#160;you have hepatitis&#160;B.&#160;&#160;Talk&#160;to your&#160;doctor&#160;first. &#160;For&#160;more details, see&#160;</p>
<p style="position:absolute;top:319px;left:128px;white-space:nowrap" class="ft550">section&#160;3,&#160;<i>Do not&#160;stop&#160;taking Biktarvy.</i><b>&#160;</b></p>
<p style="position:absolute;top:338px;left:150px;white-space:nowrap" class="ft550">&#160;</p>
<p style="position:absolute;top:353px;left:106px;white-space:nowrap" class="ft556">•&#160;</p>
<p style="position:absolute;top:358px;left:149px;white-space:nowrap" class="ft552"><b>If&#160;you have had kidney disease&#160;or&#160;if&#160;tests have shown problems&#160;with&#160;your kidneys.</b></p>
<p style="position:absolute;top:357px;left:724px;white-space:nowrap" class="ft5551"><b>&#160;&#160;</b>Your&#160;</p>
<p style="position:absolute;top:377px;left:150px;white-space:nowrap" class="ft558">doctor&#160;may order&#160;blood&#160;tests to&#160;monitor&#160;how&#160;your&#160;kidneys&#160;work&#160;when starting and&#160;during&#160;<br/>treatment&#160;with Biktarvy.&#160;</p>
<p style="position:absolute;top:415px;left:106px;white-space:nowrap" class="ft558"><b>&#160;<br/>While you are&#160;taking&#160;Biktarvy&#160;<br/></b>&#160;<br/>Once&#160;you&#160;start&#160;taking&#160;Biktarvy, look out&#160;for:&#160;<br/>&#160;</p>
<p style="position:absolute;top:506px;left:106px;white-space:nowrap" class="ft556">•&#160;</p>
<p style="position:absolute;top:511px;left:149px;white-space:nowrap" class="ft552"><b>Signs&#160;of&#160;inflammation or infection&#160;</b></p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft556">•&#160;</p>
<p style="position:absolute;top:531px;left:149px;white-space:nowrap" class="ft552"><b>Joint pain,&#160;stiffness</b>&#160;or&#160;<b>bone problems</b>&#160;</p>
<p style="position:absolute;top:550px;left:106px;white-space:nowrap" class="ft5512">&#160;<br/>→<b>&#160;If&#160;you&#160;notice&#160;any of&#160;these&#160;symptoms, tell&#160;your&#160;doctor immediately.</b>&#160;&#160;For&#160;more&#160;information see&#160;</p>
<p style="position:absolute;top:588px;left:128px;white-space:nowrap" class="ft550">section&#160;4,&#160;<i>Possible side&#160;effects</i>.&#160;</p>
<p style="position:absolute;top:607px;left:106px;white-space:nowrap" class="ft555">&#160;<br/>There&#160;is&#160;a possibility that&#160;you may experience kidney&#160;problems when&#160;taking Biktarvy over&#160;a long&#160;<br/>period of&#160;time&#160;(see&#160;<i>Warnings and precautions</i>).&#160;<br/>&#160;<br/>This&#160;medicine&#160;is not&#160;a&#160;cure&#160;for&#160;HIV&#160;infection. &#160;While taking&#160;Biktarvy&#160;you&#160;may&#160;still&#160;develop infections&#160;<br/>or&#160;other&#160;illnesses associated&#160;with HIV&#160;infection.&#160;<br/>&#160;<br/><b>Children and&#160;adolescents&#160;<br/></b>&#160;<br/><b>Do not give this&#160;medicine&#160;to children&#160;and&#160;adolescents</b>&#160;weighing less&#160;than&#160;25&#160;kg&#160;regardless&#160;of&#160;age.&#160;&#160;<br/>For children&#160;2 years&#160;of&#160;age&#160;and older,&#160;who weigh at&#160;least&#160;14&#160;kg but&#160;less&#160;than 25&#160;kg&#160;Biktarvy&#160;<br/>30&#160;mg/120&#160;mg/15&#160;mg&#160;film-coated tablets are&#160;available.&#160;The use&#160;of&#160;Biktarvy&#160;in&#160;children under&#160;2&#160;years&#160;<br/>of&#160;age, or&#160;weighing&#160;less than 14&#160;kg has&#160;not&#160;yet&#160;been studied.&#160;<br/>&#160;<br/>Loss of&#160;bone&#160;mass&#160;has&#160;been&#160;reported in&#160;some children from&#160;3 to&#160;less&#160;than 12 years&#160;of&#160;age who&#160;<br/>received one&#160;of&#160;the&#160;medicinal&#160;products&#160;(tenofovir&#160;alafenamide)&#160;contained&#160;in Biktarvy.&#160;&#160;The effects&#160;on&#160;<br/>long&#160;term&#160;bone health and future fracture risk&#160;in children is&#160;uncertain.&#160;&#160;Your&#160;doctor&#160;will&#160;monitor&#160;your&#160;<br/>child’s&#160;bone&#160;health&#160;as&#160;needed.&#160;<br/>&#160;<br/><b>Other&#160;medicines&#160;and&#160;Biktarvy&#160;<br/></b>&#160;<br/><b>Tell&#160;your doctor&#160;or pharmacist&#160;if&#160;you are taking, have recently&#160;taken or might take any other&#160;<br/>medicines.</b>&#160;&#160;Biktarvy&#160;may interact&#160;with other&#160;medicines. &#160;As a&#160;result, the amounts&#160;of&#160;Biktarvy&#160;or&#160;other&#160;<br/>medicines&#160;in your&#160;blood&#160;may change. &#160;This&#160;may&#160;stop&#160;your&#160;medicines&#160;from&#160;working properly, or&#160;may&#160;<br/>make&#160;any&#160;side effects worse. &#160;In some cases, your&#160;doctor&#160;may need&#160;to adjust&#160;your&#160;dose&#160;or&#160;check your&#160;<br/>blood&#160;levels.&#160;<br/>&#160;</p>
</div>
<!-- Page 56 -->
<a name="56"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page56-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft560">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft561">56&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft5612"><b>Medicines that&#160;must&#160;never be taken&#160;with Biktarvy:</b>&#160;<br/>•&#160;</p>
<p style="position:absolute;top:109px;left:149px;white-space:nowrap" class="ft562"><b>rifampicin&#160;</b>used to&#160;treat&#160;some bacterial&#160;infections&#160;such as&#160;tuberculosis&#160;</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft566">•&#160;</p>
<p style="position:absolute;top:129px;left:149px;white-space:nowrap" class="ft565"><b>St.&#160;John’s&#160;wort&#160;</b>(<i>Hypericum&#160;perforatum</i>), a&#160;herbal&#160;remedy&#160;used&#160;for&#160;depression and anxiety, or&#160;<br/>products&#160;that&#160;contain&#160;it.&#160;</p>
<p style="position:absolute;top:167px;left:106px;white-space:nowrap" class="ft564"><b>&#160;<br/></b>→<b>&#160;</b>If&#160;you are taking any&#160;of&#160;these&#160;medicines,&#160;<b>do not&#160;take&#160;Biktarvy and&#160;tell&#160;your doctor&#160;immediately.&#160;<br/>&#160;<br/>Talk to&#160;your doctor if&#160;you&#160;are&#160;taking:&#160;<br/></b>&#160;</p>
<p style="position:absolute;top:258px;left:106px;white-space:nowrap" class="ft566">•&#160;</p>
<p style="position:absolute;top:263px;left:149px;white-space:nowrap" class="ft564"><b>medicines&#160;used for treating HIV&#160;and/or hepatitis&#160;B,</b>&#160;containing:<b>&#160;<br/></b>-&#160;</p>
<p style="position:absolute;top:282px;left:187px;white-space:nowrap" class="ft568">adefovir&#160;dipivoxil,&#160;atazanavir, bictegravir,&#160;emtricitabine, lamivudine,&#160;tenofovir&#160;<br/>alafenamide, or&#160;tenofovir&#160;disoproxil&#160;</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft566">•&#160;</p>
<p style="position:absolute;top:322px;left:149px;white-space:nowrap" class="ft565"><b>antibiotics used&#160;to&#160;treat&#160;bacterial&#160;infections,</b>&#160;containing:&#160;<br/>-&#160;</p>
<p style="position:absolute;top:340px;left:187px;white-space:nowrap" class="ft560">azithromycin,&#160;clarithromycin, rifabutin or&#160;rifapentine&#160;</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft566">•&#160;</p>
<p style="position:absolute;top:361px;left:149px;white-space:nowrap" class="ft565"><b>anticonvulsants</b>&#160;used to&#160;treat&#160;epilepsy,&#160;containing:&#160;<br/>-&#160;</p>
<p style="position:absolute;top:380px;left:187px;white-space:nowrap" class="ft560">carbamazepine,&#160;oxcarbazepine, phenobarbital&#160;or&#160;phenytoin&#160;</p>
<p style="position:absolute;top:395px;left:106px;white-space:nowrap" class="ft566">•&#160;</p>
<p style="position:absolute;top:400px;left:149px;white-space:nowrap" class="ft565"><b>immunosuppressants</b>&#160;used&#160;to control&#160;your&#160;body’s immune&#160;response after&#160;a&#160;transplant,&#160;<br/>containing ciclosporin&#160;</p>
<p style="position:absolute;top:434px;left:106px;white-space:nowrap" class="ft566">•&#160;</p>
<p style="position:absolute;top:439px;left:149px;white-space:nowrap" class="ft562"><b>ulcer-healing medicines</b>&#160;containing sucralfate&#160;</p>
<p style="position:absolute;top:458px;left:106px;white-space:nowrap" class="ft5612">&#160;<br/>→<b>&#160;Tell&#160;your doctor&#160;if&#160;you are&#160;taking any of&#160;these&#160;medicines.</b>&#160;&#160;Do not&#160;stop your&#160;treatment&#160;without&#160;</p>
<p style="position:absolute;top:496px;left:128px;white-space:nowrap" class="ft560">contacting your&#160;doctor.&#160;</p>
<p style="position:absolute;top:515px;left:106px;white-space:nowrap" class="ft565">&#160;<br/><b>Get&#160;advice&#160;from&#160;a doctor&#160;or pharmacist&#160;if&#160;you are&#160;taking:&#160;</b></p>
<p style="position:absolute;top:549px;left:106px;white-space:nowrap" class="ft566">•&#160;</p>
<p style="position:absolute;top:554px;left:149px;white-space:nowrap" class="ft565"><b>antacids</b>&#160;to treat&#160;stomach ulcers, heartburn, or&#160;acid&#160;reflux, containing aluminium&#160;and/or&#160;<br/>magnesium&#160;hydroxide&#160;&#160;</p>
<p style="position:absolute;top:588px;left:106px;white-space:nowrap" class="ft566">•&#160;</p>
<p style="position:absolute;top:593px;left:149px;white-space:nowrap" class="ft562"><b>mineral&#160;supplements&#160;</b>or<b>&#160;vitamins&#160;</b>containing&#160;magnesium&#160;or&#160;iron&#160;</p>
<p style="position:absolute;top:612px;left:106px;white-space:nowrap" class="ft5612">&#160;<br/>→<b>&#160;Get&#160;advice&#160;from&#160;your&#160;doctor or pharmacist&#160;before&#160;taking Biktarvy</b>&#160;if&#160;you&#160;are&#160;taking&#160;any of&#160;</p>
<p style="position:absolute;top:650px;left:128px;white-space:nowrap" class="ft568">these medicines.&#160;<br/><b>Antacids and&#160;magnesium&#160;supplements:&#160;</b>you will&#160;need to&#160;take&#160;Biktarvy at&#160;least&#160;2&#160;hours&#160;<b>before</b>&#160;<br/>antacids or&#160;supplements&#160;containing aluminium&#160;and/or&#160;magnesium.&#160; Or&#160;you&#160;can&#160;take Biktarvy with&#160;<br/>food at&#160;least&#160;2&#160;hours&#160;<b>after.</b>&#160;<br/><b>Iron supplements:</b>&#160;you will&#160;need to&#160;take Biktarvy at&#160;least&#160;2&#160;hours&#160;<b>before</b>&#160;iron supplements, or&#160;you&#160;<br/>can take&#160;them&#160;together&#160;with&#160;food.&#160;</p>
<p style="position:absolute;top:764px;left:106px;white-space:nowrap" class="ft563">&#160;<br/><b>Pregnancy&#160;and&#160;breast-feeding&#160;<br/></b>&#160;</p>
<p style="position:absolute;top:817px;left:106px;white-space:nowrap" class="ft566">•&#160;</p>
<p style="position:absolute;top:822px;left:149px;white-space:nowrap" class="ft565">If&#160;you are pregnant&#160;or&#160;breast-feeding,&#160;think you&#160;may be&#160;pregnant&#160;or&#160;are planning to&#160;have&#160;a&#160;baby,&#160;<br/>ask your&#160;doctor&#160;or&#160;pharmacist&#160;for&#160;advice&#160;before&#160;taking&#160;this medicine.&#160;</p>
<p style="position:absolute;top:856px;left:106px;white-space:nowrap" class="ft566">•&#160;</p>
<p style="position:absolute;top:861px;left:149px;white-space:nowrap" class="ft565">Tell&#160;your&#160;doctor&#160;immediately if&#160;you&#160;become&#160;pregnant&#160;and ask about&#160;the potential&#160;benefits and&#160;<br/>risks of&#160;your&#160;antiretroviral&#160;therapy to&#160;you and your&#160;child.&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft565">&#160;<br/>If&#160;you have taken Biktarvy&#160;during your&#160;pregnancy, your&#160;doctor&#160;may request&#160;regular&#160;blood tests and&#160;<br/>other&#160;diagnostic&#160;tests&#160;to&#160;monitor&#160;the development&#160;of&#160;your&#160;child.&#160; In children whose&#160;mothers took&#160;<br/>nucleoside&#160;reverse&#160;transcriptase&#160;inhibitors&#160;(NRTIs)&#160;during pregnancy, the benefit&#160;from&#160;the protection&#160;<br/>against&#160;HIV&#160;outweighed the risk of&#160;side effects.&#160;<br/>&#160;<br/><b>Do not breast-feed during&#160;treatment&#160;with Biktarvy.</b>&#160;&#160;This&#160;is because&#160;some of&#160;the active substances&#160;<br/>in this&#160;medicine&#160;pass into human&#160;breast&#160;milk. &#160;Breast-feeding is not&#160;recommended&#160;in women&#160;living&#160;<br/>with HIV&#160;because&#160;HIV&#160;infection can be passed on&#160;to&#160;the baby&#160;in breast&#160;milk.&#160;&#160;If&#160;you are&#160;<br/>breast-feeding, or&#160;thinking&#160;about&#160;breast-feeding, you should&#160;<b>discuss&#160;it&#160;with your&#160;doctor&#160;as soon as&#160;<br/>possible</b>.&#160;<br/><b>&#160;</b></p>
</div>
<!-- Page 57 -->
<a name="57"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page57-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft570">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft571">57&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft575"><b>Driving and&#160;using&#160;machines&#160;<br/></b>&#160;<br/>Biktarvy&#160;can cause dizziness. &#160;If&#160;you&#160;feel&#160;dizzy when taking Biktarvy,&#160;do not&#160;drive&#160;or&#160;ride&#160;a bicycle&#160;<br/>and do not&#160;use&#160;any tools&#160;or&#160;machines.&#160;<br/>&#160;<br/><b>Biktarvy contains sodium&#160;<br/></b>&#160;<br/>This&#160;medicine&#160;contains less&#160;than 1&#160;mmol&#160;sodium&#160;(23&#160;mg)&#160;per&#160;tablet,&#160;that&#160;is to say&#160;essentially&#160;<br/>‘sodium-free’.&#160;<br/>&#160;<br/>&#160;<br/><b>3.&#160;</b></p>
<p style="position:absolute;top:298px;left:149px;white-space:nowrap" class="ft572"><b>How&#160;to&#160;take&#160;Biktarvy&#160;</b></p>
<p style="position:absolute;top:317px;left:106px;white-space:nowrap" class="ft5712">&#160;<br/>Always&#160;take&#160;this&#160;medicine&#160;exactly&#160;as&#160;your&#160;doctor&#160;has&#160;told you. &#160;Check&#160;with your&#160;doctor&#160;or&#160;pharmacist&#160;<br/>if&#160;you are not&#160;sure.&#160;<br/>&#160;<br/>There&#160;are&#160;two strengths of&#160;Biktarvy&#160;tablets. Your&#160;doctor&#160;will&#160;prescribe&#160;the&#160;appropriate&#160;tablet&#160;for&#160;your&#160;<br/>age&#160;and weight.&#160;&#160;<br/>&#160;<br/><b>The&#160;recommended&#160;dose&#160;is:&#160;<br/></b>&#160;<br/><b>Adults, adolescents&#160;and&#160;children&#160;who&#160;weigh at&#160;least&#160;25&#160;kg:</b>&#160;one&#160;tablet&#160;each day&#160;with or&#160;without&#160;food&#160;<br/>(one&#160;50&#160;mg/200&#160;mg/25&#160;mg&#160;tablet).&#160;<br/>&#160;<br/>Due to&#160;the bitter&#160;taste,&#160;it&#160;is&#160;recommended&#160;not&#160;to chew or&#160;crush&#160;the&#160;tablet.&#160;<br/>If&#160;you have&#160;difficulty&#160;swallowing the&#160;tablet&#160;whole,&#160;you&#160;can split&#160;it&#160;in half. Take&#160;both halves of&#160;the&#160;<br/>tablet&#160;one after&#160;the&#160;other&#160;to&#160;get&#160;the&#160;full&#160;dose. Do not&#160;store the split&#160;tablet.&#160;<br/>&#160;<br/>The Biktarvy 30-day&#160;blister&#160;pack contains four&#160;7-blister&#160;strips and one&#160;2-blister&#160;strip. To help&#160;track&#160;<br/>taking your&#160;medication over&#160;30 days,&#160;the 7-blister&#160;strips have&#160;days&#160;of&#160;the week printed&#160;and you&#160;can&#160;<br/>write the relevant&#160;days of&#160;the week on the 2-blister&#160;strip.&#160;&#160;<br/>The 90-day&#160;multipack&#160;contains&#160;three&#160;30-day packs&#160;together.&#160;<br/>&#160;<br/>→<b>&#160;Get&#160;advice&#160;from&#160;a doctor&#160;or pharmacist&#160;if&#160;you are&#160;taking:&#160;</b></p>
<p style="position:absolute;top:730px;left:106px;white-space:nowrap" class="ft576">•&#160;</p>
<p style="position:absolute;top:735px;left:149px;white-space:nowrap" class="ft575"><b>antacids</b>&#160;to treat&#160;stomach ulcers, heartburn, or&#160;acid&#160;reflux, containing aluminium&#160;and/or&#160;<br/>magnesium&#160;hydroxide&#160;</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft576">•&#160;</p>
<p style="position:absolute;top:775px;left:149px;white-space:nowrap" class="ft572"><b>mineral&#160;supplements</b>&#160;or&#160;<b>vitamins</b>&#160;containing&#160;magnesium&#160;or&#160;iron&#160;</p>
<p style="position:absolute;top:790px;left:106px;white-space:nowrap" class="ft578">→<b>&#160;See section&#160;2&#160;for&#160;more information&#160;</b>on taking these&#160;medicines&#160;with&#160;Biktarvy.&#160;<br/>&#160;<br/>If&#160;you are on dialysis,&#160;take&#160;your&#160;daily dose of&#160;Biktarvy&#160;following completion of&#160;dialysis.&#160;<br/>&#160;<br/><b>If&#160;you&#160;take&#160;more&#160;Biktarvy&#160;than&#160;you&#160;should&#160;<br/></b>&#160;<br/>If&#160;you take&#160;more than the&#160;recommended dose&#160;of&#160;Biktarvy&#160;you&#160;may be at&#160;higher&#160;risk of&#160;side&#160;effects of&#160;<br/>this medicine (see&#160;section&#160;4,&#160;<i>Possible side effects</i>).&#160;<br/>&#160;<br/>Contact&#160;your&#160;doctor&#160;or&#160;nearest&#160;emergency department&#160;immediately&#160;for&#160;advice.&#160;&#160;Keep or&#160;take the tablet&#160;<br/>bottle or&#160;carton with you so&#160;that&#160;you&#160;can easily&#160;describe what&#160;you have taken.&#160;<br/>&#160;<br/><b>If&#160;you&#160;forget&#160;to take&#160;Biktarvy&#160;<br/></b>&#160;<br/>It&#160;is&#160;important&#160;not&#160;to&#160;miss&#160;a&#160;dose&#160;of&#160;Biktarvy.&#160;<br/>&#160;</p>
</div>
<!-- Page 58 -->
<a name="58"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page58-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft580">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft581">58&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft5812">If&#160;you&#160;miss&#160;a dose:&#160;<br/>•&#160;</p>
<p style="position:absolute;top:109px;left:149px;white-space:nowrap" class="ft585"><b>If&#160;you notice&#160;within&#160;18&#160;hours</b>&#160;of&#160;the&#160;time you usually&#160;take&#160;Biktarvy, you&#160;must&#160;take the&#160;tablet&#160;as&#160;<br/>soon as possible. &#160;Then&#160;take the&#160;next&#160;dose as&#160;usual.&#160;</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft586">•&#160;</p>
<p style="position:absolute;top:148px;left:149px;white-space:nowrap" class="ft585"><b>If&#160;you notice&#160;18&#160;hours&#160;or&#160;more</b>&#160;after&#160;the time you&#160;usually take&#160;Biktarvy,&#160;then do&#160;not&#160;take&#160;the&#160;<br/>missed&#160;dose.&#160; Wait&#160;and&#160;take&#160;the next&#160;dose&#160;at&#160;your&#160;usual&#160;time.&#160;</p>
<p style="position:absolute;top:186px;left:106px;white-space:nowrap" class="ft5812">&#160;<br/><b>If&#160;you vomit&#160;</b>less&#160;than&#160;1&#160;hour&#160;after&#160;taking&#160;Biktarvy,&#160;take another&#160;tablet. &#160;If&#160;you vomit&#160;more&#160;than&#160;1&#160;hour&#160;<br/>after&#160;taking&#160;Biktarvy&#160;you do not&#160;need&#160;to&#160;take&#160;another&#160;tablet&#160;until&#160;your&#160;next&#160;regularly scheduled&#160;tablet.&#160;<br/>&#160;<br/><b>Do not stop taking&#160;Biktarvy&#160;<br/></b>&#160;<br/><b>Do not stop taking&#160;Biktarvy&#160;without&#160;talking to your&#160;doctor.</b>&#160;&#160;Stopping&#160;Biktarvy&#160;can seriously affect&#160;<br/>how&#160;future&#160;treatment&#160;works. &#160;If&#160;Biktarvy&#160;is&#160;stopped&#160;for&#160;any reason, speak&#160;to your&#160;doctor&#160;before you&#160;<br/>restart&#160;taking&#160;Biktarvy&#160;tablets.&#160;<br/>&#160;<br/><b>When your&#160;supply of&#160;Biktarvy&#160;starts&#160;to run&#160;low,</b>&#160;get&#160;more from&#160;your&#160;doctor&#160;or&#160;pharmacist. &#160;This&#160;is&#160;<br/>very&#160;important&#160;because the&#160;amount&#160;of&#160;virus&#160;may start&#160;to increase&#160;if&#160;the&#160;medicine&#160;is stopped&#160;for&#160;even&#160;a&#160;<br/>short&#160;time. &#160;The disease&#160;may then&#160;become&#160;harder&#160;to&#160;treat.&#160;<br/>&#160;<br/><b>If&#160;you have both HIV&#160;infection&#160;and&#160;hepatitis&#160;B,</b>&#160;it&#160;is&#160;especially&#160;important&#160;not&#160;to&#160;stop your&#160;Biktarvy&#160;<br/>treatment&#160;without&#160;talking&#160;to&#160;your&#160;doctor&#160;first.&#160;&#160;You may require blood&#160;tests&#160;for&#160;several&#160;months after&#160;<br/>stopping&#160;treatment. &#160;In some patients with&#160;advanced&#160;liver&#160;disease or&#160;cirrhosis,&#160;stopping&#160;treatment&#160;is&#160;<br/>not&#160;recommended as&#160;this&#160;may lead to worsening of&#160;your&#160;hepatitis, which&#160;may&#160;be life-threatening.&#160;<br/>&#160;<br/>→<b>&#160;Tell&#160;your&#160;doctor&#160;immediately</b>&#160;about&#160;new or&#160;unusual&#160;symptoms after&#160;you&#160;stop treatment,&#160;</p>
<p style="position:absolute;top:566px;left:128px;white-space:nowrap" class="ft580">particularly&#160;symptoms you&#160;associate with hepatitis&#160;B&#160;infection.&#160;</p>
<p style="position:absolute;top:585px;left:106px;white-space:nowrap" class="ft588">&#160;<br/>If&#160;you have any&#160;further&#160;questions on&#160;the use&#160;of&#160;this&#160;medicine, ask your&#160;doctor&#160;or&#160;pharmacist.&#160;<br/>&#160;<br/>&#160;<br/><b>4.&#160;</b></p>
<p style="position:absolute;top:661px;left:149px;white-space:nowrap" class="ft582"><b>Possible&#160;side&#160;effects&#160;</b></p>
<p style="position:absolute;top:680px;left:106px;white-space:nowrap" class="ft584">&#160;<br/>Like&#160;all&#160;medicines,&#160;this medicine can cause&#160;side effects, although not&#160;everybody gets&#160;them.&#160;<br/>&#160;<br/><b>Possible&#160;side&#160;effects:&#160;tell&#160;a&#160;doctor immediately&#160;<br/></b>&#160;</p>
<p style="position:absolute;top:770px;left:106px;white-space:nowrap" class="ft586">•&#160;</p>
<p style="position:absolute;top:776px;left:149px;white-space:nowrap" class="ft5813"><b>Any signs&#160;of&#160;inflammation or infection.</b>&#160;&#160;In some patients with advanced HIV&#160;infection&#160;<br/>(AIDS) and a history of&#160;opportunistic infections&#160;(infections that&#160;occur&#160;in people with&#160;a weak&#160;<br/>immune system), signs&#160;and&#160;symptoms of&#160;inflammation&#160;from&#160;previous&#160;infections&#160;may occur&#160;soon&#160;<br/>after&#160;HIV&#160;treatment&#160;is&#160;started. &#160;It&#160;is thought&#160;that&#160;these&#160;symptoms are due&#160;to an&#160;improvement&#160;in&#160;<br/>the body’s immune&#160;response, enabling the body to&#160;fight&#160;infections&#160;that&#160;may have&#160;been present&#160;<br/>with no&#160;obvious&#160;symptoms.&#160;</p>
<p style="position:absolute;top:890px;left:106px;white-space:nowrap" class="ft5812">&#160;<br/>•&#160;</p>
<p style="position:absolute;top:910px;left:149px;white-space:nowrap" class="ft585"><b>Autoimmune disorders,</b>&#160;when the immune&#160;system&#160;attacks&#160;healthy body tissue,&#160;may also occur&#160;<br/>after&#160;you start&#160;taking&#160;medicines&#160;for&#160;HIV&#160;infection. &#160;Autoimmune disorders may occur&#160;many&#160;<br/>months after&#160;the&#160;start&#160;of&#160;treatment. &#160;Look&#160;out&#160;for&#160;any&#160;symptoms of&#160;infection or&#160;other&#160;symptoms&#160;<br/>such as:&#160;<br/>-&#160;</p>
<p style="position:absolute;top:986px;left:191px;white-space:nowrap" class="ft580">muscle weakness&#160;</p>
<p style="position:absolute;top:1005px;left:149px;white-space:nowrap" class="ft580">-&#160;</p>
<p style="position:absolute;top:1005px;left:191px;white-space:nowrap" class="ft580">weakness beginning&#160;in&#160;the&#160;hands&#160;and feet&#160;and&#160;moving&#160;up towards&#160;the&#160;trunk of&#160;the&#160;body&#160;</p>
<p style="position:absolute;top:1024px;left:149px;white-space:nowrap" class="ft580">-&#160;</p>
<p style="position:absolute;top:1024px;left:191px;white-space:nowrap" class="ft580">palpitations,&#160;tremor&#160;or&#160;hyperactivity&#160;</p>
<p style="position:absolute;top:1043px;left:149px;white-space:nowrap" class="ft580">&#160;</p>
<p style="position:absolute;top:1058px;left:106px;white-space:nowrap" class="ft5848">→<b>&#160;If&#160;you notice&#160;these or&#160;any&#160;symptoms of&#160;inflammation or infection, tell&#160;your doctor&#160;</b></p>
<p style="position:absolute;top:1081px;left:128px;white-space:nowrap" class="ft582"><b>immediately.&#160;</b></p>
<p style="position:absolute;top:1099px;left:106px;white-space:nowrap" class="ft5841">&#160;<br/><b>Common&#160;side effects&#160;<br/></b>(<i>may&#160;affect&#160;up to&#160;1 in&#160;10 people</i>)<i>&#160;<br/></i>•&#160;</p>
<p style="position:absolute;top:1158px;left:149px;white-space:nowrap" class="ft580">depression&#160;</p>
</div>
<!-- Page 59 -->
<a name="59"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page59-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft590">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft591">59&#160;</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft596">•&#160;</p>
<p style="position:absolute;top:90px;left:149px;white-space:nowrap" class="ft590">abnormal&#160;dreams&#160;</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft596">•&#160;</p>
<p style="position:absolute;top:110px;left:149px;white-space:nowrap" class="ft590">headache&#160;</p>
<p style="position:absolute;top:125px;left:106px;white-space:nowrap" class="ft596">•&#160;</p>
<p style="position:absolute;top:131px;left:149px;white-space:nowrap" class="ft590">dizziness&#160;</p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft596">•&#160;</p>
<p style="position:absolute;top:151px;left:149px;white-space:nowrap" class="ft590">diarrhoea&#160;</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft596">•&#160;</p>
<p style="position:absolute;top:171px;left:149px;white-space:nowrap" class="ft590">feeling&#160;sick (<i>nausea</i>)&#160;</p>
<p style="position:absolute;top:186px;left:106px;white-space:nowrap" class="ft596">•&#160;</p>
<p style="position:absolute;top:191px;left:149px;white-space:nowrap" class="ft590">tiredness&#160;(<i>fatigue</i>)&#160;</p>
<p style="position:absolute;top:210px;left:106px;white-space:nowrap" class="ft5912">&#160;<br/><b>Uncommon side effects&#160;<br/></b>(<i>may affect&#160;up to&#160;1 in&#160;100&#160;people</i>)&#160;<br/>•&#160;</p>
<p style="position:absolute;top:268px;left:149px;white-space:nowrap" class="ft590">anaemia&#160;</p>
<p style="position:absolute;top:283px;left:106px;white-space:nowrap" class="ft596">•&#160;</p>
<p style="position:absolute;top:288px;left:149px;white-space:nowrap" class="ft590">vomiting&#160;</p>
<p style="position:absolute;top:303px;left:106px;white-space:nowrap" class="ft596">•&#160;</p>
<p style="position:absolute;top:309px;left:149px;white-space:nowrap" class="ft590">stomach&#160;pain&#160;</p>
<p style="position:absolute;top:323px;left:106px;white-space:nowrap" class="ft596">•&#160;</p>
<p style="position:absolute;top:329px;left:149px;white-space:nowrap" class="ft590">problems with digestion&#160;resulting&#160;in discomfort&#160;after&#160;meals&#160;(<i>dyspepsia</i>)&#160;</p>
<p style="position:absolute;top:344px;left:106px;white-space:nowrap" class="ft596">•&#160;</p>
<p style="position:absolute;top:349px;left:149px;white-space:nowrap" class="ft590">wind (<i>flatulence</i>)&#160;</p>
<p style="position:absolute;top:364px;left:106px;white-space:nowrap" class="ft596">•&#160;</p>
<p style="position:absolute;top:369px;left:149px;white-space:nowrap" class="ft590">swelling&#160;of&#160;the&#160;face, lips,&#160;tongue or&#160;throat&#160;(<i>angioedema</i>)&#160;</p>
<p style="position:absolute;top:384px;left:106px;white-space:nowrap" class="ft596">•&#160;</p>
<p style="position:absolute;top:389px;left:149px;white-space:nowrap" class="ft590">itching&#160;(<i>pruritus</i>)&#160;</p>
<p style="position:absolute;top:404px;left:106px;white-space:nowrap" class="ft596">•&#160;</p>
<p style="position:absolute;top:409px;left:149px;white-space:nowrap" class="ft590">rash&#160;</p>
<p style="position:absolute;top:424px;left:106px;white-space:nowrap" class="ft596">•&#160;</p>
<p style="position:absolute;top:430px;left:149px;white-space:nowrap" class="ft590">hives&#160;(<i>urticaria</i>)&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft596">•&#160;</p>
<p style="position:absolute;top:450px;left:149px;white-space:nowrap" class="ft590">joint&#160;pain&#160;(<i>arthralgia</i>)&#160;</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft596">•&#160;</p>
<p style="position:absolute;top:470px;left:149px;white-space:nowrap" class="ft595">suicidal&#160;thoughts&#160;and suicide attempt&#160;(particularly&#160;in&#160;patients who have had&#160;depression or&#160;<br/>mental&#160;health problems before)&#160;</p>
<p style="position:absolute;top:504px;left:106px;white-space:nowrap" class="ft596">•&#160;</p>
<p style="position:absolute;top:509px;left:149px;white-space:nowrap" class="ft590">anxiety&#160;</p>
<p style="position:absolute;top:524px;left:106px;white-space:nowrap" class="ft596">•&#160;</p>
<p style="position:absolute;top:529px;left:149px;white-space:nowrap" class="ft590">sleep disorders&#160;</p>
<p style="position:absolute;top:548px;left:106px;white-space:nowrap" class="ft5912">&#160;<br/><i>Blood&#160;tests may&#160;also show:</i>&#160;<br/>•&#160;</p>
<p style="position:absolute;top:587px;left:149px;white-space:nowrap" class="ft590">higher&#160;levels of&#160;substances&#160;called bilirubin&#160;and/or&#160;serum&#160;creatinine&#160;in&#160;the&#160;blood&#160;</p>
<p style="position:absolute;top:606px;left:106px;white-space:nowrap" class="ft593">&#160;<br/><b>Rare&#160;side effects&#160;&#160;<br/></b><i>(may&#160;affect&#160;up to&#160;1 in&#160;1000&#160;people)<b>&#160;</b></i></p>
<p style="position:absolute;top:659px;left:106px;white-space:nowrap" class="ft596">•&#160;</p>
<p style="position:absolute;top:664px;left:149px;white-space:nowrap" class="ft595">Stevens-Johnson syndrome&#160;(SJS)&#160;is&#160;a serious&#160;life-threatening condition which usually starts&#160;<br/>with&#160;flu-&#160;like&#160;symptoms. A&#160;few days later&#160;other&#160;symptoms appear&#160;including:&#160;<br/>-&#160;</p>
<p style="position:absolute;top:702px;left:191px;white-space:nowrap" class="ft590">Painful&#160;red or&#160;purple skin&#160;that&#160;looks&#160;burned and peels&#160;off&#160;</p>
<p style="position:absolute;top:721px;left:149px;white-space:nowrap" class="ft590">-&#160;</p>
<p style="position:absolute;top:721px;left:191px;white-space:nowrap" class="ft590">Blisters on&#160;your&#160;skin,&#160;mouth, nose,&#160;and genitals&#160;</p>
<p style="position:absolute;top:740px;left:149px;white-space:nowrap" class="ft590">-&#160;</p>
<p style="position:absolute;top:740px;left:191px;white-space:nowrap" class="ft598">Red, painful, watery&#160;eyes&#160;<br/>&#160;</p>
<p style="position:absolute;top:775px;left:106px;white-space:nowrap" class="ft5948">→<b>&#160;If&#160;you have any&#160;of&#160;these symptoms,&#160;stop your&#160;medicine&#160;immediately and&#160;tell&#160;your doctor&#160;</b></p>
<p style="position:absolute;top:797px;left:128px;white-space:nowrap" class="ft592"><b>straight&#160;away.&#160;</b></p>
<p style="position:absolute;top:833px;left:106px;white-space:nowrap" class="ft598">→<b>&#160;If&#160;any of&#160;the side effects get&#160;serious, tell&#160;your doctor.&#160;<br/></b>&#160;<br/><b>Other&#160;effects that&#160;may be&#160;seen during&#160;HIV&#160;treatment&#160;<br/></b>&#160;<br/>The frequency of&#160;the following side effects is not&#160;known (frequency cannot&#160;be&#160;estimated&#160;from&#160;the&#160;<br/>available data).&#160;<br/>&#160;</p>
<p style="position:absolute;top:966px;left:106px;white-space:nowrap" class="ft596">•&#160;</p>
<p style="position:absolute;top:971px;left:149px;white-space:nowrap" class="ft598"><b>Bone problems.</b>&#160;&#160;Some patients taking combination antiretroviral&#160;medicines&#160;such&#160;as&#160;Biktarvy&#160;<br/>may develop a&#160;bone&#160;disease&#160;called&#160;<i>osteonecrosis</i>&#160;(death&#160;of&#160;bone tissue caused by&#160;loss&#160;of&#160;blood&#160;<br/>supply to&#160;the&#160;bone). &#160;Taking this type of&#160;medicine for&#160;a long&#160;time, taking corticosteroids,&#160;<br/>drinking&#160;alcohol, having&#160;a&#160;very weak immune&#160;system,&#160;and being overweight,&#160;may&#160;be some of&#160;<br/>the&#160;many&#160;risk&#160;factors for&#160;developing&#160;this disease. &#160;Signs of&#160;osteonecrosis&#160;are:&#160;<br/>-&#160;</p>
<p style="position:absolute;top:1066px;left:191px;white-space:nowrap" class="ft590">joint&#160;stiffness&#160;</p>
<p style="position:absolute;top:1085px;left:149px;white-space:nowrap" class="ft590">-&#160;</p>
<p style="position:absolute;top:1085px;left:191px;white-space:nowrap" class="ft590">joint&#160;aches&#160;and pains (especially of&#160;the hip, knee&#160;and shoulder)&#160;</p>
<p style="position:absolute;top:1104px;left:149px;white-space:nowrap" class="ft590">-&#160;</p>
<p style="position:absolute;top:1104px;left:191px;white-space:nowrap" class="ft590">difficulty&#160;with&#160;movement&#160;</p>
<p style="position:absolute;top:1119px;left:106px;white-space:nowrap" class="ft5950">→<b>&#160;If&#160;you notice&#160;any of&#160;these&#160;symptoms tell&#160;your doctor.&#160;<br/></b>&#160;</p>
</div>
<!-- Page 60 -->
<a name="60"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page60-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft600">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft601">60&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft605">During HIV&#160;therapy there&#160;may be an&#160;increase&#160;in weight&#160;and&#160;in&#160;levels&#160;of&#160;blood&#160;lipids and glucose. &#160;This&#160;<br/>is partly&#160;linked&#160;to restored&#160;health and life style, and&#160;in&#160;the case&#160;of&#160;blood&#160;lipids sometimes&#160;to&#160;the HIV&#160;<br/>medicines&#160;themselves. &#160;Your&#160;doctor&#160;will&#160;test&#160;for&#160;these&#160;changes.&#160;<br/>&#160;<br/><b>Reporting of&#160;side effects&#160;<br/></b>If&#160;you get&#160;any&#160;side effects, talk&#160;to your&#160;doctor&#160;or&#160;pharmacist.&#160;&#160;This&#160;includes&#160;any possible&#160;side effects&#160;<br/>not&#160;listed&#160;in&#160;this leaflet.&#160;&#160;You can also&#160;report&#160;side effects directly&#160;via the national&#160;reporting&#160;system&#160;<br/>listed&#160;i<a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">n&#160;Appendix&#160;V.</a>&#160;&#160;By reporting&#160;side effects you&#160;can help&#160;provide&#160;more&#160;information on&#160;the&#160;safety&#160;<br/>of&#160;this&#160;medicine.&#160;<br/>&#160;<br/>&#160;<br/><b>5.&#160;</b></p>
<p style="position:absolute;top:298px;left:149px;white-space:nowrap" class="ft602"><b>How&#160;to&#160;store&#160;Biktarvy&#160;</b></p>
<p style="position:absolute;top:317px;left:106px;white-space:nowrap" class="ft608">&#160;<br/>Keep this&#160;medicine&#160;out&#160;of&#160;the sight&#160;and&#160;reach of&#160;children.&#160;<br/>&#160;<br/>Do not&#160;use this&#160;medicine&#160;after&#160;the&#160;expiry&#160;date which is&#160;stated on the carton and&#160;bottle&#160;or&#160;blister&#160;strips&#160;<br/>after&#160;{EXP}. &#160;The expiry date&#160;refers to&#160;the&#160;last&#160;day of&#160;that&#160;month.&#160;<br/>&#160;<br/><b>Bottle&#160;<br/></b>Store&#160;in&#160;the&#160;original&#160;package in order&#160;to protect&#160;from&#160;moisture. &#160;Keep&#160;the&#160;bottle tightly&#160;closed.&#160;&#160;Do not&#160;<br/>use&#160;if&#160;the seal&#160;over&#160;the bottle opening&#160;is broken or&#160;missing.&#160;<br/>&#160;<br/><b>Blister&#160;<br/></b>Store&#160;in&#160;the&#160;original&#160;package in order&#160;to protect&#160;from&#160;moisture. &#160;Do not&#160;use if&#160;foil&#160;over&#160;blister&#160;is broken&#160;<br/>or&#160;pierced.&#160;<br/>&#160;<br/>Do not&#160;throw&#160;away any&#160;medicines&#160;via wastewater&#160;or&#160;household waste.&#160;&#160;Ask your&#160;pharmacist&#160;how&#160;to&#160;<br/>throw&#160;away&#160;medicines&#160;you&#160;no longer&#160;use. &#160;These&#160;measures&#160;will&#160;help protect&#160;the environment.&#160;<br/>&#160;<br/>&#160;<br/><b>6.&#160;</b></p>
<p style="position:absolute;top:658px;left:149px;white-space:nowrap" class="ft602"><b>Contents of&#160;the pack and&#160;other&#160;information&#160;</b></p>
<p style="position:absolute;top:677px;left:106px;white-space:nowrap" class="ft605">&#160;<br/><b>What Biktarvy contains&#160;<br/></b>&#160;<br/><b>The active&#160;substances are</b>&#160;bictegravir, emtricitabine and tenofovir&#160;alafenamide. &#160;Each Biktarvy&#160;<br/>50&#160;mg/200&#160;mg/25&#160;mg&#160;tablet&#160;contains bictegravir&#160;sodium&#160;equivalent&#160;to 50&#160;mg of&#160;bictegravir,&#160;200&#160;mg of&#160;<br/>emtricitabine&#160;and&#160;tenofovir&#160;alafenamide&#160;fumarate&#160;equivalent&#160;to 25&#160;mg of&#160;tenofovir&#160;alafenamide.&#160;<br/>&#160;<br/><b>The other ingredients are&#160;<br/>&#160;<br/></b><i>Tablet&#160;core&#160;<br/></i>Microcrystalline&#160;cellulose&#160;(E460), croscarmellose&#160;sodium&#160;(E468),&#160;magnesium&#160;stearate (E470b).&#160;<br/>&#160;<br/><i>Film-coating&#160;<br/></i>Polyvinyl&#160;alcohol&#160;(E203),&#160;titanium&#160;dioxide&#160;(E171), macrogol&#160;(E1521), talc&#160;(E553b), iron oxide red&#160;<br/>(E172), iron oxide&#160;black (E172).&#160;<br/>&#160;<br/><b>What&#160;Biktarvy looks&#160;like&#160;and&#160;contents&#160;of&#160;the pack&#160;<br/></b>&#160;<br/>Biktarvy&#160;50&#160;mg/200&#160;mg/25&#160;mg&#160;film-coated&#160;tablets&#160;are&#160;purplish-brown, capsule-shaped,&#160;film-coated&#160;<br/>tablets debossed on one side with&#160;“GSI” and&#160;“9883”&#160;on the other&#160;side.&#160;&#160;<br/>&#160;<br/>The tablets&#160;may be supplied either&#160;in&#160;a bottle or&#160;in a blister&#160;pack. Not&#160;all&#160;pack&#160;sizes may be&#160;marketed.&#160;<br/><b>&#160;</b></p>
</div>
<!-- Page 61 -->
<a name="61"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft6152{font-size:14px;font-family:BCDGEE+Verdana;color:#000000;}
-->
</style>
<div id="page61-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft610">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft611">61&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft615"><b>Bottle</b>&#160;<br/>Biktarvy&#160;comes&#160;in bottles&#160;of&#160;30&#160;tablets and&#160;in packs made up of&#160;3&#160;bottles, each containing&#160;30&#160;tablets. &#160;<br/>Each bottle contains a&#160;silica&#160;gel&#160;desiccant&#160;that&#160;must&#160;be&#160;kept&#160;in&#160;the bottle&#160;to help&#160;protect&#160;your&#160;tablets. &#160;<br/>The silica&#160;gel&#160;desiccant&#160;is&#160;contained&#160;in&#160;a separate&#160;sachet&#160;or&#160;canister&#160;and should not&#160;be swallowed.&#160;<br/>&#160;<br/><b>Blister&#160;<br/></b>Biktarvy 50&#160;mg/200&#160;mg/25&#160;mg tablets also come in&#160;blister&#160;packs of&#160;30&#160;tablets and&#160;in multipacks&#160;<br/>comprising&#160;3&#160;cartons,&#160;each&#160;containing 30&#160;tablets. &#160;Each&#160;individual&#160;pack&#160;contains 4&#160;x&#160;blister&#160;strips&#160;<br/>containing 7&#160;tablets and&#160;1&#160;x&#160;blister&#160;strip containing 2&#160;tablets.&#160;&#160;Each&#160;blister&#160;cavity&#160;contains&#160;a&#160;desiccant,&#160;<br/>which&#160;should not&#160;be&#160;removed or&#160;swallowed.&#160;<br/>&#160;<br/><b>Marketing&#160;Authorisation&#160;Holder&#160;<br/></b>Gilead Sciences&#160;Ireland UC&#160;<br/>Carrigtohill&#160;<br/>County Cork, T45 DP77&#160;<br/>Ireland&#160;<br/>&#160;<br/><b>Manufacturer&#160;<br/></b>Gilead Sciences&#160;Ireland UC&#160;<br/>IDA&#160;Business&#160;&amp;&#160;Technology Park&#160;<br/>Carrigtohill&#160;<br/>County Cork&#160;<br/>Ireland&#160;<br/>&#160;<br/>For any&#160;information about&#160;this&#160;medicine, please&#160;contact&#160;the&#160;local&#160;representative of&#160;the&#160;Marketing&#160;<br/>Authorisation Holder:&#160;<br/>&#160;</p>
<p style="position:absolute;top:601px;left:115px;white-space:nowrap" class="ft618"><b>België/Belgique/Belgien&#160;<br/></b>Gilead Sciences&#160;Belgium&#160;SRL-BV&#160;<br/>Tél/Tel:&#160;+ 32 (0)&#160;24 01 35&#160;50&#160;<br/>&#160;</p>
<p style="position:absolute;top:601px;left:463px;white-space:nowrap" class="ft618"><b>Lietuva&#160;<br/></b>Gilead Sciences&#160;Ireland UC&#160;<br/>Tel.:&#160;+ 353&#160;(0)&#160;1 686&#160;1888&#160;<br/>&#160;</p>
<p style="position:absolute;top:674px;left:115px;white-space:nowrap" class="ft6113"><b>България&#160;<br/></b>Gilead Sciences&#160;Ireland UC&#160;<br/>Тел.:&#160;+ 353&#160;(0)&#160;1 686 1888&#160;<br/>&#160;</p>
<p style="position:absolute;top:677px;left:463px;white-space:nowrap" class="ft615"><b>Luxembourg/Luxemburg&#160;<br/></b>Gilead Sciences&#160;Belgium&#160;SRL-BV&#160;<br/>Tél/Tel:&#160;+ 32 (0)&#160;24 01 35&#160;50&#160;<br/>&#160;</p>
<p style="position:absolute;top:750px;left:115px;white-space:nowrap" class="ft615"><b>Česká republika&#160;<br/></b>Gilead Sciences&#160;s.r.o.&#160;<br/>Tel:&#160;+ 420&#160;(0)&#160;910&#160;871&#160;986&#160;<br/>&#160;</p>
<p style="position:absolute;top:753px;left:463px;white-space:nowrap" class="ft615"><b>Magyarország&#160;<br/></b>Gilead Sciences&#160;Ireland UC&#160;<br/>Tel.:&#160;+ 353&#160;(0)&#160;1 686&#160;1888&#160;<br/>&#160;</p>
<p style="position:absolute;top:829px;left:115px;white-space:nowrap" class="ft618"><b>Danmark&#160;<br/></b>Gilead Sciences&#160;Sweden AB&#160;<br/>Tlf:&#160;+ 46&#160;(0)&#160;8 5057&#160;1849&#160;<br/>&#160;</p>
<p style="position:absolute;top:829px;left:463px;white-space:nowrap" class="ft618"><b>Malta&#160;<br/></b>Gilead Sciences&#160;Ireland UC&#160;<br/>Tel:&#160;+ 353&#160;(0)&#160;1 686&#160;1888&#160;<br/>&#160;</p>
<p style="position:absolute;top:905px;left:115px;white-space:nowrap" class="ft615"><b>Deutschland&#160;<br/></b>Gilead Sciences&#160;GmbH&#160;<br/>Tel:&#160;+ 49&#160;(0)&#160;89 899890-0&#160;<br/>&#160;</p>
<p style="position:absolute;top:905px;left:463px;white-space:nowrap" class="ft615"><b>Nederland&#160;<br/></b>Gilead Sciences&#160;Netherlands B.V.&#160;<br/>Tel:&#160;+ 31&#160;(0)&#160;20 718&#160;36 98&#160;<br/>&#160;</p>
<p style="position:absolute;top:981px;left:115px;white-space:nowrap" class="ft615"><b>Eesti&#160;<br/></b>Gilead Sciences&#160;Ireland UC&#160;<br/>Tel.:&#160;+ 353&#160;(0)&#160;1 686&#160;1888&#160;</p>
<p style="position:absolute;top:981px;left:463px;white-space:nowrap" class="ft618"><b>Norge&#160;<br/></b>Gilead Sciences&#160;Sweden AB&#160;<br/>Tlf:&#160;+ 46&#160;(0)&#160;8 5057&#160;1849&#160;<br/>&#160;</p>
<p style="position:absolute;top:1053px;left:115px;white-space:nowrap" class="ft6113"><b>Ελλάδα&#160;<br/></b>Gilead Sciences&#160;Ελλάς&#160;Μ.ΕΠΕ.&#160;<br/>Τηλ:&#160;+ 30 (0)&#160;210 8930&#160;100&#160;<br/>&#160;</p>
<p style="position:absolute;top:1057px;left:463px;white-space:nowrap" class="ft618"><b>Österreich&#160;<br/></b>Gilead Sciences&#160;GesmbH&#160;<br/>Tel:&#160;+ 43&#160;(0)&#160;1 260 830&#160;<br/>&#160;</p>
</div>
<!-- Page 62 -->
<a name="62"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page62-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:59px;left:106px;white-space:nowrap" class="ft620">&#160;</p>
<p style="position:absolute;top:1197px;left:426px;white-space:nowrap" class="ft621">62&#160;</p>
<p style="position:absolute;top:89px;left:115px;white-space:nowrap" class="ft628"><b>España&#160;<br/></b>Gilead Sciences, S.L.&#160;<br/>Tel:&#160;+ 34&#160;(0)&#160;91 378&#160;98 30&#160;<br/>&#160;</p>
<p style="position:absolute;top:89px;left:463px;white-space:nowrap" class="ft628"><b>Polska&#160;<br/></b>Gilead Sciences&#160;Poland&#160;Sp.&#160;z o.o.&#160;<br/>Tel.:&#160;+ 48&#160;(0)&#160;22 262&#160;8702&#160;<br/>&#160;</p>
<p style="position:absolute;top:165px;left:115px;white-space:nowrap" class="ft625"><b>France&#160;<br/></b>Gilead Sciences&#160;<br/>Tél:&#160;+ 33&#160;(0)&#160;1 46 09&#160;41 00&#160;<br/>&#160;</p>
<p style="position:absolute;top:165px;left:463px;white-space:nowrap" class="ft625"><b>Portugal&#160;<br/></b>Gilead Sciences, Lda.&#160;<br/>Tel:&#160;+ 351&#160;(0)&#160;21 7928790&#160;<br/>&#160;</p>
<p style="position:absolute;top:241px;left:115px;white-space:nowrap" class="ft625"><b>Hrvatska&#160;<br/></b>Gilead&#160;Sciences&#160;Ireland UC&#160;<br/>Tel:&#160;+ 353&#160;(0)&#160;1 686&#160;1888&#160;<br/>&#160;</p>
<p style="position:absolute;top:241px;left:463px;white-space:nowrap" class="ft625"><b>România&#160;<br/></b>Gilead Sciences&#160;(GSR)&#160;S.R.L&#160;&#160;<br/>Tel:&#160;+ 40 31 631 18 00&#160;<br/>&#160;</p>
<p style="position:absolute;top:317px;left:115px;white-space:nowrap" class="ft628"><b>Ireland&#160;<br/></b>Gilead Sciences&#160;Ireland UC&#160;<br/>Tel:&#160;+ 353&#160;(0)&#160;214 825 999&#160;<br/>&#160;</p>
<p style="position:absolute;top:317px;left:463px;white-space:nowrap" class="ft628"><b>Slovenija&#160;<br/></b>Gilead Sciences&#160;Ireland UC&#160;<br/>Tel:&#160;+ 353&#160;(0)&#160;1 686&#160;1888&#160;<br/>&#160;</p>
<p style="position:absolute;top:393px;left:115px;white-space:nowrap" class="ft625"><b>Ísland&#160;<br/></b>Gilead Sciences&#160;Sweden AB&#160;<br/>Sími:&#160;+ 46&#160;(0)&#160;8 5057 1849&#160;<br/>&#160;</p>
<p style="position:absolute;top:393px;left:463px;white-space:nowrap" class="ft625"><b>Slovenská republika&#160;<br/></b>Gilead Sciences&#160;Slovakia&#160;s.r.o.&#160;<br/>Tel:&#160;+ 421&#160;(0)&#160;232&#160;121&#160;210&#160;<br/>&#160;</p>
<p style="position:absolute;top:469px;left:115px;white-space:nowrap" class="ft628"><b>Italia&#160;<br/></b>Gilead Sciences&#160;S.r.l.&#160;<br/>Tel:&#160;+ 39 02 439201&#160;<br/>&#160;</p>
<p style="position:absolute;top:469px;left:463px;white-space:nowrap" class="ft628"><b>Suomi/Finland&#160;<br/></b>Gilead Sciences&#160;Sweden AB&#160;<br/>Puh/Tel:&#160;+ 46&#160;(0)&#160;8&#160;5057 1849&#160;<br/>&#160;</p>
<p style="position:absolute;top:541px;left:115px;white-space:nowrap" class="ft6213"><b>Κύπρος&#160;<br/></b>Gilead Sciences&#160;Ελλάς&#160;Μ.ΕΠΕ.&#160;<br/>Τηλ:&#160;+ 30 (0)&#160;210 8930&#160;100&#160;<br/>&#160;</p>
<p style="position:absolute;top:544px;left:463px;white-space:nowrap" class="ft628"><b>Sverige&#160;<br/></b>Gilead Sciences&#160;Sweden AB&#160;<br/>Tel:&#160;+ 46&#160;(0)&#160;8 5057&#160;1849&#160;<br/>&#160;</p>
<p style="position:absolute;top:620px;left:115px;white-space:nowrap" class="ft625"><b>Latvija&#160;<br/></b>Gilead Sciences&#160;Ireland UC&#160;<br/>Tel.:&#160;+ 353&#160;(0)&#160;1 686&#160;1888&#160;<br/>&#160;</p>
<p style="position:absolute;top:620px;left:463px;white-space:nowrap" class="ft625"><b>United&#160;Kingdom&#160;(Northern Ireland)&#160;&#160;<br/></b>Gilead Sciences&#160;Ireland UC&#160;<br/>Tel:&#160;+ 44&#160;(0)&#160;8000 113 700&#160;<br/>&#160;</p>
<p style="position:absolute;top:696px;left:106px;white-space:nowrap" class="ft628"><b>&#160;<br/>This&#160;leaflet&#160;was&#160;last&#160;revised in&#160;.&#160;<br/></b>&#160;<br/>Detailed&#160;information on&#160;this medicine&#160;is&#160;available on&#160;the European&#160;Medicines Agency web&#160;site:&#160;<br/><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu.</a>&#160;<br/>&#160;</p>
</div>
<a name="outline"></a><h1>Document Outline</h1>
<ul>
<li><a href="biktarvy-epar-product-information_en.html#1">SUMMARY OF PRODUCT CHARACTERISTICS</a></li>
<li><a href="biktarvy-epar-product-information_en.html#29">A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE</a></li>
<li><a href="biktarvy-epar-product-information_en.html#29">B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</a></li>
<li><a href="biktarvy-epar-product-information_en.html#29">C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</a></li>
<li><a href="biktarvy-epar-product-information_en.html#29">D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</a></li>
<li><a href="biktarvy-epar-product-information_en.html#31">A. LABELLING</a></li>
<li><a href="biktarvy-epar-product-information_en.html#44">B. PACKAGE LEAFLET</a></li>
</ul>
<hr/>
</body>
</html>
